CN116745415A - Engineered CRISPR-CAS proteins and methods of use thereof - Google Patents

Engineered CRISPR-CAS proteins and methods of use thereof Download PDF

Info

Publication number
CN116745415A
CN116745415A CN202180072987.6A CN202180072987A CN116745415A CN 116745415 A CN116745415 A CN 116745415A CN 202180072987 A CN202180072987 A CN 202180072987A CN 116745415 A CN116745415 A CN 116745415A
Authority
CN
China
Prior art keywords
domain
protein
crispr
engineered protein
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180072987.6A
Other languages
Chinese (zh)
Inventor
S·L·古菲
J·M·瓦特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pairing Plant Service Co ltd
Original Assignee
Pairing Plant Service Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pairing Plant Service Co ltd filed Critical Pairing Plant Service Co ltd
Publication of CN116745415A publication Critical patent/CN116745415A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/85Fusion polypeptide containing an RNA binding domain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Described herein are engineered CRISPR-Cas proteins and methods of using such proteins. In particular a V-type CRISPR-Cas nuclease, such as Cas12a, having a nuclease or nickase domain from a non-V-type CRISPR-Cas nuclease inserted in the inter-domain region between the Rec1 and Rec2 domains. Also described herein are complexes, compositions, and systems comprising the engineered proteins of the invention, each of which can be used to modify or edit a target nucleic acid. The engineered protein of the invention may be an enzyme and/or may be an RNA-guided DNA binding protein.

Description

Engineered CRISPR-CAS proteins and methods of use thereof
Statement regarding electronic application to sequence listing
Instead of paper copies, a sequence listing in ASCII text format was provided, which was submitted according to 37 c.f.r. ≡1.821, named 1499-37wo_st25, size 922,217 bytes, generated at 2021, 8, 27 days, and submitted via EFS-Web. The disclosure of this sequence listing is hereby incorporated by reference into the specification.
Technical Field
The present invention relates to engineered proteins (e.g., engineered enzymes) and methods of using such proteins. The invention also relates to compositions and systems for modifying or editing target nucleic acids.
Background
Type II CRISPR endonucleases (including widely used SpCas 9) share a common DNA cleavage mechanism. Enzymes in this family contain two nuclease domains (HNH and RuvC), each of which cleaves a single DNA strand. When the Cas9-sgRNA complex (or Cas9-crRNA-trRNA complex) binds to its target DNA sequence, the target DNA strand binds to the RNA spacer sequence, rather than the target DNA strand forming a single-stranded loop. The HNH domain of Cas9 cleaves the target DNA strand and the RuvC domain cleaves the non-target strand (fig. 1). As shown in fig. 1, for a type II CRISPR endonuclease (e.g., cas 9), the target DNA strand and the non-target DNA strand are simultaneously cleaved by HNH and RuvC domains, respectively, forming a blunt-ended double-strand break.
Unlike type II CRISPR endonucleases, a type V CRISPR endonuclease (e.g., cas12 a) has only one nuclease domain, which cleaves two DNA strands in sequence starting from a non-target strand. As shown in fig. 2, for a V-type endonuclease (e.g., cas12 a), the RuvC domain cleaves the non-target DNA strand and the target DNA strand sequentially, resulting in a staggered double strand break.
Although type II and V CRISPR endonucleases perform similar functions, their mechanisms and structures are quite different. These two different types are believed to have evolved from different precursors, and only the RuvC domain shares any significant sequence or structural homology between the two types. Type V CRISPR endonucleases lack the HNH domain responsible for cleavage of the target strand in type II enzymes. In contrast, the RuvC domain in the V-type CRISPR endonuclease cleaves two DNA strands in sequence starting from a non-target strand (fig. 2). Thus, the catalytic residues of the mutant RuvC domain prevent all nuclease activity and produce an inactivated enzyme, rather than a target strand-cutting enzyme. Non-target strand-cutting enzyme mutations have been identified in Cas12 a; however, this mutation is outside of the RuvC domain and is believed to act by reducing the overall catalytic efficiency of the enzyme. There is no V-type CRISPR target strand-cutting enzyme and no clear production method in view of the differences in structure and mechanism of action of V-type CRISPR endonucleases compared to type II CRISPR endonucleases.
Disclosure of Invention
The first aspect of the invention relates to an engineered protein comprising at least two different polypeptides, wherein one of the at least two different polypeptides is a first CRISPR-Cas effect polypeptide that is a first portion of a first V-type CRISPR-Cas effect protein and the first CRISPR-Cas effect polypeptide is free of nuclease domains; and wherein the other of the at least two different polypeptides is a heterologous polypeptide that is heterologous to and is not part of the V-type CRISPR-Cas effect protein.
Another aspect of the invention relates to an engineered protein comprising: a first nuclease domain, wherein the first nuclease domain is a target strand nickase domain or portion thereof, wherein the first nuclease domain is not a V-type nuclease domain or portion thereof; and the first CRISPR-Cas effect polypeptide is part of a V-type CRISPR-Cas effect protein. In some embodiments, the first nuclease domain is a target strand-specific nicking enzyme domain or a target strand-nicking enzyme domain and a non-target strand-nicking enzyme domain.
Another aspect of the invention relates to an engineered protein comprising: a first polypeptide that is a first portion of a first V-type CRISPR-Cas effect protein; a second polypeptide that is a second portion of the first V-type CRISPR-Cas effect protein; and a heterologous polypeptide heterologous to the first V-type CRISPR-Cas effect protein, wherein the heterologous polypeptide is located between the first polypeptide and the second polypeptide, and the heterologous polypeptide is located in the engineered protein at a position corresponding to the inter-domain region of the first V-type CRISPR-Cas effect protein.
Another aspect of the invention relates to an engineered protein comprising a sequence identical to SEQ ID NO:2-17 or 125-132, optionally wherein the engineered protein comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2-17 or 125-132.
Another aspect of the invention relates to a composition (e.g., base editing composition) or system comprising: an engineered protein as described herein; a guide nucleic acid (e.g., a guide RNA), and optionally a deaminase, optionally wherein the engineered protein, the guide nucleic acid, and optionally the deaminase form a complex or are contained in a complex.
Another aspect of the invention relates to a composite comprising: an engineered protein as described herein; guide nucleic acids (e.g., guide RNAs); and optionally deaminase.
Another aspect of the invention relates to a nucleic acid molecule comprising a nucleotide sequence encoding an engineered protein as described herein.
Another aspect of the invention relates to a method of modifying a target nucleic acid, the method comprising: contacting a target nucleic acid with an engineered protein as described herein and a guide nucleic acid (e.g., guide RNA), optionally wherein the engineered protein and guide nucleic acid form a complex or are contained in a complex, thereby modifying the target nucleic acid.
Another aspect of the invention relates to a method of increasing the efficiency of modifying a target nucleic acid, the method comprising: contacting a target nucleic acid with an engineered protein as described herein and a guide nucleic acid (e.g., guide RNA), optionally wherein the engineered protein and guide nucleic acid form a complex or are contained in a complex, thereby modifying the target nucleic acid.
The invention also provides expression cassettes and/or vectors comprising the nucleic acid constructs of the invention, and cells comprising the polypeptides, fusion proteins and/or nucleic acid constructs of the invention. Furthermore, the invention provides a kit comprising the nucleic acid construct of the invention and an expression cassette, vector and/or cell comprising the same.
It is noted that aspects of the invention described with respect to one embodiment may be incorporated into a different embodiment, although not specifically described with respect thereto. That is, all embodiments and/or features of any of the embodiments may be combined in any manner and/or combination. Applicant reserves the right to alter any initially filed claim and/or correspondingly filed any new claim, including the right to be able to modify any initially filed claim to rely on and/or incorporate any feature of any other claim or claims, although not initially claimed in this manner. These and other objects and/or aspects of the invention are explained in detail in the description set forth below. Other features, advantages and details of the present invention will be understood by those of ordinary skill in the art from a reading of the accompanying drawings and the detailed description of the preferred embodiments that follow, such description being merely illustrative of the invention.
Brief Description of Drawings
Fig. 1 is a diagram depicting the mechanism of action of a type II CRISPR endonuclease.
Fig. 2 is a diagram depicting the mechanism of action of a V-type CRISPR endonuclease.
Fig. 3 is the crystal structure of SpCas9 (PDB ID 4UN 3) bound to a single guide RNA (sgRNA) and target DNA. The domains shown are as follows: ruvC, bridged helix, rec1, rec2, HNH and PAM interact.
Fig. 4 is a schematic representation of Cas12a domain facing the Rec leaf. From this perspective, a portion of the crRNA/target DNA duplex is significantly exposed at the surface of Cas12 a.
Fig. 5 is a superposition of HNH domains from SpCas9 on candidate insertion sites in LbCas12 a.
FIG. 6 is a diagram depicting the soluble fraction of lysed E.coli expressing HNH-3287, 3288, 3289, 3290, 3296, 3297, 3298 and 3299.
Fig. 7 is a graph depicting the nicking activity of purified HNH-3287, 3288, 3289, 3290, 3296, 3297 and 3298.
FIG. 8 is an image of a gel indicating soluble expression of a nicking enzyme in E.coli according to some embodiments of the invention.
FIG. 9 is an image of a gel indicating that a nicking enzyme according to some embodiments of the present invention may nick a DNA substrate.
FIG. 10 is an image of a gel indicating that a nicking enzyme according to some embodiments of the present invention may be RNA dependent.
FIG. 11 is an image of a gel indicating that a nicking enzyme according to some embodiments of the present invention may act as a DNA nicking enzyme.
FIG. 12 is a diagram showing labeled target strands.
FIG. 13 is a diagram showing labeled non-target strands.
FIG. 14 is an image of a gel comprising a sample incubated with labeled target strands.
FIG. 15 is an image of a gel comprising a sample incubated with labeled non-target strands.
FIG. 16 is an image showing the entire gel of the lanes of FIGS. 14 and 15 and the control lane.
FIG. 17 is a graph showing the editing efficiency of individual enzyme pairings according to some embodiments of the invention.
Fig. 18-21 are graphs showing the percentages of C-to-T editing for various target regions corresponding to respective spacers: FANCF spacer 1 (FIG. 18), FANCF spacer 2 (FIG. 19), AAVS1 spacer 1 (FIG. 20), and AAVS1 spacer 2 (FIG. 21).
Fig. 22-23 are graphs showing the percentages of a-to-G editing of various target regions corresponding to respective spacers: RNF2 spacer 1 (fig. 22) and RNF2 spacer 2 (fig. 23).
Detailed Description
The invention will now be described hereinafter with reference to the accompanying drawings and examples, in which embodiments of the invention are shown. This description is not intended to be an inventory of all the different ways in which the invention may be practiced or to be added to all of the features of the invention. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Thus, the present invention contemplates that in some embodiments of the invention, any feature or combination of features set forth herein may be excluded or omitted. Furthermore, many variations and additions to the various embodiments set forth herein will be apparent to those skilled in the art in light of the present disclosure, without departing from the invention. Thus, the following description is intended to illustrate some specific embodiments of the invention, and not to exhaustively specify all permutations, combinations, and variations thereof.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
All publications, patent applications, patents, and other references cited herein are incorporated by reference in their entirety for the teachings relating to the sentences and/or paragraphs in which the references are presented.
The various features of the invention described herein are specifically intended to be used in any combination unless the context indicates otherwise. Furthermore, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein may be excluded or omitted. For purposes of illustration, if the specification states that the composition comprises components A, B and C, it is specifically intended that either one of A, B or C, or a combination thereof, may be omitted and disclaimed, alone or in any combination.
As used in the description of the invention and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
Also as used herein, "and/or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").
The term "about" as used herein in reference to a measurable value, such as an amount or concentration, is intended to encompass variations of + -10%, + -5%, + -1%, + -0.5% or even + -0.1% of the specified value, as well as the specified value. For example, where X is a measurable value "about X" is intended to include X as well as variations of 10%, + -5%, + -1%, + -0.5%, or even+ -0.1% of X. The ranges of measurable values provided herein can include any other ranges and/or individual values therein.
As used herein, phrases such as "between X and Y" and "between about X and Y" should be construed to include X and Y. As used herein, a phrase such as "between about X and Y" means "between about X and about Y" and a phrase such as "from about X to Y" means "from about X to about Y".
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if ranges 10 to 15 are disclosed, 11, 12, 13, and 14 are also disclosed.
As used herein, the terms "comprises," "comprising," and "includes" specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
As used herein, the transitional phrase "consisting essentially of … …" means that the scope of the claims should be interpreted to include the specific materials or steps recited in the claims, as well as those materials or steps that do not materially affect the basic and novel characteristics of the claimed invention. Accordingly, the term "consisting essentially of … …" is not intended to be interpreted as equivalent to "comprising" when used in the claims of the present invention.
As used herein, the terms "increase", "increasing", "enhancing", "improving" and "improving" (and grammatical variants thereof) describe, for example, an increase of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 300%, 400%, 500% or more compared to another measurable property or quantity (e.g., a control value).
As used herein, the terms "reduced", "reduced" and "lessened" (and grammatical variants thereof) describe, for example, a reduction of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% compared to another measurable property or quantity (e.g., a control value). In some embodiments, the reduction may result in no or substantially no (i.e., insignificant amounts, e.g., less than about 10% or even 5%) detectable activity or amount.
A "heterologous nucleotide sequence" or "recombinant nucleotide sequence" is a nucleotide sequence that is not naturally associated with the host cell into which it is introduced, including non-naturally occurring multiple copies of naturally occurring nucleotide sequences.
"native" or "wild-type" nucleic acid, nucleotide sequence, polypeptide, or amino acid sequence refers to a naturally occurring or endogenous nucleic acid, nucleotide sequence, polypeptide, or amino acid sequence. Thus, for example, a "wild-type mRNA" is an mRNA that is naturally occurring in or endogenous to a reference organism. A "homologous" nucleic acid sequence is a nucleotide sequence that is naturally associated with the host cell into which it is introduced.
As used herein, the terms "nucleic acid", "nucleic acid molecule", "nucleotide sequence" and "polynucleotide" refer to RNA or DNA that is linear or branched, single-or double-stranded, or a mixture thereof. The term also includes RNA/DNA mixtures. When dsRNA is synthetically produced, less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine, and the like can also be used for antisense, dsRNA, and ribozyme pairing. For example, polynucleotides containing C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and are potent antisense inhibitors of gene expression. Other modifications may also be made, such as modifications to the phosphodiester backbone, or the 2' -hydroxy group in the ribose sugar of RNA.
As used herein, the term "nucleotide sequence" refers to a heteropolymer of nucleotides or the sequence of these nucleotides from the 5 'end to the 3' end of a nucleic acid molecule, and includes DNA or RNA molecules, including cDNA, DNA fragments or portions, genomic DNA, synthetic (e.g., chemically synthesized) DNA, plasmid DNA, mRNA, and antisense RNA, any of which may be single-stranded or double-stranded. The terms "nucleotide sequence", "nucleic acid molecule", "nucleic acid construct", "recombinant nucleic acid", "oligonucleotide" and "polynucleotide" are also used interchangeably herein to refer to heteropolymers of nucleotides. The nucleic acid molecules and/or nucleotide sequences provided herein are presented in a 5 'to 3' direction from left to right herein and are represented using standard codes representing the nucleotide characters described in U.S. sequence rules, 37CFR ≡1.821-1.825 and World Intellectual Property Organization (WIPO) standard st.25. As used herein, a "5 'region" may refer to a region of a polynucleotide closest to the 5' end of the polynucleotide. Thus, for example, an element in the 5 'region of a polynucleotide may be located anywhere from a first nucleotide located at the 5' end of the polynucleotide to a nucleotide located in the middle of the polynucleotide. As used herein, a "3 'region" may refer to a region of a polynucleotide that is closest to the 3' end of the polynucleotide. Thus, for example, elements in the 3 'region of a polynucleotide may be located anywhere from a first nucleotide located at the 3' end of the polynucleotide to a nucleotide located in the middle of the polynucleotide.
As used herein, the term "gene" refers to a nucleic acid molecule that can be used to produce mRNA, antisense RNA, miRNA, anti-microRNA antisense oligodeoxynucleotide (AMO), and the like. Genes may or may not be useful for producing functional proteins or gene products. Genes may include coding and non-coding regions (e.g., introns, regulatory elements, promoters, enhancers, termination sequences, and/or 5 'and 3' non-translated regions).
A polynucleotide, gene, or polypeptide may be "isolated," which refers to a nucleic acid or polypeptide that is substantially or essentially free of components normally associated with the nucleic acid or polypeptide, respectively, in its natural state. In some embodiments, these components include other cellular material, media from recombinant production, and/or various chemicals for chemical synthesis of nucleic acids or polypeptides.
The term "mutation" refers to a mutation (e.g., missense or nonsense, or an insertion or deletion of a single base pair that results in a frame shift), an insertion, a deletion, and/or a truncation. When a mutation is a substitution of one residue in an amino acid sequence with another residue, or a deletion or insertion of one or more residues in the sequence, the mutation is typically described by identifying the original residue, then the position of that residue in the sequence, and the identity of the newly substituted residue.
As used herein, the term "complementary" or "complementarity" refers to the natural binding of polynucleotides by base pairing under the conditions of salt and temperature allowed. For example, the sequence "A-G-T" (5 'to 3') binds to the complementary sequence "T-C-A" (3 'to 5'). Complementarity between two single-stranded molecules may be "partial," in which only some nucleotides bind, or when there is complete complementarity between the single-stranded molecules, the complementarity may be complete. The degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands.
As used herein, "complementary" may refer to 100% complementarity to a control nucleotide sequence, or it may refer to less than 100% complementarity (e.g., "substantially complementary," e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, etc. complementarity).
A "portion" or "fragment" of a nucleotide sequence or polypeptide (including a domain) will be understood to refer to, consist essentially of, and/or consist of a nucleotide sequence or polypeptide having a reduced length (e.g., reduced by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more residues (e.g., nucleotides or peptides)) relative to a reference nucleotide sequence or polypeptide, respectively, and including the same or nearly the same (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) consecutive residues, respectively, as the reference nucleotide sequence or polypeptide. Such nucleic acid fragments or portions according to the invention may, where appropriate, be included in larger polynucleotides of which such nucleic acid fragments or portions are a component. For example, the repeat sequence of the guide nucleic acid of the invention can include a portion of a wild-type CRISPR-Cas repeat sequence (e.g., a wild-type V-type CRISPR Cas repeat sequence, e.g., a repeat sequence from a CRISPR Cas system including, but not limited to, cas12a (Cpf 1), cas12b, cas12C (C2C 3), cas12d (CasY), cas12e (CasX), cas12g, cas12h, cas12i, C2C1, C2C4, C2C5, C2C8, C2C9, C2C10, cas14a, cas14b, and/or Cas14C, etc.).
Different nucleic acids or proteins having homology are referred to herein as "homologs". The term homologue includes homologous sequences from the same and other species and orthologous sequences from the same and other species. "homology" refers to the level of similarity in terms of percent positional identity (i.e., sequence similarity or identity) of two or more nucleic acid and/or amino acid sequences. Homology also refers to the concept of similar functional properties between different nucleic acids or proteins. Thus, the compositions and methods of the invention also include homologs of the nucleotide sequences and polypeptides of the invention. As used herein, "ortholog" or "ortholog" refers to homologous nucleotide sequences and/or amino acid sequences in different species that are produced from a common ancestral gene during speciation. The homologs or orthologs of a nucleotide sequence of the invention have substantial sequence identity (e.g., at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100%) with the nucleotide sequence of the invention.
As used herein, "sequence identity" refers to the degree to which two optimally aligned polynucleotide or polypeptide sequences remain unchanged throughout the window of alignment of components (e.g., nucleotides or amino acids). "identity" can be readily calculated by known methods, including but not limited to those described in the following: computational Molecular Biology (Lesk, a.m., ed.) Oxford University Press, new York (1988); biocomputing: informatics and Genome Projects (Smith, d.w., ed.) Academic Press, new York (1993); computer Analysis of Sequence Data Part I (Griffin, a.m. and Griffin, h.g., eds.) Humana Press, new Jersey (1994); sequence Analysis in Molecular Biology (von Heinje, g., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, m. And Devereux, j., eds.) stock Press, new York (1991).
As used herein, the term "percent sequence identity" or "percent identity" refers to the percentage of identical nucleotides in a linear polynucleotide sequence of a reference ("query") polynucleotide molecule (or its complementary strand) as compared to a test ("subject") polynucleotide molecule (or its complementary strand) when the two sequences are optimally aligned. In some embodiments, "percent identity" may refer to the percentage of identical amino acids in an amino acid sequence as compared to a reference polypeptide.
As used herein, the phrase "substantially identical" or "substantial identity" in the context of two nucleic acid molecules, nucleotide sequences, or protein sequences refers to two or more sequences or subsequences that have at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. In some embodiments of the invention, substantial identity exists over a contiguous nucleotide region of a nucleotide sequence of the invention, the region having a length of from about 10 nucleotides to about 20 nucleotides, from about 10 nucleotides to about 25 nucleotides, from about 10 nucleotides to about 30 nucleotides, from about 15 nucleotides to about 25 nucleotides, from about 30 nucleotides to about 40 nucleotides, from about 50 nucleotides to about 60 nucleotides, from about 70 nucleotides to about 80 nucleotides, from about 90 nucleotides to about 100 nucleotides, or more, and any range therein, up to the full length of the sequence. In some embodiments, the nucleotide sequences may be substantially identical over at least about 20 nucleotides (e.g., about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleotides). In some embodiments, substantially identical nucleotide or protein sequences perform the same function as substantially identical nucleotides (or encoded protein sequences) thereto.
For sequence comparison, typically one sequence serves as a reference sequence for comparison to the test sequence. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, subsequence coordinates are designated as necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity of the one or more test sequences relative to the reference sequence based on the specified program parameters.
Optimal alignment of sequences for alignment of comparison windows is well known to those skilled in the art and can be achieved by means of local homology algorithms such as Smith and Waterman, homology alignment algorithms of Needleman and Wunsch, tools for searching similarity methods of Pearson and Lipman and optionally computerized implementation of such algorithms such as GAP, BESTFIT, FASTA and TFASTA (asWisconsin/>(Accelrys inc., part of San Diego, CA.). "identity score" of an aligned segment of a test sequence and a reference sequence refers to the number of identical components shared by the two aligned sequences divided by the total number of components in the reference sequence segment (e.g., the entire reference sequence or a smaller defined portion of the reference sequence). Percent sequence identity is expressed as the identity score multiplied by 100. The comparison of one or more polynucleotide sequences may be with a full length polynucleotide sequence or a portion thereof, or with a longer polynucleotide sequence. For the purposes of the present invention, the "percent identity" can also be determined using BLASTX version 2.0 (nucleotide sequence for translation) and BLASTN version 2.0 (nucleotide sequence for polynucleotide sequence).
Two nucleotide sequences may also be considered to be substantially complementary when the two sequences hybridize to each other under stringent conditions. In some representative embodiments, two nucleotide sequences that are considered to be substantially complementary hybridize to each other under highly stringent conditions.
"stringent hybridization conditions" and "stringent hybridization wash conditions" are sequence-dependent in the context of nucleic acid hybridization experiments (e.g., southern and Northern hybridizations) and are different under different environmental parameters. Extensive guidelines for nucleic acid hybridization are found in Tijssen Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes part I chapter 2"Overview of principles of hybridization and the strategy of nucleic acid probe assays"Elsevier,New York (1993). Generally, highly stringent hybridization and wash conditions are selected to be specific for the particular sequence at a defined ionic strength and pH (T m ) About 5 ℃ lower.
T m Is the temperature (at the prescribed ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. The very stringent conditions are chosen to be equal to T for the particular probe m . In Southern or northern blotting, an example of stringent hybridization conditions for hybridization of complementary nucleotide sequences having more than 100 complementary residues on a filter is hybridization of 50% formamide with 1mg heparin at 42℃overnight. An example of highly stringent wash conditions is 0.1M NaCl at 72℃for about 15 minutes. An example of stringent wash conditions is a 0.2 XSSC wash at 65℃for 15 minutes (SSC buffer is described in Sambrook below). Typically, a low stringency wash is performed prior to a high stringency wash to remove background probe signal. For example, an example of moderately stringent washes of a duplex of more than 100 nucleotides is 1XSSC at 45℃for 15 minutes. For example, an example of a low stringency wash of a duplex of more than 100 nucleotides is 4-6 XSSC at 40℃for 15 minutes. For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve a salt concentration of less than about 1.0M Na ion, typically about 0.01 to 1.0M Na ion concentration (or other salt), at a pH of 7.0 to 8.3, and the temperature is typically at least about 30 ℃. The addition of destabilizing agents (e.g. formamide) is also possible Stringent conditions are reached. In general, a signal-to-noise ratio of 2x (or higher) that observed for unrelated probes in a particular hybridization assay indicates detection of specific hybridization. If the proteins they encode are substantially identical, the nucleotide sequences that do not hybridize to each other under stringent conditions remain substantially identical. This may occur, for example, when a copy of a nucleotide sequence is created using the maximum codon degeneracy permitted by the genetic code.
The polynucleotides and/or recombinant nucleic acid constructs of the invention may be codon optimized for expression. In some embodiments, polynucleotides, nucleic acid constructs, expression cassettes, and/or vectors of the invention (e.g., comprising/encoding an engineered protein, a nucleic acid binding domain (e.g., a DNA binding domain, such as a sequence-specific DNA binding domain from a polynucleotide-guided endonuclease, a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), an Argonaute protein, and/or a CRISPR-Cas effect protein), a guide nucleic acid, a cytosine deaminase, and/or an adenine deaminase) can be codon optimized for expression in an organism (e.g., an animal, plant, fungus, archaebacteria, or bacterium). In some embodiments, the codon-optimized nucleic acid constructs, polynucleotides, expression cassettes, and/or vectors of the invention have about 70% to about 99.9% (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or 100%) or more identity to a reference nucleic acid construct, polynucleotide, expression cassette, and/or vector that has not been codon-optimized.
In any of the embodiments described herein, the polynucleotides or nucleic acid constructs of the invention can be operably associated with a variety of promoters and/or other regulatory elements for expression in their organisms or cells (e.g., plants and/or cells of plants). Thus, in some embodiments, a polynucleotide or nucleic acid construct of the invention may further comprise one or more promoters, introns, enhancers and/or terminators operably linked to one or more nucleotide sequences. In some embodiments, the promoter may be operably associated with an intron (e.g., ubi1 promoter and intron). In some embodiments, the promoter associated with an intron may be referred to as a "promoter region" (e.g., ubi1 promoter and intron).
As used herein, "operably linked" or "operably associated with" a polynucleotide refers to the elements shown being functionally related to each other, and typically also physically related. Thus, as used herein, the term "operably linked" or "operably linked" refers to a functionally linked nucleotide sequence on a single nucleic acid molecule. Thus, a first nucleotide sequence operably linked to a second nucleotide sequence refers to the situation when the first nucleotide sequence is in functional relationship with the second nucleotide sequence. For example, a promoter is operably associated with a nucleotide sequence if it affects the transcription or expression of the nucleotide sequence. Those skilled in the art will appreciate that a control sequence (e.g., a promoter) need not be contiguous with the nucleotide sequence to which it is operably linked, so long as the function of the control sequence is to direct its expression. Thus, for example, an inserted untranslated but transcribed nucleic acid sequence can be present between the promoter and the nucleotide sequence, and the promoter can still be considered "operably linked" to the nucleotide sequence.
As used herein, the term "linked" or "fusion" with respect to polypeptides refers to the linkage of one polypeptide to another polypeptide. The polypeptide may be linked or fused to another polypeptide (at the N-terminus or C-terminus) either directly (e.g., via a peptide bond) or via a linker (e.g., a peptide linker).
The term "linker" with respect to a polypeptide is art-recognized and refers to a chemical group, or a molecule that links two molecules or moieties (e.g., two domains of a fusion protein), such as a CRISPR-Cas effect protein and a peptide tag and/or a polypeptide of interest. The linker may consist of a single linker molecule (e.g., a single amino acid) or may comprise more than one linker molecule. In some embodiments, the linker may be an organic molecule, group, polymer, or chemical moiety, such as a divalent organic moiety. In some embodiments, the linker may be an amino acid or it may be a peptide. In some embodiments, the linker is a peptide.
In some embodiments, peptide linkers useful in the present invention may be about 2 to about 100 or more amino acids in length, such as about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids (e.g., about 2 to about 40, about 2 to about 50, about 2 to about 60, about 4 to about 40, about 4 to about 50, about 4 to about 60, about 5 to about 40, about 5 to about 50, about 5 to about 60, about 9 to about 40, about 9 to about 50, about 9 to about 60, about 10 to about 40, about 10 to about 50, about 10 to about 60, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 amino acids to about 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85. 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids in length (e.g., about 105, 110, 115, 120, 130, 140, 150 or more amino acids in length). In some embodiments, the peptide linker may be a GS linker. In some embodiments, the peptide linker has the amino acid sequence of SEQ ID NO: 18-47. In some embodiments, the peptide linker may comprise (GGS) n 、GS、SG、GSSG(SEQ ID NO:175)、S(GGS) n (SEQ ID NO: 42), SGGS (SEQ ID NO: 43) or (GGGGS) n (SEQ ID NO: 44), wherein n is 1 to 20An integer (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, the peptide linker may comprise the amino acid sequence: SGGSGGSGGS (SEQ ID NO: 45). In some embodiments, the peptide linker may comprise the amino acid sequence: SGSETPGTSESATPES (SEQ ID NO: 46), also known as the XTEN linker. In some embodiments, the peptide linker may comprise the amino acid sequence: SGGSSGGSSGSETPGTSESATPESSGGSSGGS (SEQ ID NO: 47), also known as GS-XTEN-GS linker.
As used herein, the term "ligate" or "fusion" with respect to polynucleotides refers to the attachment of one polynucleotide to another polynucleotide. In some embodiments, two or more polynucleotide molecules may be linked by a linker, which may be an organic molecule, a group, a polymer, or a chemical moiety, such as a divalent organic moiety. Polynucleotides may be linked or fused to another polynucleotide (at the 5 'end or the 3' end) by covalent or non-covalent bonding or binding, including, for example, watson-Crick base pairing, or by one or more linking nucleotides. In some embodiments, a polynucleotide motif of a structure may be inserted into another polynucleotide sequence (e.g., to guide the extension of a hairpin structure in RNA). In some embodiments, the connecting nucleotide can be a naturally occurring nucleotide. In some embodiments, the connecting nucleotide may be a non-naturally occurring nucleotide.
A "promoter" is a nucleotide sequence that controls or regulates transcription of a nucleotide sequence (e.g., a coding sequence) operably associated with the promoter. The coding sequence controlled or regulated by the promoter may encode a polypeptide and/or a functional RNA. In general, a "promoter" refers to a nucleotide sequence that contains an RNA polymerase II binding site and directs transcription initiation. Typically, the promoter is located 5' or upstream relative to the start of the coding region of the corresponding coding sequence. Promoters may contain other elements that act as regulators of gene expression; for example a promoter region. These include TATA box consensus sequences, and are typically CAAT box consensus sequences (Breathnach and Chambon, (1981) Annu. Rev. Biochem. 50:349). In plants, the CAAT box can be replaced by the AGGA box (Messing et al (1983), in Genetic Engineering of Plants, T.Kosuge, C.Meredith and A. Hollander (eds.), plenum Press, pp. 211-227). In some embodiments, the promoter region may comprise at least one intron (e.g., SEQ ID NO:48 or SEQ ID NO: 49).
Promoters useful in the present invention may include, for example, constitutive, inducible, time-regulated, developmentally-regulated, chemically-regulated, tissue-preferred, and/or tissue-specific promoters for use in preparing recombinant nucleic acid molecules, such as "synthetic nucleic acid constructs" or "protein-RNA complexes. These different types of promoters are known in the art.
The choice of promoter may vary depending on the temporal and spatial requirements of the expression and may also vary based on the host cell to be transformed. Promoters for many different organisms are well known in the art. Based on the broad knowledge available in the art, suitable promoters can be selected for the particular host organism of interest. Thus, for example, much is known about promoters upstream of genes that are highly constitutively expressed in model organisms, and such knowledge can be appropriately accessed and implemented in other systems.
In some embodiments, promoters that function in plants may be used with the constructs of the invention. Non-limiting examples of promoters that can be used to drive expression in plants include the promoter of the RubisCo small subunit Gene 1 (PrbcS 1), the promoter of the actin Gene (Pactin), the promoter of the nitrate reductase Gene (Pnr), and the promoter of the repetitive carbonic anhydrase Gene 1 (Pdca 1) (see Walker et al, plant Cell rep.23:727-735 (2005); li et al, gene 403:132-142 (2007); li et al, mol biol. Rep.37:1143-1154 (2010)). PrbcS1 and Pactin are constitutive promoters and Pnr and Pdca1 are inducible promoters. Pnr is nitrate-induced and ammonium-inhibited (Li et al, gene 403:132-142 (2007)), and Pdca1 is salt-induced (Li et al, mol biol. Rep.37:1143-1154 (2010)).
Examples of constitutive promoters that can be used in plants include, but are not limited to, the Plant viral promoter (cmp) (U.S. Pat. No. 7,166,770), the rice actin 1 promoter (Wang et al (1992) mol.cell.biol.12:3399-3406; and U.S. Pat. No. 5,641,876), the CaMV 35S promoter (Odell et al (1985) Nature 313:810-812), the CaMV 19S promoter (Lawton et al (1987) Plant mol.biol.9:315-324), the nos promoter (Ebert et al (1987) Proc.Natl.Acad.Sci USA 84:5745-5749), the Adh promoter (Walker et al (1987) Proc.Natl.Acad.Sci.USA 84:6624-6629), the sucrose synthase promoter (Yang & Russell (1990) Proc.4187.Sci.4144-USA) and the ubiquitin promoter. Constitutive promoters derived from ubiquitin accumulate in many cell types. Ubiquitin promoters have been cloned from several plant species, such as sunflower (Binet et al, 1991.Plant Science 79:87-94), maize (Christensen et al, 1989.Plant Molec.Biol.12:619-632) and Arabidopsis (Norris et al, 1993.Plant Molec.Biol.21:895-906), for transgenic plants. Maize ubiquitin promoter (UbiP) has been developed in transgenic monocot systems, the sequence and construction of vectors for monocot transformation are disclosed in european patent publication EP 0342926. Ubiquitin promoters are suitable for expression of the nucleotide sequences of the invention in transgenic plants, in particular monocotyledonous plants. Furthermore, the promoter expression cassette described by McElroy et al (mol. Gen. Genet.231:150-160 (1991)) can be readily modified to express the nucleotide sequences of the invention and is particularly suitable for monocot hosts.
In some embodiments, a tissue-specific/tissue-preferred promoter may be used to express a heterologous polynucleotide in a plant cell. Tissue-specific or preferred expression patterns include, but are not limited to, green tissue-specific or preferred, root-specific or preferred, stem-specific or preferred, flower-specific or preferred, or pollen-specific or preferred. Promoters suitable for expression in green tissues include many genes regulating the involvement in photosynthesis, many of which have been cloned from monocots and dicots. In one embodiment, the promoter useful in the present invention is the maize PEPC promoter from the phosphoenolcarboxylase gene (Hudspeth&Grula, plant molecular. Biol.12:579-589 (1989)). Non-limiting examples of tissue-specific promoters include those encoding seed storage proteins (e.g., beta-conglycinin, cruciferin, napin, and phaseolin), zein, or oilGenes for bulk proteins (e.g., oleosins) or proteins involved in fatty acid biosynthesis, including acyl carrier proteins, stearoyl-ACP desaturases and fatty acid desaturases (fad 2-1), and other nucleic acids expressed during embryo development (e.g., bce4, see, e.g., kridl et al (1991) Seed sci. Res.1:209-219; and those promoters associated with EP patent No. 255378). Tissue-specific or tissue-preferred promoters useful for expressing the nucleotide sequences of the invention in plants, particularly maize, include, but are not limited to, those expressed directly in roots, marrow, leaves or pollen. Such promoters are disclosed, for example, in WO93/07278, the disclosure of which is incorporated herein by reference. Other non-limiting examples of tissue-specific or tissue-preferred promoters useful in the present invention are the cotton rubisco promoter disclosed in U.S. patent 6,040,504; the rice sucrose synthase promoter disclosed in U.S. Pat. No. 5,604,121; the root-specific promoter described by de Framond (FEBS 290:103-106 (1991); european patent EP0452269 to Ciba-Geigy); the stem-specific promoter described in U.S. patent 5,625,136 (Ciba-Geigy), which drives expression of the maize trpA gene; the cerrtrum yellow roll virus promoter disclosed in WO 01/73087; and pollen specific or preferred promoters including, but not limited to, proOsLPS10 and ProOsLPS11 from rice (Nguyen et al, plant Biotechnol. Reports 9 (5): 297-306 (2015)), zmSTK2_USP from maize (Wang et al, genome 60 (6): 485-495 (2017)), LAT52 and LAT59 from tomato (Tshell et al, development109 (3): 705-713 (1990)), zm13 (U.S. Pat. No. 10,421,972), PLA from Arabidopsis thaliana 2 Delta promoter (U.S. Pat. No. 7,141,424) and/or ZmC5 promoter from maize (International PCT publication No. WO 1999/042587).
Other examples of Plant tissue specific/tissue preferred promoters include, but are not limited to, root hair specific cis-element (RHE) (Kim et al, the Plant Cell 18:2958-2970 (2006)), root specific promoter RCc3 (Jeong et al, plant Physiol.153:185-197 (2010)) and RB7 (U.S. Pat. No. 5459252), lectin promoter (Lindstrom et al (1990) der. Genet.11:160-167; and Vodkin (1983) prog.biol.Res.138:87-98), the maize alcohol dehydrogenase 1 promoter (Dennis et al (1984) Nucleic Acids Res.12:3983-4000), the S-adenosyl-L-methionine synthetase (SAMS) (Vander Mijnsbrugge et al (1996) Plant and Cell Physiology,37 (8): 1108-1115), the maize light harvesting composite promoter (Bansal et al (1992) Proc.Acad.Sci.USA 89:3654-3658), the maize heat shock protein promoter (O 'Dell et al EMBO J.5:451-458; and Rochester et al (1986) EMBO J.5:451-458), the small subunit RuBP carboxylase promoter (Cashmore "Nuclear genes encoding The small subunit of ribulose-L," 5-bisphosphate carboxylase "pp.29-39 in Genetic Engineering of Plants (Hollaen ed.; plum Press, gen 3; and Prinsen.Sci.Sci.6) and The human mann 1-35 (1989) and The maize heat shock protein promoter (O' Dell et al (1985) EMBO J.5:451-458; and The maize light dehydrogenase 1) (1986) and The maize light harvesting composite promoter (35:37) (Mandarin The same) and The maize plasmid (1989) mannase plasmid (Flex. Prinsen.3) and The maize plasmid (Prinsen.1) and Proc.Acl. Acl. Sci.6) (1986) and The maize protein promoter (1986), as above), the petunia Niu Chaer ketoisomerase promoter (van Tunen et al (1988) EMBO J.7:1257-1263), the glycine-rich protein 1 promoter (Keller et al (1989) Genes Dev.3:1639-1646), the truncated CaMV 35S promoter (O' Dell et al (1985) Nature 313:810-812), the potato patatin promoter (Wenzler et al (1989) Plant mol.biol.13:347-354), the root cell promoter (Yamamoto et al (1990) Nucleic Acids Res.18:7449), the maize zein promoter (Kriz et al (1987) mol.Gen.Genet.207:90-98; lanbridge et al (1983) Cell 34:1015-1022; reina et al (1990) Nucleic Acids Res.18:6425; reina et al (1990) Nucleic Acids Res.18:7449; and Wandelt et al (1989) Nucleic Acids Res.17:2354), the globulin-1 promoter (Belanger et al (1991) Genetics 129:863-872), the α -tubulin cab promoter (Sullivan et al (1989) mol. Gen. Genet. 215:431-440), the PEPCase promoter (Hudspeth & Grula (1989) Plant mol. Biol.12:579-589), the R gene complex-related promoter (Chandler et al (1989) Plant Cell 1:1175-1183) and the chalcone synthase promoter (Franken et al (1991) EMBO J.10:2605-2612).
Useful for seed-specific expression are the pea globulin promoters (Czako et al (1992) mol. Gen. Genet.235:33-40; and seed-specific promoters disclosed in U.S. Pat. No. 5,625,136 promoters useful for expression in mature leaves are those that are switched at the beginning of senescence, for example SAG promoters from Arabidopsis (Gan et al (1995) Science 270:1986-1988).
Furthermore, a promoter functioning in chloroplasts may be used. Non-limiting examples of such promoters include phage T3 gene 9' UTR and other promoters disclosed in U.S. Pat. No. 7,579,516. Other promoters useful in the present invention include, but are not limited to, the S-E9 small subunit RuBP carboxylase promoter and the Kunitz trypsin inhibitor gene promoter (Kti 3).
Other regulatory elements useful in the present invention include, but are not limited to, introns, enhancers, termination sequences and/or 5 'and 3' untranslated regions.
Introns useful in the present invention may be introns identified and isolated in plants and then inserted into expression cassettes for transformation of the plants. As will be appreciated by those of skill in the art, introns may comprise sequences required for self-excision and are incorporated into the nucleic acid construct/expression cassette in-frame. Introns may be used as spacer sequences to separate multiple protein coding sequences in a nucleic acid construct, or introns may be used within a protein coding sequence, for example, to stabilize mRNA. If they are used in protein coding sequences, they will be inserted "in frame" and contain a cleavage site. Introns may also be associated with promoters to improve or modify expression. For example, promoter/intron combinations useful in the present invention include, but are not limited to, combinations of the maize Ubi1 promoter and introns.
Non-limiting examples of introns that may be used in the present invention include introns from the ADHI gene (e.g., adh1-S introns 1, 2 and 6), ubiquitin gene (Ubi 1), the RuBisCO small subunit (rbcS) gene, the RuBisCO large subunit (rbcL) gene, the actin gene (e.g., actin-1 intron), the pyruvate dehydrogenase kinase gene (pdk), the nitrate reductase gene (nr), the repetitive carbonic anhydrase gene 1 (Tdca 1), the psbA gene, the atpA gene, or any combination thereof.
As used herein, an "editing system" refers to any site-specific (e.g., sequence-specific) nucleic acid editing system now known or later developed that can introduce modifications (e.g., mutations) in a nucleic acid in a target-specific manner. For example, editing systems (e.g., site and/or sequence specific editing systems) can include, but are not limited to, CRISPR-Cas editing systems, meganuclease editing systems, zinc Finger Nuclease (ZFN) editing systems, transcription activator-like effector nuclease (TALEN) editing systems, base editing systems, and/or guide editing systems, each of which can comprise one or more polypeptides and/or one or more polynucleotides that, when present together and/or expressed (e.g., as a system) in a composition and/or cell, can modify (e.g., mutate) a target nucleic acid in a sequence specific manner. In some embodiments, an editing system (e.g., a site and/or sequence specific editing system) can comprise one or more polynucleotides and/or one or more polypeptides, including but not limited to a nucleic acid binding domain (e.g., a DNA binding domain), a nuclease, another polypeptide, and/or a polynucleotide. In some embodiments, CRISPR-Cas editing systems comprising the engineered proteins of the invention are provided and/or used.
In some embodiments, the editing system comprises one or more sequence-specific nucleic acid binding polypeptides (e.g., DNA binding domains) that can be derived from, for example, a polynucleotide-guided endonuclease, a CRISPR-Cas endonuclease (e.g., a CRISPR-Cas effector protein), a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), and/or an Argonaute protein. In some embodiments, the editing system comprises one or more cleaving polypeptides (e.g., nucleases), including, but not limited to, endonucleases (e.g., fok 1), polynucleotide-guided endonucleases, CRISPR-Cas endonucleases (e.g., CRISPR-Cas effector proteins), zinc finger nucleases, and/or transcription activating factor-like effector nucleases (TALENs).
As used herein, a "nucleic acid binding domain" refers to a polypeptide or domain that binds or is capable of binding a nucleic acid (e.g., a target nucleic acid). The DNA binding domain is an exemplary nucleic acid binding domain and may be a site and/or sequence specific nucleic acid binding domain. In some embodiments, the nucleic acid binding domain can be a sequence-specific nucleic acid binding domain, such as, but not limited to, a sequence-specific binding domain from, for example, a polynucleotide-guided endonuclease, a CRISPR-Cas effect protein (e.g., a CRISPR-Cas endonuclease), a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), and/or an Argonaute protein. In some embodiments, the nucleic acid binding domain comprises a cleavage domain (e.g., a nuclease domain), such as, but not limited to, an endonuclease (e.g., fok 1), a polynucleotide-guided endonuclease, a CRISPR-Cas endonuclease, a zinc finger nuclease, and/or a transcription activated factor-like effector nuclease (TALEN). In some embodiments, a nucleic acid binding domain is a polypeptide that can associate (e.g., form a complex) with one or more nucleic acid molecules (e.g., form a complex with a guide nucleic acid described herein), which can direct or guide the nucleic acid binding domain to a particular target nucleotide sequence (e.g., a genomic locus) that is complementary to one or more nucleic acid molecules (or portions or regions thereof), thereby causing the nucleic acid binding domain to bind to the particular target site. In some embodiments, the nucleic acid binding domain is a CRISPR-Cas effector protein as described herein.
In some embodiments, the editing system comprises or is a ribonucleoprotein, such as an assembled ribonucleoprotein complex (e.g., ribonucleoprotein comprising CRISPR-Cas effector protein, guide nucleic acid, and optionally deaminase). In some embodiments, the ribonucleoproteins of the editing system can be assembled together (e.g., a pre-assembled ribonucleoprotein comprising CRISPR-Cas effector protein, guide nucleic acid, and optionally deaminase), such as when contacted with a target nucleic acid or when introduced into a cell (e.g., a plant cell). In some embodiments, the ribonucleoprotein of the editing system can be assembled into a complex (e.g., a covalently and/or non-covalently bound complex), while a portion of the ribonucleoprotein contacts the target nucleic acid and/or is assembled after and/or during introduction into a plant cell. In some embodiments, when introduced into a plant cell, the editing system may be assembled (e.g., into a covalently and/or non-covalently bound complex). In some embodiments, the ribonucleoprotein may comprise an engineered protein, a guide nucleic acid, and optionally a deaminase.
As used herein, the term "transgenic" or "transgenic" refers to at least one nucleic acid sequence that is taken from the genome of an organism or produced synthetically, which is then introduced into a host cell (e.g., a plant cell) or organism or tissue of interest, and subsequently integrated into the host's genome by a "stable" transformation or transfection method. Conversely, the term "transient" transformation or transfection or introduction refers to the manner in which molecular means (including at least one nucleic acid (DNA, RNA, single-or double-stranded or mixtures thereof) and/or at least one amino acid sequence, optionally including suitable chemical or biological agents) are directed to effect transfer into at least one compartment of interest of a cell (including but not limited to cytoplasm, organelles, including nuclei, mitochondria, vacuoles, chloroplasts) or into a membrane, resulting in transcription and/or translation and/or association and/or activity of the introduced at least one molecule, but not to effect stable integration or incorporation into the genome, and thus no inheritance of the corresponding at least one molecule introduced into the genome of the cell. The term "transgene-free" refers to the situation where no transgene is present or found in the genome of the host cell or tissue or organism of interest.
In some embodiments, the polynucleotides and/or nucleic acid constructs of the invention may be "expression cassettes" or may be contained within expression cassettes. As used herein, an "expression cassette" refers to a recombinant nucleic acid molecule comprising, for example, a nucleic acid construct of the invention (e.g., a polynucleotide encoding an engineered protein, a polynucleotide encoding a cytosine deaminase, a polynucleotide encoding an adenine deaminase, a polynucleotide encoding a deaminase fusion protein, a polynucleotide encoding a peptide tag, a polynucleotide encoding an affinity polypeptide, a polynucleotide encoding a glycosylase, and/or a polynucleotide comprising a guide nucleic acid), wherein the nucleic acid construct is operably associated with at least one control sequence (e.g., a promoter). Thus, some embodiments of the invention provide expression cassettes designed for expression of, for example, the nucleic acid constructs of the invention. When the expression cassette comprises more than one polynucleotide, the polynucleotides may be operably linked to a single promoter that drives expression of all polynucleotides, or the polynucleotides may be operably linked to one or more separate promoters (e.g., three polynucleotides may be driven by one, two, or three promoters in any combination). Thus, for example, a polynucleotide encoding an engineered protein, a polynucleotide encoding a deaminase (e.g., adenine deaminase), and a polynucleotide containing a guide nucleic acid contained in an expression cassette may each be operably associated with a single promoter or one or more of the one or more nucleotides may be operably associated with separate promoters (e.g., two or three promoters) in any combination (which may be the same or different from each other).
In some embodiments, expression cassettes comprising the polynucleotide/nucleic acid constructs of the invention can be optimized for expression in an organism (e.g., animal, plant, bacteria, etc.).
An expression cassette comprising a nucleic acid construct of the invention may be chimeric, meaning that at least one component thereof is heterologous with respect to at least one other component thereof (e.g., a promoter from a host organism operably linked to a polynucleotide of interest expressed in the host organism, wherein the polynucleotide of interest is from an organism different from the host or is not normally associated with the promoter). The expression cassette may also be one that occurs naturally but has been obtained in a recombinant form that can be used for heterologous expression.
The expression cassette may optionally include transcriptional and/or translational termination regions (i.e., termination regions) and/or enhancer regions that function in the selected host cell. A variety of transcription terminators and enhancers are known in the art and can be used in the expression cassette. Transcription terminators are responsible for termination of transcription and correct mRNA polyadenylation. The termination region and/or enhancer region may be native to the transcription initiation region, native to the gene encoding the CRISPR-Cas effect protein or the gene encoding the deaminase, native to the host cell, or native to another source (e.g., foreign or heterologous to the promoter, to the gene encoding the CRISPR-Cas effect protein or the gene encoding the deaminase, to the host cell, or any combination thereof).
The expression cassettes of the invention may also include polynucleotides encoding selectable markers, which can be used to select transformed host cells. As used herein, "selectable marker" refers to a polynucleotide sequence that, when expressed, confers a different phenotype on a host cell expressing the marker, thereby allowing differentiation of such transformed cells from cells not bearing the marker. Such polynucleotide sequences may encode selectable or screenable markers, depending on whether the marker confers a trait that can be selected by chemical means, such as by use of a selection agent (e.g., an antibiotic, etc.), or whether the marker is simply a trait that can be identified by observation or testing, such as by screening (e.g., fluorescence). Many examples of suitable selectable markers are known in the art and may be used in the expression cassettes described herein.
The expression cassettes, nucleic acid molecules/constructs and polynucleotide sequences described herein may be used in combination with vectors. The term "vector" refers to a composition for transferring, delivering, or introducing a nucleic acid (or nucleic acids) into a cell. The vector comprises a nucleic acid construct comprising one or more nucleotide sequences to be transferred, delivered or introduced. Vectors for host bioconversion are well known in the art. Non-limiting examples of general types of vectors include viral vectors, plasmid vectors, phage vectors, phagemid vectors, cosmid vectors, fosmid vectors, phage, artificial chromosomes, minicircles or agrobacterium binary vectors in double-stranded or single-stranded linear or circular form, which may or may not be self-propagating or mobile. In some embodiments, the viral vector may include, but is not limited to, a retrovirus, lentivirus, adenovirus, adeno-associated virus, or herpes simplex virus vector. The vectors defined herein may be transformed into a prokaryotic or eukaryotic host by integration into the cell genome or by presence extrachromosomal (e.g., an autonomously replicating plasmid with an origin of replication). Also included are shuttle vectors, which means DNA vectors capable of replication (naturally or by design) in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eukaryotes (e.g. higher plant, mammalian, yeast or fungal cells). In some embodiments, the nucleic acid in the vector is under the control of and operably linked to a suitable promoter or other regulatory element for transcription in a host cell. The vector may be a bifunctional expression vector that functions in a plurality of hosts. In the case of genomic DNA, this may comprise its own promoter and/or other regulatory elements, while in the case of cDNA, this may be under the control of a suitable promoter and/or other regulatory elements for expression in the host cell. Thus, the nucleic acid constructs of the invention and/or expression cassettes comprising the same may be contained in vectors as described herein and known in the art.
As used herein, "contacted," "contacted," and grammatical variations thereof refer to bringing together components of a desired reaction under conditions suitable for performing the desired reaction (e.g., transformation, transcriptional control, genome editing, nicking, and/or cleavage). Thus, for example, a target nucleic acid can be contacted with a nucleic acid construct of the invention encoding, for example, a nucleic acid binding domain (e.g., a DNA binding domain, such as a sequence specific DNA binding protein (e.g., a polynucleotide-guided endonuclease, a CRISPR-Cas effect protein (e.g., a CRISPR-Cas endonuclease), a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), and/or an Argonaute protein)), a guide nucleic acid, and optionally a cytosine deaminase and/or an adenine deaminase under conditions of expression of the nucleic acid binding domain (e.g., a CRISPR-Cas effect protein), and the nucleic acid binding domain forms a complex with the guide nucleic acid, and optionally the complex hybridizes to the target nucleic acid, and the cytosine deaminase and/or adenine deaminase is recruited to the nucleic acid binding domain (and thus recruited to the target nucleic acid), or the cytosine deaminase and/or adenine deaminase is fused to the nucleic acid binding domain, thereby modifying the target nucleic acid. In some embodiments, cytosine deaminase and/or adenine deaminase and a nucleic acid binding domain are localized to a target nucleic acid, optionally by covalent and/or non-covalent interactions.
In some embodiments, the target nucleic acid may be contacted with a nucleic acid construct of the invention encoding an engineered protein, a guide nucleic acid, and optionally a cytosine deaminase and/or an adenine deaminase under conditions that express the engineered protein, or the target nucleic acid may be contacted with the engineered protein, guide nucleic acid, and optionally a cytosine deaminase and/or an adenine deaminase. The engineered protein can form a complex with the guide nucleic acid, and the complex can hybridize to the target nucleic acid, and optionally recruit cytosine deaminase and/or adenine deaminase to the engineered protein (and thus to the target nucleic acid) or fuse the cytosine deaminase and/or adenine deaminase to the engineered protein, thereby modifying the target nucleic acid. Cytosine deaminase and/or adenine deaminase and engineered proteins may be optionally localized to a target nucleic acid by covalent and/or non-covalent interactions.
As used herein, "modification" or "modified" with respect to a target nucleic acid includes editing (e.g., mutating), covalently modifying, exchanging/substituting nucleic acids/nucleotide bases, deleting, cleaving and/or nicking the target nucleic acid to provide a modified nucleic acid and/or altering transcriptional control of the target nucleic acid to provide a modified nucleic acid. In some embodiments, the modification may include any size of insertion and/or deletion and/or any type of single base change (SNP). In some embodiments, the modification comprises a SNP. In some embodiments, the modification comprises exchanging and/or substituting one or more (e.g., 1, 2, 3, 4,5, or more) nucleotides. In some embodiments, the length of an insertion or deletion can be from about 1 base to about 30,000 bases (e.g., lengths of about 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400 410, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,500, 16,000, 17,000, 17,17,000, 17,500, 18,500, 19,000, 19,500, 500, 19,500, 18,500, 500, and so that the rest can be detected 20,000, 20,500, 21,000, 21,500, 22,000, 22,500, 23,000, 23,500, 24,000, 24,500, 25,000, 25,500, 26,000, 26,500, 27,000, 27,500, 28,000, 28,500, 29,000, 29,500, 30,000 bases or more, or any value or range therein. Thus, in some embodiments, the first and second substrates, the length of the insertion or deletion may be about 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 to about 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 bases or more, or any value or range therein; from about 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 bases to about 310, 320, 330, 340, 350, 360, 370, 380 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 bases or more, or any value or range therein; a length of about 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 bases to about 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, or 10,000 bases or more, or any value or range therein; or from about 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, or 700 bases to about 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 bases or more, or any value or range therein. In some embodiments, the length of an insertion or deletion can be from about 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, or 10,000 bases to about 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 20,500, 21,000, 21,500, 22,000, 22,500, 23,000, 23,500, 24,000, 24,500, 25,500, 26,000, 26,500, 27,000, 27,500, 28,000, 28,500, 29,000, or more bases, or any range therein, or more.
As used herein, "recruit," "recruit," or "recruited" refers to the attraction of one or more polypeptides or polynucleotides to another polypeptide or polynucleotide (e.g., to a particular location in the genome) using protein-protein interactions, nucleic acid-protein interactions (e.g., RNA-protein interactions), and/or chemical interactions. Protein-protein interactions may include, but are not limited to, peptide tags (epitopes, multimerization epitopes) and corresponding affinity polypeptides, RNA recruitment motifs and corresponding affinity polypeptides, and/or chemical interactions. Exemplary chemical interactions of polypeptides and polynucleotides that may be used for recruitment purposes may include, but are not limited to, rapamycin-induced dimerization of FRB-FKBP; biotin-streptavidin interactions; SNAP tags (Hussain et al, curr Pharm Des.19 (30): 5437-42 (2013)); halo tags (Los et al ACS Chem biol.3 (6): 373-82 (2008)); CLIP tags (Gautier et al Chemistry & Biology 15:128-136 (2008)); compound-induced DmrA-DmrC heterodimers (Tak et al, nat Methods 14 (12): 1163-1166 (2017)); the bifunctional ligand approach (fusing two protein binding chemicals together) (Voβ et al Curr Opin Chemical Biology 28:194-201 (2015)) (e.g., dihydrofolate reductase (DHFR) (Kopyteck et al Cell Cehm Biol 7 (5): 313-321 (2000)).
"introduced", "introduced" (and grammatical variants thereof) in the context of a polynucleotide or editing system of interest means that the nucleotide sequence of interest (e.g., a polynucleotide, nucleic acid construct, and/or guide nucleic acid) and/or the editing system (e.g., a polynucleotide, polypeptide, and/or ribonucleoprotein) is presented to a host organism or a cell of the organism (e.g., a host cell; e.g., a plant cell) in a manner such that the nucleotide sequence and/or editing system can access the interior of the cell. Thus, for example, a nucleic acid construct of the invention encoding an engineered protein, a guide nucleic acid and a cytosine deaminase and/or an adenine deaminase can be introduced into a cell of an organism to transform the cell with the engineered protein, guide nucleic acid and cytosine deaminase and/or adenine deaminase. In some embodiments, the engineered protein and/or the guide nucleic acid may be introduced into a cell of an organism, optionally, wherein the engineered protein and guide nucleic acid may be included in a complex (e.g., ribonucleoprotein). In some embodiments, the organism is a eukaryote (e.g., a mammal, such as a human).
As used herein, the term "transformation" refers to the introduction of a heterologous nucleic acid, polypeptide, and/or ribonucleoprotein into a cell. Transformation of cells may be stable or transient. Thus, in some embodiments, a host cell or host organism may be stably transformed with a polynucleotide/nucleic acid molecule of the invention. In some embodiments, a host cell or host organism can be transiently transformed with a nucleic acid construct, polypeptide, and/or ribonucleoprotein of the invention.
In the context of polynucleotides, polypeptides and/or ribonucleoproteins, "transient transformation" refers to the introduction of a polynucleotide, polypeptide and/or ribonucleoprotein into a cell and not integration into the genome of the cell.
In the context of introducing a polynucleotide into a cell, "stably introduced" or "stably introduced" means that the introduced polynucleotide is stably incorporated into the genome of the cell, and thus the cell is stably transformed with the polynucleotide.
As used herein, "stably transformed" or "stably transformed" refers to the introduction of a nucleic acid molecule into a cell and integration into the genome of the cell. Thus, the integrated nucleic acid molecule can be inherited by its offspring, more specifically, by the offspring of multiple successive generations. As used herein, "genome" includes nuclear and plastid genomes, and thus includes the integration of nucleic acids into, for example, the chloroplast or mitochondrial genome. As used herein, stable transformation may also refer to transgenes maintained extrachromosomally, e.g., as minichromosomes or plasmids.
Transient transformation may be detected, for example, by enzyme-linked immunosorbent assay (ELISA) or western blot, which may detect the presence of a peptide or polypeptide encoded by one or more transgenes introduced into the organism. Stable transformation of a cell can be detected, for example, by Southern blot hybridization assays of genomic DNA of the cell with a nucleic acid sequence that specifically hybridizes to a nucleotide sequence of a transgene introduced into an organism (e.g., a plant). Stable transformation of a cell can be detected, for example, by Northern blot hybridization assays of RNA of the cell with nucleic acid sequences that specifically hybridize to nucleotide sequences of transgenes introduced into the host organism. Stable transformation of cells can also be detected by, for example, polymerase Chain Reaction (PCR) or other amplification reactions well known in the art, using specific primer sequences that hybridize to the target sequence of the transgene, resulting in amplification of the transgene sequence, which can be detected according to standard methods. Transformation may also be detected by direct sequencing and/or hybridization protocols well known in the art.
Thus, in some embodiments, the nucleotide sequences, polynucleotides, nucleic acid constructs and/or expression cassettes of the invention may be transiently expressed and/or they may be stably incorporated into the genome of a host organism. Thus, in some embodiments, the nucleic acid constructs of the invention may be transiently introduced into cells having the guide nucleic acid, and thus, no DNA remains in the cells.
The nucleic acid constructs, polypeptides and/or ribonucleoproteins of the invention may be introduced into cells by any method known to those of skill in the art. In some embodiments, transformation methods include, but are not limited to, nucleic acid delivery mediated by bacteria (e.g., by agrobacterium), virus-mediated nucleic acid delivery, silicon carbide and/or nucleic acid whisker-mediated nucleic acid delivery, liposome-mediated transformation of nucleic acid delivery, microinjection, microprojectile bombardment, calcium phosphate-mediated transformation, cyclodextrin-mediated transformation, electroporation, nanoparticle-mediated transformation, sonication, permeation, PEG-mediated nucleic acid uptake, and any other electrical, chemical, physical (mechanical) and/or biological mechanism that results in the introduction of a nucleic acid into a cell (e.g., a plant cell or an animal cell), including any combination thereof. In some embodiments of the invention, transformation of the cell comprises nuclear transformation. In some embodiments, transformation of the cell includes plastid transformation (e.g., chloroplast transformation). In some embodiments, the recombinant nucleic acid constructs of the invention may be introduced into cells by conventional breeding techniques.
Procedures for transforming eukaryotes and prokaryotes are well known and conventional in the art and are described throughout the literature (see, e.g., jiang et al, 2013.Nat. Biotechnol.31:233-239; ran et al, nature Protocols 8:2281-2308 (2013)). General guidelines for various plant transformation methods known in the art include Miki et al ("Procedures for Introducing Foreign DNA into Plants" in Methods in Plant Molecular Biology and Biotechnology, glick, B.R. and Thompson, J.E., eds. (CRC Press, inc., boca Raton, 1993), pages 67-88) and Rakowoczy-Trojanowska (cell.mol.biol.Lett.7:849-858 (2002)).
Thus, the nucleotide sequence, polypeptide and/or ribonucleoprotein may be introduced into the host organism or cell thereof in any manner well known in the art. The methods of the invention do not depend on the particular method of introducing one or more nucleotide sequences, polypeptides and/or ribonucleoproteins into an organism, so long as they are capable of entering the interior of at least one cell of the organism. When multiple nucleotide sequences, polypeptides and/or ribonucleoproteins are introduced, they may be assembled as part of a single nucleic acid construct, or assembled as separate nucleic acid constructs, and may be located on the same or different nucleic acid constructs. Thus, the nucleotide sequence, polypeptide and/or ribonucleoprotein may be introduced into the cell of interest in a single transformation event and/or in separate transformation events, or in related cases, the nucleotide sequence may be incorporated into a plant, e.g., as part of a breeding program. In some embodiments, the cell is a eukaryotic cell (e.g., a mammalian cell such as a human cell or a plant cell).
In some embodiments, a nucleic acid construct of the invention (e.g., a polynucleotide encoding an engineered protein of the invention, a polynucleotide encoding a deaminase and/or a guide nucleic acid and/or an expression cassette and/or a vector comprising the same) may be operably linked to at least one regulatory sequence, optionally, wherein the at least one regulatory sequence may be codon optimized for expression in a plant. In some embodiments, the at least one regulatory sequence may be, for example, a promoter, an operator, a terminator, or an enhancer. In some embodiments, at least one regulatory sequence may be a promoter. In some embodiments, the regulatory sequence may be an intron. In some embodiments, the at least one regulatory sequence may be, for example, a promoter operably associated with an intron or a promoter region comprising an intron. In some embodiments, the at least one regulatory sequence may be, for example, a ubiquitin promoter and its associated introns (e.g., alfalfa (Medicago truncatula) and/or corn (Zea mays) and its associated introns). In some embodiments, the at least one regulatory sequence may be a terminator nucleotide sequence and/or an enhancer nucleotide sequence.
In some embodiments, the nucleic acid constructs of the invention may be operably associated with a promoter region, wherein the promoter region comprises an intron, optionally wherein the promoter region may be an ubiquitin promoter and intron (e.g., alfalfa (Medicago) or maize ubiquitin promoter and intron, e.g., SEQ ID NO:48 or SEQ ID NO: 49). In some embodiments, the nucleic acid constructs of the invention operably associated with a promoter region comprising an intron may be codon optimized for expression in a plant.
In some embodiments, a nucleic acid construct of the invention may encode one or more (e.g., 1, 2, 3, 4, or more) polypeptides of interest, optionally wherein the one or more polypeptides of interest may be codon optimized for expression in a plant. In some embodiments, the engineered proteins may comprise one or more (e.g., 1, 2, 3, 4, or more) polypeptides of interest. For example, a heterologous polypeptide of an engineered protein may comprise or be a polypeptide of interest.
Polypeptides of interest useful in the present invention may include, but are not limited to, polypeptides or protein domains having deaminase activity, nickase activity, recombinase activity, transposase activity, methylase activity, glycosylase (DNA glycosylase) activity, glycosylase inhibitor activity (e.g., uracil-DNA glycosylase inhibitor (UGI)), demethylase activity, transcriptional activation activity, transcriptional repression activity, transcriptional release factor activity, histone modification activity, nuclease activity, single-stranded RNA cleavage activity, double-stranded RNA cleavage activity, restriction endonuclease activity (e.g., fok 1), nucleic acid binding activity, methyltransferase activity, DNA repair activity, DNA damage activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity, transposase activity, polymerase activity, ligase activity, helicase activity, nuclear localization sequence or activity, affinity polypeptide, peptide tag and/or photo-lyase activity. In some embodiments, the polypeptide of interest is a Fok1 nuclease or uracil-DNA glycosylase inhibitor. When encoded in a nucleic acid (polynucleotide, expression cassette, and/or vector), the encoded polypeptide or protein domain may be codon optimized for expression in an organism. In some embodiments, the polypeptide of interest can be linked to an engineered protein or CRISPR-Cas effect protein domain of the invention to provide a CRISPR-Cas fusion protein. In some embodiments, a CRISPR-Cas fusion protein comprising a CRISPR-Cas effect protein domain linked to a peptide tag may also be linked to a polypeptide of interest (e.g., a CRISPR-Cas effect protein domain may be linked, for example, to a peptide tag (or an affinity polypeptide) and, for example, to a polypeptide of interest.
In some embodiments, the editing system of the invention comprises a CRISPR-Cas effect protein. As used herein, a "CRISPR-Cas effector protein" is a cleavage, or nicking of a nucleic acid; binding nucleic acids (e.g., target nucleic acids and/or guide nucleic acids); and/or identifying, recognizing or binding a protein or polypeptide of a guide nucleic acid as defined herein. In some embodiments, the CRISPR-Cas effector protein may be an enzyme (e.g., nuclease, endonuclease, nickase, etc.) and/or may function as an enzyme. In some embodiments, the CRISPR-Cas effector protein refers to a CRISPR-Cas nuclease. In some embodiments, the CRISPR-Cas effector protein comprises nuclease activity and/or nickase activity, comprises a nuclease domain whose nuclease activity and/or nickase activity has been reduced or eliminated, comprises single-stranded DNA cleavage activity (ssdnase activity) or has single-stranded dnase activity that has been reduced or eliminated, and/or comprises self-processing rnase activity or has self-processing rnase activity that has been reduced or eliminated. The CRISPR-Cas effect protein can bind to a target nucleic acid. The CRISPR-Cas effect protein may be a I, II, III, IV, V or VI type CRISPR-Cas effect protein. In some embodiments, the CRISPR-Cas effector protein may be from a type I CRISPR-Cas system, a type II CRISPR-Cas system, a type III CRISPR-Cas system, a type IV CRISPR-Cas system, a type V CRISPR-Cas system, or a type VI CRISPR-Cas system. In some embodiments, a CRISPR-Cas effect protein of the invention may be from a type II CRISPR-Cas system or a type V CRISPR-Cas system. In some embodiments, the CRISPR-Cas effector protein may be a type II CRISPR-Cas effector protein, such as a Cas9 effector protein. In some embodiments, the CRISPR-Cas effector protein may be a V-type CRISPR-Cas effector protein, such as a Cas12 effector protein. In some embodiments, the CRISPR-Cas effector protein may be Cas12a and optionally may have the amino acid sequence of SEQ ID NO:50-66 and/or the amino acid sequence of any one of SEQ ID NOs: 67-69. In some embodiments, the CRISPR-Cas effector protein may be active Cas12a and optionally may have the amino acid sequence of SEQ ID NO:58, and a sequence of amino acids. In some embodiments, the CRISPR-Cas effector protein may be inactive (i.e., dead) Cas12a and optionally may have the amino acid sequence of SEQ ID NO: 50. In some embodiments, the CRISPR-Cas effector protein may be Cas12b and optionally may have the amino acid sequence of SEQ ID NO: 151.
Exemplary CRISPR-Cas effector proteins include, but are not limited to, cas9, C2C1, C2C3, cas12a (also known as Cpf 1), cas12b, cas12C, cas12d, cas12e, cas13a, cas13b, cas13C, cas13d, cas1B, cas2, cas3', cas3", cas4, cas5, cas6, cas7, cas8, cas9 (also known as Csnl and Csx 12), cas10, csyl, csy2, csy3, csel, cse2, cscl, csc2, csa5, csn2, csm3, csm4, csm5, csm6, cmrl, cmr3, cmr4, cmr5, cmr6, csbl, csb2, csb3, csxl7, csxl4, csx10, x16, csaX, csx3, csxl5, csxf, csf2, csf (Csf) and nucleic acids, optionally, wherein the CRISPR-Cas effector protein can be a Cas9, cas12a (Cpf 1), cas12b, cas12C (C2C 3), cas12d (CasY), cas12e (CasX), cas12g, cas12h, cas12i, C2C4, C2C5, C2C8, C2C9, C2C10, cas14a, cas14b, and/or Cas14C effector protein.
In some embodiments, CRISPR-Cas effector proteins useful in the present invention may comprise mutations in their nuclease active sites and/or nuclease domains (e.g., ruvC, HNH, e.g., ruvC site of Cas12a nuclease domain; e.g., ruvC site and/or HNH site of Cas9 nuclease domain). CRISPR-Cas effect proteins having mutations in their nuclease active site and/or nuclease domain and thus no longer comprising nuclease activity are often referred to as "inactive" or "dead", e.g. dCas9. In some embodiments, a CRISPR-Cas effect protein having a mutation in its nuclease active site and/or nuclease domain may have impaired or reduced activity (e.g., nickase activity) compared to the same CRISPR-Cas effect protein without the mutation.
The CRISPR Cas9 effector protein or Cas9 useful in the present invention can be any known or later identified Cas9 nuclease. In some embodiments, cas9 of the invention may be a protein from, for example, several species of Streptococcus (Streptococcus spp.) (e.g., streptococcus pyogenes, streptococcus thermophilus), lactobacillus (Lactobacillus spp.), bifidobacterium (bifidum spp.), candelas (Kandleria spp.), leuconostoc (Leuconostoc spp.), staphylococcus spp.), pediococcus (Oenococcus spp.), pediococcus spp, weissella spp, and/or us Lu Senshi. In some embodiments, the CRISPR-Cas effector protein may be Cas9 and optionally may have the amino acid sequence of SEQ ID NO:70-80 or 140-143 and/or the nucleotide sequence of any one of SEQ ID NOs: 81-82, and a sequence of any one of amino acids.
In some embodiments, the CRISPR-Cas effector protein may be Cas9 derived from Streptococcus pyogenes (Streptococcus pyogenes) and/or may recognize the PAM sequence motif NGG, NAG, NGA (Mali et al, science 2013;339 (6121): 823-826). In some embodiments, the CRISPR-Cas effector protein may be Cas9 derived from streptococcus thermophilus (Streptococcus thermophiles) and/or may recognize PAM sequence motifs NGGNG and/or nniagaaw (w=a or T) (see, e.g., horvath et al, science,2010;327 (5962): 167-170, and devau et al, J Bacteriol2008;190 (4): 1390-1400). In some embodiments, the CRISPR-Cas effector protein may be Cas9 derived from streptococcus mutans (Streptococcus mutans) and/or may recognize PAM sequence motifs NGG and/or NAAR (r=a or G) (see, e.g., devau et al, J BACTERIOL2008;190 (4): 1390-1400). In some embodiments, the CRISPR-Cas effector protein may be Cas9 derived from streptococcus aureus (Streptococcus aureus) and/or may recognize the PAM sequence motif NNGRR (r=a or G). In some embodiments, the CRISPR-Cas effector protein may be Cas9 derived from streptococcus aureus (s.aureus) and/or may recognize PAM sequence motif N GRRT (r=a or G). In some embodiments, the CRISPR-Cas effector protein may be Cas9 derived from streptococcus aureus (s.aureus) and/or may recognize the PAM sequence motif N GRRV (r=a or G). In some embodiments, the CRISPR-Cas effector protein may be Cas9 derived from neisseria meningitidis (Neisseria meningitidis) and/or may recognize PAM sequence motifs N GATT or N GCTT (r=a or G, v= A, G or C) (see, e.g., hou et al, PNAS 2013,1-6). In the foregoing embodiments of this paragraph, N in the PAM sequence motif can be any nucleotide residue, such as any of A, G, C or T. In some embodiments, the CRISPR-Cas effector protein may be Cas13 derived from ciliated bacteria (Leptotrichia shahii) and/or may recognize a single 3' a, U or C pre-spacer sequence flanking sequence (PFS) (or RNA PAM (rPAM)) sequence motif that may be located within the target nucleic acid.
The V-type CRISPR-Cas effector protein useful in embodiments of the present invention can be any V-type CRISPR-Cas nuclease. Exemplary V-type CRISPR-Cas effector proteins include, but are not limited to, cas12a (Cpf 1), cas12b, cas12C (C2C 3), cas12d (CasY), cas12e (CasX), cas12g, cas12h, cas12i, C2C1, C2C4, C2C5, C2C8, C2C9, C2C10, cas14a, cas14b, and/or Cas14C nucleases. In some embodiments, the V-type CRISPR-Cas effect protein can be Cas12a. In some embodiments, the V-type CRISPR-Cas effect protein can be a nickase, optionally a Cas12a nickase. In some embodiments, the type V CRISPR-Cas effect protein can be Cas12b (e.g., SEQ ID NO: 151).
In some embodiments, the CRISPR-Cas effector protein may be a V-type Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) -Cas nuclease. Cas12a differs from the more known type II CRISPR Cas9 nucleases in several respects. For example, cas9 recognizes a G-rich pre-spacer adjacent motif (PAM) that is located 3' (3 ' -NGG) of its guide RNA (gRNA, sgRNA, crRNA, crDNA, CRISPR array) binding site (pre-spacer, target nucleic acid, target DNA), while Cas12a recognizes a T-rich PAM (5 ' -TTN,5' -TTTN) located 5' of the target nucleic acid. In fact, the directions in which Cas9 and Cas12a bind their guide RNAs are very nearly opposite with respect to their N and C termini. Furthermore, cas12a enzymes use single guide RNAs (grnas, CRISPR arrays, crrnas), rather than double guide RNAs (sgrnas (e.g., crrnas and tracrrnas)) found in natural Cas9 systems, and Cas12a processes its own grnas. Furthermore, cas12a nuclease activity produces staggered DNA double strand breaks, rather than blunt ends produced by Cas9 nuclease activity, and Cas12a relies on a single RuvC domain to cleave both DNA strands, while Cas9 utilizes HNH and RuvC domains for cleavage.
The CRISPR Cas12a effector protein useful in the present invention may be any known or later identified Cas12a (previously referred to as Cpf 1) (see, e.g., U.S. patent No. 9,790,490, the disclosure of which is incorporated herein by reference for its Cpf1 (Cas 12 a) sequence). The term "Cas12a" refers to an RNA-guided protein that may have nuclease activity, which protein comprises a guide nucleic acid binding domain and an active, inactive or partially active DNA cleavage domain, such that the RNA-guided nuclease activity of Cas12a may be active, inactive or partially active, respectively. In some embodiments, cas12a useful in the present invention may comprise a mutation in the nuclease active site (e.g., ruvC site of Cas12a domain). Cas12a having a mutation in its nuclease domain and/or nuclease active site and thus no longer comprising nuclease activity is commonly referred to as dead Cas12a (e.g., dCas12 a). In some embodiments, cas12a having a mutation in its nuclease domain and/or nuclease active site may have impaired activity, e.g., may have reduced nickase activity.
In some embodiments, the CRISPR-Cas effect protein may be optimized for expression in an organism (e.g., in an animal (e.g., a mammal, such as a human), a plant, a fungus, an archaebacteria, or a bacterium). In some embodiments, a CRISPR-Cas effector protein (e.g., cas12a polypeptide/domain or Cas9 polypeptide/domain) can be optimized for expression in a plant.
Any deaminase domain/polypeptide useful for base editing may be used with the present invention. As used herein, "cytosine deaminase" and "cytidine deaminase" refer to a polypeptide or domain thereof that catalyzes or is capable of catalyzing the deamination of cytosine, as the polypeptide or domain catalyzes or is capable of catalyzing the removal of amine groups from cytosine bases. Thus, cytosine deaminase may result in conversion of cytosine to thymidine (via uracil intermediates), leading to C-to-T conversion or G-to-a conversion in the complementary strand in the genome. Thus, in some embodiments, a cytosine deaminase encoded by a polynucleotide of the invention produces a C.fwdarw.T conversion in the sense (e.g., "+"; template) strand of a target nucleic acid or a G.fwdarw.A conversion in the antisense (e.g., "-", complementary) strand of a target nucleic acid. In some embodiments, the cytosine deaminase encoded by a polynucleotide of the invention produces a C to T, G or a conversion in the complementary strand in the genome.
The cytosine deaminase that can be used in the present invention can be any known or later identified cytosine deaminase from any organism (see, e.g., U.S. Pat. No. 10,167,457 and Thuronyi et al Nat. Biotechnol.37:1070-1079 (2019), each of which is incorporated herein by reference for its disclosure of cytosine deaminase). Cytosine deaminase can catalyze the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. Thus, in some embodiments, a deaminase or deaminase domain useful in the present invention may be a cytidine deaminase domain that catalyzes the hydrolytic deamination of cytosine to uracil. In some embodiments, the cytosine deaminase may be a variant of a naturally occurring cytosine deaminase, including, but not limited to, a primate (e.g., human, monkey, chimpanzee, gorilla), dog, cow, rat, or mouse. Thus, in some embodiments, cytosine deaminase useful in the invention may be about 70% to about 100% identical to a wild-type cytosine deaminase (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a naturally occurring cytosine deaminase, and any range or value therein).
In some embodiments, the cytosine deaminase useful in the invention may be an apolipoprotein B mRNA-editing complex (apodec) family deaminase. In some embodiments, the cytosine deaminase may be an apodec 1 deaminase, an apodec 2 deaminase, an apodec 3A deaminase, an apodec 3B deaminase, an apodec 3C deaminase, an apodec 3D deaminase, an apodec 3F deaminase, an apodec 3G deaminase, an apodec 3H deaminase, an apodec 4 deaminase, a human activation induced deaminase (hAID), a rAPOBEC1, a FERNY, and/or CDA1, optionally pmCDA1, atCDA1 (e.g., at2G 19570), and evolutionary versions thereof. Evolved deaminases are disclosed, for example, in U.S. Pat. No. 10,113,163, gaudelli et al, nature 551 (7681): 464-471 (2017)), and Thuronyi et al (Nature Biotechnology 37:1070-1079 (2019)), the disclosures of each of which are incorporated herein by reference for their deaminases and evolved deaminases. In some embodiments, the cytosine deaminase may be a polypeptide having the amino acid sequence of SEQ ID NO:83, and an apodec 1 deaminase of amino acid sequence. In some embodiments, the cytosine deaminase may be a polypeptide having the amino acid sequence of SEQ ID NO:84, and an apodec 3A deaminase of amino acid sequence. In some embodiments, the cytosine deaminase may be a CDA1 deaminase, optionally having the amino acid sequence of SEQ ID NO:85, and a CDA1 of the amino acid sequence. In some embodiments, the cytosine deaminase may be a FERNY deaminase, optionally having the amino acid sequence of SEQ ID NO:86, and a ferriy amino acid sequence. In some embodiments, the cytosine deaminase may be a rAPOBEC1 deaminase, optionally having the amino acid sequence of SEQ ID NO:87, and rAPOBEC1 deaminase of the amino acid sequence. In some embodiments, the cytosine deaminase may be an hAID deaminase, optionally having the amino acid sequence of SEQ ID NO:88 or SEQ ID NO:89, and a fragment thereof. In some embodiments, cytosine deaminase useful in the invention may be about 70% to about 100% identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% identical) to the amino acid sequence of a naturally occurring cytosine deaminase (e.g., "evolved deaminase"), see, e.g., SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO: 92. In some embodiments, cytosine deaminase useful in the invention can hybridize to SEQ ID NO:83-92 (e.g., about 70% to about 99.5% identical (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% identical) to the amino acid sequence of any of SEQ ID NOs 83-92 (e.g., at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identical) to the amino acid sequence of any of SEQ ID NOs 83-92. In some embodiments, the polynucleotide encoding the cytosine deaminase may be codon optimized for expression in a plant, and the codon optimized polypeptide may be about 70% to 99.5% identical to the reference polynucleotide.
As used herein, "adenine deaminase" and "adenosine deaminase" refer to polypeptides or domains thereof that catalyze or are capable of catalyzing the hydrolytic deamination of adenine or adenosine (e.g., removal of an amine group from adenine). In some embodiments, the adenine deaminase may catalyze the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively. In some embodiments, the adenosine deaminase may catalyze the hydrolytic deamination of adenine or adenosine in DNA. In some embodiments, the adenine deaminase encoded by a nucleic acid construct of the present invention can produce an A.fwdarw.G transition of a sense (e.g., "+"; template) strand of a target nucleic acid or a T.fwdarw.C transition in an antisense (e.g., "-", complementary) strand of a target nucleic acid. The adenine deaminase useful in the present invention may be any known or later identified adenine deaminase from any organism (see, e.g., U.S. patent No. 10,113,163, the disclosure of which is incorporated herein by reference).
In some embodiments, the adenosine deaminase may be a variant of a naturally occurring adenine deaminase. Thus, in some embodiments, an adenosine deaminase may have about 70% to 100% identity to a wild-type adenine deaminase (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a naturally-occurring adenine deaminase, as well as any range or value therein). In some embodiments, one or more deaminase is not present in nature and may be referred to as an engineered, mutated or evolved adenosine deaminase. Thus, for example, an engineered, mutated, or evolved adenine deaminase polypeptide or adenine deaminase domain may have about 70% to 99.9% identity to a naturally occurring adenine deaminase polypeptide/domain (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identity to a naturally occurring adenine deaminase polypeptide or adenine deaminase domain, and any range or value therein). In some embodiments, the adenosine deaminase may be from a bacterium (e.g., escherichia coli, staphylococcus aureus, haemophilus influenzae, bacillus crescent, etc.). In some embodiments, polynucleotides encoding adenine deaminase polypeptides/domains may be codon optimized for expression in plants.
In some embodiments, the adenine deaminase domain may be a wild-type tRNA specific adenosine deaminase domain, such as a tRNA specific adenosine deaminase (TadA) and/or a mutated/evolved adenosine deaminase domain, such as a mutated/evolved tRNA specific adenosine deaminase domain (TadA). In some embodiments, the TadA domain may be from e. In some embodiments, a TadA can be modified, e.g., truncated, by deleting one or more N-terminal and/or C-terminal amino acids relative to the full-length TadA (e.g., potentially deleting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20N-terminal and/or C-terminal amino acid residues relative to the full-length TadA). In some embodiments, the TadA polypeptide or TadA domain does not comprise an N-terminal methionine. In some embodiments, the wild-type escherichia coli TadA comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the mutant/evolved escherichia coli TadA comprises SEQ ID NO:94-97, and a sequence of any one of amino acids. In some embodiments, the polynucleotide encoding TadA/TadA may be codon optimized for expression in a plant. In some embodiments, the adenine deaminase may comprise SEQ ID NO:98-103, or a portion or all of the amino acid sequence of any one of claims. In some embodiments, the adenine deaminase may comprise SEQ ID NO:93-103, or a portion of any one of seq id no.
In some embodiments, the nucleic acid constructs of the invention may further encode a glycosylase inhibitor (e.g., uracil Glycosylase Inhibitor (UGI), e.g., uracil-DNA glycosylase inhibitor). In some embodiments, the invention provides fusion proteins comprising an engineered protein and UGI and/or one or more polynucleotides encoding the same, optionally wherein one or more polynucleotides may be codon optimized for expression in a plant.
The "uracil glycosylase inhibitor" useful in the present invention can be any protein or polypeptide capable of inhibiting uracil-DNA glycosylase base excision repair enzymes. In some embodiments, the UGI domain comprises a wild-type UGI or fragment thereof. In some embodiments, a UGI domain for use in the invention can be about 70% to about 100% identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% identical, and any range or value therein) to the amino acid sequence of a naturally occurring UGI domain. In some embodiments, the UGI domain may comprise SEQ ID NO:104 or amino acid sequence identical to SEQ ID NO:104 (e.g., at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identical to the amino acid sequence of SEQ ID NO: 104). For example, in some embodiments, the UGI domain may comprise SEQ ID NO:104, which hybridizes to the amino acid sequence of SEQ ID NO:104 (e.g., 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 consecutive nucleotides; e.g., about 10, 15, 20, 25, 30, 35, 40, 45 to about 50, 55, 60, 65, 70, 75, 80 consecutive nucleotides). In some embodiments, the UGI domain can be a variant of a known UGI (e.g., SEQ ID NO: 104) that has about 70% to about 99.5% identity (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identity, and any range or value therein) to the known UGI. In some embodiments, the polynucleotide encoding the UGI can be codon optimized for expression in a plant (e.g., a plant), and the codon optimized polypeptide can be about 70% to about 99.5% identical to the reference polynucleotide.
The engineered proteins can be used in combination with guide nucleic acids (e.g., guide RNAs (grnas), CRISPR arrays, CRISPR RNA, crrnas) designed to function with the engineered proteins to modify target nucleic acids. The guide nucleic acid for use in the present invention may comprise at least one spacer sequence and at least one repeat sequence. The guide nucleic acid is capable of forming a complex with the engineered protein (e.g., with a nuclease domain of the engineered protein) and the spacer sequence is capable of hybridizing to the target nucleic acid, thereby directing the complex to the target nucleic acid, wherein the target nucleic acid can be modified (e.g., cleaved or edited) and/or modulated (e.g., transcription regulated) by a deaminase (e.g., cytosine deaminase and/or adenine deaminase, optionally present in and/or recruited to the complex).
In some embodiments, an engineered protein comprising a Cas9 domain (or a nucleic acid construct encoding the same) can be used in combination with a Cas9 guide nucleic acid to modify a target nucleic acid, and a deaminase (e.g., cytosine and/or adenine) can be linked to or form a complex with the engineered protein. Cytosine deaminase deaminates cytosine bases in the target nucleic acid, thereby editing the target nucleic acid. Adenine deaminase deaminates the adenosine base in the target nucleic acid, thereby editing the target nucleic acid.
Similarly, the engineered protein can comprise a Cas12a domain (or other selected CRISPR-Cas nuclease, e.g., C2C1, C2C3, cas12b, cas12C, cas12d, cas12e, cas13a, cas13b, cas13C, cas13d, cas1B, cas2, cas3', cas3", cas4, cas5, cas6, cas7, cas8, cas9 (also known as Csnl and Csx 12), cas10, csyl, csy2, csy3, csel, cse2, cscl, csc2, csa5, csn2, csm3, csm4, csm5, csm6, cmrl 3, cmr4, cmr5, cmr6, csbl, csb2, b3, csxl7, xl4, x10, csx16, csx3, csxl5, csxf) and/or a nucleic acid domain can be modified with a nucleic acid or a nucleic acid enzyme (or a nucleic acid domain of a nucleic acid of a selected or a combination thereof) to allow for the cleavage of the amino-acid domain from the Cas domain or the nucleic acid to be specifically or the nucleic acid domain.
As used herein, "guide nucleic acid," "guide RNA," "gRNA," "CRISPR RNA/DNA," "crRNA," or "crDNA" refers to a DNA comprising at least one spacer sequence and at least one repeat sequence (e.g., a repeat sequence of the V-type Cas12a CRISPR-Cas system, or a fragment or portion thereof) that is complementary to (and hybridizes to) a target DNA (e.g., a pre-spacer sequence); a repeat sequence of a type II Cas9 CRISPR-Cas system, or a fragment thereof; a repeat sequence of a type V C2C1CRISPR Cas system, or a fragment thereof, e.g., a repeat sequence of C2C3, cas12a (also known as Cpf 1), cas12b, cas12C, cas12d, cas12e, cas13a, cas13b, cas13C, cas13d, casl, cas1B, cas2, cas3', cas3", cas4, cas5, cas6, cas7, cas8, cas9 (also known as Csnl and Csx 12), cas10, csyl, csy2, csy3, csel, cse2, cscl, csc2, csa5, csn2, csm3, csm4, csm5, csm6, cmrl, cmr3, cmr4, cmr5, cmr6, csbl, csb2, csb3, csxl7, csxl4, csx10, x16, ax, csx3, csxl5, csxl, csf2, csf, and/or a fragment thereof, may be attached to the end of the Cas system, or a repeat sequence thereof. In some embodiments, the guide nucleic acid comprises DNA. In some embodiments, the guide nucleic acid comprises RNA (e.g., is a guide RNA). The design of the grnas of the invention can be based on type I, type II, type III, type IV, type V, or type VI CRISPR-Cas systems.
In some embodiments, cas12a gRNA from 5 'to 3' can comprise a repeat sequence (full length or a portion thereof ("handle"); e.g., a pseudo-junction like structure) and a spacer sequence.
In some embodiments, the guide nucleic acid can comprise more than one repeat-spacer sequence (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more repeat-spacer sequences) (e.g., a repeat-spacer-repeat sequence, e.g., a repeat-spacer-repeat-spacer, etc.). The guide nucleic acids of the invention are synthetic, artificial and do not exist in nature. grnas can be long and can be used as aptamers (as in MS2 recruitment strategies) or other RNA structures that are suspended on spacers.
As used herein, "repeat sequence" refers to, for example, any repeat sequence of a wild-type CRISPR Cas locus (e.g., cas9 locus, cas12a locus, C2C1 locus, etc.) or a repeat sequence of a synthetic crRNA that functions with a CRISPR-Cas effector protein encoded by a nucleic acid construct of the invention. The repeat sequence useful in the present invention can be any known or later identified repeat sequence of a CRISPR-Cas locus (e.g., type I, type II, type III, type IV, type V, or type VI), or it can be a synthetic repeat sequence designed to function in a type I, type II, type III, type IV, type V, or type VI CRISPR-Cas system. The repeat sequence may comprise a hairpin structure and/or a stem loop structure. In some embodiments, the repeated sequence may form a pseudo-junction-like structure (i.e., a "handle") at its 5' end. Thus, in some embodiments, the repeat sequence may be identical or substantially identical to a repeat sequence from a wild-type I CRISPR-Cas locus, type II, CRISPR-Cas locus, type III, CRISPR-Cas locus, type IV CRISPR-Cas locus, type V CRISPR-Cas locus, and/or type VI CRISPR-Cas locus. The repeat sequence from the wild-type CRISPR-Cas locus can be determined by established algorithms, for example using a CRISPR finder provided by CRISPRdb (see Grissa et al, nucleic Acids res.35 (Web Server issue): W52-7). In some embodiments, the repeat sequence or portion thereof is linked at its 3 'end to the 5' end of the spacer sequence, thereby forming a repeat sequence-spacer sequence (e.g., guide nucleic acid, guide RNA/DNA, crRNA, crDNA).
In some embodiments, the repeat sequence comprises, consists essentially of, or consists of at least 10 nucleotides, depending on whether the particular repeat sequence and the guide nucleic acid comprising the repeat sequence are processed or unprocessed (e.g., about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 to 100 or more nucleotides, or any range or value therein; e.g., about). In some embodiments, the repeat sequence comprises, consists essentially of, or consists of about 10 to about 20, about 10 to about 30, about 10 to about 45, about 10 to about 50, about 15 to about 30, about 15 to about 40, about 15 to about 45, about 15 to about 50, about 20 to about 30, about 20 to about 40, about 20 to about 50, about 30 to about 40, about 40 to about 80, about 50 to about 100, or more nucleotides.
The repeat sequence linked to the 5' end of the spacer sequence may comprise a portion of the repeat sequence (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more consecutive nucleotides of the wild-type repeat sequence). In some embodiments, a portion of the repeat sequence linked to the 5 'end of the spacer sequence can be about 5 to about 10 contiguous nucleotides (e.g., about 5, 6, 7, 8, 9, 10 nucleotides) in length and have at least 90% sequence identity (e.g., at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the same region (e.g., the 5' end) of the wild-type CRISPR Cas repeat nucleotide sequence. In some embodiments, a portion of the repeat sequence may comprise a pseudo-junction-like structure (e.g., a "handle") at its 5' end.
As used herein, a "spacer sequence" is a nucleotide sequence that is complementary to a target nucleic acid (e.g., target DNA) (e.g., a pre-spacer). The spacer sequence can be fully complementary or substantially complementary (e.g., at least about 70% complementary (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more)) to the target nucleic acid. Thus, in some embodiments, the spacer sequence can have one, two, three, four, or five mismatches, which can be contiguous or non-contiguous, as compared to the target nucleic acid. In some embodiments, the spacer sequence can have 70% complementarity to the target nucleic acid. In other embodiments, the spacer nucleotide sequence may have 80% complementarity to the target nucleic acid. In other embodiments, the spacer nucleotide sequence can have 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% complementarity, etc. to the target nucleic acid (pre-spacer). In some embodiments, the spacer sequence is 100% complementary to the target nucleic acid. The spacer sequence can have a length of about 15 nucleotides to about 30 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides or any range or value therein). Thus, in some embodiments, a spacer sequence can have complete complementarity or substantial complementarity over a region of a target nucleic acid (e.g., a pre-spacer) that is at least about 15 nucleotides to about 30 nucleotides in length. In some embodiments, the spacer is about 20 nucleotides in length. In some embodiments, the spacer is about 21, 22, or 23 nucleotides in length.
In some embodiments, the 5 'region of the spacer sequence of the guide nucleic acid can be fully complementary to the target nucleic acid while the 3' region of the spacer can be substantially complementary to the target nucleic acid (e.g., for the spacer in a V-type CRISPR-Cas system), or the 3 'region of the spacer sequence of the guide nucleic acid can be fully complementary to the target nucleic acid while the 5' region of the spacer can be substantially complementary to the target nucleic acid (e.g., for the spacer in a II-type CRISPR-Cas system), thus the overall complementarity of the spacer sequence to the target nucleic acid may be less than 100%. Thus, for example, in a guide nucleic acid of a V-type CRISPR-Cas system, the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides (i.e., the seed region) in the 5 'region of a spacer sequence of, for example, 20 nucleotides can be 100% complementary to a target nucleic acid, while the remaining nucleotides in the 3' region of the spacer sequence are substantially complementary (e.g., at least about 70% complementary) to the target nucleic acid. In some embodiments, the first 1 to 8 nucleotides (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8 nucleotides and any range therein) of the 5 'end of the spacer sequence can be 100% complementary to the target nucleic acid, while the remaining nucleotides of the 3' region of the spacer sequence are substantially complementary (e.g., at least about 50% complementary (e.g., 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more)) to the target nucleic acid.
As a further example, in a guide nucleic acid of a type II CRISPR-Cas system, the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides (i.e., the seed region) in the 3 'region of a spacer sequence of, for example, 20 nucleotides can be 100% complementary to a target nucleic acid, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary (e.g., at least about 70% complementary) to the target nucleic acid. In some embodiments, the first 1 to 10 nucleotides (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides, and any range therein) of the 3 'end of the spacer sequence can be 100% complementary to the target nucleic acid, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary (e.g., at least about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more or any range or value therein)) to the target nucleic acid. The recruitment guide RNA also comprises one or more recruitment motifs described herein, which may be linked to the 5 'or 3' end of the guide, or which may be inserted into the recruitment guide nucleic acid (e.g., within the hairpin loop)).
In some embodiments, the seed region of the spacer may be about 8 to about 10 nucleotides, about 5 to about 6 nucleotides, or about 6 nucleotides in length.
"target nucleic acid," "target DNA," "target nucleotide sequence," "target region," and "target region in a genome" are used interchangeably herein and refer to a region of an organism (e.g., a plant) genome that comprises a sequence that is fully complementary (100% complementary) or substantially complementary (e.g., at least 70% complementary (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more)) to a spacer sequence in a guide nucleic acid defined herein. The target nucleic acid is targeted by the editing system (or components thereof) as described herein. The target region useful for a CRISPR-Cas system can be in close proximity to 3 '(e.g., a V-type CRISPR-Cas system) or 5' (e.g., a type II CRISPR-Cas system) of a PAM sequence in an organism genome (e.g., a plant genome or a mammalian (e.g., human) genome). The target region may be selected from any region of at least 15 contiguous nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides, etc.) immediately adjacent to the PAM sequence.
As used herein, "pre-spacer sequence" or "pre-spacer" refers to a sequence that is fully or substantially complementary (and can hybridize) to a spacer sequence of a guide nucleic acid. In some embodiments, the pre-spacer is all or a portion of a target nucleic acid as defined herein that is fully or substantially complementary (and can hybridize) to a spacer sequence of a CRISPR repeat-spacer sequence (e.g., a guide nucleic acid, a CRISPR array, a crRNA).
In the case of V-type CRISPR-Cas (e.g., cas12 a) systems and II-type CRISPR-Cas (Cas 9) systems, the pre-spacer sequence flanks (e.g., is immediately adjacent to) the pre-spacer adjacent motif (PAM). For type IV CRISPR-Cas systems, PAM is located at the 5 'end of the non-target strand and the 3' end of the target strand (see below for example).
In the case of a type II CRISPR-Cas (e.g., cas 9) system, the PAM is immediately 3' of the target region. PAM of the type I CRISPR-Cas system is located 5' of the target strand. There is no known PAM for a type III CRISPR-Cas system. Makarova et al describe the nomenclature of all categories, types and sub-types of CRISPR systems (Nature Reviews Microbiology13:722-736 (2015)). The guide structure and PAM are described by R.Barrangou (Genome biol.16:247 (2015)).
Typical Cas12a PAM is T-rich. In some embodiments, a typical Cas12 aam sequence may be 5' -TTN, 5' -TTTN, or 5' -TTTV. In some embodiments, a typical Cas9 (e.g., streptococcus pyogenes) PAM may be 5'-NGG-3'. In some embodiments, atypical PAM may be used, but may be less efficient.
Additional PAM sequences can be determined by one skilled in the art through established experimentation and calculation methods. Thus, for example, experimental methods include targeting sequences flanking all possible nucleotide sequences and identifying sequence members that do not undergo targeting, such as by transformation of the target plasmid DNA (Esvelt et al 2013.Nat.Methods 10:1116-1121; jiang et al 2013.Nat. Biotechnol. 31:233-239). In some aspects, the computational method may include BLAST searches of the natural spacers to identify the original target DNA sequence in the phage or plasmid, and alignment of these sequences to determine conserved sequences adjacent to the target sequence (Briner and Barrangou.2014.appl.environ.Microbiol.80:994-1001; mojica et al 2009.Microbiology 155:733-740).
In some embodiments, the invention provides expression cassettes and/or vectors comprising the nucleic acid constructs of the invention (e.g., one or more components of the editing systems of the invention). In some embodiments, expression cassettes and/or vectors comprising the nucleic acid constructs and/or one or more guide nucleic acids of the invention may be provided. In some embodiments, the nucleic acid constructs of the invention encode an engineered protein and/or deaminase, and each may be contained on the same or separate expression cassette or vector as the expression cassette or vector comprising the one or more guide nucleic acids. When the nucleic acid construct encoding a component of the engineered protein or editing system is contained on an expression cassette or vector separate from the expression cassette or vector containing the guide nucleic acid, the target nucleic acid may be contacted with the expression cassette or vector encoding the component of the engineered protein or editing system in any order with each other (e.g., provided together) and with the guide nucleic acid, e.g., before, simultaneously with, or after providing the expression cassette containing the guide nucleic acid (e.g., contacting with the target nucleic acid).
Methods of recruiting one or more components of an editing system to each other and/or to a target nucleic acid are known in the art and may include the use of peptide tags or affinity polypeptides that interact with peptide tags. In some embodiments, the guide nucleic acid can be linked to an RNA recruitment motif, and the deaminase can be linked to an affinity polypeptide capable of interacting with the RNA recruitment motif, thereby recruiting the deaminase to the target nucleic acid. Alternatively, chemical interactions can be used to recruit polypeptides (e.g., deaminase) to a target nucleic acid.
Peptide tags (e.g., epitopes) useful in the present invention may include, but are not limited to, GCN4 peptide tags (e.g., sun-Tag), c-Myc affinity tags, HA affinity tags, his affinity tags, S affinity tags, methionine-His affinity tags, RGD-His affinity tags, FLAG octapeptide, strep tags or strep Tag II, V5 tags, and/or VSV-G epitopes. Any epitope that can be linked to a polypeptide and that exists in a corresponding affinity polypeptide that can be linked to another polypeptide can be used in the present invention as a peptide tag. In some embodiments, the peptide tag may comprise 1 or 2 or more copies of the peptide tag (e.g., repeat unit, multimerization epitope (e.g., tandem repeat)) (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more repeat units). In some embodiments, the affinity polypeptide that interacts/binds to the peptide tag may be an antibody. In some embodiments, the antibody may be an scFv antibody. In some embodiments, the affinity polypeptide that binds to the peptide tag may be synthetic (e.g., evolved for affinity interactions), including, but not limited to, affibody, anticalin, monobody and/or DARPin (see, e.g., sha et al, protein sci.26 (5): 910-924 (2017)); gilbreth (Curr Opin Struc Biol (4): 413-420 (2013)), U.S. patent No. 9,982,053, each of which is incorporated herein by reference in its entirety for the teachings of affibody, anticalin, monobody and/or DARPin.
In some embodiments, the leader nucleic acid can be linked to an RNA recruitment motif, and the polypeptide to be recruited (e.g., deaminase) can be fused to an affinity polypeptide that binds to the RNA recruitment motif, wherein the leader binds to the target nucleic acid and the RNA recruitment motif binds to the affinity polypeptide, thereby recruiting the polypeptide to the leader and contacting the target nucleic acid with the polypeptide (e.g., deaminase). In some embodiments, two or more polypeptides may be recruited to a guide nucleic acid, thereby contacting a target nucleic acid with two or more polypeptides (e.g., deaminase).
In some embodiments of the invention, the guide RNA may be linked to one or two or more RNA recruitment motifs (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more motifs; e.g., at least 10 to about 25 motifs), optionally wherein the two or more RNA recruitment motifs may be the same RNA recruitment motif or different RNA recruitment motifs. In some embodiments, the RNA recruitment motif and corresponding affinity polypeptide may include, but are not limited to, a telomerase Ku binding motif (e.g., ku binding hairpin) and corresponding affinity polypeptide Ku (e.g., ku heterodimer), a telomerase Sm7 binding motif and corresponding affinity polypeptide Sm7, MS2 phage operon stem loop and corresponding affinity polypeptide MS2 coat protein (MCP), PP7 phage operon stem loop and corresponding affinity polypeptide PP7 coat protein (PCP), sfMu phage Com stem loop and corresponding affinity polypeptide Com RNA binding protein, PUF Binding Site (PBS) and affinity polypeptide pumiio/fem-3 mRNA binding factor (PUF), and/or synthetic RNA-aptamers and aptamer ligands as corresponding affinity polypeptides. In some embodiments, the RNA recruitment motif and corresponding affinity polypeptide may be the MS2 phage operon stem loop and the affinity polypeptide MS2 coat protein (MCP). In some embodiments, the RNA recruitment motif and corresponding affinity polypeptide may be a PUF Binding Site (PBS) and an affinity polypeptide Pumilio/fem-3mRNA binding factor (PUF). Exemplary RNA recruitment motifs and corresponding affinity polypeptides useful in the invention may include, but are not limited to, SEQ ID NO:108-118.
In some embodiments, the components used to recruit polypeptides and nucleic acids may be those that act through chemical interactions, which may include, but are not limited to, rapamycin-induced dimerization of FRB-FKBP; biotin-streptavidin; SNAP tags; halo tags; a CLIP tag; compound-induced DmrA-DmrC heterodimers; bifunctional ligands (e.g., a fusion of two protein binding chemicals together; e.g., dihydrofolate reductase (DHFR).
In some embodiments, a nucleic acid construct, expression cassette or vector of the invention optimized for expression in a plant may be about 70% to 100% identical (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100%) to a nucleic acid construct, expression cassette or vector comprising the same polynucleotide that is not codon optimized for expression in a plant.
As described herein, a "peptide tag" may be used to recruit one or more polypeptides. The peptide tag may be any polypeptide capable of being bound by a corresponding affinity polypeptide. Peptide tags may also be referred to as "epitopes," when provided in multiple copies, as "multimerization epitopes. Exemplary peptide tags may include, but are not limited to, GCN4 peptide tags (e.g., sun-Tag), c-Myc affinity tags, HA affinity tags, his affinity tags, S affinity tags, methionine-His affinity tags, RGD-His affinity tags, FLAG octapeptide, strep Tag or strep Tag II, V5 tags, and/or VSV-G epitopes. In some embodiments, the peptide tag may also include a phosphorylated tyrosine in the context of a specific sequence recognized by the SH2 domain, a characteristic consensus sequence comprising phosphoserine recognized by the 14-3-3 protein, a proline-rich peptide motif recognized by the SH3 domain, a PDZ protein interaction domain or PDZ signal sequence, and an AGO hook motif from a plant. Peptide tags are disclosed in WO2018/136783 and U.S. patent application publication No. 2017/0219596, the disclosures of which are incorporated herein by reference. Peptide tags useful in the present invention may include, but are not limited to, SEQ ID NO:119 and SEQ ID NO:120. affinity polypeptides for use with peptide tags include, but are not limited to, SEQ ID NO:121.
The peptide tag may comprise or be present in one copy or 2 or more copies of the peptide tag (e.g., a multimeric peptide tag or multimeric epitope) (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 9, 20, 21, 22, 23, 24, or 25 or more peptide tags). When multimerized, the peptide tags may be directly fused to each other or they may be linked to each other via one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids, optionally about 3 to about 10, about 4 to about 10, about 5 to about 15, or about 5 to about 20 amino acids, etc., and any value or range therein). Thus, in some embodiments, a CRISPR-Cas effect protein of the invention may comprise a CRISPR-Cas effect protein domain fused to one peptide tag or two or more peptide tags, optionally wherein two or more peptide tags are fused to each other via one or more amino acid residues. In some embodiments, the peptide tag useful in the present invention can be a single copy of a GCN4 peptide tag or epitope, or can be a multimerized GCN4 epitope comprising about 2 to about 25 or more copies of the peptide tag (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more copies of the GCN4 epitope or any range therein).
In some embodiments, the peptide tag can be fused to a CRISPR-Cas polypeptide or domain. In some embodiments, the peptide tag can be fused or linked to the C-terminus of the CRISPR-Cas effect protein to form a CRISPR-Cas fusion protein. In some embodiments, the peptide tag can be fused or linked to the N-terminus of the CRISPR-Cas effect protein to form a CRISPR-Cas fusion protein. In some embodiments, the peptide tag can be fused within the CRISPR-Cas effect protein (e.g., the peptide tag can be in a loop region of the CRISPR-Cas effect protein). In some embodiments, the peptide tag may be fused to a cytosine deaminase and/or an adenine deaminase.
An "affinity polypeptide" (e.g., a "recruitment polypeptide") refers to any polypeptide that is capable of binding to its corresponding peptide tag, or RNA recruitment motif. The peptide-tagged affinity polypeptide may be, for example, an antibody and/or a single chain antibody, each of which specifically binds to the peptide tag. In some embodiments, the peptide-tagged antibody may be, but is not limited to, an scFv antibody. In some embodiments, the affinity polypeptide can be fused or linked to the N-terminus of a deaminase (e.g., cytosine deaminase or adenine deaminase). In some embodiments, the affinity polypeptide is stable under reducing conditions of the cell or cell extract.
As described herein, the nucleic acid constructs and/or guide nucleic acids of the invention may be contained in one or more expression cassettes. In some embodiments, the nucleic acid constructs of the invention may be contained in the same or separate expression cassette or vector as the expression cassette or vector comprising the guide nucleic acid and/or the recruitment guide nucleic acid.
When used in combination with a guide nucleic acid and a recruiting guide nucleic acid, the nucleic acid constructs (as well as expression cassettes and vectors comprising the same) of the invention may be used to modify a target nucleic acid and/or its expression. The target nucleic acid may be contacted with the nucleic acid construct of the invention and/or the expression cassette and/or vector comprising the same, either before, simultaneously with, or after contacting the target nucleic acid with the guide nucleic acid/recruitment guide nucleic acid (and/or the expression cassette and vector comprising the same).
According to an embodiment of the present invention, an engineered protein is provided. As used herein, an "engineered protein" refers to a polypeptide comprising a polypeptide from a CRISPR-Cas effect protein (i.e., a CRISPR-Cas effect polypeptide) and a polypeptide heterologous to the CRISPR-Cas effect polypeptide (i.e., a heterologous polypeptide). Polypeptides from a CRISPR-Cas effect protein are referred to herein as "CRISPR-Cas effect polypeptides" that are part of a CRISPR-Cas effect protein. Thus, as used herein, a "CRISPR-Cas effect polypeptide" does not include all CRISPR-Cas effect proteins and therefore has a reduced number of amino acids compared to the number of amino acids of a CRISPR-Cas effect protein. In some embodiments, the CRISPR-Cas effect polypeptide lacks a nuclease domain (e.g., lacks a RuvC domain). A polypeptide heterologous to a CRISPR-Cas effect polypeptide is referred to herein as a heterologous polypeptide. The heterologous polypeptide may be a polypeptide of interest as described herein. In some embodiments, the engineered protein comprises all or a portion of a deaminase domain (e.g., cytosine deaminase and/or adenine deaminase), which can be linked to any portion of the engineered protein. For example, in some embodiments, all or a portion of the deaminase domain is linked to the N-or C-terminus of a CRISPR-Cas effect polypeptide and/or to the N-or C-terminus of an engineered protein. In some embodiments, all or a portion of the deaminase domain is located between two portions of an engineered protein. The engineered protein may cleave, or nick a nucleic acid; binding nucleic acids (e.g., target nucleic acids and/or guide nucleic acids); and/or identifying, recognizing or binding a guide nucleic acid as defined herein. In some embodiments, the engineered protein or portion thereof may be an enzyme (e.g., nuclease, endonuclease, nickase, etc.) and/or may function as an enzyme. In some embodiments, the engineered protein of the invention is an RNA-guided DNA binding protein. In some embodiments, the engineered protein is present in and/or forms a complex with a guide nucleic acid that is a single guide nucleic acid (e.g., a gRNA, a CRISPR array, and/or a crRNA), optionally wherein the guide nucleic acid is a single crRNA. In some embodiments, the complex comprises an engineered protein and a guide nucleic acid, and the guide nucleic acid and/or the complex consists of a single guide nucleic acid (e.g., a single crRNA). In some embodiments, the engineered protein binds to a single guide nucleic acid (e.g., a single crRNA), recognizes and/or binds to a target nucleic acid, and has nuclease activity, optionally wherein the engineered protein cleaves a target strand of the target nucleic acid.
In some embodiments, the engineered protein comprises a first CRISPR-Cas effect polypeptide and a heterologous polypeptide. The first CRISPR-Cas effect polypeptide may be free of nuclease domains, optionally free of RuvC domains. The heterologous polypeptide can be linked to the N-or C-terminus of the first CRISPR-Cas effect polypeptide, optionally with or without a linker (e.g., a peptide linker). In some embodiments, the first CRISPR-Cas effect polypeptide is part of a first CRISPR-Cas effect protein (e.g., part of a V-type CRISPR-Cas effect protein, e.g., part of Cas12 a). In some embodiments, the heterologous polypeptide comprises a nuclease domain, optionally comprising a HNH domain (e.g., the HNH domain comprises a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of one or more of SEQ ID NOs: 1 or 169-174). In some embodiments, the heterologous polypeptide comprises a HNH domain from a CRISPR-Cas effect protein and/or comprises a sequence identical to SEQ ID NO:1 or 172, has a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some embodiments, the heterologous polypeptide comprises a HNH domain that is not from a CRISPR-Cas effect protein and/or comprises a sequence that hybridizes to SEQ ID NO:169-171 or 173-174 has a sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some embodiments, the heterologous polypeptide is a polypeptide from a CRISPR-Cas effect protein, optionally, wherein the heterologous polypeptide is from a type of CRISPR-Cas effect protein (e.g., a type II CRISPR-Cas effect protein) that is different from the type of first CRISPR-Cas effect protein of which the first CRISPR-Cas effect polypeptide is a part (e.g., a type IV CRISPR-Cas effect protein).
In some embodiments, the engineered protein comprises a first CRISPR-Cas effect polypeptide, a heterologous polypeptide, and a second CRISPR-Cas effect polypeptide, which may be linked together in any order. In some embodiments, the first CRISPR-Cas effect polypeptide may be devoid of RuvC domains. The heterologous polypeptide can be linked to the N-or C-terminus of the first CRISPR-Cas effect polypeptide, optionally with or without a linker (e.g., a peptide linker), and/or the heterologous polypeptide can be linked to the N-or C-terminus of the second CRISPR-Cas effect polypeptide, optionally with or without a linker (e.g., a peptide linker). In some embodiments, the heterologous polypeptide is located between the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide. In some embodiments, the first CRISPR-Cas effect polypeptide is part of a first CRISPR-Cas effect protein (e.g., part of a V-type CRISPR-Cas effect protein, such as part of Cas12 a) and the second CRISPR-Cas effect polypeptide is part of a second CRISPR-Cas effect protein (e.g., part of a V-type CRISPR-Cas effect protein, such as part of Cas12 a), wherein the first CRISPR-Cas effect protein and the second CRISPR-Cas effect protein may be the same protein or different proteins. In some embodiments, the first CRISPR-Cas effect protein and the second CRISPR-Cas effect protein are the same, and thus the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are portions from the same protein, but may be different portions of the CRISPR-Cas effect protein. The first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide may have different sequences. In some embodiments, the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide may comprise the same sequence. In some embodiments, the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide together provide the complete sequence of the CRISPR-Cas effect protein. In some embodiments, the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide together do not constitute the complete sequence of the CRISPR-Cas effect protein (i.e., a portion of the CRISPR-Cas effect protein sequence is not present in both sequences of the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide); for example, 1 or 5 to 10, 15, 20, 25, 30 or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more amino acids) of the CRISPR-Cas effect protein may not be present in the sequences of the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide. In some embodiments, the heterologous polypeptide comprises a nuclease domain, optionally comprising an HNH domain (e.g., HNH domain from a type II CRISPR-Cas effect protein). In some embodiments, the heterologous polypeptide comprises a HNH domain that is not from a CRISPR-Cas effect protein. In some embodiments, the heterologous polypeptide is a polypeptide from a CRISPR-Cas effect protein, optionally, wherein the heterologous polypeptide is from a type of CRISPR-Cas effect protein (e.g., a type II CRISPR-Cas effect protein) that is different from the type of first CRISPR-Cas effect protein of which the first CRISPR-Cas effect polypeptide is a part and/or the type of second CRISPR-Cas effect protein of which the second CRISPR-Cas effect polypeptide is a part. In some embodiments, the heterologous polypeptide is from a type II CRISPR-Cas effect protein (e.g., is a portion of a type II CRISPR-Cas effect protein (e.g., HNH domain or portion thereof)), the first CRISPR-Cas effect polypeptide is a portion of a type IV CRISPR-Cas effect protein, the second CRISPR-Cas effect polypeptide is a portion of a type IV CRISPR-Cas effect protein, wherein the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are different. In some embodiments, the heterologous polypeptide is heterologous to one of the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide. In some embodiments, the heterologous polypeptide is heterologous to both the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide.
As used herein, a "heterologous polypeptide" refers to a polypeptide that does not occur naturally as compared to the CRISPR-Cas effect polypeptide of the engineered protein. Thus, a heterologous polypeptide of an engineered protein is not found in nature in at least one CRISPR-Cas effect polypeptide of the engineered protein, and thus the heterologous polypeptide is non-naturally occurring relative to the at least one CRISPR-Cas effect polypeptide. For example, an engineered protein of the invention includes a CRISPR-Cas effect polypeptide that is part of a CRISPR-Cas effect protein, and the engineered protein includes a heterologous polypeptide, and the heterologous polypeptide is non-naturally occurring as compared to a CRISPR-Cas effect polypeptide that does not have the heterologous polypeptide and the CRISPR-Cas effect polypeptide (e.g., the CRISPR-Cas effect polypeptide does not have the heterologous polypeptide and the CRISPR-Cas effect polypeptide or precedes the CRISPR-Cas effect polypeptide that includes (e.g., is inserted or fused); in some embodiments, the CRISPR-Cas effect protein of which the heterologous polypeptide is part is heterologous to the CRISPR-Cas effect polypeptide. In some embodiments, the engineered protein comprises a heterologous polypeptide, a first CRISPR-Cas effect polypeptide that is part of a first CRISPR-Cas effect protein, and a second CRISPR-Cas effect polypeptide that is part of a second CRISPR-Cas effect protein, and the heterologous polypeptide does not naturally occur (i.e., is heterologous) in the first CRISPR-Cas effect polypeptide, the first CRISPR-Cas effect protein, the second CRISPR-Cas effect protein, and the second CRISPR-Cas effect protein. Similarly, the nucleotide sequence encoding the heterologous polypeptide is heterologous (i.e., non-naturally occurring as compared to) to the nucleotide sequence encoding the CRISPR-Cas effect polypeptide of the engineered protein.
In some embodiments, the heterologous polypeptide comprises a polypeptide or domain from a different type of protein than the CRISPR-Cas effect polypeptide of the engineered protein. In some embodiments, the engineered proteins comprise one or more (e.g., 1, 2, 3, or more) portions (i.e., one or more CRISPR-Cas effect polypeptides therefrom) of a type V CRISPR-Cas effect protein (e.g., cas12 a) and one or more (e.g., 1, 2, 3, or more) polypeptides from a different type of CRISPR-Cas effect protein (e.g., type II CRISPR-Cas effect protein). When two or more portions or polypeptides are from the same protein and are each present in an engineered protein, the two or more portions or polypeptides may be separated from each other in the engineered protein by a linker and/or a heterologous polypeptide (i.e., the two or more portions or polypeptides may not be directly linked) or may be in a different order than the order in which they are derived from the protein (e.g., wild-type protein and/or CRISPR-Cas effect protein). In some embodiments, the engineered protein comprises one or more (e.g., 1, 2, 3, or more) portions (i.e., one or more CRISPR-Cas effect polypeptides therefrom) of a type V CRISPR-Cas effect protein (e.g., cas12 a) and at least one polypeptide from a type II CRISPR-Cas effect protein (e.g., cas 9) and/or at least a portion of a type II CRISPR-Cas effect protein. In some embodiments, the engineered protein comprises a first CRISPR-Cas effect polypeptide that is part of a type V CRISPR-Cas effect protein (e.g., cas12 a) and a heterologous polypeptide from a type II CRISPR-Cas effect protein (e.g., cas 9). In some embodiments, the engineered protein comprises a first CRISPR-Cas effect polypeptide that is part of a V-type CRISPR-Cas effect protein (e.g., cas12 a), a heterologous polypeptide from a type II CRISPR-Cas effect protein (e.g., cas 9), and a second CRISPR-Cas effect polypeptide that is part of a V-type CRISPR-Cas effect protein (e.g., cas12 a), optionally, wherein the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are different parts from the same V-type CRISPR-Cas effect protein (e.g., cas12 a). In some embodiments, the engineered protein comprises a first CRISPR-Cas effect polypeptide that is part of a V-type CRISPR-Cas effect protein (e.g., cas12 a), a heterologous polypeptide comprising a HNH domain or a portion thereof, and a second CRISPR-Cas effect polypeptide that is part of a V-type CRISPR-Cas effect protein (e.g., cas12 a), optionally wherein the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are different portions from the same V-type CRISPR-Cas effect protein (e.g., cas12 a).
In some embodiments, the engineered protein comprises one or more (e.g., 1, 2, 3, or more) domains or portions thereof from a type V CRISPR-Cas effect protein (e.g., cas12 a), and one or more (e.g., 1, 2, 3, or more) domains or portions thereof from a different type of CRISPR-Cas effect protein, such as a type II CRISPR-Cas effect protein. In some embodiments, the engineered protein comprises one or more (e.g., 1, 2, 3, or more) domains or portions thereof from a type V CRISPR-Cas effect protein (e.g., cas12 a), and at least one domain or portion thereof from a type II CRISPR-Cas effect protein (e.g., cas 9). In some embodiments, the heterologous polypeptide of the engineered protein does not interfere with or adversely affect the activity of the CRISPR-Cas effect polypeptide and/or one or more domains of the CRISPR-Cas effect polypeptide (e.g., ruvC domains).
The heterologous polypeptide may be about 10 to about 300 amino acids in length, for example about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acids to about 110, 125, 150, 175, 200, 225, 250, 275, or 300 amino acids. In some embodiments, the heterologous polypeptide is about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 amino acids in length. In some embodiments, the heterologous polypeptide has a length of about 120, 125, 130, 135, or 140 amino acids to about 145, 150, 155, or 160 amino acids. In some embodiments, the heterologous polypeptide is 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, or 160 amino acids in length. In some embodiments, the heterologous polypeptide is located between the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide, and the heterologous polypeptide is heterologous to one or both of the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide.
In some embodiments, the CRISPR-Cas effect polypeptide is about 100, 150, 200, or 250 amino acids to about 300, 350, or 400 amino acids in length. In some embodiments, the CRISPR-Cas effect polypeptide is about 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, or 400 amino acids in length. In some embodiments, the CRISPR-Cas effect polypeptide is about 800, 850, or 900 amino acids to about 950, 1,000, 1,050, or 1,100 amino acids in length. In some embodiments, the CRISPR-Cas effect polypeptide is about 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1,000, 1,010, 1,020, 1,030, 1,040, 1,050, 1,060, 1,070, 1,080, 1,090, 1,100 amino acids in length. In some embodiments, the engineered protein comprises a first CRISPR-Cas effect polypeptide of about 100, 150, 200, or 250 amino acids to about 300, 350, or 400 amino acids in length, a heterologous polypeptide of about 10, 50, 100, or 140 amino acids to about 160, 200, 250, or 300 amino acids in length; and a second CRISPR-Cas effect polypeptide of about 100, 200, 300, 400, 500, 600, 700, 800, 850, or 900 amino acids to about 950, 1,000, 1,050, or 1,100 amino acids in length.
In some embodiments, the heterologous polypeptide comprises a nuclease domain or portion thereof, which may be referred to herein as a "heterologous nuclease domain or portion thereof" in that the nuclease domain or portion thereof from the heterologous polypeptide is heterologous to one or more CRISPR-Cas effect polypeptides present in the engineered protein. The heterologous polypeptide may be a DNA nuclease domain or a portion thereof. In some embodiments, the heterologous nuclease domain or portion thereof is from a CRISPR-Cas effector protein. In some embodiments, the heterologous nuclease domain or portion thereof is not from a CRISPR-Cas effector protein. In some embodiments, the heterologous nuclease domain or portion thereof is from a bacterial protein, optionally wherein the heterologous nuclease domain or portion thereof is from a restriction endonuclease, homing endonuclease, colicin, sepsis protein, reverse transcriptase, dnase and/or an independent HNH domain. In some embodiments, the engineered protein comprises a heterologous polypeptide comprising a nuclease domain or portion thereof (i.e., a heterologous nuclease domain or portion thereof), and the engineered protein is a nuclease that optionally cleaves a target strand of a target nucleic acid and/or a non-target strand of a target nucleic acid. In some embodiments, the engineered protein cleaves the target strand of the target nucleic acid and the non-target strand of the target nucleic acid and provides blunt-ended double-strand breaks of the target nucleic acid or staggered double-strand breaks of the target nucleic acid. In some embodiments, the engineered protein cleaves a target strand of the target nucleic acid and a non-target strand of the target nucleic acid, and the distance (e.g., the number of nucleotides) between the cleavage sites is 0, 1, 2, 3, 4, or 5 nucleotides to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides.
In some embodiments, the heterologous nuclease domain or portion thereof can be a target strand nickase domain or portion thereof. As used herein, a "target strand nicking enzyme domain or portion thereof" refers to a polypeptide that has nicking enzyme activity on the target strand of a target nucleic acid when the domain or portion thereof is in its native protein. That is, a target strand nickase domain or portion thereof can or is capable of nicking (e.g., cutting or cleaving) a target strand (also referred to as a sense (e.g., a "+"; template) strand) of a target nucleic acid when the domain or portion thereof is in its native protein. For example, the HNH domain of Cas9 nicks and/or has nickase activity to the target strand of a target nucleic acid. As used herein, "nicking enzyme activity" refers to single strand breaks in nucleic acids.
In some embodiments, the target strand nickase domain or portion thereof may have nickase activity on the target strand of a target nucleic acid when present in an engineered protein. In some embodiments, the target strand-nicking enzyme domain or portion thereof, when present in an engineered protein, can have nicking enzyme activity on a non-target strand (also referred to as an antisense (e.g., "-", complementary) strand) of a target nucleic acid. When the target strand-cutting enzyme domain or portion thereof in the engineered protein has a cutting enzyme activity on both the target strand and the non-target strand, the target strand-cutting enzyme domain or portion thereof can cut both strands in sequence. In some embodiments, the target strand-cutting enzyme domain or portion thereof in the engineered protein has a higher activity (e.g., enzymatic activity) on the target strand of the target nucleic acid than on the non-target strand. For example, when present in an engineered protein, a target strand-cutting enzyme domain or portion thereof may cut a target strand of a target nucleic acid more preferentially or faster than a non-target strand of the target nucleic acid.
As used herein, a "target strand-specific nicking enzyme domain" refers to a polypeptide that has nicking enzyme activity only on the target strand of a target nucleic acid and does not nick non-target strands of the target nucleic acid. As used herein, a "non-target strand specific nicking enzyme domain" refers to a polypeptide that has nicking enzyme activity only on non-target strands of a target nucleic acid and does not nick the target strands of the target nucleic acid. As used herein, "target strand and non-target strand nicking enzyme domain" refers to a polypeptide having nicking enzyme activity for both the target strand and the non-target strand of a target nucleic acid. In some embodiments, the engineered protein comprises a target strand-nicking enzyme domain or portion thereof, and the target strand-nicking enzyme domain or portion thereof is a target strand-specific nicking enzyme domain in the engineered protein. In some embodiments, the engineered protein comprises a target strand-nicking enzyme domain or portion thereof, and the target strand-nicking enzyme domain or portion thereof is a non-target strand-specific nicking enzyme domain in the engineered protein. In some embodiments, the engineered protein comprises a target strand-nicking enzyme domain or portion thereof, and the target strand-nicking enzyme domain or portion thereof is a target strand and a non-target strand-nicking enzyme domain in the engineered protein.
The engineered protein may comprise a heterologous polypeptide comprising a target chain nickase domain or a portion thereof. Thus, the engineered protein may have nickase activity on the target strand of the target nucleic acid and/or the non-target strand of the target nucleic acid. Thus, the engineered protein may be a target strand-cutting enzyme and/or a non-target strand-cutting enzyme. "target strand incision enzyme" as used herein with respect to an engineered protein refers to an engineered protein that can or is capable of cleaving a target strand of a target nucleic acid. As used herein with respect to an engineered protein, "non-target strand-cutting enzyme" refers to an engineered protein that can or is capable of cutting a non-target strand of a target nucleic acid. "target strand and non-target strand nicking enzyme" as used herein with respect to an engineered protein refers to an engineered protein that can or is capable of cleaving the target strand and non-target strand of a target nucleic acid in any order (e.g., sequentially or simultaneously). In some embodiments, the engineered protein is a target strand nickase and/or has nickase activity on a target strand of a target nucleic acid. In some embodiments, the engineered protein is a non-target strand nickase and/or has nickase activity on a non-target strand of a target nucleic acid. In some embodiments, the engineered proteins are and/or have nicking enzyme activity on target strands and non-target strands of the target nucleic acid.
In some embodiments, the heterologous polypeptide of the engineered protein comprises a target strand-nicking enzyme domain or portion thereof, and the target strand-nicking enzyme domain or portion thereof of the engineered protein has nicking enzyme activity on the target strand of the target nucleic acid, so the engineered protein is a target strand-nicking enzyme. In some embodiments, the heterologous polypeptide of the engineered protein comprises a target strand-nicking enzyme domain or portion thereof, and the target strand-nicking enzyme domain or portion thereof of the engineered protein has nicking enzyme activity on a non-target strand of the target nucleic acid, so the engineered protein is a non-target strand-nicking enzyme. In some embodiments, the heterologous polypeptide of the engineered protein comprises a target strand nickase domain or portion thereof, and the target strand nickase domain or portion thereof of the engineered protein has nickase active acids for both the target strand and the non-target strand of the target nucleic acid, thus the engineered protein is a target strand and a non-target strand nickase. In some embodiments, the heterologous polypeptide of the engineered protein comprises a target strand nickase domain or portion thereof, and the target strand nickase domain or portion thereof of the engineered protein has nickase activity for at least the target strand of the target nucleic acid, and the CRISPR-Cas effect polypeptide of the engineered protein comprises a nuclease domain or portion thereof having nickase activity for at least the non-target strand of the target nucleic acid, thus the engineered protein is a target strand and a non-target strand nickase. In some embodiments, the CRISPR-Cas effect polypeptide of the engineered protein comprises a nuclease domain or portion thereof that is a target strand and a non-target strand nickase domain or portion thereof, but the nuclease domain or portion thereof is inactivated such that nuclease activity on the target strand is inactivated, such that the target strand of the target nucleic acid is not nicked by the nuclease domain or portion thereof.
In some embodiments, the engineered proteins may comprise one or more (e.g., 1, 2, or more) nuclease domains, or portions thereof. In some embodiments, the engineered protein comprises at least two different nuclease domains or portions thereof. In some embodiments, the engineered protein may comprise a native nuclease domain, optionally one or more (e.g., 1, 2, or more) native nuclease domains. As used herein, a "native nuclease domain" refers to a nuclease domain that naturally occurs in a CRISPR-Cas effector protein. In some embodiments, the engineered protein comprises a first heterologous nuclease domain (e.g., from and/or present in a heterologous polypeptide) and a second nuclease domain. The second nuclease domain can be from and/or present in a CRISPR-Cas effector protein. In some embodiments, the first nuclease domain can be a native nuclease domain and/or the second nuclease domain can be a native nuclease domain. In some embodiments, the second nuclease domain is a target strand and a non-target strand nicking enzyme domain or a portion thereof. As used herein, "non-target strand and target strand nicking enzyme domain or portion thereof" refers to a polypeptide that has nicking enzyme activity on a non-target strand of a target nucleic acid and on a target strand of a target nucleic acid when its domain or portion thereof is in its native protein and cleaves the non-target strand prior to the target strand or more preferentially or faster than the target strand. The non-target strand and the target strand incision enzyme domain or portions thereof can provide staggered double strand breaks in the target nucleic acid. In some embodiments, the second nuclease domain is active. In some embodiments, the second nuclease domain is inactivated (i.e., dead, inactivated or lacking nicking enzyme activity). In some embodiments, the second nuclease domain nicks only non-target strands of the target nucleic acid and/or comprises a mutation that inactivates nicking the nicking enzyme activity of the target strands of the target nucleic acid. The nuclease domain or portion thereof in the engineered protein can be inactivated by a mutation in the nuclease domain or portion thereof that removes or inactivates the nicking enzyme activity. In some embodiments, the engineered protein comprises a nuclease domain or portion thereof from a type V CRISPR-Cas effector protein, such as Cas12a (e.g., from one of SEQ ID NOs: 50-66) or Cas12b (e.g., from SEQ ID NO: 151). In some embodiments, the nuclease domain is a RuvC domain from a V-type CRISPR-Cas effector protein, such as Cas12a or Cas12 b. The engineered protein may comprise one or more nuclease domains that provide blunt end double-strand breaks of the target nucleic acid or staggered double-strand breaks of the target nucleic acid.
In some embodiments, the heterologous polypeptide of the engineered protein comprises all or a portion of the HNH domain of a CRISPR-Cas effect protein. The heterologous polypeptide and/or HNH domain may comprise and/or form a zinc finger motif. In some embodiments, the heterologous polypeptide and/or HNH domain is about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acids to about 110, 125, 150, 175, 200, 225, 250, 275, or 300 amino acids in length. The heterologous polypeptide and/or HNH domain may comprise about 25 or 30 to about 40 or 45 amino acids and/or may comprise one or at least two histidines and asparagines optionally in nucleic acid binding and cleavage sites. In some embodiments, the heterologous polypeptide and/or HNH domain may comprise about 25 or 30 to about 40 or 45 amino acids, including two histidines and one asparagine, present in and/or forming a zinc finger motif. The heterologous polypeptide and/or HNH domain may comprise and/or form two antiparallel β chains connected by a loop and/or may comprise an α -helix, optionally wherein histidine is present in at least one β chain, asparagine is present in the loop, and/or histidine or asparagine is present in the α -helix. The heterologous polypeptide may comprise all or a portion of an HNH domain having a structure such as Pediaditakis M et al Journal of Bacteriology 194 (22); 6184-6194. In some embodiments, the heterologous polypeptide of the engineered protein comprises all or a portion of the HNH domain of a type II CRISPR-Cas effector protein (e.g., cas9 HNH domain). The heterologous polypeptide of the engineered protein may comprise all or a portion of an inactive HNH domain (e.g., cas9 HNH domain). The HNH domain or portion thereof may have an inactivating mutation (e.g., a mutation that removes the nicking enzyme activity). In some embodiments, the heterologous polypeptide of the engineered protein comprises all or a portion of the HNH domain with an inactivating mutation and/or the HNH domain is inactive (e.g., does not have nicking enzyme activity). In some embodiments, the heterologous polypeptide of the engineered protein comprises all or a portion of an inactivated HNH domain having an H840A mutation. In some embodiments, the heterologous polypeptide of the engineered protein comprises a sequence that hybridizes to SEQ ID NO:1 or 169-174 has an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some embodiments, the heterologous polypeptide of the engineered protein comprises SEQ ID NO:1 or 169-174.
In some embodiments, the heterologous polypeptide of the engineered protein comprises an amino acid sequence that, when the amino acid sequence of the heterologous polypeptide and the amino acid sequence of SEQ ID NO:81, the amino acid sequence corresponding to SEQ ID NO:81 has an amino acid at position 839 which is not a histidine residue. In some embodiments, the heterologous polypeptide of the engineered protein comprises an amino acid sequence that, when the amino acid sequence of the heterologous polypeptide and the amino acid sequence of SEQ ID NO:1, the amino acid sequence corresponds to SEQ ID NO:1 has an amino acid other than a histidine residue at position 75. In some embodiments, the heterologous polypeptide of the engineered protein comprises an amino acid sequence that, when the amino acid sequence of the heterologous polypeptide and the amino acid sequence of SEQ ID NO:81, the amino acid sequence corresponding to SEQ ID NO:81 has an alanine residue at position 839 of amino acid number. In some embodiments, the heterologous polypeptide of the engineered protein comprises an amino acid sequence that, when the amino acid sequence of the heterologous polypeptide and the amino acid sequence of SEQ ID NO:1, the amino acid sequence corresponds to SEQ ID NO:1 has an alanine residue at position 75 of amino acid number.
In some embodiments, the heterologous polypeptide of the engineered protein can be located between and/or linked (e.g., directly or indirectly) to two contiguous or non-contiguous amino acids present in the CRISPR-Cas effect protein. In some embodiments, the engineered protein is prepared by inserting a heterologous polypeptide between two consecutive or non-consecutive amino acids of a CRISPR-Cas effect protein or a portion thereof. In some embodiments, the engineered protein may comprise a first CRISPR-Cas effect polypeptide, a heterologous polypeptide, and a second CRISPR-Cas effect polypeptide in an amino-terminal to carboxy-terminal direction, wherein the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are from the same CRISPR-Cas effect protein.
In some embodiments, the CRISPR-Cas effect polypeptide comprises a portion of a V-type CRISPR-Cas effect protein, such as Cas12a or Cas12 b. The CRISPR-Cas effect polypeptide may comprise all or a portion of a nucleic acid binding domain, e.g., a nucleic acid binding domain from a type V CRISPR-Cas effect protein (e.g., cas12a or Cas12 b). In some embodiments, the CRISPR-Cas effect polypeptide of the engineered protein comprises a sequence identical to SEQ ID NO: a portion of the amino acid sequence of one or more of 50-66 or 151 has an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some embodiments, the CRISPR-Cas effect polypeptide comprises SEQ ID NO:50-66 or 151. In some embodiments, the engineered protein comprises SEQ ID NO: two or more (e.g., 2, 3, 4, or more) separate portions of the amino acid sequence of any of 50-66 or 151.
In some embodiments, an engineered protein of the invention may lack about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more amino acids present in a CRISPR-Cas effect protein (e.g., a protein having the sequence of any one of SEQ ID NOs: 50-66 or 151). In some embodiments, an engineered protein of the invention may lack 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids present in a CRISPR-Cas effect protein (e.g., a protein having the sequence of any one of SEQ ID NOs: 50-66 or 151). For example, an engineered protein may lack a sequence derived from SEQ ID NO:50 or SEQ ID NO:58 amino acid residues 283 through 293; from SEQ ID NO:55 to amino acid residue 331 to 341; from SEQ ID NO:51 from amino acid residue 312 to amino acid residue 322; or from a sequence which is identical to SEQ ID NO: 50. 51, 58 or 55 (e.g., from amino acid residues corresponding to amino acid residues 283-293 when the sequence (e.g., SEQ ID NO: 52) is optimally aligned with SEQ ID NO: 50). In some embodiments, the engineered protein lacks an inter-domain region (e.g., a region located between two domains, e.g., two adjacent domains) in one or more (e.g., 1, 2, 3, 4, or more) of the CRISPR-Cas effect protein (e.g., a protein having the sequence of any of SEQ ID NOs: 50-66 or 151) present in the engineered protein that is part of it.
In some embodiments, the heterologous polypeptide of the engineered protein can be located between and/or linked (e.g., directly or indirectly) to two contiguous or non-contiguous amino acids of a CRISPR-Cas effect protein (e.g., a CRISPR-Cas effect protein having the amino acid sequence of any of SEQ ID NOs 50-66 or 151). For example, the engineered protein may comprise, from N-terminus to C-terminus, a first CRISPR-Cas effect polypeptide, a HNH domain, and a second CRISPR-Cas effect polypeptide, wherein the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are each part of a CRISPR-Cas effect protein and the last amino acid residue at the C-terminus of the first CRISPR-Cas effect polypeptide and the first amino acid residue at the N-terminus of the second CRISPR-Cas effect polypeptide are two consecutive or non-consecutive amino acid residues of the CRISPR-Cas effect protein. The heterologous polypeptide can be directly linked to one or both of two contiguous or non-contiguous amino acids of the CRISPR-Cas effect protein (i.e., no linker is used to link one end of the heterologous polypeptide to the end of the CRISPR-Cas effect polypeptide that is part of the CRISPR-Cas effect protein). In some embodiments, the heterologous polypeptide can be indirectly linked (e.g., via a linker, such as a peptide linker) to one or both of two contiguous or non-contiguous amino acids of the CRISPR-Cas effect protein. In some embodiments, the heterologous polypeptide of the engineered protein can be located between and/or linked (e.g., directly or indirectly) to two consecutive amino acids of a CRISPR-Cas effect protein (e.g., a CRISPR-Cas effect protein having the amino acid sequence of any of SEQ ID NOs 50-66 or 151). In some embodiments, the heterologous polypeptide of the engineered protein can be located between and/or linked (e.g., directly or indirectly) to two non-contiguous amino acids of a CRISPR-Cas effect protein (e.g., a CRISPR-Cas effect protein having the amino acid sequence of any of SEQ ID NOs 50-66 or 151).
In some embodiments, the two consecutive or non-consecutive amino acids are two consecutive or non-consecutive amino acid residues from amino acid residue 250, 260, 270, or 280 to amino acid residue 290, 300, 310, 320, 330, 340, or 350, respectively. In some embodiments, the heterologous polypeptide may be between and/or linked (e.g., directly or indirectly) to two consecutive or non-consecutive amino acids, which are two of the following amino acid residues: amino acid residues 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280,281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 326, 327, 328, 329, 330, 325, 332, 333, 334, 335, 337, 338, 340,341, 342, 348, 344, 349, 346, and 350 of a CRISPR-Cas effect protein (e.g., CRISPR-Cas effect protein having the amino acid sequence of any one of SEQ ID nos. 50-66 or 151). In some embodiments, the heterologous polypeptide of the engineered protein can be between and/or linked (e.g., directly or indirectly) to two non-contiguous amino acids of a CRISPR-Cas effect protein (e.g., a CRISPR-Cas effect protein having the amino acid sequence of any of SEQ ID NOs: 50-66 or 151), wherein one of the two non-contiguous amino acid residues is amino acid residue 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280,281, 282, 283, 284, or 285, and the other of the two non-contiguous amino acid residues is amino acid residue 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, or, optionally, SEQ ID NO:50-66 or 151. In some embodiments, the heterologous polypeptide is located between and/or linked (e.g., directly or indirectly) to amino acid residues 290 and 291, amino acid residues 291 and 292, amino acid residues 292 and 293, amino acid residues 293 and 294, amino acid residues 320 and 321, amino acid residues 321 and 322, amino acid residues 339 and 340, or amino acid residues 340 and 341 of a CRISPR-Cas effect protein (e.g., a CRISPR-Cas effect protein having the amino acid sequence of any of SEQ ID NOs 50-66 or 151). For example, in some embodiments, the heterologous polypeptide may be located in SEQ ID NO: amino acid residues 290 and 291 of 50; SEQ ID NO: amino acid residues 291 and 292 of 50; SEQ ID NO: amino acid residues 291 and 292 of 58; SEQ ID NO: amino acid residues 292 and 293 of 58; SEQ ID NO:51 amino acid residues 320 and 321; SEQ ID NO:51 amino acid residues 321 and 322; SEQ ID NO:51 amino acid residues 322 and 323; SEQ ID NO:55, amino acid residues 339 and 340; SEQ ID NO:55, amino acid residues 340 and 341; or with SEQ ID NO: 50. 51, 58 or 55 (e.g., amino acid residues corresponding to amino acid residues 291 and 292 when the sequence (e.g., SEQ ID NO: 52) is optimally aligned with SEQ ID NO: 50) and/or linked (e.g., directly or indirectly) thereto. In some embodiments, the heterologous polypeptide of the engineered protein can be in an inter-domain region of the CRISPR-Cas effect protein (e.g., in a region between two domains, e.g., two adjacent domains). In some embodiments, the heterologous polypeptide may be located in the engineered protein such that it is adjacent to the exposed portion of the target strand of the target nucleic acid.
In some embodiments, the engineered protein comprises all or a portion of a wedge domain, a Rec1 domain, a Rec2 domain, a PAM interaction domain, a RuvC domain, a bridged helix, and/or a Nuc domain (each of which may be from a type V CRISPR-Cas effector protein, e.g., cas12a, cas12b, and/or a protein having the sequence of any one of SEQ ID NOs 50-66 or 151). In some embodiments, the engineered protein comprises all or a portion of the Cas12a domain, the structure of which is as described by Yamano, takashi et al, mol Cell 67:633-645 (2017). In some embodiments, the heterologous polypeptide of the engineered protein may be located between the polypeptide for all or a portion of the Rec1 domain and the polypeptide for all or a portion of the Rec2 domain, each of which Rec1 domain and Rec2 domain may be from a type V CRISPR-Cas effector protein such as Cas12a, cas12b and/or a polypeptide having the sequence of SEQ ID NO:50-66 or 151. In some embodiments, all or a portion of the heterologous polypeptide is located on an exposed surface or interface of the engineered protein. In some embodiments, the CRISPR-Cas effect polypeptide of the engineered protein comprises all or a portion of a RuvC domain. As will be appreciated by those of skill in the art, some domains (e.g., wedge-shaped domain and RuvC domain of Cas12 a) are not contiguous in sequence and may be split into two or more (e.g., 2, 3, 4, or more) non-contiguous sequences. For example, the polypeptide of Cas12 may have, from N-terminus to C-terminus: the first part of the wedge domain (WED-1), the Rec1 domain, the Rec2 domain, the second part of the wedge domain (WED-2), the PAM interaction domain (PI), the third part of the wedge domain (WED-3), the first part of the RuvC domain (RuvC-1), the bridge helix, the second part of the RuvC domain (RuvC-2), the Nuc domain, and the third part of the RuvC domain (RuvC-3). In some embodiments, the engineered protein comprises all or a portion of an active RuvC domain. In some embodiments, the engineered protein comprises all or a portion of an inactivated RuvC domain, optionally all or a portion of an inactivated RuvC domain having a D10A mutation. In some embodiments, the engineered protein comprises all or a portion of an inactivated RuvC domain, and a polypeptide comprising all or a portion of the inactivated RuvC domain hybridizes to the polypeptide of SEQ ID NO:50 when optimally aligned corresponds to SEQ ID NO: the 50 amino acid residue 831 has an alanine at position, optionally wherein the mutation is referred to as a D10A and/or D832A mutation.
The CRISPR-Cas effect polypeptide may comprise a nuclease, optionally a RuvC-like nuclease. In some embodiments, the CRISPR-Cas effect polypeptide comprises a RuvC domain or a portion thereof. In some embodiments, the CRISPR-Cas effect polypeptide comprises a nuclease in the RNase H superfamily. In some embodiments, the CRISPR-Cas effect polypeptide comprises an RNase H-like enzyme with a catalytic core that may comprise a β -sheet comprising 5 β -strands, in order of 32 145, optionally wherein β -strand 2 is antiparallel to another β -strand. The central β -sheet may be flanked on both sides by α -helices, the number of which may vary between relevant enzymes. In some embodiments, the CRISPR-Cas effect polypeptide comprises an rnaseAn H-like catalytic core wherein the active site residues comprise one or more of aspartic acid, glutamic acid, and histidine. In some embodiments, a CRISPR-Cas effect polypeptide comprising an RNase H-like catalytic core may comprise a negatively charged side chain in the active site of the RNase H-like polypeptide that participates in coordinating a divalent metal ion, either directly or through a water molecule. In some embodiments, the CRISPR-Cas effect polypeptide comprises an RNase H-like catalytic core using a dual ion-dependent catalytic mechanism, optionally wherein the ion is Mg 2+ And/or Mn 2+ . In some embodiments, the CRISPR-Cas effect polypeptide comprises a nuclease and/or an RNase H-like nuclease, such as Majorek KA et al, nucleic Acids res.2014;42 (7) described in 4160-4179, which is incorporated herein by reference in its entirety.
In some embodiments, the CRISPR-Cas effect polypeptide comprises one or more (e.g., 1, 2, 3, 4, or more) mutations. The one or more mutations may be to improve or modify the activity of the heterologous polypeptide and/or the activity of the CRISPR-Cas effect polypeptide. In some embodiments, the CRISPR-Cas effect polypeptide may comprise an inactivating mutation, e.g., a D10A mutation in the RuvC domain. In some embodiments, the CRISPR-Cas effect polypeptide comprises all or a portion of the Rec1 domain that comprises one or more (e.g., 1, 2, 3, 4, or more) mutations, such as mutations in one or more of amino acid residues 243-253 of a CRISPR-Cas effect protein (e.g., a CRISPR-Cas effect protein having the amino acid sequence of any of SEQ ID NOs: 50-66 or 151) and/or sequence GFVTESGEKIK (SEQ ID NO: 122). In some embodiments, the CRISPR-Cas effect polypeptide comprises hairpin and/or sequence GFVTESGEKIK (SEQ ID NO: 122), and one or more amino acid residues in the hairpin and/or sequence may be mutated. In some embodiments, the CRISPR-Cas effect polypeptide comprises a hairpin and/or sequence GFVTESGEKIK (SEQ ID NO: 122) and all or a portion of the hairpin and/or sequence is deleted. In some embodiments, the CRISPR-Cas effect polypeptide comprises hairpin and/or sequence GFVTESGEKIK (SEQ ID NO: 122) and 1, 2, 3, 4, 5 or more amino acid residues are added at one or both ends of the hairpin and/or sequence.
In some embodiments, the engineered protein comprises, from N-terminus to C-terminus, a first CRISPR-Cas effect polypeptide, a HNH domain, and a second CRISPR-Cas effect polypeptide, wherein the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are each part of a deactivated LbCas12a (e.g., lbCas12a having the sequence of SEQ ID NO: 50) and the last amino acid residue at the C-terminus of the first CRISPR-Cas effect polypeptide and the first amino acid residue at the N-terminus of the second CRISPR-Cas effect polypeptide are two consecutive amino acid residues of the deactivated LbCas12 a. The HNH domain may be from streptococcus pyogenes Cas9 (SpCas 9) and/or may have a sequence comprising SEQ ID NO: 1. In some embodiments, the HNH domain may have the amino acid sequence of SEQ ID NO:1 or 169-174. The HNH domain may be located in the engineered protein such that it is adjacent to an exposed portion of the target strand of the target nucleic acid. The engineered protein may be a target strand-cutting enzyme. In some embodiments, the engineered protein creates a nick only on the target DNA strand. In some embodiments, the engineered proteins are target strand and non-target strand nicking enzymes.
One or more (e.g., 1, 2, 3, 4, or more) linkers may be present in the engineered protein. For example, a linker may be present between the CRISPR-Cas effect polypeptide and the heterologous polypeptide. In some embodiments, a linker may be present between the first CRISPR-Cas effect polypeptide and the heterologous polypeptide and a linker may be present between the heterologous polypeptide and the second CRISPR-Cas effect polypeptide. Exemplary linkers include, but are not limited to, those described herein. In some embodiments, the linker comprises 1 to 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids and/or comprises glycine and/or serine. In some embodiments, the linker comprises 1, 2, 3, or 4 amino acids, which are glycine and/or serine. In some embodiments, the engineered protein lacks a linker between the CRISPR-Cas effect polypeptide and the heterologous polypeptide. In some embodiments, the heterologous polypeptide is indirectly linked to the N-terminal amino acid residue of the CRISPR-Cas effect polypeptide via a linker and/or the heterologous polypeptide is indirectly linked to the C-terminal amino acid residue of the CRISPR-Cas effect polypeptide via a linker.
In some embodiments, the heterologous polypeptide is directly linked (i.e., without a linker) to an amino acid residue at the N-terminus of the CRISPR-Cas effect polypeptide and/or the heterologous polypeptide is directly linked (i.e., without a linker) to an amino acid residue at the C-terminus of the CRISPR-Cas effect polypeptide.
The engineered protein may comprise a sequence identical to SEQ ID NO:2-17, 125-132, or 157-168 has an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity. In some embodiments, the engineered protein comprises and/or has the amino acid sequence of SEQ ID NO:2-17, 125-132 or 157-168. The engineered protein may have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to all or a portion of the amino acid sequence of the wild-type CRISPR-Cas effect protein. In some embodiments, the engineered protein hybridizes to SEQ ID NO: all or a portion of the amino acid sequence of any one of 50-66 or 151 has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity. In some embodiments, the engineered protein hybridizes to SEQ ID NO: all or a portion of the amino acid sequence of any of 50-66 or 151 has about 70%, 75%, or 80% to about 85%, 90%, 95%, or 98% sequence identity.
The engineered protein may have increased efficiency compared to a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein), e.g., increased efficiency in nicking the target strand and/or non-target strand of a target nucleic acid. In some embodiments, the engineered protein can have increased efficiency in nicking the target strand of a target nucleic acid as compared to a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein). In some embodiments, the engineered protein can provide an increased number of target strand breaks in the target nucleic acid as compared to the number of target strand breaks in the target nucleic acid using a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein). In some embodiments, the engineered protein can have increased efficiency of modifying the target nucleic acid as compared to a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein).
Compositions, complexes, and systems comprising engineered proteins may be provided according to embodiments of the present invention. In some embodiments, the compositions, complexes, and/or systems comprising the engineered proteins may be base editing compositions, complexes, and/or systems. The compositions, complexes, and/or systems of the invention can include a guide nucleic acid (e.g., a guide RNA) and/or a deaminase (e.g., a cytosine deaminase and/or an adenine deaminase). In some embodiments, the engineered protein, the guide nucleic acid, and optionally the deaminase form a complex or are contained in a complex (e.g., ribonucleoprotein). The engineered protein, the guide nucleic acid, and optionally the deaminase may not naturally occur together and/or the complex comprising the engineered protein, the guide nucleic acid, and optionally the deaminase may not naturally occur together. In some embodiments, the engineered protein comprises and/or is fused to a deaminase (e.g., adenine deaminase and/or cytosine deaminase).
Also provided herein are nucleic acid molecules encoding the engineered proteins of the invention and expression cassettes and/or vectors comprising the nucleic acid molecules of the invention.
According to some embodiments, a method is provided that includes contacting a target nucleic acid with an engineered protein of the invention, a guide nucleic acid (e.g., guide RNA), and optionally a deaminase. In some embodiments, the engineered protein, the guide nucleic acid, and/or the deaminase form a complex or are contained in a complex. In some embodiments, the method can modify the target nucleic acid and/or can provide one or more single strand breaks in the target nucleic acid.
In some embodiments, compositions, systems, methods, and/or complexes comprising an engineered protein can have increased efficiency as compared to compositions, systems, methods, and/or complexes comprising a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein). In some embodiments, compositions, systems, methods, and/or complexes comprising an engineered protein that is a target strand nickase may have increased efficiency as compared to compositions, systems, methods, and/or complexes comprising a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein). This may be because nicking the target strand may increase the efficiency of the genome editing tool (e.g., base editor and/or base diversifier). In some embodiments, the compositions, systems, methods, and/or complexes comprising the engineered protein can provide an increased number of target strand breaks in a target nucleic acid as compared to the number of target strand breaks in a target nucleic acid using compositions, systems, methods, and/or complexes comprising a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein).
The engineered proteins and/or compositions, systems, methods, and/or complexes comprising the engineered proteins can provide improved or altered indel size and/or composition, improved or altered deletion size in a target nucleic acid, improved or altered nicking capability on any strand (i.e., target strand or non-target strand of a target nucleic acid), and/or increased nuclease activity compared to a CRISPR-Cas effect protein (e.g., cas12a, CRISPR-Cas effect protein having the sequence of SEQ ID NO:50-66 or 151, and/or a composition, system, method, and/or complex comprising a CRISPR-Cas effect protein (e.g., cas12a, CRISPR-Cas effect protein having the sequence of SEQ ID NO:50-66 or 151), and/or a CRISPR-Cas effect protein. In some embodiments, the engineered proteins and/or compositions, systems, methods, and/or complexes comprising the engineered proteins confer nuclease function to a catalytically inactive CRISPR-Cas effect protein. In some embodiments, the engineered protein and/or the composition, system, method, and/or complex comprising the engineered protein provides a different edit profile and/or a different cleavage pattern of the target nucleic acid compared to the edit profile and/or a different cleavage pattern of the CRISPR-Cas effect protein (e.g., cas12a, CRISPR-Cas effect protein having the sequence of SEQ ID NO:50-66 or 151, and/or wild-type CRISPR-Cas effect protein) and/or to the composition, system, method, and/or complex comprising the CRISPR-Cas effect protein (e.g., cas12a, CRISPR-Cas effect protein having the sequence of SEQ ID NO:50-66 or 151, and/or wild-type CRISPR-Cas effect protein).
In some embodiments, the methods of the invention can have increased efficiency of modifying a target nucleic acid compared to the efficiency of a control method (e.g., a method comprising contacting the target nucleic acid with a CRISPR-Cas effect protein (e.g., cas12a, a CRISPR-Cas effect protein having the sequence of SEQ ID NOs: 50-66 or 151, and/or a wild-type CRISPR-Cas effect protein).
As described herein, the engineered proteins, nucleic acids, expression cassettes and/or vectors of the invention may be codon optimized for expression in an organism. The organisms useful in the present invention may be any organism or cell thereof for which a nucleic acid modification may be useful. Organisms may include, but are not limited to, any animal (e.g., mammal), any plant, any fungus, any archaebacteria, or any bacterium. In some embodiments, the organism may be a plant or a cell thereof. In some embodiments, the organism is an animal, such as a mammal (e.g., a human).
The target nucleic acid may be a genomic sequence from any organism (e.g., a eukaryotic organism such as a mammal or a plant). In some embodiments, the target nucleic acid is a genomic sequence from a model organism (e.g., without limitation, escherichia coli), an immortalized human cell line (e.g., HEK293, heLa, etc.), caenorhabditis elegans (Caenorhabditis elegans), and/or drosophila melanogaster (Drosophila Melanogaster)). In some embodiments, the target nucleic acid is a genomic sequence from a non-model organism. Exemplary non-model organisms include, but are not limited to, crop plants (e.g., fruit crop plants, vegetable crop plants, and/or field crop plants) and/or animals such as humans, primates, and/or mice. In some embodiments, the non-model organism is a crop plant, such as corn, soybean, wheat, or canola. In some embodiments, the non-model organism is an animal for the testing and/or use of a human therapeutic agent.
The nucleic acid constructs of the invention can be used to modify a target nucleic acid of any plant or plant part. Any plant (or grouping of plants, e.g., grouping into genus or higher classes) can be modified using the engineered proteins of the invention, including angiosperms, gymnosperms, monocots, dicots, C3, C4, CAM plants, bryophytes, ferns and/or ferns, microalgae and/or kelp. The plants and/or plant parts useful in the present invention may be plants and/or plant parts of any plant species/kind/variety. As used herein, the term "plant part" includes, but is not limited to, embryos, pollen, ovules, seeds, leaves, stems, shoots, flowers, branches, fruits, kernels, ears, corn cobs, husks, stalks, roots, root tips, anthers, plant cells, including plant cells intact in a plant and/or part of a plant, plant protoplasts, plant tissue, plant cell tissue culture, plant callus, plant clumps, and the like. As used herein, "bud" refers to an aerial part that includes leaves and stems. Furthermore, as used herein, "plant cell" refers to the structural and physiological units of a plant, which includes the cell wall and may also refer to protoplasts. The plant cells may be in the form of isolated single cells, or may be cultured cells, or may be part of a higher tissue unit such as plant tissue or plant organs.
Non-limiting examples of plants that can be used in the present invention include turf grasses (e.g., bluegrass, bentgrass, ryegrass, fescue), feather reed grasses, cluster grass, miscanthus, arundo donax, switchgrass, vegetable crops, including artichoke, kohlrabi, sesame, leek, asparagus, lettuce (e.g., head, leaf lettuce), yellow-fleshy, melons (e.g., melon, watermelon, melon (crenhaw), cantaloupe), brassica crops (e.g., cabbage, broccoli, kale, kohlrabi, chinese cabbage), cardoni, carrot, napa, okra, onion, celery, parsley, chick pea, european radish, chicory, capsicum, potato, cucurbits (e.g., zucchini, cucumber, zucchini, caraa, etc.) pumpkin, squash, white melon, watermelon, cantaloupe), radish, dried onion, turnip cabbage, eggplant, salomus, broadleaf chicory, chives, chicory, garlic, spinach, green onion, pumpkin, green vegetables, beets (beet and fodder beet), sweet potato, leaf beet, horseradish, tomato, turnip and spices; fruit crops such as apples, apricots, cherries, nectarines, peaches, pears, plums, cherries, quince, figs, nuts (e.g., chestnuts, pecans, pistachios, hazelnuts, pistachios, peanuts, walnuts, macadamia nuts, almonds, etc.), citrus (e.g., clemen's citrus, kumquats, oranges, grapefruits, oranges, tangerines (mandarin), lemons, lime, etc.), blueberries, blackberries, boysenberries, cowberry fruits, gooseberries, raspberries, strawberries, blackberries, grapes (wine and table), avocados, bananas, kiwi fruits, persimmons, pomegranates, pineapple, tropical fruits, pear fruits, melons, mangoes, papaya and litchis, field crop plants such as clover, alfalfa, timothy, evening primrose, meadow foam, corn/maize (field, sweet, popcorn), hops, jojoba, buckwheat, safflower, quinoa, wheat, rice, barley, rye, millet, sorghum, oat, triticale, milo, tobacco, kapok, leguminous plants (e.g., green and dried), lentils, peas, soybeans), oil plants (canola, canola oil crops (canola), mustard, poppy, olives, sunflower, coconut, castor oil plants, cocoa beans, groundnuts, oil palms), duckweed, arabidopsis (Arabidopsis), fiber plants (cotton, flax, hemp, jute), cannabis (e.g., cannabis (Cannabis sativa), cannabis (Cannabis indica) and amethy Cannabis (Cannabis ruderalis)), campaceae (cinnamon bark), camphor) or plants such as coffee, sugar cane, tea and natural rubber plants; and/or potted plants, such as flowering plants, cactus, fleshy plants and/or ornamental plants (e.g., roses, tulips, violet), and trees such as woods (broadleaf and evergreen trees, e.g., conifers; e.g., elms, ash, oaks, maples, fir, spruce, cedar, pine, birch, cypress, eucalyptus, willow), as well as bushes and other nursery stock. In some embodiments, the nucleic acid constructs of the invention and/or expression cassettes and/or vectors encoding the same may be used to modify corn, soybean, wheat, canola oil crops, rice, tomato, pepper, sunflower, raspberry, blackberry, and/or cherry.
In some embodiments, the invention provides cells (e.g., plant cells, animal cells, bacterial cells, archaeal cells, etc.) comprising a polypeptide, polynucleotide, nucleic acid construct, expression cassette, or vector of the invention.
The invention also includes one or more kits for practicing the methods of the invention. The kit of the present invention may include reagents, buffers, and devices for mixing, measuring, sorting, labeling, etc., suitable for modifying target nucleic acids, as well as instructions, etc.
In some embodiments, the invention provides a kit comprising one or more nucleic acid constructs of the invention and/or expression cassettes and/or vectors and/or cells comprising the same as described herein, and optionally instructions for use thereof. In some embodiments, the kit may further comprise a CRISPR-Cas guide nucleic acid (corresponding to an engineered protein that may be encoded by a polynucleotide of the invention) and/or an expression cassette and/or vector and/or cell comprising the same. In some embodiments, the guide nucleic acid may be provided on the same expression cassette and/or vector as the one or more nucleic acid constructs of the invention. In some embodiments, the guide nucleic acid may be provided on an expression cassette or vector separate from an expression cassette or vector comprising one or more nucleic acid constructs of the invention.
Thus, in some embodiments, a kit is provided comprising a nucleic acid construct comprising (a) a polynucleotide as provided herein and (b) a promoter that drives expression of the polynucleotide of (a). In some embodiments, the kit may further comprise a nucleic acid construct encoding the guide nucleic acid, wherein the construct comprises cloning sites for cloning nucleic acid sequences identical or complementary to the target nucleic acid sequence into the backbone of the guide nucleic acid.
In some embodiments, the nucleic acid construct of the invention may be an mRNA that may encode one or more introns within the encoded polynucleotide. In some embodiments, the nucleic acid constructs of the invention and/or expression cassettes and/or vectors comprising the same may further encode one or more selectable markers (e.g., nucleic acids encoding antibiotic resistance genes, herbicide resistance genes, etc.) useful in identifying transformants.
The polypeptides, polynucleotides, nucleic acid constructs, expression cassettes, vectors, compositions, kits, systems and/or cells of the invention may comprise SEQ ID NO:1-175, or a portion of one or more of the sequences. In some embodiments, the polypeptides, polynucleotides, nucleic acid constructs, expression cassettes, vectors, compositions, kits, systems and/or cells of the invention may comprise SEQ ID NO:1-175, at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of contiguous amino acids of one or more of the sequences.
The invention will now be described with reference to the following examples. It should be understood that these examples are not intended to limit the scope of the claims to the present invention, but are intended as examples of certain embodiments. Any variations of the exemplary methods that occur to those skilled in the art are intended to fall within the scope of the present invention.
Examples
Example 1:
using prior domain annotation and visual inspection of the SpCas9 crystal structure (PDB ID 4UN 3) in PyMOL (PyMOL molecular graphics system, version 2.0.Schrodinger, llc), the complete HNH domain from SpCas9 was first identified (fig. 3) and its residue boundaries were determined. This domain is mainly resolved in the crystal structure, but several residues linking the N-terminal end of the HNH domain and the Rec1 domain are not resolved in the crystal structure. The position of the Cas9 target DNA strand cleavage site relative to the HNH domain is also recorded. This relative orientation is mimicked in the subsequent rational positioning of HNH domains relative to the target DNA strand of Cas12 a.
The crystal structure of the LbCas12a ternary complex (PDB ID 5 XUS) was next examined to locate the accessible region of the target DNA strand. Although the side of the target DNA/crRNA duplex closest to the RuvC domain is severely shielded by the other Cas12a domain, there is an exposed portion of the target DNA on the other side of the protein (shown by the left arrow in fig. 4) at the interface between the Rec1 and Rec2 domains (fig. 4). The linker connecting the two domains (indicated by the right arrow in fig. 4) is located near this exposed site and has little interaction with other residues in LbCas12 a; the linker is selected as a candidate site for domain insertion.
To determine the precise location of the SpCas9 HNH domain relative to LbCas12a, the DNA bases exposed in the groove between Rec1 and Rec2 domains of LbCas12a were next identified. The HNH domain and its target DNA (four bases, two on each side of the cleavage site) were then considered as one unit, and the alignment of HNH target DNA with the exposed target strand of LbCas12a was tested in a sliding window using PyMOL until an alignment was identified that placed the HNH domain near the insertion loop and that minimized collisions with other domains of LbCas12 a. The position of the HNH domain was then manually adjusted using PyMOL to minimize the collision between HNH and Cas12 a.
The final selected positions of HNH domains are shown in figure 5. Although the C-terminus of the HNH domain is very close to the C-terminus of the insert, the N-terminus of HNH is relatively far from the insert; however, this structure does not include unstructured residues linking the SpCas9 Rec1 and HNH domains. Highly conserved hairpins in this region that interact with the target DNA/crRNA duplex are further identified as potential sites for post-design.
To prepare the Cas12a-HNH fusion structure for computational linker modeling, the N-terminus of the HNH domain was initially extended by adding residues from SpCas9 that connect Rec1 and HNH domains (and are not resolved in the SpCas9 crystal structure) using PyMOL. The resulting structure was exported and prepared for linker modeling using custom Python scripts that insert HNH domain residues into possible insertion sites in the entire insertion loop as shown in table 1.
Table 1: preliminary calculation of possible insertion sites in Cas12a screening results.
Rapid computational screening was performed using the Rosetta Remodel protocol contained in the Rosetta macromolecular modeling software package (Huang p.s. et al 2011) to test the ability of HNH domain ends to ligate to both ends of the linker cleavage site. For each insertion point, ten loop closure iterations (no sequence design or insertion) were performed. The number of times that the linker was able to successfully join in these ten iterations was calculated and compared (table 1). Two of these insertion sites were then selected for more thorough linker modeling based on a combination of their successful closed-loop rates and manual checks, including variations in linker length (shown in bold in table 1).
For both selected insertion sites, fine-grained testing was then performed using small (2 to 4 residues) glycine-serine insertions or deletions in the N-terminal and C-terminal linkers and using more thorough sampling (100 iterations each). Possible deletion residues are selected based on manual examination of the sequence. Based on the linker modeling results, eight designs (four per insertion site) were selected for experimental testing, including an extension of 0, 2, or 4 residues for the N-terminal linker and an extension of 0 or 2 residues for the C-terminal linker.
Example 2:
DNA coding regions for the 8 LbCAs12a-HNH constructs (HNH-3287, HNH-3288, HNH-3289, HNH-3290, HNH-3296, HNH-3297, HNH-3298 and HNH-3299) with the 6-histidine tag were synthesized using solid state synthesis. The coding region was cloned into the pET28a plasmid (Novagen) behind the inducible T7 promoter and transfected into BL21 (DE 3) -Star cells (Invitrogen) and inoculated on kanamycin. Single colonies were grown in 30ml Luria Broth at 37℃to an A600 optical density of 0.5. 500mM IPTG was added and cooled to 18℃for expression for 18 hours. Cells were pelleted and lysed with BugBuster Master Mix (Millipore) according to manufacturer's instructions. Cell debris was pelleted and the soluble fractions were imaged on a 4-12% Bis-Tis PAGE gel (Invitrogen) under reducing conditions and visualized using coomassie staining. All eight HNH constructs showed soluble protein expression at about 160kDa MW (fig. 6, arrow).
Soluble protein expression of all eight constructs comprising HNH nucleases in the middle of Cas12a protein demonstrates the quality of the fusion design. Inserting large domains in between proteins typically results in the expression of insoluble proteins or in the absence of expression in E.coli. Observations that all eight proteins were highly expressed indicated that the chimeric proteins folded correctly and did not result in disruption of any of the protein folds.
The expression protocol was repeated to produce a protein suitable for nuclease assays. After precipitation of the eight constructs, E.coli cells were frozen, thawed and suspended in buffer A (20 mM HEPES-KOH pH7.5, 500mM NaCl, 10% glycerol, 2mM TCEP and 10mM imidazole pH 7.5). 0.3mg/ml lysozyme was added and cells were incubated for 20 minutes at room temperature and then sonicated (QSONIca) with a 1/8 inch tip, 25% power, 10 second burst for 2.25 minutes followed by 30 second rest. Cell debris was pelleted, the supernatant was loaded onto Ni-NTA agarose (Bio-Rad), washed with 20mM imidazole in buffer A, and eluted with 300mM imidazole in buffer A. The approximate concentration of protein was 0.5 to 2mg/ml in 200 μl total eluate (estimated by NanoDrop a280 absorbance).
Example 3:
plasmid-based assays were used to evaluate the nicking activity of purified HNH-3287, HNH-3288, HNH-3289, HNH-3290, HNH-3296, HNH-3297 and HNH-3298. The principle of plasmid nicking assay works by extracting supercoiled plasmid from bacteria on agarose gel to a smaller extent than linearized double-nicked plasmid running gel. Furthermore, if only one strand is nicked, the plasmid runs even larger than the linearized plasmid. This assay has been widely used in the CRISPR field to evaluate whether an enzyme is a double-stranded nuclease or a single-stranded nuclease (Jinek et al, science.2012Aug 17;337 (6096): 816-21) (Zetsche et al, cell.2015Oct22;163 (3): 759-71).
Sequence 5'-TTTAGGAATCCCTTCTGCAGCACCTGG-3' (SEQ ID NO: 123), in which the pre-spacer adjacent motif (PAM) is shown in bold, was synthesized and cloned into the pUC18 plasmid. Plasmids were expressed in DH 5. Alpha. Cells and purified using plasmid miniprep kit (Qiagen). CRISPR RNA molecules were synthesized (Synthesis) without any chemical modification using the sequence 5'-AAUUUCUACU AAGUGUAGAU GGAAUCCCUU CUGCAGCACC UGG-3' (SEQ ID NO: 124), wherein the part complementary to the plasmid is shown in bold. mu.L of the reaction was assembled in a 10:10:1 RNA to protein to plasmid ratio, incubated at 37℃for 15 minutes, heat inactivated at 85℃for 2 minutes, and loaded onto a 1% agarose gel containing 1/100v/v SYBR-Safe stain (Invitrogen).
The proteins tested were wild-type LbCas12a (wtLbCas 12 a), lbCas12a-R1138A and various chimeric HNH proteins. R1138A is a point mutation in LbCAs12a that corresponds to the known non-template strand-cutting enzyme mutation of AsCas12a (R1226A) (Yamano T et al, cell.2016May 5;165 (4): 949-62). The concentrations tested for wtLbCas12a and LbCas12a-R1138 were 33nM. The lower 9nM is used for various HNH constructs to distinguish the most active nucleases by slightly approaching the expected Kd rather than making a complete cut.
The resulting gels (FIG. 7) demonstrate that HNH-3287, HNH-3288, HNH-3289, HNH-3290, HNH-3296, HNH-3297 and HNH-3298 are all nicking enzymes, with a nicking percentage from 25% efficiency to 75% efficiency (upper band (nicked plasmid) compared to lower band (supercoiled plasmid) at these low 9nM protein concentrations. Longer incubation times or higher concentrations resulted in complete gaps, but did not allow comparison of the relative mutant activities. Chimeric HNH-3298 appeared to have the highest percentage of nicking activity at 37℃for 15 min at 9nM [ protein ].
Example 4:
Method
protein expression and purification
For initial testing of expression and activity, his tagged protein SYN3287 (SEQ ID NO: 125), SYN3288 (SEQ ID NO: 126), SYN3289 (SEQ ID NO:127 SYN3290 (SEQ ID NO:128 SYN3296 (SEQ ID NO:129 SYN3297 (SEQ ID NO:130 SYN3298 (SEQ ID NO:131 And SYN3299 (SEQ ID NO:132 BL21 cells in 30mL culture. Each protein comprises an active HNH domain and an inactive RuvC domain. Cells were pelleted, frozen overnight, and lysed by sonication. Then use HisPur TM The Ni-NTA column coarsely purified the protein from the lysate.
For the determination of SYN3298 and SYN3289, the proteins were expressed in the same manner, but with the following changes: proteins were expressed in 1L culture and purified by FPLC using a HisTrap-HF column. The fractions containing the protein of interest were further purified by cation exchange and stored in 50% glycerol.
Plasmid nickase assay
To determine the activity of the purified protein as a nicking enzyme or nuclease, 30. Mu.L of reaction solution was prepared containing 1 XNEBuffer 3.1, 100 femtomoles of DNA substrate, aliquots of purified protein and the appropriate guide RNA (1 picomole of each unless otherwise indicated). The reaction was incubated at 37℃for 30 min, quenched by proteinase K digestion at room temperature for 20 min, and separated on a 1% agarose gel. The target site for plasmid nickase assay has the sequence SEQ ID NO:133.
fluorescence nickase assay
The DNA substrate is produced by annealing a labeled (SEQ ID NO: 134) and an unlabeled (SEQ ID NO: 135) DNA strand to produce a substrate labeled with Cy5 on a strand containing PAM or not containing PAM. The spacer for this assay comprises SEQ ID NO: 150. The nicking reaction was prepared as described for the plasmid nicking enzyme assay and incubated at 37℃for 30 minutes. The reaction was terminated by digesting the sample with proteinase K for 10 minutes. All samples were then mixed with urea loading buffer to a 1x concentration and heated to 90 ℃ for 5 minutes to denature the substrate. Samples were isolated by running on a 6% tbe urea gel at 4 ℃ and 100V.
HEK293T cell transfection
Eukaryotic HEK293T (ATCC CRL-3216) cells were supplemented with 10% (v/v) FBS (FBS)Dulbecco's modified Eagle Medium plus GlutaMax (ThermoFisher) at 37℃and 5% CO 2 And (5) culturing. The protein component was synthesized using gene synthesis and subsequently cloned into a plasmid with the CMV promoter. The guide RNA was cloned with a human U6 promoter. HEK293T cells were seeded on 48-well collagen-coated BioCoat plates (Corning). Cells were transfected at about 70% confluence. 375ng of CRISPR plasmid and 125ng of guide RNA expression plasmid were transfected per well using 1.5. Mu.l Lipofectamine 3000 (ThermoFisher Scientific) according to the manufacturer's protocol. Genomic DNA of transfected cells was obtained after 3 days and indels were detected and quantified using high throughput Illumina amplicon sequencing.
To determine on which strand a designed protein preferentially nicks, pairs of guides are designed so that the Cas9 guide and the guide for the designed protein on the same strand will cleave close to each other (within-10 bp). Each test was designed to pair with a nuclease-dead SpCas9, spCas 9D 10A target strand nickase or SpCas 9H 840A non-target strand nickase. If the synthetic nickase and its paired Cas9 nickase cleave the opposite strand, then the editing frequency is expected to be higher than if the same strand were cleaved due to the generation of double strand breaks.
Results
His-tagged engineered synthetic nickases were successfully expressed in BL21 E.coli.
After crude purification of the designed nicking enzyme as described above, all samples showed bands of the expected size (-160 kDa) as shown in FIG. 8, indicating soluble expression of the nicking enzyme in E.coli.
Initial plasmid nicking activity observed from crude purification of the synthesized nicking enzyme.
The plasmid nickase assay was performed as described in the methods section above using the nickase crude purification shown in FIG. 8. Because of the low yields of some purifications, all designed nicking enzymes were tested at low concentrations so that they could be directly compared. As can be seen in fig. 9, all designs, except one, showed bands indicating the presence of nicked plasmids that were more pronounced than in the negative control samples, indicating that these designs were able to nick DNA substrates.
RNA dependence of plasmid nicks was performed using a crude purified synthetic nickase.
To ensure that the nicking and cleavage of the observed plasmid is primer dependent, rather than due to random nuclease activity, plasmid nickase assays were repeated for the selected design in the presence of the targeted crRNA. As shown in FIG. 10, SYN3288, SYN3296 and SYN3298 were designed to show a decrease in the amount of uncleaved plasmid in the presence of crRNA, indicating that their nuclease activity was RNA dependent.
Plasmid nicking activity of purified synthetic nicking enzyme SYN 3298.
Different amounts of protein + leader were tested relative to the concentration of LbCas12a control used (e.g., 30x indicates that 30 picomoles of protein and leader were included in the reaction). Nicking and a lesser degree of cleavage of the plasmid were observed at all concentrations tested for SYN3298 (fig. 11), confirming that the design served as a DNA nicking enzyme.
Fluorescence nicking enzyme assays were performed using purified synthetic nicking enzymes SYN3298 and SYN 3289.
Substrates with fluorescent Cy5 labels on target (fig. 12) or non-target (fig. 13) were incubated with engineered nicking enzymes (which included active HNH domain and inactive RuvC domain), lbCas12a or LbCas12a R1138A mutants (a non-target strand nicking enzyme) and separated on denaturing TBE-urea gels. A change in the position of the marked strip indicates that the strand was cut. Fig. 14 shows a portion of the gel of the sample incubated with the labeled target strand, fig. 15 shows a portion of the gel of the sample incubated with the labeled non-target strand, and fig. 16 shows the entire gel with the control, the sample incubated with the labeled target strand (boxed lane indicated as "a"), and the sample incubated with the labeled non-target strand (boxed lane indicated as "b"). SYN3298 shows a band at the expected position of the target DNA strand, but not the cleavage substrate of the target DNA strand, indicating that it acts as a target strand nickase.
Sequence-based strand-specific nickase assay of genomic DNA in HEK293T cells.
The synthetic nickase is co-transfected with Cas9 (H840A) or Cas9 (D10A) in the vicinity of the Cas9 nickase, e.g., cleaving a target strand (e.g., cas9 (D10A)) or a non-target strand (e.g., cas9 (H840A)). Information on the spacer used in the sequence-based strand-specific nicking enzyme assay is provided in table 2. The upstream guide refers to which spacer will be expected to be cut closer to the 5' end of the PAM-containing DNA strand. An estimated distance between cleavage sites is determined based on the predicted cleavage sites for each native nuclease domain.
Table 2: spacer information for sequence-based strand-specific nicking enzyme assays.
When Cas9 nickases were paired with nuclease dead LbCas12a at the same target site, the editing efficiency of each enzyme pairing was normalized to the observed indel level (fig. 17). The numbers in brackets in fig. 17 represent the editing efficiency observed before normalization. If the target strand is preferentially cleaved by the Synthase (SYN) (i.e.SYN 3289, SYN3290 or SYN 3298), then (H480A:: SYN)/(D10A:: SYN) >1. If the Synthetase (SYN) (i.e., SYN3289, SYN3290 or SYN 3298) preferentially cleaves the non-target strand, (H480A:: SYN)/(D10A:: SYN) <1.
To determine on which strand a designed protein preferentially nicks, pairs of guides are designed such that the Cas9 guide and the guide for the designed protein on the same strand will cleave close to each other (within-10 bp). Each test was designed to pair with a nuclease-dead SpCas9, spCas 9D 10A target strand nickase or SpCas 9H 840A non-target strand nickase. If the synthetic nickase and its paired Cas9 nickase cleave the opposite strand, a higher editing frequency is expected to be seen compared to cleaving the same strand due to the generation of double strand breaks. In comparison to Cas9 target strand nickase, when all designed nickases were paired with Cas9 non-target strand nickase, an increased indel frequency (approximately 3-fold increase) was always observed, indicating that the designed nickases preferentially cut the target DNA strand.
Example 5:
cytosine base editing data were obtained for the base editors combining A3A cytosine deaminase (SEQ ID NO: 152) with SYN3289, SYN3290 or SYN3298 (FIGS. 18-21). Three structures were tested for each enzyme: A3A was fused to the N-terminus of the synthetase using a linker (SEQ ID NO: 22) and using SEQ ID NO:45 fusion of UGI (SEQ ID NO: 104) to the C-terminus of the synthetase to provide the sequence of SEQ ID NO:160-162; A3A was fused to the N-terminus of the synthetase using previously published linkers (SEQ ID NO:153; li et al, nat Biotechnol 36,324-327 (2018)) and using SEQ ID NO:154 fusion of UGI (SEQ ID NO: 104) to the C-terminus of the synthetase to provide the sequence of SEQ ID NO:163-165; or Suntag-based recruitment of UGI fused to the C-terminus of A3A (SEQ ID NO: 152) (SEQ ID NO: 104) to provide recruitment to the sequence of SEQ ID NO:157-159, the peptide tag synthase of SEQ ID NO:156. all percentages shown in fig. 18-21 represent averages of three data points. All enzymes tested exhibited cytosine base editing in all three test configurations. The spacer of fig. 18 is SEQ ID NO:144, the spacer of fig. 19 is SEQ ID NO:145, the spacer of fig. 20 is SEQ ID NO:146 and the spacer of fig. 21 is SEQ ID NO:147.
Example 6:
adenine base editing data were obtained for synthases SYN3289, SYN3290 and SYN3298 as N-terminal fusions with TadA8e adenine deaminase (fig. 22-23). The synthetase was fused to TadA8e (SEQ ID NO: 155) using a linker (SEQ ID NO: 47) to provide SEQ ID NO:166-168. All percentages as shown in fig. 22-23 represent averages of three data points. When fused to TadA8e, all three tested designs exhibited adenine base editing activity. The spacer of fig. 22 is SEQ ID NO:148, the spacer of fig. 23 is SEQ ID NO:149.
the foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
Sequence listing
<110> paired plant service Co., ltd
GUFFY, Sharon L.
WATTS, Joseph M.
<120> engineered CRISPR-CAS proteins and methods of use thereof
<130> 1499.37.WO
<150> US 63/071,734
<151> 2020-08-28
<160> 175
<170> PatentIn version 3.5
<210> 1
<211> 144
<212> PRT
<213> Streptococcus species
<400> 1
Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met
1 5 10 15
Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys
20 25 30
Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu
35 40 45
Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp
50 55 60
Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser
65 70 75 80
Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp
85 90 95
Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys
100 105 110
Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr
115 120 125
Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser
130 135 140
<210> 2
<211> 1373
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 2
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser
290 295 300
Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser
305 310 315 320
Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu
325 330 335
Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp
340 345 350
Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile
355 360 365
Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu
370 375 380
Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu
385 390 395 400
Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala
405 410 415
Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg
420 425 430
Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val
435 440 445
Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys
450 455 460
Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly
465 470 475 480
Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile
485 490 495
Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp
500 505 510
Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp
515 520 525
Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln
530 535 540
Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys
545 550 555 560
Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser
565 570 575
Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys
580 585 590
Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val
595 600 605
Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu
610 615 620
Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp
625 630 635 640
Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val
645 650 655
Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn
660 665 670
Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg
675 680 685
Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp
690 695 700
Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn
705 710 715 720
Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys
725 730 735
Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn
740 745 750
Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys
755 760 765
Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe
770 775 780
Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe
785 790 795 800
Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
805 810 815
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
820 825 830
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln
835 840 845
Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
850 855 860
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln
865 870 875 880
Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu
885 890 895
Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn
900 905 910
Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val
915 920 925
Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro
930 935 940
Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu
945 950 955 960
Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile
965 970 975
Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys
980 985 990
Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe
995 1000 1005
Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys
1010 1015 1020
Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile
1025 1030 1035
Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val
1040 1045 1050
His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala
1055 1060 1065
Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val
1070 1075 1080
Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys
1085 1090 1095
Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly
1100 1105 1110
Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe
1115 1120 1125
Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala
1130 1135 1140
Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu
1145 1150 1155
Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile
1160 1165 1170
Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe
1175 1180 1185
Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp
1190 1195 1200
Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg
1205 1210 1215
Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu
1220 1225 1230
Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly
1235 1240 1245
Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln
1250 1255 1260
Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu
1265 1270 1275
Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp
1280 1285 1290
Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp
1295 1300 1305
Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn
1310 1315 1320
Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp
1325 1330 1335
Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys
1340 1345 1350
Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln
1355 1360 1365
Thr Ser Val Lys His
1370
<210> 3
<211> 1375
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 3
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys
290 295 300
Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu
305 310 315 320
Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln
325 330 335
Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr
340 345 350
Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp
355 360 365
His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys
370 375 380
Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro
385 390 395 400
Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu
405 410 415
Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala
420 425 430
Glu Arg Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu
435 440 445
Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser
450 455 460
Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser
465 470 475 480
Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys
485 490 495
Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu
500 505 510
Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr
515 520 525
Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu
530 535 540
Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys
545 550 555 560
Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr
565 570 575
Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser
580 585 590
Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp
595 600 605
Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly
610 615 620
Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala
625 630 635 640
Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn
645 650 655
Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe
660 665 670
Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp
675 680 685
Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile
690 695 700
Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp
705 710 715 720
Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro
725 730 735
Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr
740 745 750
Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe
755 760 765
Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp
770 775 780
Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr
785 790 795 800
Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe
805 810 815
Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala
820 825 830
Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
835 840 845
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
850 855 860
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His
865 870 875 880
Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
885 890 895
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile
900 905 910
Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr
915 920 925
Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His
930 935 940
Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn
945 950 955 960
Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile
965 970 975
Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp
980 985 990
Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn
995 1000 1005
Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu
1010 1015 1020
Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr
1025 1030 1035
Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln
1040 1045 1050
Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val
1055 1060 1065
Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val
1070 1075 1080
Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile
1085 1090 1095
Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala
1100 1105 1110
Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu
1115 1120 1125
Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile
1130 1135 1140
Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val
1145 1150 1155
Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys
1160 1165 1170
Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp
1175 1180 1185
Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp
1190 1195 1200
Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg
1205 1210 1215
Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp
1220 1225 1230
Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys
1235 1240 1245
Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys
1250 1255 1260
Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met
1265 1270 1275
Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp
1280 1285 1290
Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe
1295 1300 1305
Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro
1310 1315 1320
Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val
1325 1330 1335
Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu
1340 1345 1350
Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr
1355 1360 1365
Ala Gln Thr Ser Val Lys His
1370 1375
<210> 4
<211> 1377
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 4
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly
290 295 300
Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys
305 310 315 320
Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln
325 330 335
Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp
340 345 350
Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp
355 360 365
Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp
370 375 380
Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn
385 390 395 400
Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln
405 410 415
Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
420 425 430
Lys Ala Glu Arg Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu
435 440 445
Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe
450 455 460
Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr
465 470 475 480
Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile
485 490 495
Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn
500 505 510
Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu
515 520 525
Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe
530 535 540
Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val
545 550 555 560
Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys
565 570 575
Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu
580 585 590
Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu
595 600 605
Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly
610 615 620
Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val
625 630 635 640
Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile
645 650 655
Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu
660 665 670
Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu
675 680 685
Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu
690 695 700
Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys
705 710 715 720
Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro
725 730 735
Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met
740 745 750
Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly
755 760 765
Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu
770 775 780
Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn
785 790 795 800
Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala
805 810 815
Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu
820 825 830
Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu
835 840 845
Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly
850 855 860
Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
865 870 875 880
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
885 890 895
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser
900 905 910
Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
915 920 925
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu
930 935 940
Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys
945 950 955 960
Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr
965 970 975
Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val
980 985 990
Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile
995 1000 1005
Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser
1010 1015 1020
Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn
1025 1030 1035
Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile
1040 1045 1050
Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp
1055 1060 1065
Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser
1070 1075 1080
Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met
1085 1090 1095
Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro
1100 1105 1110
Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys
1115 1120 1125
Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe
1130 1135 1140
Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly
1145 1150 1155
Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser
1160 1165 1170
Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu
1175 1180 1185
Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg
1190 1195 1200
Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly
1205 1210 1215
Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe
1220 1225 1230
Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe
1235 1240 1245
Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu
1250 1255 1260
Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala
1265 1270 1275
Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg
1280 1285 1290
Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly
1295 1300 1305
Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile
1310 1315 1320
Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg
1325 1330 1335
Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu
1340 1345 1350
Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu
1355 1360 1365
Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 5
<211> 1379
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 5
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly
290 295 300
Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys
305 310 315 320
Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln
325 330 335
Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp
340 345 350
Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp
355 360 365
Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp
370 375 380
Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn
385 390 395 400
Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln
405 410 415
Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
420 425 430
Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Glu Gly Tyr Thr Ser Asp
435 440 445
Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu
450 455 460
Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp
465 470 475 480
Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser
485 490 495
Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys
500 505 510
Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val
515 520 525
Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly
530 535 540
Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser
545 550 555 560
Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile
565 570 575
Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val
580 585 590
Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys
595 600 605
Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe
610 615 620
Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp
625 630 635 640
Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp
645 650 655
Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe
660 665 670
Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp
675 680 685
Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr
690 695 700
Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile
705 710 715 720
Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu
725 730 735
Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys
740 745 750
Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys
755 760 765
Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His
770 775 780
Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp
785 790 795 800
Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp
805 810 815
Ile Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser
820 825 830
Phe Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly
835 840 845
Lys Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser
850 855 860
His Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp
865 870 875 880
Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe
885 890 895
Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
900 905 910
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
915 920 925
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln
930 935 940
Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
945 950 955 960
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn
965 970 975
Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile
980 985 990
Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
995 1000 1005
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1010 1015 1020
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1025 1030 1035
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1040 1045 1050
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1055 1060 1065
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1070 1075 1080
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1085 1090 1095
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1100 1105 1110
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1115 1120 1125
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1130 1135 1140
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1145 1150 1155
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1160 1165 1170
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1175 1180 1185
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1190 1195 1200
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1205 1210 1215
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1220 1225 1230
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1235 1240 1245
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1250 1255 1260
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1265 1270 1275
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1280 1285 1290
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1295 1300 1305
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1310 1315 1320
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1325 1330 1335
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1340 1345 1350
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1355 1360 1365
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 6
<211> 1373
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 6
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn
290 295 300
Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly
305 310 315 320
Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn
325 330 335
Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val
340 345 350
Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His
355 360 365
Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val
370 375 380
Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser
385 390 395 400
Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn
405 410 415
Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu
420 425 430
Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val
435 440 445
Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys
450 455 460
Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly
465 470 475 480
Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile
485 490 495
Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp
500 505 510
Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp
515 520 525
Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln
530 535 540
Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys
545 550 555 560
Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser
565 570 575
Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys
580 585 590
Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val
595 600 605
Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu
610 615 620
Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp
625 630 635 640
Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val
645 650 655
Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn
660 665 670
Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg
675 680 685
Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp
690 695 700
Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn
705 710 715 720
Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys
725 730 735
Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn
740 745 750
Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys
755 760 765
Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe
770 775 780
Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe
785 790 795 800
Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
805 810 815
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
820 825 830
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln
835 840 845
Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
850 855 860
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln
865 870 875 880
Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu
885 890 895
Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn
900 905 910
Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val
915 920 925
Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro
930 935 940
Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu
945 950 955 960
Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile
965 970 975
Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys
980 985 990
Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe
995 1000 1005
Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys
1010 1015 1020
Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile
1025 1030 1035
Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val
1040 1045 1050
His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala
1055 1060 1065
Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val
1070 1075 1080
Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys
1085 1090 1095
Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly
1100 1105 1110
Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe
1115 1120 1125
Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala
1130 1135 1140
Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu
1145 1150 1155
Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile
1160 1165 1170
Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe
1175 1180 1185
Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp
1190 1195 1200
Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg
1205 1210 1215
Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu
1220 1225 1230
Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly
1235 1240 1245
Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln
1250 1255 1260
Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu
1265 1270 1275
Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp
1280 1285 1290
Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp
1295 1300 1305
Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn
1310 1315 1320
Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp
1325 1330 1335
Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys
1340 1345 1350
Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln
1355 1360 1365
Thr Ser Val Lys His
1370
<210> 7
<211> 1375
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 7
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Glu Asn Gln Thr Thr Gln Lys Gly Gln
290 295 300
Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu
305 310 315 320
Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu
325 330 335
Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met
340 345 350
Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val
355 360 365
Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn
370 375 380
Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val
385 390 395 400
Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu
405 410 415
Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys
420 425 430
Ala Glu Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu Val Leu
435 440 445
Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser
450 455 460
Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser
465 470 475 480
Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys
485 490 495
Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu
500 505 510
Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr
515 520 525
Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu
530 535 540
Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys
545 550 555 560
Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr
565 570 575
Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser
580 585 590
Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp
595 600 605
Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly
610 615 620
Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala
625 630 635 640
Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn
645 650 655
Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe
660 665 670
Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp
675 680 685
Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile
690 695 700
Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp
705 710 715 720
Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro
725 730 735
Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr
740 745 750
Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe
755 760 765
Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp
770 775 780
Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr
785 790 795 800
Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe
805 810 815
Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala
820 825 830
Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
835 840 845
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
850 855 860
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His
865 870 875 880
Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
885 890 895
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile
900 905 910
Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr
915 920 925
Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His
930 935 940
Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn
945 950 955 960
Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile
965 970 975
Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp
980 985 990
Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn
995 1000 1005
Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu
1010 1015 1020
Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr
1025 1030 1035
Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln
1040 1045 1050
Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val
1055 1060 1065
Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val
1070 1075 1080
Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile
1085 1090 1095
Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala
1100 1105 1110
Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu
1115 1120 1125
Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile
1130 1135 1140
Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val
1145 1150 1155
Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys
1160 1165 1170
Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp
1175 1180 1185
Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp
1190 1195 1200
Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg
1205 1210 1215
Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp
1220 1225 1230
Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys
1235 1240 1245
Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys
1250 1255 1260
Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met
1265 1270 1275
Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp
1280 1285 1290
Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe
1295 1300 1305
Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro
1310 1315 1320
Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val
1325 1330 1335
Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu
1340 1345 1350
Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr
1355 1360 1365
Ala Gln Thr Ser Val Lys His
1370 1375
<210> 8
<211> 1377
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 8
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
290 295 300
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
305 310 315 320
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
325 330 335
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
340 345 350
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
355 360 365
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
370 375 380
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
385 390 395 400
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
405 410 415
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
420 425 430
Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu
435 440 445
Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe
450 455 460
Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr
465 470 475 480
Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile
485 490 495
Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn
500 505 510
Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu
515 520 525
Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe
530 535 540
Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val
545 550 555 560
Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys
565 570 575
Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu
580 585 590
Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu
595 600 605
Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly
610 615 620
Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val
625 630 635 640
Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile
645 650 655
Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu
660 665 670
Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu
675 680 685
Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu
690 695 700
Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys
705 710 715 720
Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro
725 730 735
Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met
740 745 750
Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly
755 760 765
Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu
770 775 780
Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn
785 790 795 800
Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala
805 810 815
Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu
820 825 830
Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu
835 840 845
Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly
850 855 860
Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
865 870 875 880
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
885 890 895
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser
900 905 910
Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
915 920 925
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu
930 935 940
Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys
945 950 955 960
Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr
965 970 975
Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val
980 985 990
Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile
995 1000 1005
Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser
1010 1015 1020
Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn
1025 1030 1035
Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile
1040 1045 1050
Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp
1055 1060 1065
Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser
1070 1075 1080
Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met
1085 1090 1095
Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro
1100 1105 1110
Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys
1115 1120 1125
Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe
1130 1135 1140
Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly
1145 1150 1155
Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser
1160 1165 1170
Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu
1175 1180 1185
Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg
1190 1195 1200
Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly
1205 1210 1215
Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe
1220 1225 1230
Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe
1235 1240 1245
Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu
1250 1255 1260
Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala
1265 1270 1275
Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg
1280 1285 1290
Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly
1295 1300 1305
Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile
1310 1315 1320
Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg
1325 1330 1335
Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu
1340 1345 1350
Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu
1355 1360 1365
Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 9
<211> 1379
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 9
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
290 295 300
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
305 310 315 320
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
325 330 335
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
340 345 350
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
355 360 365
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
370 375 380
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
385 390 395 400
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
405 410 415
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
420 425 430
Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Gly Tyr Thr Ser Asp
435 440 445
Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu
450 455 460
Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp
465 470 475 480
Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser
485 490 495
Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys
500 505 510
Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val
515 520 525
Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly
530 535 540
Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser
545 550 555 560
Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile
565 570 575
Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val
580 585 590
Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys
595 600 605
Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe
610 615 620
Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp
625 630 635 640
Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp
645 650 655
Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe
660 665 670
Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp
675 680 685
Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr
690 695 700
Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile
705 710 715 720
Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu
725 730 735
Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys
740 745 750
Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys
755 760 765
Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His
770 775 780
Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp
785 790 795 800
Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp
805 810 815
Ile Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser
820 825 830
Phe Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly
835 840 845
Lys Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser
850 855 860
His Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp
865 870 875 880
Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe
885 890 895
Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
900 905 910
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
915 920 925
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln
930 935 940
Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
945 950 955 960
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn
965 970 975
Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile
980 985 990
Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
995 1000 1005
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1010 1015 1020
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1025 1030 1035
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1040 1045 1050
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1055 1060 1065
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1070 1075 1080
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1085 1090 1095
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1100 1105 1110
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1115 1120 1125
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1130 1135 1140
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1145 1150 1155
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1160 1165 1170
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1175 1180 1185
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1190 1195 1200
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1205 1210 1215
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1220 1225 1230
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1235 1240 1245
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1250 1255 1260
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1265 1270 1275
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1280 1285 1290
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1295 1300 1305
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1310 1315 1320
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1325 1330 1335
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1340 1345 1350
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1355 1360 1365
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 10
<211> 1373
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 10
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser
290 295 300
Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser
305 310 315 320
Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu
325 330 335
Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp
340 345 350
Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile
355 360 365
Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu
370 375 380
Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu
385 390 395 400
Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala
405 410 415
Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg
420 425 430
Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val
435 440 445
Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys
450 455 460
Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly
465 470 475 480
Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile
485 490 495
Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp
500 505 510
Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp
515 520 525
Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln
530 535 540
Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys
545 550 555 560
Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser
565 570 575
Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys
580 585 590
Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val
595 600 605
Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu
610 615 620
Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp
625 630 635 640
Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val
645 650 655
Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn
660 665 670
Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg
675 680 685
Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp
690 695 700
Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn
705 710 715 720
Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys
725 730 735
Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn
740 745 750
Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys
755 760 765
Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe
770 775 780
Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe
785 790 795 800
Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
805 810 815
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
820 825 830
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln
835 840 845
Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
850 855 860
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln
865 870 875 880
Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu
885 890 895
Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn
900 905 910
Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val
915 920 925
Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro
930 935 940
Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu
945 950 955 960
Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile
965 970 975
Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys
980 985 990
Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe
995 1000 1005
Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys
1010 1015 1020
Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile
1025 1030 1035
Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val
1040 1045 1050
His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala
1055 1060 1065
Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val
1070 1075 1080
Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys
1085 1090 1095
Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly
1100 1105 1110
Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe
1115 1120 1125
Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala
1130 1135 1140
Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu
1145 1150 1155
Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile
1160 1165 1170
Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe
1175 1180 1185
Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp
1190 1195 1200
Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg
1205 1210 1215
Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu
1220 1225 1230
Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly
1235 1240 1245
Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln
1250 1255 1260
Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu
1265 1270 1275
Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp
1280 1285 1290
Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp
1295 1300 1305
Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn
1310 1315 1320
Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp
1325 1330 1335
Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys
1340 1345 1350
Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln
1355 1360 1365
Thr Ser Val Lys His
1370
<210> 11
<211> 1375
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 11
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys
290 295 300
Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu
305 310 315 320
Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln
325 330 335
Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr
340 345 350
Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp
355 360 365
His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys
370 375 380
Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro
385 390 395 400
Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu
405 410 415
Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala
420 425 430
Glu Arg Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu
435 440 445
Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser
450 455 460
Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser
465 470 475 480
Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys
485 490 495
Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu
500 505 510
Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr
515 520 525
Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu
530 535 540
Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys
545 550 555 560
Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr
565 570 575
Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser
580 585 590
Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp
595 600 605
Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly
610 615 620
Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala
625 630 635 640
Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn
645 650 655
Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe
660 665 670
Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp
675 680 685
Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile
690 695 700
Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp
705 710 715 720
Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro
725 730 735
Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr
740 745 750
Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe
755 760 765
Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp
770 775 780
Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr
785 790 795 800
Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe
805 810 815
Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala
820 825 830
Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
835 840 845
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
850 855 860
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His
865 870 875 880
Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
885 890 895
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile
900 905 910
Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr
915 920 925
Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His
930 935 940
Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn
945 950 955 960
Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile
965 970 975
Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp
980 985 990
Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn
995 1000 1005
Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu
1010 1015 1020
Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr
1025 1030 1035
Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln
1040 1045 1050
Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val
1055 1060 1065
Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val
1070 1075 1080
Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile
1085 1090 1095
Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala
1100 1105 1110
Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu
1115 1120 1125
Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile
1130 1135 1140
Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val
1145 1150 1155
Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys
1160 1165 1170
Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp
1175 1180 1185
Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp
1190 1195 1200
Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg
1205 1210 1215
Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp
1220 1225 1230
Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys
1235 1240 1245
Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys
1250 1255 1260
Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met
1265 1270 1275
Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp
1280 1285 1290
Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe
1295 1300 1305
Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro
1310 1315 1320
Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val
1325 1330 1335
Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu
1340 1345 1350
Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr
1355 1360 1365
Ala Gln Thr Ser Val Lys His
1370 1375
<210> 12
<211> 1377
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 12
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly
290 295 300
Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys
305 310 315 320
Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln
325 330 335
Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp
340 345 350
Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp
355 360 365
Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp
370 375 380
Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn
385 390 395 400
Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln
405 410 415
Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
420 425 430
Lys Ala Glu Arg Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu
435 440 445
Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe
450 455 460
Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr
465 470 475 480
Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile
485 490 495
Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn
500 505 510
Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu
515 520 525
Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe
530 535 540
Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val
545 550 555 560
Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys
565 570 575
Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu
580 585 590
Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu
595 600 605
Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly
610 615 620
Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val
625 630 635 640
Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile
645 650 655
Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu
660 665 670
Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu
675 680 685
Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu
690 695 700
Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys
705 710 715 720
Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro
725 730 735
Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met
740 745 750
Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly
755 760 765
Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu
770 775 780
Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn
785 790 795 800
Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala
805 810 815
Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu
820 825 830
Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu
835 840 845
Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly
850 855 860
Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
865 870 875 880
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
885 890 895
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser
900 905 910
Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
915 920 925
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu
930 935 940
Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys
945 950 955 960
Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr
965 970 975
Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val
980 985 990
Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile
995 1000 1005
Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser
1010 1015 1020
Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn
1025 1030 1035
Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile
1040 1045 1050
Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp
1055 1060 1065
Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser
1070 1075 1080
Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met
1085 1090 1095
Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro
1100 1105 1110
Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys
1115 1120 1125
Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe
1130 1135 1140
Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly
1145 1150 1155
Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser
1160 1165 1170
Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu
1175 1180 1185
Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg
1190 1195 1200
Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly
1205 1210 1215
Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe
1220 1225 1230
Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe
1235 1240 1245
Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu
1250 1255 1260
Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala
1265 1270 1275
Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg
1280 1285 1290
Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly
1295 1300 1305
Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile
1310 1315 1320
Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg
1325 1330 1335
Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu
1340 1345 1350
Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu
1355 1360 1365
Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 13
<211> 1379
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 13
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly
290 295 300
Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys
305 310 315 320
Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln
325 330 335
Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp
340 345 350
Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp
355 360 365
Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp
370 375 380
Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn
385 390 395 400
Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln
405 410 415
Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
420 425 430
Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Glu Gly Tyr Thr Ser Asp
435 440 445
Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu
450 455 460
Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp
465 470 475 480
Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser
485 490 495
Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys
500 505 510
Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val
515 520 525
Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly
530 535 540
Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser
545 550 555 560
Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile
565 570 575
Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val
580 585 590
Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys
595 600 605
Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe
610 615 620
Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp
625 630 635 640
Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp
645 650 655
Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe
660 665 670
Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp
675 680 685
Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr
690 695 700
Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile
705 710 715 720
Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu
725 730 735
Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys
740 745 750
Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys
755 760 765
Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His
770 775 780
Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp
785 790 795 800
Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp
805 810 815
Ile Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser
820 825 830
Phe Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly
835 840 845
Lys Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser
850 855 860
His Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp
865 870 875 880
Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe
885 890 895
Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
900 905 910
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
915 920 925
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln
930 935 940
Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
945 950 955 960
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn
965 970 975
Pro Tyr Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile
980 985 990
Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
995 1000 1005
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1010 1015 1020
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1025 1030 1035
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1040 1045 1050
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1055 1060 1065
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1070 1075 1080
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1085 1090 1095
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1100 1105 1110
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1115 1120 1125
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1130 1135 1140
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1145 1150 1155
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1160 1165 1170
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1175 1180 1185
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1190 1195 1200
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1205 1210 1215
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1220 1225 1230
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1235 1240 1245
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1250 1255 1260
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1265 1270 1275
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1280 1285 1290
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1295 1300 1305
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1310 1315 1320
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1325 1330 1335
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1340 1345 1350
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1355 1360 1365
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 14
<211> 1373
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 14
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn
290 295 300
Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly
305 310 315 320
Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn
325 330 335
Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val
340 345 350
Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His
355 360 365
Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val
370 375 380
Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser
385 390 395 400
Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn
405 410 415
Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu
420 425 430
Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val
435 440 445
Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys
450 455 460
Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly
465 470 475 480
Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile
485 490 495
Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp
500 505 510
Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp
515 520 525
Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln
530 535 540
Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys
545 550 555 560
Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser
565 570 575
Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys
580 585 590
Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val
595 600 605
Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu
610 615 620
Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp
625 630 635 640
Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val
645 650 655
Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn
660 665 670
Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg
675 680 685
Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp
690 695 700
Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn
705 710 715 720
Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys
725 730 735
Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn
740 745 750
Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys
755 760 765
Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe
770 775 780
Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe
785 790 795 800
Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
805 810 815
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
820 825 830
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln
835 840 845
Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
850 855 860
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln
865 870 875 880
Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu
885 890 895
Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn
900 905 910
Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val
915 920 925
Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro
930 935 940
Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu
945 950 955 960
Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile
965 970 975
Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys
980 985 990
Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe
995 1000 1005
Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys
1010 1015 1020
Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile
1025 1030 1035
Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val
1040 1045 1050
His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala
1055 1060 1065
Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val
1070 1075 1080
Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys
1085 1090 1095
Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly
1100 1105 1110
Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe
1115 1120 1125
Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala
1130 1135 1140
Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu
1145 1150 1155
Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile
1160 1165 1170
Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe
1175 1180 1185
Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp
1190 1195 1200
Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg
1205 1210 1215
Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu
1220 1225 1230
Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly
1235 1240 1245
Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln
1250 1255 1260
Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu
1265 1270 1275
Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp
1280 1285 1290
Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp
1295 1300 1305
Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn
1310 1315 1320
Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp
1325 1330 1335
Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys
1340 1345 1350
Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln
1355 1360 1365
Thr Ser Val Lys His
1370
<210> 15
<211> 1375
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 15
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Glu Asn Gln Thr Thr Gln Lys Gly Gln
290 295 300
Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu
305 310 315 320
Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu
325 330 335
Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met
340 345 350
Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val
355 360 365
Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn
370 375 380
Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val
385 390 395 400
Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu
405 410 415
Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys
420 425 430
Ala Glu Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu Val Leu
435 440 445
Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser
450 455 460
Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser
465 470 475 480
Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys
485 490 495
Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu
500 505 510
Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr
515 520 525
Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu
530 535 540
Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys
545 550 555 560
Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr
565 570 575
Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser
580 585 590
Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp
595 600 605
Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly
610 615 620
Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala
625 630 635 640
Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn
645 650 655
Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe
660 665 670
Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp
675 680 685
Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile
690 695 700
Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp
705 710 715 720
Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro
725 730 735
Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr
740 745 750
Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe
755 760 765
Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp
770 775 780
Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr
785 790 795 800
Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe
805 810 815
Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala
820 825 830
Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
835 840 845
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
850 855 860
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His
865 870 875 880
Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
885 890 895
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile
900 905 910
Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr
915 920 925
Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His
930 935 940
Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn
945 950 955 960
Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile
965 970 975
Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp
980 985 990
Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn
995 1000 1005
Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu
1010 1015 1020
Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr
1025 1030 1035
Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln
1040 1045 1050
Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val
1055 1060 1065
Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val
1070 1075 1080
Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile
1085 1090 1095
Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala
1100 1105 1110
Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu
1115 1120 1125
Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile
1130 1135 1140
Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val
1145 1150 1155
Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys
1160 1165 1170
Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp
1175 1180 1185
Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp
1190 1195 1200
Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg
1205 1210 1215
Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp
1220 1225 1230
Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys
1235 1240 1245
Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys
1250 1255 1260
Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met
1265 1270 1275
Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp
1280 1285 1290
Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe
1295 1300 1305
Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro
1310 1315 1320
Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val
1325 1330 1335
Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu
1340 1345 1350
Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr
1355 1360 1365
Ala Gln Thr Ser Val Lys His
1370 1375
<210> 16
<211> 1377
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 16
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
290 295 300
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
305 310 315 320
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
325 330 335
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
340 345 350
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
355 360 365
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
370 375 380
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
385 390 395 400
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
405 410 415
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
420 425 430
Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu
435 440 445
Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe
450 455 460
Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr
465 470 475 480
Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile
485 490 495
Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn
500 505 510
Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu
515 520 525
Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe
530 535 540
Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val
545 550 555 560
Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys
565 570 575
Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu
580 585 590
Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu
595 600 605
Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly
610 615 620
Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val
625 630 635 640
Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile
645 650 655
Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu
660 665 670
Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu
675 680 685
Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu
690 695 700
Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys
705 710 715 720
Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro
725 730 735
Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met
740 745 750
Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly
755 760 765
Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu
770 775 780
Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn
785 790 795 800
Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala
805 810 815
Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu
820 825 830
Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu
835 840 845
Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly
850 855 860
Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
865 870 875 880
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
885 890 895
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser
900 905 910
Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
915 920 925
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu
930 935 940
Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys
945 950 955 960
Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr
965 970 975
Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val
980 985 990
Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile
995 1000 1005
Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser
1010 1015 1020
Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn
1025 1030 1035
Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile
1040 1045 1050
Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp
1055 1060 1065
Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser
1070 1075 1080
Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met
1085 1090 1095
Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro
1100 1105 1110
Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys
1115 1120 1125
Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe
1130 1135 1140
Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly
1145 1150 1155
Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser
1160 1165 1170
Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu
1175 1180 1185
Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg
1190 1195 1200
Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly
1205 1210 1215
Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe
1220 1225 1230
Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe
1235 1240 1245
Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu
1250 1255 1260
Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala
1265 1270 1275
Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg
1280 1285 1290
Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly
1295 1300 1305
Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile
1310 1315 1320
Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg
1325 1330 1335
Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu
1340 1345 1350
Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu
1355 1360 1365
Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 17
<211> 1379
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 17
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
290 295 300
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
305 310 315 320
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
325 330 335
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
340 345 350
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
355 360 365
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
370 375 380
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
385 390 395 400
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
405 410 415
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
420 425 430
Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Gly Tyr Thr Ser Asp
435 440 445
Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu
450 455 460
Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp
465 470 475 480
Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser
485 490 495
Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys
500 505 510
Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val
515 520 525
Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly
530 535 540
Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser
545 550 555 560
Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile
565 570 575
Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val
580 585 590
Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys
595 600 605
Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe
610 615 620
Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp
625 630 635 640
Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp
645 650 655
Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe
660 665 670
Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp
675 680 685
Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr
690 695 700
Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile
705 710 715 720
Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu
725 730 735
Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys
740 745 750
Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys
755 760 765
Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His
770 775 780
Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp
785 790 795 800
Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp
805 810 815
Ile Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser
820 825 830
Phe Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly
835 840 845
Lys Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser
850 855 860
His Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp
865 870 875 880
Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe
885 890 895
Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
900 905 910
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
915 920 925
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln
930 935 940
Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
945 950 955 960
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn
965 970 975
Pro Tyr Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile
980 985 990
Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
995 1000 1005
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1010 1015 1020
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1025 1030 1035
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1040 1045 1050
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1055 1060 1065
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1070 1075 1080
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1085 1090 1095
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1100 1105 1110
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1115 1120 1125
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1130 1135 1140
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1145 1150 1155
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1160 1165 1170
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1175 1180 1185
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1190 1195 1200
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1205 1210 1215
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1220 1225 1230
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1235 1240 1245
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1250 1255 1260
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1265 1270 1275
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1280 1285 1290
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1295 1300 1305
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1310 1315 1320
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1325 1330 1335
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1340 1345 1350
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1355 1360 1365
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 18
<211> 36
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 18
Glu Lys Ser Lys Asn Asp Arg Ser Lys Pro Gln Pro Ser Asp Asp Arg
1 5 10 15
Asp Arg Gln Pro Pro Ser Gly Glu Asp Tyr Pro Glu Trp Lys Ala Pro
20 25 30
Gly Glu Tyr Glu
35
<210> 19
<211> 34
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 19
Gln Glu Pro Lys Pro Gln Asp Gln Ser Ser Glu Val Pro Pro Pro Pro
1 5 10 15
Gly Ser Gln Lys Pro Gly Thr Lys Glu Pro His Asp Ser Lys Ser Ser
20 25 30
Gly Pro
<210> 20
<211> 34
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 20
Pro Asp Asn Ser Ser Gly Gln Lys Leu Gln Leu Pro Gln Pro Ser Asp
1 5 10 15
Lys Pro Gln Asp Ser Arg Glu Lys Ser Asp Ser Leu Pro Ser Asp Lys
20 25 30
Arg Asp
<210> 21
<211> 36
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 21
Pro Asp Asn Ser Thr Leu Gln Thr Leu Gln Leu Pro Gln Pro Thr Pro
1 5 10 15
Ser Ser Thr Asp Thr Gln Gln Thr Ser Asp Thr Asp Pro Glu Asp Thr
20 25 30
Thr Asp Val Ile
35
<210> 22
<211> 30
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 22
Ser Thr Ser Gln Ser Asp Gly Ser Ser Val Pro Ala Asp Ile Asp Gln
1 5 10 15
Ser Ser Asp Ser Asp Gln Ser Ser Ser Gln Gly Gln Pro Gly
20 25 30
<210> 23
<211> 14
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 23
Ala Lys Pro Asp Asp Glu Ser Gln Lys Pro Pro Gln Asp Asp
1 5 10
<210> 24
<211> 14
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 24
Leu Gln Leu Glu Pro Gly Pro Thr Thr Pro Glu Tyr Pro Ile
1 5 10
<210> 25
<211> 14
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 25
Ile Gln Leu Pro Pro Ser Asp Thr Thr Pro Glu Asn Pro Ile
1 5 10
<210> 26
<211> 12
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 26
Glu Ser Asn Asp Asn Ser Gln Val Pro Pro Ser Leu
1 5 10
<210> 27
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 27
Ser Glu Gln Gln Glu Tyr Pro Gly Ser Gly
1 5 10
<210> 28
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 28
Asn Asn Ser Glu Gln Gln Glu Asn Pro Ala
1 5 10
<210> 29
<211> 12
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 29
Ser Thr Asp Gly Ser Gly Gln Pro Lys His Lys Pro
1 5 10
<210> 30
<211> 20
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 30
Pro Lys Pro Ser Ser Glu Ser Gly Glu Arg Tyr Glu Gln Gln Pro Glu
1 5 10 15
Pro Pro Pro Pro
20
<210> 31
<211> 16
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 31
Lys Gly Gly Gly Gly Glu Pro Asp Glu Lys Arg Pro Ser Gln Ser Ser
1 5 10 15
<210> 32
<211> 14
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 32
Tyr Ala Gly Gly Thr Pro Lys Glu Pro Pro Pro Pro Asn Ser
1 5 10
<210> 33
<211> 14
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 33
Pro Leu Val Ala Gly Gly Thr Pro Phe Glu Pro Pro Pro Pro
1 5 10
<210> 34
<211> 14
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 34
Pro Gln Pro Asp Glu Arg Ser Gln Ile Pro Asp Asn Lys Glu
1 5 10
<210> 35
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 35
Tyr Thr Asp Glu Lys Pro Leu Pro Arg Ser
1 5 10
<210> 36
<211> 12
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 36
Ser His Pro Pro Gln Glu Pro Pro Gln Ser Asn Leu
1 5 10
<210> 37
<211> 16
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 37
Ser Glu Ser Pro Ser Lys Gln Gln Pro Glu Pro Lys Ser Ser Lys Gly
1 5 10 15
<210> 38
<211> 16
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 38
Ser Glu Ser Pro Thr Asn Gln Gln Pro Glu Pro Gln Trp Thr Thr Asp
1 5 10 15
<210> 39
<211> 16
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 39
Gly Gly Ser Lys Gly Pro Pro Pro Ser Pro Pro Pro Pro Gln Pro Glu
1 5 10 15
<210> 40
<211> 16
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 40
Gly Pro Leu Pro Ala Pro Pro Pro Gln Pro Pro Pro Pro Gln Pro Asn
1 5 10 15
<210> 41
<211> 14
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 41
Arg Pro Leu Pro His Asp Asn Asn Lys Gln Asp Tyr Ser Lys
1 5 10
<210> 42
<211> 61
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (8)..(9)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (11)..(12)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (14)..(15)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (17)..(18)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (20)..(21)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (22)..(22)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (23)..(24)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (25)..(25)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (26)..(27)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (29)..(30)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (32)..(33)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (34)..(34)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (35)..(36)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (37)..(37)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (38)..(39)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (40)..(40)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (41)..(42)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (43)..(43)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (44)..(45)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (46)..(46)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (47)..(48)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (49)..(49)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (50)..(51)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (52)..(52)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (53)..(54)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (55)..(55)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (56)..(57)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (58)..(58)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (59)..(60)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (61)..(61)
<223> Xaa present or absent and Ser when present
<400> 42
Ser Gly Gly Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
<210> 43
<211> 4
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 43
Ser Gly Gly Ser
1
<210> 44
<211> 100
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<220>
<221> MISC_FEATURE
<222> (6)..(9)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (11)..(14)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (16)..(19)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (21)..(24)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (25)..(25)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (26)..(29)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (30)..(30)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (31)..(34)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (35)..(35)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (36)..(39)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (40)..(40)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (41)..(44)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (45)..(45)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (46)..(49)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (50)..(50)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (51)..(54)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (55)..(55)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (56)..(59)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (60)..(60)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (61)..(64)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (65)..(65)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (66)..(69)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (70)..(70)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (71)..(74)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (75)..(75)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (76)..(79)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (80)..(80)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (81)..(84)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (85)..(85)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (86)..(89)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (90)..(90)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (91)..(94)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (95)..(95)
<223> Xaa present or absent and Ser when present
<220>
<221> MISC_FEATURE
<222> (96)..(99)
<223> Xaa present or absent and Gly when present
<220>
<221> MISC_FEATURE
<222> (100)..(100)
<223> Xaa present or absent and Ser when present
<400> 44
Gly Gly Gly Gly Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
85 90 95
Xaa Xaa Xaa Xaa
100
<210> 45
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 45
Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10
<210> 46
<211> 16
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 46
Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser
1 5 10 15
<210> 47
<211> 32
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 47
Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly Ser Glu Thr Pro Gly Thr
1 5 10 15
Ser Glu Ser Ala Thr Pro Glu Ser Ser Gly Gly Ser Ser Gly Gly Ser
20 25 30
<210> 48
<211> 1592
<212> DNA
<213> Tribulus alfalfa
<400> 48
actgttaata atttttaaac gtcagcgcac taaaaaaacg aaaagacgga cacgtgaaaa 60
taaaaaacac acactagttt atgacgcaat actattttac ttatgatttg ggtacattag 120
acaaaaccgt gaaagagatg tatcagctat gaaacctgta tacttcaata cagagactta 180
ctcatatcgg atacgtacgc acgaagtatc atattaatta ttttaatttt taataaatat 240
tttatcggat acttatgtga tactctacat atacacaagg atatttctaa gatactttat 300
agatacgtat cctagaaaaa catgaagagt aaaaaagtga gacaatgttg taaaaattca 360
ttataaatgt atatgattca attttagata tgcatcagta taattgattc tcgatgaaac 420
acttaaaatt atatttcttg tggaagaacg tagcgagaga ggtgattcag ttagacaaca 480
ttaaataaaa ttaatgttaa gttcttttaa tgatgtttct ctcaatatca catcatatga 540
aaatgtaata tgatttataa gaaaattttt aaaaaattta ttttaataat cacatgtact 600
attttttaaa aattgtatct tttataataa tacaataata aagagtaatc agtgttaatt 660
tttcttcaaa tataagtttt attataaatc attgttaacg tatcataagt cattaccgta 720
tcgtatctta attttttttt aaaaaccgct aattcacgta cccgtattgt attgtacccg 780
cacctgtatc acaatcgatc ttagttagaa gaattgtctc gaggcggtgc aagacagcat 840
ataatagacg tggactctct tataccaaac gttgtcgtat cacaaagggt taggtaacaa 900
gtcacagttt gtccacgtgt cacgttttaa ttggaagagg tgccgttggc gtaatataac 960
agccaatcga tttttgctat aaaagcaaat caggtaaact aaacttcttc attcttttct 1020
tccccatcgc tacaaaaccg gttcctttgg aaaagagatt cattcaaacc tagcacccaa 1080
ttccgtttca aggtataatc tactttctat tcttcgatta ttttattatt attagctact 1140
atcgtttaat cgatcttttc ttttgatccg tcaaatttaa attcaattag ggttttgttc 1200
ttttctttca tctgattgaa atccttctga attgaaccgt ttacttgatt ttactgttta 1260
ttgtatgatt taatcctttg tttttcaaag acagtcttta gattgtgatt aggggttcat 1320
ataaattttt agatttggat ttttgtattg tatgattcaa aaaatacgtc ctttaattag 1380
attagtacat ggatattttt tacccgattt attgattgtc agggagaatt tgatgagcaa 1440
gtttttttga tgtctgttgt aaattgaatt gattataatt gctgatctgc tgcttccagt 1500
tttcataacc catattcttt taaccttgtt gtacacacaa tgaaaaattg gtgattgatt 1560
catttgtttt tctttgtttt ggattataca gg 1592
<210> 49
<211> 2000
<212> DNA
<213> corn
<400> 49
gtcgtgcccc tctctagaga taaagagcat tgcatgtcta aagtataaaa aattaccaca 60
tatttttttg tcacacttat ttgaagtgta gtttatctat ctctatacat atatttaaac 120
ttcactctac aaataatata gtctataata ctaaaataat attagtgttt tagaggatca 180
tataaataaa ctgctagaca tggtctaaag gataattgaa tattttgaca atctacagtt 240
ttatcttttt agtgtgcatg tgatctctct gttttttttg caaatagctt gacctatata 300
atacttcatc cattttatta gtacatccat ttaggattta gggttgatgg tttctataga 360
ctaattttta gtacatccat tttattcttt ttagtctcta aattttttaa aactaaaact 420
ctattttagt tttttattta ataatttaga tataaaatga aataaaataa attgactaca 480
aataaaacaa atacccttta agaaataaaa aaactaagca aacatttttc ttgtttcgag 540
tagataatga caggctgttc aacgccgtcg acgagtctaa cggacaccaa ccagcgaacc 600
agcagcgtcg cgtcgggcca agcgaagcag acggcacggc atctctgtag ctgcctctgg 660
acccctctcg agagttccgc tccaccgttg gacttgctcc gctgtcggca tccagaaatt 720
gcgtggcgga gcggcagacg tgaggcggca cggcaggcgg cctcttcctc ctctcacggc 780
accggcagct acgggggatt cctttcccac cgctccttcg ctttcccttc ctcgcccgcc 840
gtaataaata gacaccccct ccacaccctc tttccccaac ctcgtgttcg ttcggagcgc 900
acacacacgc aaccagatct cccccaaatc cagccgtcgg cacctccgct tcaaggtacg 960
ccgctcatcc tccccccccc cctctctcta ccttctctag atcggcgatc cggtccatgg 1020
ttagggcccg gtagttctac ttctgttcat gtttgtgtta gagcaaacat gttcatgttc 1080
atgtttgtga tgatgtggtc tggttgggcg gtcgttctag atcggagtag gatactgttt 1140
caagctacct ggtggattta ttaattttgt atctgtatgt gtgtgccata catcttcata 1200
gttacgagtt taagatgatg gatggaaata tcgatctagg ataggtatac atgttgatgc 1260
gggttttact gatgcatata cagagatgct ttttttctcg cttggttgtg atgatatggt 1320
ctggttgggc ggtcgttcta gatcggagta gaatactgtt tcaaactacc tggtggattt 1380
attaaaggat aaagggtcgt tctagatcgg agtagaatac tgtttcaaac tacctggtgg 1440
atttattaaa ggatctgtat gtatgtgcct acatcttcat agttacgagt ttaagatgat 1500
ggatggaaat atcgatctag gataggtata catgttgatg cgggttttac tgatgcatat 1560
acagagatgc tttttttcgc ttggttgtga tgatgtggtc tggttgggcg gtcgttctag 1620
atcggagtag aatactgttt caaactacct ggtggattta ttaattttgt atctttatgt 1680
gtgtgccata catcttcata gttacgagtt taagatgatg gatggaaata ttgatctagg 1740
ataggtatac atgttgatgt gggttttact gatgcatata catgatggca tatgcggcat 1800
ctattcatat gctctaacct tgagtaccta tctattataa taaacaagta tgttttataa 1860
ttattttgat cttgatatac ttggatgatg gcatatgcag cagctatatg tggatttttt 1920
agccctgcct tcatacgcta tttatttgct tggtactgtt tcttttgtcc gatgctcacc 1980
ctgttgtttg gtgatacttc 2000
<210> 50
<211> 1227
<212> PRT
<213> unknown
<220>
<223> Mao Luoke bacterium
<400> 50
Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys Thr Leu
1 5 10 15
Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile Asp Asn
20 25 30
Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys Gly
35 40 45
Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn Asp Val
50 55 60
Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser Leu Phe
65 70 75 80
Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn Leu
85 90 95
Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn Glu
100 105 110
Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile Leu Pro
115 120 125
Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser Phe Asn
130 135 140
Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn Met
145 150 155 160
Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile Asn
165 170 175
Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys Val
180 185 190
Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu Lys Ile
195 200 205
Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu Phe Phe
210 215 220
Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile Ile
225 230 235 240
Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn Glu
245 250 255
Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys Phe
260 265 270
Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu Ser Phe
275 280 285
Tyr Gly Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg
290 295 300
Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu
305 310 315 320
Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe
325 330 335
Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly
340 345 350
Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile
355 360 365
His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg
370 375 380
Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln
385 390 395 400
Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile
405 410 415
Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu
420 425 430
Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn
435 440 445
Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser
450 455 460
Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn
465 470 475 480
Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu
485 490 495
Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln
500 505 510
Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln
515 520 525
Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr
530 535 540
Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys
545 550 555 560
Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn
565 570 575
Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu
580 585 590
Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser
595 600 605
Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp
610 615 620
Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp
625 630 635 640
Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn Phe
645 650 655
Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu Val
660 665 670
Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys Glu
675 680 685
Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile Tyr
690 695 700
Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu His Thr
705 710 715 720
Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln Ile Arg
725 730 735
Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu Lys Lys
740 745 750
Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn Lys Asn
755 760 765
Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val Tyr Lys
770 775 780
Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro Ile Ala
785 790 795 800
Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu Val Arg
805 810 815
Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile Ala Arg
820 825 830
Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly Asn
835 840 845
Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly
850 855 860
Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys
865 870 875 880
Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys
885 890 895
Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu
900 905 910
Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser
915 920 925
Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys
930 935 940
Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys
945 950 955 960
Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
965 970 975
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile
980 985 990
Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly
995 1000 1005
Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser
1010 1015 1020
Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu
1025 1030 1035
Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg
1040 1045 1050
Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly
1055 1060 1065
Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe
1070 1075 1080
Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe
1085 1090 1095
Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu
1100 1105 1110
Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala
1115 1120 1125
Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg
1130 1135 1140
Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly
1145 1150 1155
Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile
1160 1165 1170
Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg
1175 1180 1185
Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu
1190 1195 1200
Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu
1205 1210 1215
Glu Tyr Ala Gln Thr Ser Val Lys His
1220 1225
<210> 51
<211> 1307
<212> PRT
<213> amino acid coccus species
<400> 51
Met Thr Gln Phe Glu Gly Phe Thr Asn Leu Tyr Gln Val Ser Lys Thr
1 5 10 15
Leu Arg Phe Glu Leu Ile Pro Gln Gly Lys Thr Leu Lys His Ile Gln
20 25 30
Glu Gln Gly Phe Ile Glu Glu Asp Lys Ala Arg Asn Asp His Tyr Lys
35 40 45
Glu Leu Lys Pro Ile Ile Asp Arg Ile Tyr Lys Thr Tyr Ala Asp Gln
50 55 60
Cys Leu Gln Leu Val Gln Leu Asp Trp Glu Asn Leu Ser Ala Ala Ile
65 70 75 80
Asp Ser Tyr Arg Lys Glu Lys Thr Glu Glu Thr Arg Asn Ala Leu Ile
85 90 95
Glu Glu Gln Ala Thr Tyr Arg Asn Ala Ile His Asp Tyr Phe Ile Gly
100 105 110
Arg Thr Asp Asn Leu Thr Asp Ala Ile Asn Lys Arg His Ala Glu Ile
115 120 125
Tyr Lys Gly Leu Phe Lys Ala Glu Leu Phe Asn Gly Lys Val Leu Lys
130 135 140
Gln Leu Gly Thr Val Thr Thr Thr Glu His Glu Asn Ala Leu Leu Arg
145 150 155 160
Ser Phe Asp Lys Phe Thr Thr Tyr Phe Ser Gly Phe Tyr Glu Asn Arg
165 170 175
Lys Asn Val Phe Ser Ala Glu Asp Ile Ser Thr Ala Ile Pro His Arg
180 185 190
Ile Val Gln Asp Asn Phe Pro Lys Phe Lys Glu Asn Cys His Ile Phe
195 200 205
Thr Arg Leu Ile Thr Ala Val Pro Ser Leu Arg Glu His Phe Glu Asn
210 215 220
Val Lys Lys Ala Ile Gly Ile Phe Val Ser Thr Ser Ile Glu Glu Val
225 230 235 240
Phe Ser Phe Pro Phe Tyr Asn Gln Leu Leu Thr Gln Thr Gln Ile Asp
245 250 255
Leu Tyr Asn Gln Leu Leu Gly Gly Ile Ser Arg Glu Ala Gly Thr Glu
260 265 270
Lys Ile Lys Gly Leu Asn Glu Val Leu Asn Leu Ala Ile Gln Lys Asn
275 280 285
Asp Glu Thr Ala His Ile Ile Ala Ser Leu Pro His Arg Phe Ile Pro
290 295 300
Leu Phe Lys Gln Ile Leu Ser Asp Arg Asn Thr Leu Ser Phe Ile Leu
305 310 315 320
Glu Glu Phe Lys Ser Asp Glu Glu Val Ile Gln Ser Phe Cys Lys Tyr
325 330 335
Lys Thr Leu Leu Arg Asn Glu Asn Val Leu Glu Thr Ala Glu Ala Leu
340 345 350
Phe Asn Glu Leu Asn Ser Ile Asp Leu Thr His Ile Phe Ile Ser His
355 360 365
Lys Lys Leu Glu Thr Ile Ser Ser Ala Leu Cys Asp His Trp Asp Thr
370 375 380
Leu Arg Asn Ala Leu Tyr Glu Arg Arg Ile Ser Glu Leu Thr Gly Lys
385 390 395 400
Ile Thr Lys Ser Ala Lys Glu Lys Val Gln Arg Ser Leu Lys His Glu
405 410 415
Asp Ile Asn Leu Gln Glu Ile Ile Ser Ala Ala Gly Lys Glu Leu Ser
420 425 430
Glu Ala Phe Lys Gln Lys Thr Ser Glu Ile Leu Ser His Ala His Ala
435 440 445
Ala Leu Asp Gln Pro Leu Pro Thr Thr Leu Lys Lys Gln Glu Glu Lys
450 455 460
Glu Ile Leu Lys Ser Gln Leu Asp Ser Leu Leu Gly Leu Tyr His Leu
465 470 475 480
Leu Asp Trp Phe Ala Val Asp Glu Ser Asn Glu Val Asp Pro Glu Phe
485 490 495
Ser Ala Arg Leu Thr Gly Ile Lys Leu Glu Met Glu Pro Ser Leu Ser
500 505 510
Phe Tyr Asn Lys Ala Arg Asn Tyr Ala Thr Lys Lys Pro Tyr Ser Val
515 520 525
Glu Lys Phe Lys Leu Asn Phe Gln Met Pro Thr Leu Ala Ser Gly Trp
530 535 540
Asp Val Asn Lys Glu Lys Asn Asn Gly Ala Ile Leu Phe Val Lys Asn
545 550 555 560
Gly Leu Tyr Tyr Leu Gly Ile Met Pro Lys Gln Lys Gly Arg Tyr Lys
565 570 575
Ala Leu Ser Phe Glu Pro Thr Glu Lys Thr Ser Glu Gly Phe Asp Lys
580 585 590
Met Tyr Tyr Asp Tyr Phe Pro Asp Ala Ala Lys Met Ile Pro Lys Cys
595 600 605
Ser Thr Gln Leu Lys Ala Val Thr Ala His Phe Gln Thr His Thr Thr
610 615 620
Pro Ile Leu Leu Ser Asn Asn Phe Ile Glu Pro Leu Glu Ile Thr Lys
625 630 635 640
Glu Ile Tyr Asp Leu Asn Asn Pro Glu Lys Glu Pro Lys Lys Phe Gln
645 650 655
Thr Ala Tyr Ala Lys Lys Thr Gly Asp Gln Lys Gly Tyr Arg Glu Ala
660 665 670
Leu Cys Lys Trp Ile Asp Phe Thr Arg Asp Phe Leu Ser Lys Tyr Thr
675 680 685
Lys Thr Thr Ser Ile Asp Leu Ser Ser Leu Arg Pro Ser Ser Gln Tyr
690 695 700
Lys Asp Leu Gly Glu Tyr Tyr Ala Glu Leu Asn Pro Leu Leu Tyr His
705 710 715 720
Ile Ser Phe Gln Arg Ile Ala Glu Lys Glu Ile Met Asp Ala Val Glu
725 730 735
Thr Gly Lys Leu Tyr Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ala Lys
740 745 750
Gly His His Gly Lys Pro Asn Leu His Thr Leu Tyr Trp Thr Gly Leu
755 760 765
Phe Ser Pro Glu Asn Leu Ala Lys Thr Ser Ile Lys Leu Asn Gly Gln
770 775 780
Ala Glu Leu Phe Tyr Arg Pro Lys Ser Arg Met Lys Arg Met Ala His
785 790 795 800
Arg Leu Gly Glu Lys Met Leu Asn Lys Lys Leu Lys Asp Gln Lys Thr
805 810 815
Pro Ile Pro Asp Thr Leu Tyr Gln Glu Leu Tyr Asp Tyr Val Asn His
820 825 830
Arg Leu Ser His Asp Leu Ser Asp Glu Ala Arg Ala Leu Leu Pro Asn
835 840 845
Val Ile Thr Lys Glu Val Ser His Glu Ile Ile Lys Asp Arg Arg Phe
850 855 860
Thr Ser Asp Lys Phe Phe Phe His Val Pro Ile Thr Leu Asn Tyr Gln
865 870 875 880
Ala Ala Asn Ser Pro Ser Lys Phe Asn Gln Arg Val Asn Ala Tyr Leu
885 890 895
Lys Glu His Pro Glu Thr Pro Ile Ile Gly Ile Asp Arg Gly Glu Arg
900 905 910
Asn Leu Ile Tyr Ile Thr Val Ile Asp Ser Thr Gly Lys Ile Leu Glu
915 920 925
Gln Arg Ser Leu Asn Thr Ile Gln Gln Phe Asp Tyr Gln Lys Lys Leu
930 935 940
Asp Asn Arg Glu Lys Glu Arg Val Ala Ala Arg Gln Ala Trp Ser Val
945 950 955 960
Val Gly Thr Ile Lys Asp Leu Lys Gln Gly Tyr Leu Ser Gln Val Ile
965 970 975
His Glu Ile Val Asp Leu Met Ile His Tyr Gln Ala Val Val Val Leu
980 985 990
Glu Asn Leu Asn Phe Gly Phe Lys Ser Lys Arg Thr Gly Ile Ala Glu
995 1000 1005
Lys Ala Val Tyr Gln Gln Phe Glu Lys Met Leu Ile Asp Lys Leu
1010 1015 1020
Asn Cys Leu Val Leu Lys Asp Tyr Pro Ala Glu Lys Val Gly Gly
1025 1030 1035
Val Leu Asn Pro Tyr Gln Leu Thr Asp Gln Phe Thr Ser Phe Ala
1040 1045 1050
Lys Met Gly Thr Gln Ser Gly Phe Leu Phe Tyr Val Pro Ala Pro
1055 1060 1065
Tyr Thr Ser Lys Ile Asp Pro Leu Thr Gly Phe Val Asp Pro Phe
1070 1075 1080
Val Trp Lys Thr Ile Lys Asn His Glu Ser Arg Lys His Phe Leu
1085 1090 1095
Glu Gly Phe Asp Phe Leu His Tyr Asp Val Lys Thr Gly Asp Phe
1100 1105 1110
Ile Leu His Phe Lys Met Asn Arg Asn Leu Ser Phe Gln Arg Gly
1115 1120 1125
Leu Pro Gly Phe Met Pro Ala Trp Asp Ile Val Phe Glu Lys Asn
1130 1135 1140
Glu Thr Gln Phe Asp Ala Lys Gly Thr Pro Phe Ile Ala Gly Lys
1145 1150 1155
Arg Ile Val Pro Val Ile Glu Asn His Arg Phe Thr Gly Arg Tyr
1160 1165 1170
Arg Asp Leu Tyr Pro Ala Asn Glu Leu Ile Ala Leu Leu Glu Glu
1175 1180 1185
Lys Gly Ile Val Phe Arg Asp Gly Ser Asn Ile Leu Pro Lys Leu
1190 1195 1200
Leu Glu Asn Asp Asp Ser His Ala Ile Asp Thr Met Val Ala Leu
1205 1210 1215
Ile Arg Ser Val Leu Gln Met Arg Asn Ser Asn Ala Ala Thr Gly
1220 1225 1230
Glu Asp Tyr Ile Asn Ser Pro Val Arg Asp Leu Asn Gly Val Cys
1235 1240 1245
Phe Asp Ser Arg Phe Gln Asn Pro Glu Trp Pro Met Asp Ala Asp
1250 1255 1260
Ala Asn Gly Ala Tyr His Ile Ala Leu Lys Gly Gln Leu Leu Leu
1265 1270 1275
Asn His Leu Lys Glu Ser Lys Asp Leu Lys Leu Gln Asn Gly Ile
1280 1285 1290
Ser Asn Gln Asp Trp Leu Ala Tyr Ile Gln Glu Leu Arg Asn
1295 1300 1305
<210> 52
<211> 1241
<212> PRT
<213> Butyrivibrio proteoclasticus
<400> 52
Met Leu Leu Tyr Glu Asn Tyr Thr Lys Arg Asn Gln Ile Thr Lys Ser
1 5 10 15
Leu Arg Leu Glu Leu Arg Pro Gln Gly Lys Thr Leu Arg Asn Ile Lys
20 25 30
Glu Leu Asn Leu Leu Glu Gln Asp Lys Ala Ile Tyr Ala Leu Leu Glu
35 40 45
Arg Leu Lys Pro Val Ile Asp Glu Gly Ile Lys Asp Ile Ala Arg Asp
50 55 60
Thr Leu Lys Asn Cys Glu Leu Ser Phe Glu Lys Leu Tyr Glu His Phe
65 70 75 80
Leu Ser Gly Asp Lys Lys Ala Tyr Ala Lys Glu Ser Glu Arg Leu Lys
85 90 95
Lys Glu Ile Val Lys Thr Leu Ile Lys Asn Leu Pro Glu Gly Ile Gly
100 105 110
Lys Ile Ser Glu Ile Asn Ser Ala Lys Tyr Leu Asn Gly Val Leu Tyr
115 120 125
Asp Phe Ile Asp Lys Thr His Lys Asp Ser Glu Glu Lys Gln Asn Ile
130 135 140
Leu Ser Asp Ile Leu Glu Thr Lys Gly Tyr Leu Ala Leu Phe Ser Lys
145 150 155 160
Phe Leu Thr Ser Arg Ile Thr Thr Leu Glu Gln Ser Met Pro Lys Arg
165 170 175
Val Ile Glu Asn Phe Glu Ile Tyr Ala Ala Asn Ile Pro Lys Met Gln
180 185 190
Asp Ala Leu Glu Arg Gly Ala Val Ser Phe Ala Ile Glu Tyr Glu Ser
195 200 205
Ile Cys Ser Val Asp Tyr Tyr Asn Gln Ile Leu Ser Gln Glu Asp Ile
210 215 220
Asp Ser Tyr Asn Arg Leu Ile Ser Gly Ile Met Asp Glu Asp Gly Ala
225 230 235 240
Lys Glu Lys Gly Ile Asn Gln Thr Ile Ser Glu Lys Asn Ile Lys Ile
245 250 255
Lys Ser Glu His Leu Glu Glu Lys Pro Phe Arg Ile Leu Lys Gln Leu
260 265 270
His Lys Gln Ile Leu Glu Glu Arg Glu Lys Ala Phe Thr Ile Asp His
275 280 285
Ile Asp Ser Asp Glu Glu Val Val Gln Val Thr Lys Glu Ala Phe Glu
290 295 300
Gln Thr Lys Glu Gln Trp Glu Asn Ile Lys Lys Ile Asn Gly Phe Tyr
305 310 315 320
Ala Lys Asp Pro Gly Asp Ile Thr Leu Phe Ile Val Val Gly Pro Asn
325 330 335
Gln Thr His Val Leu Ser Gln Leu Ile Tyr Gly Glu His Asp Arg Ile
340 345 350
Arg Leu Leu Leu Glu Glu Tyr Glu Lys Asn Thr Leu Glu Val Leu Pro
355 360 365
Arg Arg Thr Lys Ser Glu Asp Ala Arg Tyr Asp Lys Phe Val Asn Ala
370 375 380
Val Pro Lys Lys Val Ala Lys Glu Ser His Thr Phe Asp Gly Leu Gln
385 390 395 400
Lys Met Thr Gly Asp Asp Arg Leu Phe Ile Leu Tyr Arg Asp Glu Leu
405 410 415
Ala Arg Asn Tyr Met Arg Ile Lys Glu Ala Tyr Gly Thr Phe Glu Arg
420 425 430
Asp Ile Leu Lys Ser Arg Arg Gly Ile Lys Gly Asn Arg Asp Val Gln
435 440 445
Glu Ser Leu Val Ser Phe Tyr Asp Glu Leu Thr Lys Phe Arg Ser Ala
450 455 460
Leu Arg Ile Ile Asn Ser Gly Asn Asp Glu Lys Ala Asp Pro Ile Phe
465 470 475 480
Tyr Asn Thr Phe Asp Gly Ile Phe Glu Lys Ala Asn Arg Thr Tyr Lys
485 490 495
Ala Glu Asn Leu Cys Arg Asn Tyr Val Thr Lys Ser Pro Ala Asp Asp
500 505 510
Ala Arg Ile Met Ala Ser Cys Leu Gly Thr Pro Ala Arg Leu Arg Thr
515 520 525
His Trp Trp Asn Gly Glu Glu Asn Phe Ala Ile Asn Asp Val Ala Met
530 535 540
Ile Arg Arg Gly Asp Glu Tyr Tyr Tyr Phe Val Leu Thr Pro Asp Val
545 550 555 560
Lys Pro Val Asp Leu Lys Thr Lys Asp Glu Thr Asp Ala Gln Ile Phe
565 570 575
Val Gln Arg Lys Gly Ala Lys Ser Phe Leu Gly Leu Pro Lys Ala Leu
580 585 590
Phe Lys Cys Ile Leu Glu Pro Tyr Phe Glu Ser Pro Glu His Lys Asn
595 600 605
Asp Lys Asn Cys Val Ile Glu Glu Tyr Val Ser Lys Pro Leu Thr Ile
610 615 620
Asp Arg Arg Ala Tyr Asp Ile Phe Lys Asn Gly Thr Phe Lys Lys Thr
625 630 635 640
Asn Ile Gly Ile Asp Gly Leu Thr Glu Glu Lys Phe Lys Asp Asp Cys
645 650 655
Arg Tyr Leu Ile Asp Val Tyr Lys Glu Phe Ile Ala Val Tyr Thr Arg
660 665 670
Tyr Ser Cys Phe Asn Met Ser Gly Leu Lys Arg Ala Asp Glu Tyr Asn
675 680 685
Asp Ile Gly Glu Phe Phe Ser Asp Val Asp Thr Arg Leu Cys Thr Met
690 695 700
Glu Trp Ile Pro Val Ser Phe Glu Arg Ile Asn Asp Met Val Asp Lys
705 710 715 720
Lys Glu Gly Leu Leu Phe Leu Val Arg Ser Met Phe Leu Tyr Asn Arg
725 730 735
Pro Arg Lys Pro Tyr Glu Arg Thr Phe Ile Gln Leu Phe Ser Asp Ser
740 745 750
Asn Met Glu His Thr Ser Met Leu Leu Asn Ser Arg Ala Met Ile Gln
755 760 765
Tyr Arg Ala Ala Ser Leu Pro Arg Arg Val Thr His Lys Lys Gly Ser
770 775 780
Ile Leu Val Ala Leu Arg Asp Ser Asn Gly Glu His Ile Pro Met His
785 790 795 800
Ile Arg Glu Ala Ile Tyr Lys Met Lys Asn Asn Phe Asp Ile Ser Ser
805 810 815
Glu Asp Phe Ile Met Ala Lys Ala Tyr Leu Ala Glu His Asp Val Ala
820 825 830
Ile Lys Lys Ala Asn Glu Asp Ile Ile Arg Asn Arg Arg Tyr Thr Glu
835 840 845
Asp Lys Phe Phe Leu Ser Leu Ser Tyr Thr Lys Asn Ala Asp Ile Ser
850 855 860
Ala Arg Thr Leu Asp Tyr Ile Asn Asp Lys Val Glu Glu Asp Thr Gln
865 870 875 880
Asp Ser Arg Met Ala Val Ile Val Thr Arg Asn Leu Lys Asp Leu Thr
885 890 895
Tyr Val Ala Val Val Asp Glu Lys Asn Asn Val Leu Glu Glu Lys Ser
900 905 910
Leu Asn Glu Ile Asp Gly Val Asn Tyr Arg Glu Leu Leu Lys Glu Arg
915 920 925
Thr Lys Ile Lys Tyr His Asp Lys Thr Arg Leu Trp Gln Tyr Asp Val
930 935 940
Ser Ser Lys Gly Leu Lys Glu Ala Tyr Val Glu Leu Ala Val Thr Gln
945 950 955 960
Ile Ser Lys Leu Ala Thr Lys Tyr Asn Ala Val Val Val Val Glu Ser
965 970 975
Met Ser Ser Thr Phe Lys Asp Lys Phe Ser Phe Leu Asp Glu Gln Ile
980 985 990
Phe Lys Ala Phe Glu Ala Arg Leu Cys Ala Arg Met Ser Asp Leu Ser
995 1000 1005
Phe Asn Thr Ile Lys Glu Gly Glu Ala Gly Ser Ile Ser Asn Pro
1010 1015 1020
Ile Gln Val Ser Asn Asn Asn Gly Asn Ser Tyr Gln Asp Gly Val
1025 1030 1035
Ile Tyr Phe Leu Asn Asn Ala Tyr Thr Arg Thr Leu Cys Pro Asp
1040 1045 1050
Thr Gly Phe Val Asp Val Phe Asp Lys Thr Arg Leu Ile Thr Met
1055 1060 1065
Gln Ser Lys Arg Gln Phe Phe Ala Lys Met Lys Asp Ile Arg Ile
1070 1075 1080
Asp Asp Gly Glu Met Leu Phe Thr Phe Asn Leu Glu Glu Tyr Pro
1085 1090 1095
Thr Lys Arg Leu Leu Asp Arg Lys Glu Trp Thr Val Lys Ile Ala
1100 1105 1110
Gly Asp Gly Ser Tyr Phe Asp Lys Asp Lys Gly Glu Tyr Val Tyr
1115 1120 1125
Val Asn Asp Ile Val Arg Glu Gln Ile Ile Pro Ala Leu Leu Glu
1130 1135 1140
Asp Lys Ala Val Phe Asp Gly Asn Met Ala Glu Lys Phe Leu Asp
1145 1150 1155
Lys Thr Ala Ile Ser Gly Lys Ser Val Glu Leu Ile Tyr Lys Trp
1160 1165 1170
Phe Ala Asn Ala Leu Tyr Gly Ile Ile Thr Lys Lys Asp Gly Glu
1175 1180 1185
Lys Ile Tyr Arg Ser Pro Ile Thr Gly Thr Glu Ile Asp Val Ser
1190 1195 1200
Lys Asn Thr Thr Tyr Asn Phe Gly Lys Lys Phe Met Phe Lys Gln
1205 1210 1215
Glu Tyr Arg Gly Asp Gly Asp Phe Leu Asp Ala Phe Leu Asn Tyr
1220 1225 1230
Met Gln Ala Gln Asp Ile Ala Val
1235 1240
<210> 53
<211> 1238
<212> PRT
<213> Candidatus Methanoplasma termitum
<400> 53
Met Asn Asn Tyr Asp Glu Phe Thr Lys Leu Tyr Pro Ile Gln Lys Thr
1 5 10 15
Ile Arg Phe Glu Leu Lys Pro Gln Gly Arg Thr Met Glu His Leu Glu
20 25 30
Thr Phe Asn Phe Phe Glu Glu Asp Arg Asp Arg Ala Glu Lys Tyr Lys
35 40 45
Ile Leu Lys Glu Ala Ile Asp Glu Tyr His Lys Lys Phe Ile Asp Glu
50 55 60
His Leu Thr Asn Met Ser Leu Asp Trp Asn Ser Leu Lys Gln Ile Ser
65 70 75 80
Glu Lys Tyr Tyr Lys Ser Arg Glu Glu Lys Asp Lys Lys Val Phe Leu
85 90 95
Ser Glu Gln Lys Arg Met Arg Gln Glu Ile Val Ser Glu Phe Lys Lys
100 105 110
Asp Asp Arg Phe Lys Asp Leu Phe Ser Lys Lys Leu Phe Ser Glu Leu
115 120 125
Leu Lys Glu Glu Ile Tyr Lys Lys Gly Asn His Gln Glu Ile Asp Ala
130 135 140
Leu Lys Ser Phe Asp Lys Phe Ser Gly Tyr Phe Ile Gly Leu His Glu
145 150 155 160
Asn Arg Lys Asn Met Tyr Ser Asp Gly Asp Glu Ile Thr Ala Ile Ser
165 170 175
Asn Arg Ile Val Asn Glu Asn Phe Pro Lys Phe Leu Asp Asn Leu Gln
180 185 190
Lys Tyr Gln Glu Ala Arg Lys Lys Tyr Pro Glu Trp Ile Ile Lys Ala
195 200 205
Glu Ser Ala Leu Val Ala His Asn Ile Lys Met Asp Ile Val Phe Ser
210 215 220
Leu Glu Tyr Phe Asn Lys Val Leu Asn Gln Glu Gly Ile Gln Arg Tyr
225 230 235 240
Asn Leu Ala Leu Gly Gly Tyr Val Thr Lys Ser Gly Glu Lys Met Met
245 250 255
Gly Leu Asn Asp Ala Leu Asn Leu Ala His Gln Ser Glu Lys Ser Ser
260 265 270
Lys Gly Arg Ile His Met Thr Pro Leu Phe Lys Gln Ile Leu Ser Glu
275 280 285
Lys Glu Ser Phe Ser Tyr Ile Pro Asp Val Phe Thr Glu Asp Ser Gln
290 295 300
Leu Leu Pro Ser Ile Gly Gly Phe Phe Ala Gln Ile Glu Asn Asp Lys
305 310 315 320
Asp Gly Asn Ile Phe Asp Arg Ala Leu Glu Leu Ile Ser Ser Tyr Ala
325 330 335
Glu Tyr Asp Thr Glu Arg Ile Tyr Ile Arg Gln Ala Asp Ile Asn Arg
340 345 350
Val Ser Asn Val Ile Phe Gly Glu Trp Gly Thr Leu Gly Gly Leu Met
355 360 365
Arg Glu Tyr Lys Ala Asp Ser Ile Asn Asp Ile Asn Leu Glu Arg Thr
370 375 380
Cys Lys Lys Val Asp Lys Trp Leu Asp Ser Lys Glu Phe Ala Leu Ser
385 390 395 400
Asp Val Leu Glu Ala Ile Asp Arg Thr Gly Asn Asn Asp Ala Phe Asn
405 410 415
Glu Tyr Ile Ser Lys Met Arg Thr Ala Arg Glu Lys Ile Asp Ala Ala
420 425 430
Arg Lys Glu Met Lys Phe Ile Ser Glu Lys Ile Ser Gly Asp Glu Glu
435 440 445
Ser Ile His Ile Ile Lys Thr Leu Leu Asp Ser Val Gln Gln Phe Leu
450 455 460
His Phe Phe Asn Leu Phe Lys Ala Arg Gln Asp Ile Pro Leu Asp Gly
465 470 475 480
Ala Phe Tyr Ala Glu Phe Asp Glu Val His Ser Lys Leu Phe Ala Ile
485 490 495
Val Pro Leu Tyr Asn Lys Val Arg Asn Tyr Leu Thr Lys Asn Asn Leu
500 505 510
Asn Thr Lys Lys Ile Lys Leu Asn Phe Lys Asn Pro Thr Leu Ala Asn
515 520 525
Gly Trp Asp Gln Asn Lys Val Tyr Asp Tyr Ala Ser Leu Ile Phe Leu
530 535 540
Arg Asp Gly Asn Tyr Tyr Leu Gly Ile Ile Asn Pro Lys Arg Lys Lys
545 550 555 560
Asn Ile Lys Phe Glu Gln Gly Ser Gly Asn Gly Pro Phe Tyr Arg Lys
565 570 575
Met Val Tyr Lys Gln Ile Pro Gly Pro Asn Lys Asn Leu Arg Pro Val
580 585 590
Phe Leu Thr Ser Thr Lys Gly Lys Lys Glu Tyr Lys Pro Ser Lys Glu
595 600 605
Ile Ile Glu Gly Tyr Glu Ala Asp Lys His Ile Arg Gly Asp Lys Phe
610 615 620
Asp Leu Asp Phe Cys His Lys Leu Ile Asp Phe Phe Lys Glu Ser Ile
625 630 635 640
Glu Lys His Lys Asp Trp Ser Lys Phe Asn Phe Tyr Phe Ser Pro Thr
645 650 655
Glu Ser Tyr Gly Asp Ile Ser Glu Phe Tyr Leu Asp Val Glu Lys Gln
660 665 670
Gly Tyr Arg Met His Phe Glu Asn Ile Ser Ala Glu Thr Ile Asp Glu
675 680 685
Tyr Val Glu Lys Gly Asp Leu Phe Leu Phe Gln Ile Tyr Asn Lys Asp
690 695 700
Phe Val Lys Ala Ala Thr Gly Lys Lys Asp Met His Thr Ile Tyr Trp
705 710 715 720
Asn Ala Ala Phe Ser Pro Glu Asn Leu Gln Asp Val Val Val Lys Leu
725 730 735
Asn Gly Glu Ala Glu Leu Phe Tyr Arg Asp Lys Ser Asp Ile Lys Glu
740 745 750
Ile Val His Arg Glu Gly Glu Ile Leu Val Asn Arg Thr Tyr Asn Gly
755 760 765
Arg Thr Pro Val Pro Asp Lys Ile His Lys Lys Leu Thr Asp Tyr His
770 775 780
Asn Gly Arg Thr Lys Asp Leu Gly Glu Ala Lys Glu Tyr Leu Asp Lys
785 790 795 800
Val Arg Tyr Phe Lys Ala His Tyr Asp Ile Thr Lys Asp Arg Arg Tyr
805 810 815
Leu Asn Asp Lys Ile Tyr Phe His Val Pro Leu Thr Leu Asn Phe Lys
820 825 830
Ala Asn Gly Lys Lys Asn Leu Asn Lys Met Val Ile Glu Lys Phe Leu
835 840 845
Ser Asp Glu Lys Ala His Ile Ile Gly Ile Asp Arg Gly Glu Arg Asn
850 855 860
Leu Leu Tyr Tyr Ser Ile Ile Asp Arg Ser Gly Lys Ile Ile Asp Gln
865 870 875 880
Gln Ser Leu Asn Val Ile Asp Gly Phe Asp Tyr Arg Glu Lys Leu Asn
885 890 895
Gln Arg Glu Ile Glu Met Lys Asp Ala Arg Gln Ser Trp Asn Ala Ile
900 905 910
Gly Lys Ile Lys Asp Leu Lys Glu Gly Tyr Leu Ser Lys Ala Val His
915 920 925
Glu Ile Thr Lys Met Ala Ile Gln Tyr Asn Ala Ile Val Val Met Glu
930 935 940
Glu Leu Asn Tyr Gly Phe Lys Arg Gly Arg Phe Lys Val Glu Lys Gln
945 950 955 960
Ile Tyr Gln Lys Phe Glu Asn Met Leu Ile Asp Lys Met Asn Tyr Leu
965 970 975
Val Phe Lys Asp Ala Pro Asp Glu Ser Pro Gly Gly Val Leu Asn Ala
980 985 990
Tyr Gln Leu Thr Asn Pro Leu Glu Ser Phe Ala Lys Leu Gly Lys Gln
995 1000 1005
Thr Gly Ile Leu Phe Tyr Val Pro Ala Ala Tyr Thr Ser Lys Ile
1010 1015 1020
Asp Pro Thr Thr Gly Phe Val Asn Leu Phe Asn Thr Ser Ser Lys
1025 1030 1035
Thr Asn Ala Gln Glu Arg Lys Glu Phe Leu Gln Lys Phe Glu Ser
1040 1045 1050
Ile Ser Tyr Ser Ala Lys Asp Gly Gly Ile Phe Ala Phe Ala Phe
1055 1060 1065
Asp Tyr Arg Lys Phe Gly Thr Ser Lys Thr Asp His Lys Asn Val
1070 1075 1080
Trp Thr Ala Tyr Thr Asn Gly Glu Arg Met Arg Tyr Ile Lys Glu
1085 1090 1095
Lys Lys Arg Asn Glu Leu Phe Asp Pro Ser Lys Glu Ile Lys Glu
1100 1105 1110
Ala Leu Thr Ser Ser Gly Ile Lys Tyr Asp Gly Gly Gln Asn Ile
1115 1120 1125
Leu Pro Asp Ile Leu Arg Ser Asn Asn Asn Gly Leu Ile Tyr Thr
1130 1135 1140
Met Tyr Ser Ser Phe Ile Ala Ala Ile Gln Met Arg Val Tyr Asp
1145 1150 1155
Gly Lys Glu Asp Tyr Ile Ile Ser Pro Ile Lys Asn Ser Lys Gly
1160 1165 1170
Glu Phe Phe Arg Thr Asp Pro Lys Arg Arg Glu Leu Pro Ile Asp
1175 1180 1185
Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Leu Arg Gly Glu Leu
1190 1195 1200
Thr Met Arg Ala Ile Ala Glu Lys Phe Asp Pro Asp Ser Glu Lys
1205 1210 1215
Met Ala Lys Leu Glu Leu Lys His Lys Asp Trp Phe Glu Phe Met
1220 1225 1230
Gln Thr Arg Gly Asp
1235
<210> 54
<211> 1281
<212> PRT
<213> Bacillus parapsilosis
<400> 54
Met Asn Gly Asn Arg Ser Ile Val Tyr Arg Glu Phe Val Gly Val Ile
1 5 10 15
Pro Val Ala Lys Thr Leu Arg Asn Glu Leu Arg Pro Val Gly His Thr
20 25 30
Gln Glu His Ile Ile Gln Asn Gly Leu Ile Gln Glu Asp Glu Leu Arg
35 40 45
Gln Glu Lys Ser Thr Glu Leu Lys Asn Ile Met Asp Asp Tyr Tyr Arg
50 55 60
Glu Tyr Ile Asp Lys Ser Leu Ser Gly Val Thr Asp Leu Asp Phe Thr
65 70 75 80
Leu Leu Phe Glu Leu Met Asn Leu Val Gln Ser Ser Pro Ser Lys Asp
85 90 95
Asn Lys Lys Ala Leu Glu Lys Glu Gln Ser Lys Met Arg Glu Gln Ile
100 105 110
Cys Thr His Leu Gln Ser Asp Ser Asn Tyr Lys Asn Ile Phe Asn Ala
115 120 125
Lys Leu Leu Lys Glu Ile Leu Pro Asp Phe Ile Lys Asn Tyr Asn Gln
130 135 140
Tyr Asp Val Lys Asp Lys Ala Gly Lys Leu Glu Thr Leu Ala Leu Phe
145 150 155 160
Asn Gly Phe Ser Thr Tyr Phe Thr Asp Phe Phe Glu Lys Arg Lys Asn
165 170 175
Val Phe Thr Lys Glu Ala Val Ser Thr Ser Ile Ala Tyr Arg Ile Val
180 185 190
His Glu Asn Ser Leu Ile Phe Leu Ala Asn Met Thr Ser Tyr Lys Lys
195 200 205
Ile Ser Glu Lys Ala Leu Asp Glu Ile Glu Val Ile Glu Lys Asn Asn
210 215 220
Gln Asp Lys Met Gly Asp Trp Glu Leu Asn Gln Ile Phe Asn Pro Asp
225 230 235 240
Phe Tyr Asn Met Val Leu Ile Gln Ser Gly Ile Asp Phe Tyr Asn Glu
245 250 255
Ile Cys Gly Val Val Asn Ala His Met Asn Leu Tyr Cys Gln Gln Thr
260 265 270
Lys Asn Asn Tyr Asn Leu Phe Lys Met Arg Lys Leu His Lys Gln Ile
275 280 285
Leu Ala Tyr Thr Ser Thr Ser Phe Glu Val Pro Lys Met Phe Glu Asp
290 295 300
Asp Met Ser Val Tyr Asn Ala Val Asn Ala Phe Ile Asp Glu Thr Glu
305 310 315 320
Lys Gly Asn Ile Ile Gly Lys Leu Lys Asp Ile Val Asn Lys Tyr Asp
325 330 335
Glu Leu Asp Glu Lys Arg Ile Tyr Ile Ser Lys Asp Phe Tyr Glu Thr
340 345 350
Leu Ser Cys Phe Met Ser Gly Asn Trp Asn Leu Ile Thr Gly Cys Val
355 360 365
Glu Asn Phe Tyr Asp Glu Asn Ile His Ala Lys Gly Lys Ser Lys Glu
370 375 380
Glu Lys Val Lys Lys Ala Val Lys Glu Asp Lys Tyr Lys Ser Ile Asn
385 390 395 400
Asp Val Asn Asp Leu Val Glu Lys Tyr Ile Asp Glu Lys Glu Arg Asn
405 410 415
Glu Phe Lys Asn Ser Asn Ala Lys Gln Tyr Ile Arg Glu Ile Ser Asn
420 425 430
Ile Ile Thr Asp Thr Glu Thr Ala His Leu Glu Tyr Asp Asp His Ile
435 440 445
Ser Leu Ile Glu Ser Glu Glu Lys Ala Asp Glu Met Lys Lys Arg Leu
450 455 460
Asp Met Tyr Met Asn Met Tyr His Trp Ala Lys Ala Phe Ile Val Asp
465 470 475 480
Glu Val Leu Asp Arg Asp Glu Met Phe Tyr Ser Asp Ile Asp Asp Ile
485 490 495
Tyr Asn Ile Leu Glu Asn Ile Val Pro Leu Tyr Asn Arg Val Arg Asn
500 505 510
Tyr Val Thr Gln Lys Pro Tyr Asn Ser Lys Lys Ile Lys Leu Asn Phe
515 520 525
Gln Ser Pro Thr Leu Ala Asn Gly Trp Ser Gln Ser Lys Glu Phe Asp
530 535 540
Asn Asn Ala Ile Ile Leu Ile Arg Asp Asn Lys Tyr Tyr Leu Ala Ile
545 550 555 560
Phe Asn Ala Lys Asn Lys Pro Asp Lys Lys Ile Ile Gln Gly Asn Ser
565 570 575
Asp Lys Lys Asn Asp Asn Asp Tyr Lys Lys Met Val Tyr Asn Leu Leu
580 585 590
Pro Gly Ala Asn Lys Met Leu Pro Lys Val Phe Leu Ser Lys Lys Gly
595 600 605
Ile Glu Thr Phe Lys Pro Ser Asp Tyr Ile Ile Ser Gly Tyr Asn Ala
610 615 620
His Lys His Ile Lys Thr Ser Glu Asn Phe Asp Ile Ser Phe Cys Arg
625 630 635 640
Asp Leu Ile Asp Tyr Phe Lys Asn Ser Ile Glu Lys His Ala Glu Trp
645 650 655
Arg Lys Tyr Glu Phe Lys Phe Ser Ala Thr Asp Ser Tyr Ser Asp Ile
660 665 670
Ser Glu Phe Tyr Arg Glu Val Glu Met Gln Gly Tyr Arg Ile Asp Trp
675 680 685
Thr Tyr Ile Ser Glu Ala Asp Ile Asn Lys Leu Asp Glu Glu Gly Lys
690 695 700
Ile Tyr Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ala Glu Asn Ser Thr
705 710 715 720
Gly Lys Glu Asn Leu His Thr Met Tyr Phe Lys Asn Ile Phe Ser Glu
725 730 735
Glu Asn Leu Asp Lys Ile Ile Lys Leu Asn Gly Gln Ala Glu Leu Phe
740 745 750
Tyr Arg Arg Ala Ser Val Lys Asn Pro Val Lys His Lys Lys Asp Ser
755 760 765
Val Leu Val Asn Lys Thr Tyr Lys Asn Gln Leu Asp Asn Gly Asp Val
770 775 780
Val Arg Ile Pro Ile Pro Asp Asp Ile Tyr Asn Glu Ile Tyr Lys Met
785 790 795 800
Tyr Asn Gly Tyr Ile Lys Glu Ser Asp Leu Ser Glu Ala Ala Lys Glu
805 810 815
Tyr Leu Asp Lys Val Glu Val Arg Thr Ala Gln Lys Asp Ile Val Lys
820 825 830
Asp Tyr Arg Tyr Thr Val Asp Lys Tyr Phe Ile His Thr Pro Ile Thr
835 840 845
Ile Asn Tyr Lys Val Thr Ala Arg Asn Asn Val Asn Asp Met Val Val
850 855 860
Lys Tyr Ile Ala Gln Asn Asp Asp Ile His Val Ile Gly Ile Asp Arg
865 870 875 880
Gly Glu Arg Asn Leu Ile Tyr Ile Ser Val Ile Asp Ser His Gly Asn
885 890 895
Ile Val Lys Gln Lys Ser Tyr Asn Ile Leu Asn Asn Tyr Asp Tyr Lys
900 905 910
Lys Lys Leu Val Glu Lys Glu Lys Thr Arg Glu Tyr Ala Arg Lys Asn
915 920 925
Trp Lys Ser Ile Gly Asn Ile Lys Glu Leu Lys Glu Gly Tyr Ile Ser
930 935 940
Gly Val Val His Glu Ile Ala Met Leu Ile Val Glu Tyr Asn Ala Ile
945 950 955 960
Ile Ala Met Glu Asp Leu Asn Tyr Gly Phe Lys Arg Gly Arg Phe Lys
965 970 975
Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Ser Met Leu Ile Asn Lys
980 985 990
Leu Asn Tyr Phe Ala Ser Lys Glu Lys Ser Val Asp Glu Pro Gly Gly
995 1000 1005
Leu Leu Lys Gly Tyr Gln Leu Thr Tyr Val Pro Asp Asn Ile Lys
1010 1015 1020
Asn Leu Gly Lys Gln Cys Gly Val Ile Phe Tyr Val Pro Ala Ala
1025 1030 1035
Phe Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Ile Ser Ala Phe
1040 1045 1050
Asn Phe Lys Ser Ile Ser Thr Asn Ala Ser Arg Lys Gln Phe Phe
1055 1060 1065
Met Gln Phe Asp Glu Ile Arg Tyr Cys Ala Glu Lys Asp Met Phe
1070 1075 1080
Ser Phe Gly Phe Asp Tyr Asn Asn Phe Asp Thr Tyr Asn Ile Thr
1085 1090 1095
Met Gly Lys Thr Gln Trp Thr Val Tyr Thr Asn Gly Glu Arg Leu
1100 1105 1110
Gln Ser Glu Phe Asn Asn Ala Arg Arg Thr Gly Lys Thr Lys Ser
1115 1120 1125
Ile Asn Leu Thr Glu Thr Ile Lys Leu Leu Leu Glu Asp Asn Glu
1130 1135 1140
Ile Asn Tyr Ala Asp Gly His Asp Ile Arg Ile Asp Met Glu Lys
1145 1150 1155
Met Asp Glu Asp Lys Lys Ser Glu Phe Phe Ala Gln Leu Leu Ser
1160 1165 1170
Leu Tyr Lys Leu Thr Val Gln Met Arg Asn Ser Tyr Thr Glu Ala
1175 1180 1185
Glu Glu Gln Glu Asn Gly Ile Ser Tyr Asp Lys Ile Ile Ser Pro
1190 1195 1200
Val Ile Asn Asp Glu Gly Glu Phe Phe Asp Ser Asp Asn Tyr Lys
1205 1210 1215
Glu Ser Asp Asp Lys Glu Cys Lys Met Pro Lys Asp Ala Asp Ala
1220 1225 1230
Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly Leu Tyr Glu Val Leu
1235 1240 1245
Lys Ile Lys Ser Glu Trp Thr Glu Asp Gly Phe Asp Arg Asn Cys
1250 1255 1260
Leu Lys Leu Pro His Ala Glu Trp Leu Asp Phe Ile Gln Asn Lys
1265 1270 1275
Arg Tyr Glu
1280
<210> 55
<211> 1300
<212> PRT
<213> New Fusarium Francisellae
<400> 55
Met Ser Ile Tyr Gln Glu Phe Val Asn Lys Tyr Ser Leu Ser Lys Thr
1 5 10 15
Leu Arg Phe Glu Leu Ile Pro Gln Gly Lys Thr Leu Glu Asn Ile Lys
20 25 30
Ala Arg Gly Leu Ile Leu Asp Asp Glu Lys Arg Ala Lys Asp Tyr Lys
35 40 45
Lys Ala Lys Gln Ile Ile Asp Lys Tyr His Gln Phe Phe Ile Glu Glu
50 55 60
Ile Leu Ser Ser Val Cys Ile Ser Glu Asp Leu Leu Gln Asn Tyr Ser
65 70 75 80
Asp Val Tyr Phe Lys Leu Lys Lys Ser Asp Asp Asp Asn Leu Gln Lys
85 90 95
Asp Phe Lys Ser Ala Lys Asp Thr Ile Lys Lys Gln Ile Ser Glu Tyr
100 105 110
Ile Lys Asp Ser Glu Lys Phe Lys Asn Leu Phe Asn Gln Asn Leu Ile
115 120 125
Asp Ala Lys Lys Gly Gln Glu Ser Asp Leu Ile Leu Trp Leu Lys Gln
130 135 140
Ser Lys Asp Asn Gly Ile Glu Leu Phe Lys Ala Asn Ser Asp Ile Thr
145 150 155 160
Asp Ile Asp Glu Ala Leu Glu Ile Ile Lys Ser Phe Lys Gly Trp Thr
165 170 175
Thr Tyr Phe Lys Gly Phe His Glu Asn Arg Lys Val Asn Tyr Ser Ser
180 185 190
Asn Asp Ile Pro Thr Ser Ile Ile Tyr Arg Ile Val Asp Asp Asn Leu
195 200 205
Pro Lys Phe Leu Glu Asn Lys Ala Lys Tyr Glu Ser Leu Lys Asp Lys
210 215 220
Ala Pro Glu Ala Ile Asn Tyr Glu Gln Ile Lys Lys Asp Leu Ala Glu
225 230 235 240
Glu Leu Thr Phe Asp Ile Asp Tyr Lys Thr Ser Glu Val Asn Gln Arg
245 250 255
Val Phe Ser Leu Asp Glu Val Phe Glu Ile Ala Asn Phe Asn Asn Tyr
260 265 270
Leu Asn Gln Ser Gly Ile Thr Lys Phe Asn Thr Ile Ile Gly Gly Lys
275 280 285
Phe Val Asn Gly Glu Asn Thr Lys Arg Lys Gly Ile Asn Glu Tyr Ile
290 295 300
Asn Leu Tyr Ser Gln Gln Ile Asn Asp Lys Thr Leu Lys Lys Tyr Lys
305 310 315 320
Met Ser Val Leu Phe Lys Gln Ile Leu Ser Asp Thr Glu Ser Lys Ser
325 330 335
Phe Val Ile Asp Lys Leu Glu Asp Asp Ser Asp Val Val Thr Thr Met
340 345 350
Gln Ser Phe Tyr Glu Gln Ile Ala Ala Phe Lys Thr Val Glu Glu Lys
355 360 365
Ser Ile Lys Glu Thr Leu Ser Leu Leu Phe Asp Asp Leu Lys Ala Gln
370 375 380
Lys Leu Asp Leu Ser Lys Ile Tyr Phe Lys Asn Asp Lys Ser Leu Thr
385 390 395 400
Asp Leu Ser Gln Gln Val Phe Asp Asp Tyr Ser Val Ile Gly Thr Ala
405 410 415
Val Leu Glu Tyr Ile Thr Gln Gln Ile Ala Pro Lys Asn Leu Asp Asn
420 425 430
Pro Ser Lys Lys Glu Gln Glu Leu Ile Ala Lys Lys Thr Glu Lys Ala
435 440 445
Lys Tyr Leu Ser Leu Glu Thr Ile Lys Leu Ala Leu Glu Glu Phe Asn
450 455 460
Lys His Arg Asp Ile Asp Lys Gln Cys Arg Phe Glu Glu Ile Leu Ala
465 470 475 480
Asn Phe Ala Ala Ile Pro Met Ile Phe Asp Glu Ile Ala Gln Asn Lys
485 490 495
Asp Asn Leu Ala Gln Ile Ser Ile Lys Tyr Gln Asn Gln Gly Lys Lys
500 505 510
Asp Leu Leu Gln Ala Ser Ala Glu Asp Asp Val Lys Ala Ile Lys Asp
515 520 525
Leu Leu Asp Gln Thr Asn Asn Leu Leu His Lys Leu Lys Ile Phe His
530 535 540
Ile Ser Gln Ser Glu Asp Lys Ala Asn Ile Leu Asp Lys Asp Glu His
545 550 555 560
Phe Tyr Leu Val Phe Glu Glu Cys Tyr Phe Glu Leu Ala Asn Ile Val
565 570 575
Pro Leu Tyr Asn Lys Ile Arg Asn Tyr Ile Thr Gln Lys Pro Tyr Ser
580 585 590
Asp Glu Lys Phe Lys Leu Asn Phe Glu Asn Ser Thr Leu Ala Asn Gly
595 600 605
Trp Asp Lys Asn Lys Glu Pro Asp Asn Thr Ala Ile Leu Phe Ile Lys
610 615 620
Asp Asp Lys Tyr Tyr Leu Gly Val Met Asn Lys Lys Asn Asn Lys Ile
625 630 635 640
Phe Asp Asp Lys Ala Ile Lys Glu Asn Lys Gly Glu Gly Tyr Lys Lys
645 650 655
Ile Val Tyr Lys Leu Leu Pro Gly Ala Asn Lys Met Leu Pro Lys Val
660 665 670
Phe Phe Ser Ala Lys Ser Ile Lys Phe Tyr Asn Pro Ser Glu Asp Ile
675 680 685
Leu Arg Ile Arg Asn His Ser Thr His Thr Lys Asn Gly Ser Pro Gln
690 695 700
Lys Gly Tyr Glu Lys Phe Glu Phe Asn Ile Glu Asp Cys Arg Lys Phe
705 710 715 720
Ile Asp Phe Tyr Lys Gln Ser Ile Ser Lys His Pro Glu Trp Lys Asp
725 730 735
Phe Gly Phe Arg Phe Ser Asp Thr Gln Arg Tyr Asn Ser Ile Asp Glu
740 745 750
Phe Tyr Arg Glu Val Glu Asn Gln Gly Tyr Lys Leu Thr Phe Glu Asn
755 760 765
Ile Ser Glu Ser Tyr Ile Asp Ser Val Val Asn Gln Gly Lys Leu Tyr
770 775 780
Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ser Ala Tyr Ser Lys Gly Arg
785 790 795 800
Pro Asn Leu His Thr Leu Tyr Trp Lys Ala Leu Phe Asp Glu Arg Asn
805 810 815
Leu Gln Asp Val Val Tyr Lys Leu Asn Gly Glu Ala Glu Leu Phe Tyr
820 825 830
Arg Lys Gln Ser Ile Pro Lys Lys Ile Thr His Pro Ala Lys Glu Ala
835 840 845
Ile Ala Asn Lys Asn Lys Asp Asn Pro Lys Lys Glu Ser Val Phe Glu
850 855 860
Tyr Asp Leu Ile Lys Asp Lys Arg Phe Thr Glu Asp Lys Phe Phe Phe
865 870 875 880
His Cys Pro Ile Thr Ile Asn Phe Lys Ser Ser Gly Ala Asn Lys Phe
885 890 895
Asn Asp Glu Ile Asn Leu Leu Leu Lys Glu Lys Ala Asn Asp Val His
900 905 910
Ile Leu Ser Ile Asp Arg Gly Glu Arg His Leu Ala Tyr Tyr Thr Leu
915 920 925
Val Asp Gly Lys Gly Asn Ile Ile Lys Gln Asp Thr Phe Asn Ile Ile
930 935 940
Gly Asn Asp Arg Met Lys Thr Asn Tyr His Asp Lys Leu Ala Ala Ile
945 950 955 960
Glu Lys Asp Arg Asp Ser Ala Arg Lys Asp Trp Lys Lys Ile Asn Asn
965 970 975
Ile Lys Glu Met Lys Glu Gly Tyr Leu Ser Gln Val Val His Glu Ile
980 985 990
Ala Lys Leu Val Ile Glu Tyr Asn Ala Ile Val Val Phe Glu Asp Leu
995 1000 1005
Asn Phe Gly Phe Lys Arg Gly Arg Phe Lys Val Glu Lys Gln Val
1010 1015 1020
Tyr Gln Lys Leu Glu Lys Met Leu Ile Glu Lys Leu Asn Tyr Leu
1025 1030 1035
Val Phe Lys Asp Asn Glu Phe Asp Lys Thr Gly Gly Val Leu Arg
1040 1045 1050
Ala Tyr Gln Leu Thr Ala Pro Phe Glu Thr Phe Lys Lys Met Gly
1055 1060 1065
Lys Gln Thr Gly Ile Ile Tyr Tyr Val Pro Ala Gly Phe Thr Ser
1070 1075 1080
Lys Ile Cys Pro Val Thr Gly Phe Val Asn Gln Leu Tyr Pro Lys
1085 1090 1095
Tyr Glu Ser Val Ser Lys Ser Gln Glu Phe Phe Ser Lys Phe Asp
1100 1105 1110
Lys Ile Cys Tyr Asn Leu Asp Lys Gly Tyr Phe Glu Phe Ser Phe
1115 1120 1125
Asp Tyr Lys Asn Phe Gly Asp Lys Ala Ala Lys Gly Lys Trp Thr
1130 1135 1140
Ile Ala Ser Phe Gly Ser Arg Leu Ile Asn Phe Arg Asn Ser Asp
1145 1150 1155
Lys Asn His Asn Trp Asp Thr Arg Glu Val Tyr Pro Thr Lys Glu
1160 1165 1170
Leu Glu Lys Leu Leu Lys Asp Tyr Ser Ile Glu Tyr Gly His Gly
1175 1180 1185
Glu Cys Ile Lys Ala Ala Ile Cys Gly Glu Ser Asp Lys Lys Phe
1190 1195 1200
Phe Ala Lys Leu Thr Ser Val Leu Asn Thr Ile Leu Gln Met Arg
1205 1210 1215
Asn Ser Lys Thr Gly Thr Glu Leu Asp Tyr Leu Ile Ser Pro Val
1220 1225 1230
Ala Asp Val Asn Gly Asn Phe Phe Asp Ser Arg Gln Ala Pro Lys
1235 1240 1245
Asn Met Pro Gln Asp Ala Asp Ala Asn Gly Ala Tyr His Ile Gly
1250 1255 1260
Leu Lys Gly Leu Met Leu Leu Gly Arg Ile Lys Asn Asn Gln Glu
1265 1270 1275
Gly Lys Lys Leu Asn Leu Val Ile Lys Asn Glu Glu Tyr Phe Glu
1280 1285 1290
Phe Val Gln Asn Arg Asn Asn
1295 1300
<210> 56
<211> 1206
<212> PRT
<213> unknown
<220>
<223> Mao Luoke bacterium
<400> 56
Met Tyr Tyr Glu Ser Leu Thr Lys Gln Tyr Pro Val Ser Lys Thr Ile
1 5 10 15
Arg Asn Glu Leu Ile Pro Ile Gly Lys Thr Leu Asp Asn Ile Arg Gln
20 25 30
Asn Asn Ile Leu Glu Ser Asp Val Lys Arg Lys Gln Asn Tyr Glu His
35 40 45
Val Lys Gly Ile Leu Asp Glu Tyr His Lys Gln Leu Ile Asn Glu Ala
50 55 60
Leu Asp Asn Cys Thr Leu Pro Ser Leu Lys Ile Ala Ala Glu Ile Tyr
65 70 75 80
Leu Lys Asn Gln Lys Glu Val Ser Asp Arg Glu Asp Phe Asn Lys Thr
85 90 95
Gln Asp Leu Leu Arg Lys Glu Val Val Glu Lys Leu Lys Ala His Glu
100 105 110
Asn Phe Thr Lys Ile Gly Lys Lys Asp Ile Leu Asp Leu Leu Glu Lys
115 120 125
Leu Pro Ser Ile Ser Glu Asp Asp Tyr Asn Ala Leu Glu Ser Phe Arg
130 135 140
Asn Phe Tyr Thr Tyr Phe Thr Ser Tyr Asn Lys Val Arg Glu Asn Leu
145 150 155 160
Tyr Ser Asp Lys Glu Lys Ser Ser Thr Val Ala Tyr Arg Leu Ile Asn
165 170 175
Glu Asn Phe Pro Lys Phe Leu Asp Asn Val Lys Ser Tyr Arg Phe Val
180 185 190
Lys Thr Ala Gly Ile Leu Ala Asp Gly Leu Gly Glu Glu Glu Gln Asp
195 200 205
Ser Leu Phe Ile Val Glu Thr Phe Asn Lys Thr Leu Thr Gln Asp Gly
210 215 220
Ile Asp Thr Tyr Asn Ser Gln Val Gly Lys Ile Asn Ser Ser Ile Asn
225 230 235 240
Leu Tyr Asn Gln Lys Asn Gln Lys Ala Asn Gly Phe Arg Lys Ile Pro
245 250 255
Lys Met Lys Met Leu Tyr Lys Gln Ile Leu Ser Asp Arg Glu Glu Ser
260 265 270
Phe Ile Asp Glu Phe Gln Ser Asp Glu Val Leu Ile Asp Asn Val Glu
275 280 285
Ser Tyr Gly Ser Val Leu Ile Glu Ser Leu Lys Ser Ser Lys Val Ser
290 295 300
Ala Phe Phe Asp Ala Leu Arg Glu Ser Lys Gly Lys Asn Val Tyr Val
305 310 315 320
Lys Asn Asp Leu Ala Lys Thr Ala Met Ser Val Ile Val Phe Glu Asn
325 330 335
Trp Arg Thr Phe Asp Asp Leu Leu Asn Gln Glu Tyr Asp Leu Ala Asn
340 345 350
Glu Asn Lys Lys Lys Asp Asp Lys Tyr Phe Glu Lys Arg Gln Lys Glu
355 360 365
Leu Lys Lys Asn Lys Ser Tyr Ser Leu Glu His Leu Cys Asn Leu Ser
370 375 380
Glu Asp Ser Cys Asn Leu Ile Glu Asn Tyr Ile His Gln Ile Ser Asp
385 390 395 400
Asp Ile Glu Asn Ile Ile Ile Asn Asn Glu Thr Phe Leu Arg Ile Val
405 410 415
Ile Asn Glu His Asp Arg Ser Arg Lys Leu Ala Lys Asn Arg Lys Ala
420 425 430
Val Lys Ala Ile Lys Asp Phe Leu Asp Ser Ile Lys Val Leu Glu Arg
435 440 445
Glu Leu Lys Leu Ile Asn Ser Ser Gly Gln Glu Leu Glu Lys Asp Leu
450 455 460
Ile Val Tyr Ser Ala His Glu Glu Leu Leu Val Glu Leu Lys Gln Val
465 470 475 480
Asp Ser Leu Tyr Asn Met Thr Arg Asn Tyr Leu Thr Lys Lys Pro Phe
485 490 495
Ser Thr Glu Lys Val Lys Leu Asn Phe Asn Arg Ser Thr Leu Leu Asn
500 505 510
Gly Trp Asp Arg Asn Lys Glu Thr Asp Asn Leu Gly Val Leu Leu Leu
515 520 525
Lys Asp Gly Lys Tyr Tyr Leu Gly Ile Met Asn Thr Ser Ala Asn Lys
530 535 540
Ala Phe Val Asn Pro Pro Val Ala Lys Thr Glu Lys Val Phe Lys Lys
545 550 555 560
Val Asp Tyr Lys Leu Leu Pro Val Pro Asn Gln Met Leu Pro Lys Val
565 570 575
Phe Phe Ala Lys Ser Asn Ile Asp Phe Tyr Asn Pro Ser Ser Glu Ile
580 585 590
Tyr Ser Asn Tyr Lys Lys Gly Thr His Lys Lys Gly Asn Met Phe Ser
595 600 605
Leu Glu Asp Cys His Asn Leu Ile Asp Phe Phe Lys Glu Ser Ile Ser
610 615 620
Lys His Glu Asp Trp Ser Lys Phe Gly Phe Lys Phe Asp Thr Gln Ala
625 630 635 640
Ser Tyr Asn Asp Ile Ser Glu Phe Tyr Arg Glu Val Glu Lys Gln Gly
645 650 655
Tyr Lys Leu Thr Tyr Thr Asp Ile Asp Glu Thr Tyr Ile Asn Asp Leu
660 665 670
Ile Glu Arg Asn Glu Leu Tyr Leu Phe Gln Ile Tyr Asn Lys Asp Phe
675 680 685
Ser Met Tyr Ser Lys Gly Lys Leu Asn Leu His Thr Leu Tyr Phe Met
690 695 700
Met Leu Phe Asp Gln Arg Asn Ile Asp Asp Val Val Tyr Lys Leu Asn
705 710 715 720
Gly Glu Ala Glu Val Phe Tyr Arg Pro Ala Ser Ile Ser Glu Asp Glu
725 730 735
Leu Ile Ile His Lys Ala Gly Glu Glu Ile Lys Asn Lys Asn Pro Asn
740 745 750
Arg Ala Arg Thr Lys Glu Thr Ser Thr Phe Ser Tyr Asp Ile Val Lys
755 760 765
Asp Lys Arg Tyr Ser Lys Asp Lys Phe Thr Leu His Ile Pro Ile Thr
770 775 780
Met Asn Phe Gly Val Asp Glu Val Lys Arg Phe Asn Asp Ala Val Asn
785 790 795 800
Ser Ala Ile Arg Ile Asp Glu Asn Val Asn Val Ile Gly Ile Asp Arg
805 810 815
Gly Glu Arg Asn Leu Leu Tyr Val Val Val Ile Asp Ser Lys Gly Asn
820 825 830
Ile Leu Glu Gln Ile Ser Leu Asn Ser Ile Ile Asn Lys Glu Tyr Asp
835 840 845
Ile Glu Thr Asp Tyr His Ala Leu Leu Asp Glu Arg Glu Gly Gly Arg
850 855 860
Asp Lys Ala Arg Lys Asp Trp Asn Thr Val Glu Asn Ile Arg Asp Leu
865 870 875 880
Lys Ala Gly Leu Tyr Leu Gln Val Val Asn Val Val Ala Lys Leu Val
885 890 895
Leu Lys Tyr Asn Ala Ile Ile Cys Leu Glu Asp Leu Asn Phe Gly Phe
900 905 910
Lys Arg Gly Arg Gln Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
915 920 925
Lys Met Leu Ile Asp Lys Leu Asn Tyr Leu Val Ile Asp Lys Ser Arg
930 935 940
Glu Gln Thr Ser Pro Lys Glu Leu Gly Gly Ala Leu Asn Ala Leu Gln
945 950 955 960
Leu Thr Ser Lys Phe Lys Ser Phe Lys Glu Leu Gly Lys Gln Ser Gly
965 970 975
Val Ile Tyr Tyr Val Pro Ala Tyr Leu Thr Ser Lys Ile Asp Pro Thr
980 985 990
Thr Gly Phe Ala Asn Leu Phe Tyr Met Lys Cys Glu Asn Val Glu Lys
995 1000 1005
Ser Lys Arg Phe Phe Asp Gly Phe Asp Phe Ile Arg Phe Asn Ala
1010 1015 1020
Leu Glu Asn Val Phe Glu Phe Gly Phe Asp Tyr Arg Ser Phe Thr
1025 1030 1035
Gln Arg Ala Cys Gly Ile Asn Ser Lys Trp Thr Val Cys Thr Asn
1040 1045 1050
Gly Glu Arg Ile Ile Lys Tyr Arg Asn Pro Asp Lys Asn Asn Met
1055 1060 1065
Phe Asp Glu Lys Val Val Val Val Thr Asp Glu Met Lys Asn Leu
1070 1075 1080
Phe Glu Gln Tyr Lys Ile Pro Tyr Glu Asp Gly Arg Asn Val Lys
1085 1090 1095
Asp Met Ile Ile Ser Asn Glu Glu Ala Glu Phe Tyr Arg Arg Leu
1100 1105 1110
Tyr Arg Leu Leu Gln Gln Thr Leu Gln Met Arg Asn Ser Thr Ser
1115 1120 1125
Asp Gly Thr Arg Asp Tyr Ile Ile Ser Pro Val Lys Asn Lys Arg
1130 1135 1140
Glu Ala Tyr Phe Asn Ser Glu Leu Ser Asp Gly Ser Val Pro Lys
1145 1150 1155
Asp Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Gly Leu
1160 1165 1170
Trp Val Leu Glu Gln Ile Arg Gln Lys Ser Glu Gly Glu Lys Ile
1175 1180 1185
Asn Leu Ala Met Thr Asn Ala Glu Trp Leu Glu Tyr Ala Gln Thr
1190 1195 1200
His Leu Leu
1205
<210> 57
<211> 1233
<212> PRT
<213> unknown
<220>
<223> Mao Luoke bacterium
<400> 57
Met Asp Tyr Gly Asn Gly Gln Phe Glu Arg Arg Ala Pro Leu Thr Lys
1 5 10 15
Thr Ile Thr Leu Arg Leu Lys Pro Ile Gly Glu Thr Arg Glu Thr Ile
20 25 30
Arg Glu Gln Lys Leu Leu Glu Gln Asp Ala Ala Phe Arg Lys Leu Val
35 40 45
Glu Thr Val Thr Pro Ile Val Asp Asp Cys Ile Arg Lys Ile Ala Asp
50 55 60
Asn Ala Leu Cys His Phe Gly Thr Glu Tyr Asp Phe Ser Cys Leu Gly
65 70 75 80
Asn Ala Ile Ser Lys Asn Asp Ser Lys Ala Ile Lys Lys Glu Thr Glu
85 90 95
Lys Val Glu Lys Leu Leu Ala Lys Val Leu Thr Glu Asn Leu Pro Asp
100 105 110
Gly Leu Arg Lys Val Asn Asp Ile Asn Ser Ala Ala Phe Ile Gln Asp
115 120 125
Thr Leu Thr Ser Phe Val Gln Asp Asp Ala Asp Lys Arg Val Leu Ile
130 135 140
Gln Glu Leu Lys Gly Lys Thr Val Leu Met Gln Arg Phe Leu Thr Thr
145 150 155 160
Arg Ile Thr Ala Leu Thr Val Trp Leu Pro Asp Arg Val Phe Glu Asn
165 170 175
Phe Asn Ile Phe Ile Glu Asn Ala Glu Lys Met Arg Ile Leu Leu Asp
180 185 190
Ser Pro Leu Asn Glu Lys Ile Met Lys Phe Asp Pro Asp Ala Glu Gln
195 200 205
Tyr Ala Ser Leu Glu Phe Tyr Gly Gln Cys Leu Ser Gln Lys Asp Ile
210 215 220
Asp Ser Tyr Asn Leu Ile Ile Ser Gly Ile Tyr Ala Asp Asp Glu Val
225 230 235 240
Lys Asn Pro Gly Ile Asn Glu Ile Val Lys Glu Tyr Asn Gln Gln Ile
245 250 255
Arg Gly Asp Lys Asp Glu Ser Pro Leu Pro Lys Leu Lys Lys Leu His
260 265 270
Lys Gln Ile Leu Met Pro Val Glu Lys Ala Phe Phe Val Arg Val Leu
275 280 285
Ser Asn Asp Ser Asp Ala Arg Ser Ile Leu Glu Lys Ile Leu Lys Asp
290 295 300
Thr Glu Met Leu Pro Ser Lys Ile Ile Glu Ala Met Lys Glu Ala Asp
305 310 315 320
Ala Gly Asp Ile Ala Val Tyr Gly Ser Arg Leu His Glu Leu Ser His
325 330 335
Val Ile Tyr Gly Asp His Gly Lys Leu Ser Gln Ile Ile Tyr Asp Lys
340 345 350
Glu Ser Lys Arg Ile Ser Glu Leu Met Glu Thr Leu Ser Pro Lys Glu
355 360 365
Arg Lys Glu Ser Lys Lys Arg Leu Glu Gly Leu Glu Glu His Ile Arg
370 375 380
Lys Ser Thr Tyr Thr Phe Asp Glu Leu Asn Arg Tyr Ala Glu Lys Asn
385 390 395 400
Val Met Ala Ala Tyr Ile Ala Ala Val Glu Glu Ser Cys Ala Glu Ile
405 410 415
Met Arg Lys Glu Lys Asp Leu Arg Thr Leu Leu Ser Lys Glu Asp Val
420 425 430
Lys Ile Arg Gly Asn Arg His Asn Thr Leu Ile Val Lys Asn Tyr Phe
435 440 445
Asn Ala Trp Thr Val Phe Arg Asn Leu Ile Arg Ile Leu Arg Arg Lys
450 455 460
Ser Glu Ala Glu Ile Asp Ser Asp Phe Tyr Asp Val Leu Asp Asp Ser
465 470 475 480
Val Glu Val Leu Ser Leu Thr Tyr Lys Gly Glu Asn Leu Cys Arg Ser
485 490 495
Tyr Ile Thr Lys Lys Ile Gly Ser Asp Leu Lys Pro Glu Ile Ala Thr
500 505 510
Tyr Gly Ser Ala Leu Arg Pro Asn Ser Arg Trp Trp Ser Pro Gly Glu
515 520 525
Lys Phe Asn Val Lys Phe His Thr Ile Val Arg Arg Asp Gly Arg Leu
530 535 540
Tyr Tyr Phe Ile Leu Pro Lys Gly Ala Lys Pro Val Glu Leu Glu Asp
545 550 555 560
Met Asp Gly Asp Ile Glu Cys Leu Gln Met Arg Lys Ile Pro Asn Pro
565 570 575
Thr Ile Phe Leu Pro Lys Leu Val Phe Lys Asp Pro Glu Ala Phe Phe
580 585 590
Arg Asp Asn Pro Glu Ala Asp Glu Phe Val Phe Leu Ser Gly Met Lys
595 600 605
Ala Pro Val Thr Ile Thr Arg Glu Thr Tyr Glu Ala Tyr Arg Tyr Lys
610 615 620
Leu Tyr Thr Val Gly Lys Leu Arg Asp Gly Glu Val Ser Glu Glu Glu
625 630 635 640
Tyr Lys Arg Ala Leu Leu Gln Val Leu Thr Ala Tyr Lys Glu Phe Leu
645 650 655
Glu Asn Arg Met Ile Tyr Ala Asp Leu Asn Phe Gly Phe Lys Asp Leu
660 665 670
Glu Glu Tyr Lys Asp Ser Ser Glu Phe Ile Lys Gln Val Glu Thr His
675 680 685
Asn Thr Phe Met Cys Trp Ala Lys Val Ser Ser Ser Gln Leu Asp Asp
690 695 700
Leu Val Lys Ser Gly Asn Gly Leu Leu Phe Glu Ile Trp Ser Glu Arg
705 710 715 720
Leu Glu Ser Tyr Tyr Lys Tyr Gly Asn Glu Lys Val Leu Arg Gly Tyr
725 730 735
Glu Gly Val Leu Leu Ser Ile Leu Lys Asp Glu Asn Leu Val Ser Met
740 745 750
Arg Thr Leu Leu Asn Ser Arg Pro Met Leu Val Tyr Arg Pro Lys Glu
755 760 765
Ser Ser Lys Pro Met Val Val His Arg Asp Gly Ser Arg Val Val Asp
770 775 780
Arg Phe Asp Lys Asp Gly Lys Tyr Ile Pro Pro Glu Val His Asp Glu
785 790 795 800
Leu Tyr Arg Phe Phe Asn Asn Leu Leu Ile Lys Glu Lys Leu Gly Glu
805 810 815
Lys Ala Arg Lys Ile Leu Asp Asn Lys Lys Val Lys Val Lys Val Leu
820 825 830
Glu Ser Glu Arg Val Lys Trp Ser Lys Phe Tyr Asp Glu Gln Phe Ala
835 840 845
Val Thr Phe Ser Val Lys Lys Asn Ala Asp Cys Leu Asp Thr Thr Lys
850 855 860
Asp Leu Asn Ala Glu Val Met Glu Gln Tyr Ser Glu Ser Asn Arg Leu
865 870 875 880
Ile Leu Ile Arg Asn Thr Thr Asp Ile Leu Tyr Tyr Leu Val Leu Asp
885 890 895
Lys Asn Gly Lys Val Leu Lys Gln Arg Ser Leu Asn Ile Ile Asn Asp
900 905 910
Gly Ala Arg Asp Val Asp Trp Lys Glu Arg Phe Arg Gln Val Thr Lys
915 920 925
Asp Arg Asn Glu Gly Tyr Asn Glu Trp Asp Tyr Ser Arg Thr Ser Asn
930 935 940
Asp Leu Lys Glu Val Tyr Leu Asn Tyr Ala Leu Lys Glu Ile Ala Glu
945 950 955 960
Ala Val Ile Glu Tyr Asn Ala Ile Leu Ile Ile Glu Lys Met Ser Asn
965 970 975
Ala Phe Lys Asp Lys Tyr Ser Phe Leu Asp Asp Val Thr Phe Lys Gly
980 985 990
Phe Glu Thr Lys Lys Leu Ala Lys Leu Ser Asp Leu His Phe Arg Gly
995 1000 1005
Ile Lys Asp Gly Glu Pro Cys Ser Phe Thr Asn Pro Leu Gln Leu
1010 1015 1020
Cys Gln Asn Asp Ser Asn Lys Ile Leu Gln Asp Gly Val Ile Phe
1025 1030 1035
Met Val Pro Asn Ser Met Thr Arg Ser Leu Asp Pro Asp Thr Gly
1040 1045 1050
Phe Ile Phe Ala Ile Asn Asp His Asn Ile Arg Thr Lys Lys Ala
1055 1060 1065
Lys Leu Asn Phe Leu Ser Lys Phe Asp Gln Leu Lys Val Ser Ser
1070 1075 1080
Glu Gly Cys Leu Ile Met Lys Tyr Ser Gly Asp Ser Leu Pro Thr
1085 1090 1095
His Asn Thr Asp Asn Arg Val Trp Asn Cys Cys Cys Asn His Pro
1100 1105 1110
Ile Thr Asn Tyr Asp Arg Glu Thr Lys Lys Val Glu Phe Ile Glu
1115 1120 1125
Glu Pro Val Glu Glu Leu Ser Arg Val Leu Glu Glu Asn Gly Ile
1130 1135 1140
Glu Thr Asp Thr Glu Leu Asn Lys Leu Asn Glu Arg Glu Asn Val
1145 1150 1155
Pro Gly Lys Val Val Asp Ala Ile Tyr Ser Leu Val Leu Asn Tyr
1160 1165 1170
Leu Arg Gly Thr Val Ser Gly Val Ala Gly Gln Arg Ala Val Tyr
1175 1180 1185
Tyr Ser Pro Val Thr Gly Lys Lys Tyr Asp Ile Ser Phe Ile Gln
1190 1195 1200
Ala Met Asn Leu Asn Arg Lys Cys Asp Tyr Tyr Arg Ile Gly Ser
1205 1210 1215
Lys Glu Arg Gly Glu Trp Thr Asp Phe Val Ala Gln Leu Ile Asn
1220 1225 1230
<210> 58
<211> 1227
<212> PRT
<213> unknown
<220>
<223> Mao Luoke bacterium
<400> 58
Met Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys Thr
1 5 10 15
Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile Asp
20 25 30
Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys
35 40 45
Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn Asp
50 55 60
Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser Leu
65 70 75 80
Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn
85 90 95
Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn
100 105 110
Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile Leu
115 120 125
Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser Phe
130 135 140
Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn
145 150 155 160
Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile
165 170 175
Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys
180 185 190
Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu Lys
195 200 205
Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu Phe
210 215 220
Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile
225 230 235 240
Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn
245 250 255
Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys
260 265 270
Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu Ser
275 280 285
Phe Tyr Gly Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe
290 295 300
Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys
305 310 315 320
Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile
325 330 335
Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe
340 345 350
Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp
355 360 365
Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp
370 375 380
Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu
385 390 395 400
Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu
405 410 415
Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser
420 425 430
Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys
435 440 445
Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys
450 455 460
Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr
465 470 475 480
Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile
485 490 495
Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr
500 505 510
Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro
515 520 525
Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala
530 535 540
Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys
545 550 555 560
Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly
565 570 575
Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met
580 585 590
Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro
595 600 605
Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly
610 615 620
Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys
625 630 635 640
Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn
645 650 655
Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu
660 665 670
Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys
675 680 685
Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile
690 695 700
Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu His
705 710 715 720
Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln Ile
725 730 735
Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu Lys
740 745 750
Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn Lys
755 760 765
Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val Tyr
770 775 780
Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro Ile
785 790 795 800
Ala Asn Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu
805 810 815
Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile
820 825 830
Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys
835 840 845
Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe
850 855 860
Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys
865 870 875 880
Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn
885 890 895
Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile
900 905 910
Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu
915 920 925
Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr
930 935 940
Gln Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp
945 950 955 960
Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln
965 970 975
Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly
980 985 990
Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
995 1000 1005
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1010 1015 1020
Asp Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro
1025 1030 1035
Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser
1040 1045 1050
Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr
1055 1060 1065
Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val
1070 1075 1080
Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu
1085 1090 1095
Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala
1100 1105 1110
Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met
1115 1120 1125
Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly
1130 1135 1140
Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp
1145 1150 1155
Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala
1160 1165 1170
Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala
1175 1180 1185
Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp
1190 1195 1200
Glu Lys Leu Asp Lys Val Lys Ile Ala Ser Asn Lys Glu Trp Leu
1205 1210 1215
Glu Tyr Ala Gln Thr Ser Val Lys His
1220 1225
<210> 59
<211> 1264
<212> PRT
<213> Leptospira inadai
<400> 59
Met Glu Asp Tyr Ser Gly Phe Val Asn Ile Tyr Ser Ile Gln Lys Thr
1 5 10 15
Leu Arg Phe Glu Leu Lys Pro Val Gly Lys Thr Leu Glu His Ile Glu
20 25 30
Lys Lys Gly Phe Leu Lys Lys Asp Lys Ile Arg Ala Glu Asp Tyr Lys
35 40 45
Ala Val Lys Lys Ile Ile Asp Lys Tyr His Arg Ala Tyr Ile Glu Glu
50 55 60
Val Phe Asp Ser Val Leu His Gln Lys Lys Lys Lys Asp Lys Thr Arg
65 70 75 80
Phe Ser Thr Gln Phe Ile Lys Glu Ile Lys Glu Phe Ser Glu Leu Tyr
85 90 95
Tyr Lys Thr Glu Lys Asn Ile Pro Asp Lys Glu Arg Leu Glu Ala Leu
100 105 110
Ser Glu Lys Leu Arg Lys Met Leu Val Gly Ala Phe Lys Gly Glu Phe
115 120 125
Ser Glu Glu Val Ala Glu Lys Tyr Asn Lys Asn Leu Phe Ser Lys Glu
130 135 140
Leu Ile Arg Asn Glu Ile Glu Lys Phe Cys Glu Thr Asp Glu Glu Arg
145 150 155 160
Lys Gln Val Ser Asn Phe Lys Ser Phe Thr Thr Tyr Phe Thr Gly Phe
165 170 175
His Ser Asn Arg Gln Asn Ile Tyr Ser Asp Glu Lys Lys Ser Thr Ala
180 185 190
Ile Gly Tyr Arg Ile Ile His Gln Asn Leu Pro Lys Phe Leu Asp Asn
195 200 205
Leu Lys Ile Ile Glu Ser Ile Gln Arg Arg Phe Lys Asp Phe Pro Trp
210 215 220
Ser Asp Leu Lys Lys Asn Leu Lys Lys Ile Asp Lys Asn Ile Lys Leu
225 230 235 240
Thr Glu Tyr Phe Ser Ile Asp Gly Phe Val Asn Val Leu Asn Gln Lys
245 250 255
Gly Ile Asp Ala Tyr Asn Thr Ile Leu Gly Gly Lys Ser Glu Glu Ser
260 265 270
Gly Glu Lys Ile Gln Gly Leu Asn Glu Tyr Ile Asn Leu Tyr Arg Gln
275 280 285
Lys Asn Asn Ile Asp Arg Lys Asn Pro Leu Asn Val Lys Ile Leu Phe
290 295 300
Lys Gln Ile Leu Gly Asp Arg Glu Thr Lys Ser Phe Ile Pro Glu Ala
305 310 315 320
Phe Pro Asp Asp Gln Ser Val Leu Asn Ser Ile Thr Glu Phe Ala Lys
325 330 335
Tyr Leu Lys Leu Asp Lys Lys Lys Lys Ser Ile Ile Ala Glu Leu Lys
340 345 350
Lys Phe Leu Ser Ser Phe Asn Arg Tyr Glu Leu Asp Gly Ile Tyr Leu
355 360 365
Ala Asn Asp Asn Ser Leu Ala Ser Ile Ser Thr Phe Leu Phe Asp Asp
370 375 380
Trp Ser Phe Ile Lys Lys Ser Val Ser Phe Lys Tyr Asp Glu Ser Val
385 390 395 400
Gly Asp Pro Lys Lys Lys Ile Lys Ser Pro Leu Lys Tyr Glu Lys Glu
405 410 415
Lys Glu Lys Trp Leu Lys Gln Lys Tyr Tyr Thr Ile Ser Phe Leu Asn
420 425 430
Asp Ala Ile Glu Ser Tyr Ser Lys Ser Gln Asp Glu Lys Arg Val Lys
435 440 445
Ile Arg Leu Glu Ala Tyr Phe Ala Glu Phe Lys Ser Lys Asp Asp Ala
450 455 460
Lys Lys Gln Phe Asp Leu Leu Glu Arg Ile Glu Glu Ala Tyr Ala Ile
465 470 475 480
Val Glu Pro Leu Leu Gly Ala Glu Tyr Pro Arg Asp Arg Asn Leu Lys
485 490 495
Ala Asp Lys Lys Glu Val Gly Lys Ile Lys Asp Phe Leu Asp Ser Ile
500 505 510
Lys Ser Leu Gln Phe Phe Leu Lys Pro Leu Leu Ser Ala Glu Ile Phe
515 520 525
Asp Glu Lys Asp Leu Gly Phe Tyr Asn Gln Leu Glu Gly Tyr Tyr Glu
530 535 540
Glu Ile Asp Ile Ser Gly His Leu Tyr Asn Lys Val Arg Asn Tyr Leu
545 550 555 560
Thr Gly Lys Ile Tyr Ser Lys Glu Lys Phe Lys Leu Asn Phe Glu Asn
565 570 575
Ser Thr Leu Leu Lys Gly Trp Asp Glu Asn Arg Glu Val Ala Asn Leu
580 585 590
Cys Val Ile Phe Arg Glu Asp Gln Lys Tyr Tyr Leu Gly Val Met Asp
595 600 605
Lys Glu Asn Asn Thr Ile Leu Ser Asp Ile Pro Lys Val Lys Pro Asn
610 615 620
Glu Leu Phe Tyr Glu Lys Met Val Tyr Lys Leu Ile Pro Thr Pro His
625 630 635 640
Met Gln Leu Pro Arg Ile Ile Phe Ser Ser Asp Asn Leu Ser Ile Tyr
645 650 655
Asn Pro Ser Lys Ser Ile Leu Lys Ile Arg Glu Ala Lys Ser Phe Lys
660 665 670
Glu Gly Lys Asn Phe Lys Leu Lys Asp Cys His Lys Phe Ile Asp Phe
675 680 685
Tyr Lys Glu Ser Ile Ser Lys Asn Glu Asp Trp Ser Arg Phe Asp Phe
690 695 700
Lys Phe Ser Lys Thr Ser Ser Tyr Glu Asn Ile Ser Glu Phe Tyr Arg
705 710 715 720
Glu Val Glu Arg Gln Gly Tyr Asn Leu Asp Phe Lys Lys Val Ser Lys
725 730 735
Phe Tyr Ile Asp Ser Leu Val Glu Asp Gly Lys Leu Tyr Leu Phe Gln
740 745 750
Ile Tyr Asn Lys Asp Phe Ser Ile Phe Ser Lys Gly Lys Pro Asn Leu
755 760 765
His Thr Ile Tyr Phe Arg Ser Leu Phe Ser Lys Glu Asn Leu Lys Asp
770 775 780
Val Cys Leu Lys Leu Asn Gly Glu Ala Glu Met Phe Phe Arg Lys Lys
785 790 795 800
Ser Ile Asn Tyr Asp Glu Lys Lys Lys Arg Glu Gly His His Pro Glu
805 810 815
Leu Phe Glu Lys Leu Lys Tyr Pro Ile Leu Lys Asp Lys Arg Tyr Ser
820 825 830
Glu Asp Lys Phe Gln Phe His Leu Pro Ile Ser Leu Asn Phe Lys Ser
835 840 845
Lys Glu Arg Leu Asn Phe Asn Leu Lys Val Asn Glu Phe Leu Lys Arg
850 855 860
Asn Lys Asp Ile Asn Ile Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu
865 870 875 880
Leu Tyr Leu Val Met Ile Asn Gln Lys Gly Glu Ile Leu Lys Gln Thr
885 890 895
Leu Leu Asp Ser Met Gln Ser Gly Lys Gly Arg Pro Glu Ile Asn Tyr
900 905 910
Lys Glu Lys Leu Gln Glu Lys Glu Ile Glu Arg Asp Lys Ala Arg Lys
915 920 925
Ser Trp Gly Thr Val Glu Asn Ile Lys Glu Leu Lys Glu Gly Tyr Leu
930 935 940
Ser Ile Val Ile His Gln Ile Ser Lys Leu Met Val Glu Asn Asn Ala
945 950 955 960
Ile Val Val Leu Glu Asp Leu Asn Ile Gly Phe Lys Arg Gly Arg Gln
965 970 975
Lys Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp
980 985 990
Lys Leu Asn Phe Leu Val Phe Lys Glu Asn Lys Pro Thr Glu Pro Gly
995 1000 1005
Gly Val Leu Lys Ala Tyr Gln Leu Thr Asp Glu Phe Gln Ser Phe
1010 1015 1020
Glu Lys Leu Ser Lys Gln Thr Gly Phe Leu Phe Tyr Val Pro Ser
1025 1030 1035
Trp Asn Thr Ser Lys Ile Asp Pro Arg Thr Gly Phe Ile Asp Phe
1040 1045 1050
Leu His Pro Ala Tyr Glu Asn Ile Glu Lys Ala Lys Gln Trp Ile
1055 1060 1065
Asn Lys Phe Asp Ser Ile Arg Phe Asn Ser Lys Met Asp Trp Phe
1070 1075 1080
Glu Phe Thr Ala Asp Thr Arg Lys Phe Ser Glu Asn Leu Met Leu
1085 1090 1095
Gly Lys Asn Arg Val Trp Val Ile Cys Thr Thr Asn Val Glu Arg
1100 1105 1110
Tyr Phe Thr Ser Lys Thr Ala Asn Ser Ser Ile Gln Tyr Asn Ser
1115 1120 1125
Ile Gln Ile Thr Glu Lys Leu Lys Glu Leu Phe Val Asp Ile Pro
1130 1135 1140
Phe Ser Asn Gly Gln Asp Leu Lys Pro Glu Ile Leu Arg Lys Asn
1145 1150 1155
Asp Ala Val Phe Phe Lys Ser Leu Leu Phe Tyr Ile Lys Thr Thr
1160 1165 1170
Leu Ser Leu Arg Gln Asn Asn Gly Lys Lys Gly Glu Glu Glu Lys
1175 1180 1185
Asp Phe Ile Leu Ser Pro Val Val Asp Ser Lys Gly Arg Phe Phe
1190 1195 1200
Asn Ser Leu Glu Ala Ser Asp Asp Glu Pro Lys Asp Ala Asp Ala
1205 1210 1215
Asn Gly Ala Tyr His Ile Ala Leu Lys Gly Leu Met Asn Leu Leu
1220 1225 1230
Val Leu Asn Glu Thr Lys Glu Glu Asn Leu Ser Arg Pro Lys Trp
1235 1240 1245
Lys Ile Lys Asn Lys Asp Trp Leu Glu Phe Val Trp Glu Arg Asn
1250 1255 1260
Arg
<210> 60
<211> 1373
<212> PRT
<213> Moraxella bovis (Moraxella bovoculi)
<400> 60
Met Leu Phe Gln Asp Phe Thr His Leu Tyr Pro Leu Ser Lys Thr Val
1 5 10 15
Arg Phe Glu Leu Phe Ile Asp Arg Thr Leu Glu His Ile His Ala Lys
20 25 30
Asn Phe Leu Ser Gln Asp Glu Thr Met Ala Asp Met His Gln Lys Val
35 40 45
Lys Val Ile Leu Asp Asp Tyr His Arg Asp Phe Ile Ala Asp Met Met
50 55 60
Gly Glu Val Lys Leu Thr Lys Leu Ala Glu Phe Tyr Asp Val Tyr Leu
65 70 75 80
Lys Phe Arg Lys Asn Pro Lys Asp Asp Glu Leu Gln Lys Ala Gln Leu
85 90 95
Lys Asp Leu Gln Ala Val Leu Arg Lys Glu Ile Val Lys Pro Ile Gly
100 105 110
Asn Gly Gly Lys Tyr Lys Ala Gly Tyr Asp Arg Leu Phe Gly Ala Lys
115 120 125
Leu Phe Lys Asp Gly Lys Glu Leu Gly Asp Leu Ala Lys Phe Val Ile
130 135 140
Ala Gln Glu Gly Glu Ser Ser Pro Lys Leu Ala His Leu Ala His Phe
145 150 155 160
Glu Lys Phe Ser Thr Tyr Phe Thr Gly Phe His Asp Asn Arg Lys Asn
165 170 175
Met Tyr Ser Asp Glu Asp Lys His Thr Ala Ile Ala Tyr Arg Leu Ile
180 185 190
His Glu Asn Leu Pro Arg Phe Ile Asp Asn Leu Gln Ile Leu Thr Thr
195 200 205
Ile Lys Gln Lys His Ser Ala Leu Tyr Asp Gln Ile Ile Asn Glu Leu
210 215 220
Thr Ala Ser Gly Leu Asp Val Ser Leu Ala Ser His Leu Asp Gly Tyr
225 230 235 240
His Lys Leu Leu Thr Gln Glu Gly Ile Thr Ala Tyr Asn Thr Leu Leu
245 250 255
Gly Gly Ile Ser Gly Glu Ala Gly Ser Pro Lys Ile Gln Gly Ile Asn
260 265 270
Glu Leu Ile Asn Ser His His Asn Gln His Cys His Lys Ser Glu Arg
275 280 285
Ile Ala Lys Leu Arg Pro Leu His Lys Gln Ile Leu Ser Asp Gly Met
290 295 300
Ser Val Ser Phe Leu Pro Ser Lys Phe Ala Asp Asp Ser Glu Met Cys
305 310 315 320
Gln Ala Val Asn Glu Phe Tyr Arg His Tyr Ala Asp Val Phe Ala Lys
325 330 335
Val Gln Ser Leu Phe Asp Gly Phe Asp Asp His Gln Lys Asp Gly Ile
340 345 350
Tyr Val Glu His Lys Asn Leu Asn Glu Leu Ser Lys Gln Ala Phe Gly
355 360 365
Asp Phe Ala Leu Leu Gly Arg Val Leu Asp Gly Tyr Tyr Val Asp Val
370 375 380
Val Asn Pro Glu Phe Asn Glu Arg Phe Ala Lys Ala Lys Thr Asp Asn
385 390 395 400
Ala Lys Ala Lys Leu Thr Lys Glu Lys Asp Lys Phe Ile Lys Gly Val
405 410 415
His Ser Leu Ala Ser Leu Glu Gln Ala Ile Glu His Tyr Thr Ala Arg
420 425 430
His Asp Asp Glu Ser Val Gln Ala Gly Lys Leu Gly Gln Tyr Phe Lys
435 440 445
His Gly Leu Ala Gly Val Asp Asn Pro Ile Gln Lys Ile His Asn Asn
450 455 460
His Ser Thr Ile Lys Gly Phe Leu Glu Arg Glu Arg Pro Ala Gly Glu
465 470 475 480
Arg Ala Leu Pro Lys Ile Lys Ser Gly Lys Asn Pro Glu Met Thr Gln
485 490 495
Leu Arg Gln Leu Lys Glu Leu Leu Asp Asn Ala Leu Asn Val Ala His
500 505 510
Phe Ala Lys Leu Leu Thr Thr Lys Thr Thr Leu Asp Asn Gln Asp Gly
515 520 525
Asn Phe Tyr Gly Glu Phe Gly Val Leu Tyr Asp Glu Leu Ala Lys Ile
530 535 540
Pro Thr Leu Tyr Asn Lys Val Arg Asp Tyr Leu Ser Gln Lys Pro Phe
545 550 555 560
Ser Thr Glu Lys Tyr Lys Leu Asn Phe Gly Asn Pro Thr Leu Leu Asn
565 570 575
Gly Trp Asp Leu Asn Lys Glu Lys Asp Asn Phe Gly Val Ile Leu Gln
580 585 590
Lys Asp Gly Cys Tyr Tyr Leu Ala Leu Leu Asp Lys Ala His Lys Lys
595 600 605
Val Phe Asp Asn Ala Pro Asn Thr Gly Lys Ser Ile Tyr Gln Lys Met
610 615 620
Ile Tyr Lys Tyr Leu Glu Val Arg Lys Gln Phe Pro Lys Val Phe Phe
625 630 635 640
Ser Lys Glu Ala Ile Ala Ile Asn Tyr His Pro Ser Lys Glu Leu Val
645 650 655
Glu Ile Lys Asp Lys Gly Arg Gln Arg Ser Asp Asp Glu Arg Leu Lys
660 665 670
Leu Tyr Arg Phe Ile Leu Glu Cys Leu Lys Ile His Pro Lys Tyr Asp
675 680 685
Lys Lys Phe Glu Gly Ala Ile Gly Asp Ile Gln Leu Phe Lys Lys Asp
690 695 700
Lys Lys Gly Arg Glu Val Pro Ile Ser Glu Lys Asp Leu Phe Lys Asp
705 710 715 720
Ile Asn Gly Ile Phe Ser Ser Lys Pro Lys Leu Glu Met Glu Asp Phe
725 730 735
Phe Ile Gly Glu Phe Lys Arg Tyr Asn Pro Ser Gln Asp Leu Val Asp
740 745 750
Gln Tyr Asn Ile Tyr Lys Lys Ile Asp Ser Asn Asp Asn Arg Lys Lys
755 760 765
Glu Asn Phe Tyr Asn Asn His Pro Lys Phe Lys Lys Asp Leu Val Arg
770 775 780
Tyr Tyr Tyr Glu Ser Met Cys Lys His Glu Glu Trp Glu Glu Ser Phe
785 790 795 800
Glu Phe Ser Lys Lys Leu Gln Asp Ile Gly Cys Tyr Val Asp Val Asn
805 810 815
Glu Leu Phe Thr Glu Ile Glu Thr Arg Arg Leu Asn Tyr Lys Ile Ser
820 825 830
Phe Cys Asn Ile Asn Ala Asp Tyr Ile Asp Glu Leu Val Glu Gln Gly
835 840 845
Gln Leu Tyr Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ser Pro Lys Ala
850 855 860
His Gly Lys Pro Asn Leu His Thr Leu Tyr Phe Lys Ala Leu Phe Ser
865 870 875 880
Glu Asp Asn Leu Ala Asp Pro Ile Tyr Lys Leu Asn Gly Glu Ala Gln
885 890 895
Ile Phe Tyr Arg Lys Ala Ser Leu Asp Met Asn Glu Thr Thr Ile His
900 905 910
Arg Ala Gly Glu Val Leu Glu Asn Lys Asn Pro Asp Asn Pro Lys Lys
915 920 925
Arg Gln Phe Val Tyr Asp Ile Ile Lys Asp Lys Arg Tyr Thr Gln Lys
930 935 940
Asp Phe Met Leu His Val Pro Ile Thr Met Asn Phe Gly Val Gln Gly
945 950 955 960
Met Thr Ile Lys Glu Phe Asn Lys Lys Val Asn Gln Ser Ile Gln Gln
965 970 975
Tyr Asp Glu Val Asn Val Ile Gly Ile Asp Arg Gly Glu Arg His Leu
980 985 990
Leu Tyr Leu Thr Val Ile Asn Ser Lys Gly Glu Ile Leu Glu Gln Cys
995 1000 1005
Ser Leu Asn Asp Ile Thr Thr Ala Ser Ala Asn Gly Thr Gln Met
1010 1015 1020
Thr Thr Pro Tyr His Lys Ile Leu Asp Lys Arg Glu Ile Glu Arg
1025 1030 1035
Leu Asn Ala Arg Val Gly Trp Gly Glu Ile Glu Thr Ile Lys Glu
1040 1045 1050
Leu Lys Ser Gly Tyr Leu Ser His Val Val His Gln Ile Ser Gln
1055 1060 1065
Leu Met Leu Lys Tyr Asn Ala Ile Val Val Leu Glu Asp Leu Asn
1070 1075 1080
Phe Gly Phe Lys Arg Gly Arg Phe Lys Val Glu Lys Gln Ile Tyr
1085 1090 1095
Gln Asn Phe Glu Asn Ala Leu Ile Lys Lys Leu Asn His Leu Val
1100 1105 1110
Leu Lys Asp Lys Ala Asp Asp Glu Ile Gly Ser Tyr Lys Asn Ala
1115 1120 1125
Leu Gln Leu Thr Asn Asn Phe Thr Asp Leu Lys Ser Ile Gly Lys
1130 1135 1140
Gln Thr Gly Phe Leu Phe Tyr Val Pro Ala Trp Asn Thr Ser Lys
1145 1150 1155
Ile Asp Pro Glu Thr Gly Phe Val Asp Leu Leu Lys Pro Arg Tyr
1160 1165 1170
Glu Asn Ile Gln Ala Ser Gln Ala Phe Phe Gly Lys Phe Asp Lys
1175 1180 1185
Ile Cys Tyr Asn Ala Asp Lys Asp Tyr Phe Glu Phe His Ile Asp
1190 1195 1200
Tyr Ala Lys Phe Thr Asp Lys Ala Lys Asn Ser Arg Gln Ile Trp
1205 1210 1215
Thr Ile Cys Ser His Gly Asp Lys Arg Tyr Val Tyr Asp Lys Thr
1220 1225 1230
Ala Asn Gln Asn Lys Gly Ala Ala Lys Gly Ile Asn Val Asn Asp
1235 1240 1245
Ile Leu Lys Ser Leu Phe Ala Arg His His Ile Asn Glu Lys Gln
1250 1255 1260
Pro Asn Leu Val Met Asp Ile Cys Gln Asn Asn Asp Lys Glu Phe
1265 1270 1275
His Lys Ser Leu Met Tyr Leu Leu Lys Thr Leu Leu Ala Leu Arg
1280 1285 1290
Tyr Ser Asn Ala Ser Ser Asp Glu Asp Phe Ile Leu Ser Pro Val
1295 1300 1305
Ala Asn Asp Glu Gly Val Phe Phe Asn Ser Ala Leu Ala Asp Asp
1310 1315 1320
Thr Gln Pro Gln Asn Ala Asp Ala Asn Gly Ala Tyr His Ile Ala
1325 1330 1335
Leu Lys Gly Leu Trp Leu Leu Asn Glu Leu Lys Asn Ser Asp Asp
1340 1345 1350
Leu Asn Lys Val Lys Leu Ala Ile Asp Asn Gln Thr Trp Leu Asn
1355 1360 1365
Phe Ala Gln Asn Arg
1370
<210> 61
<211> 1352
<212> PRT
<213> unknown
<220>
<223> Parcubacilli
<400> 61
Met Glu Asn Ile Phe Asp Gln Phe Ile Gly Lys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Glu Leu Lys Pro Val Gly Lys Thr Glu Asp Phe Leu
20 25 30
Lys Ile Asn Lys Val Phe Glu Lys Asp Gln Thr Ile Asp Asp Ser Tyr
35 40 45
Asn Gln Ala Lys Phe Tyr Phe Asp Ser Leu His Gln Lys Phe Ile Asp
50 55 60
Ala Ala Leu Ala Ser Asp Lys Thr Ser Glu Leu Ser Phe Gln Asn Phe
65 70 75 80
Ala Asp Val Leu Glu Lys Gln Asn Lys Ile Ile Leu Asp Lys Lys Arg
85 90 95
Glu Met Gly Ala Leu Arg Lys Arg Asp Lys Asn Ala Val Gly Ile Asp
100 105 110
Arg Leu Gln Lys Glu Ile Asn Asp Ala Glu Asp Ile Ile Gln Lys Glu
115 120 125
Lys Glu Lys Ile Tyr Lys Asp Val Arg Thr Leu Phe Asp Asn Glu Ala
130 135 140
Glu Ser Trp Lys Thr Tyr Tyr Gln Glu Arg Glu Val Asp Gly Lys Lys
145 150 155 160
Ile Thr Glu Ser Lys Ala Asp Leu Lys Gln Lys Gly Ala Asp Phe Leu
165 170 175
Thr Ala Ala Gly Ile Leu Lys Val Leu Lys Tyr Glu Phe Pro Glu Glu
180 185 190
Lys Glu Lys Glu Phe Gln Ala Lys Asn Gln Pro Ser Leu Phe Val Glu
195 200 205
Glu Lys Glu Asn Pro Gly Gln Lys Arg Tyr Ile Phe Asp Ser Phe Asp
210 215 220
Lys Phe Ala Gly Tyr Leu Thr Lys Phe Gln Gln Thr Lys Lys Asn Leu
225 230 235 240
Tyr Ala Ala Asp Gly Thr Ser Thr Ala Val Ala Thr Arg Ile Ala Asp
245 250 255
Asn Phe Ile Ile Phe His Gln Asn Thr Lys Val Phe Arg Asp Lys Tyr
260 265 270
Lys Asn Asn His Thr Asp Leu Gly Phe Asp Glu Glu Asn Ile Phe Glu
275 280 285
Ile Glu Arg Tyr Lys Asn Cys Leu Leu Gln Arg Glu Ile Glu His Ile
290 295 300
Lys Asn Glu Asn Ser Tyr Asn Lys Ile Ile Gly Arg Ile Asn Lys Lys
305 310 315 320
Ile Lys Glu Tyr Arg Asp Gln Lys Ala Lys Asp Thr Lys Leu Thr Lys
325 330 335
Ser Asp Phe Pro Phe Phe Lys Asn Leu Asp Lys Gln Ile Leu Gly Glu
340 345 350
Val Glu Lys Glu Lys Gln Leu Ile Glu Lys Thr Arg Glu Lys Thr Glu
355 360 365
Glu Asp Val Leu Ile Glu Arg Phe Lys Glu Phe Ile Glu Asn Asn Glu
370 375 380
Glu Arg Phe Thr Ala Ala Lys Lys Leu Met Asn Ala Phe Cys Asn Gly
385 390 395 400
Glu Phe Glu Ser Glu Tyr Glu Gly Ile Tyr Leu Lys Asn Lys Ala Ile
405 410 415
Asn Thr Ile Ser Arg Arg Trp Phe Val Ser Asp Arg Asp Phe Glu Leu
420 425 430
Lys Leu Pro Gln Gln Lys Ser Lys Asn Lys Ser Glu Lys Asn Glu Pro
435 440 445
Lys Val Lys Lys Phe Ile Ser Ile Ala Glu Ile Lys Asn Ala Val Glu
450 455 460
Glu Leu Asp Gly Asp Ile Phe Lys Ala Val Phe Tyr Asp Lys Lys Ile
465 470 475 480
Ile Ala Gln Gly Gly Ser Lys Leu Glu Gln Phe Leu Val Ile Trp Lys
485 490 495
Tyr Glu Phe Glu Tyr Leu Phe Arg Asp Ile Glu Arg Glu Asn Gly Glu
500 505 510
Lys Leu Leu Gly Tyr Asp Ser Cys Leu Lys Ile Ala Lys Gln Leu Gly
515 520 525
Ile Phe Pro Gln Glu Lys Glu Ala Arg Glu Lys Ala Thr Ala Val Ile
530 535 540
Lys Asn Tyr Ala Asp Ala Gly Leu Gly Ile Phe Gln Met Met Lys Tyr
545 550 555 560
Phe Ser Leu Asp Asp Lys Asp Arg Lys Asn Thr Pro Gly Gln Leu Ser
565 570 575
Thr Asn Phe Tyr Ala Glu Tyr Asp Gly Tyr Tyr Lys Asp Phe Glu Phe
580 585 590
Ile Lys Tyr Tyr Asn Glu Phe Arg Asn Phe Ile Thr Lys Lys Pro Phe
595 600 605
Asp Glu Asp Lys Ile Lys Leu Asn Phe Glu Asn Gly Ala Leu Leu Lys
610 615 620
Gly Trp Asp Glu Asn Lys Glu Tyr Asp Phe Met Gly Val Ile Leu Lys
625 630 635 640
Lys Glu Gly Arg Leu Tyr Leu Gly Ile Met His Lys Asn His Arg Lys
645 650 655
Leu Phe Gln Ser Met Gly Asn Ala Lys Gly Asp Asn Ala Asn Arg Tyr
660 665 670
Gln Lys Met Ile Tyr Lys Gln Ile Ala Asp Ala Ser Lys Asp Val Pro
675 680 685
Arg Leu Leu Leu Thr Ser Lys Lys Ala Met Glu Lys Phe Lys Pro Ser
690 695 700
Gln Glu Ile Leu Arg Ile Lys Lys Glu Lys Thr Phe Lys Arg Glu Ser
705 710 715 720
Lys Asn Phe Ser Leu Arg Asp Leu His Ala Leu Ile Glu Tyr Tyr Arg
725 730 735
Asn Cys Ile Pro Gln Tyr Ser Asn Trp Ser Phe Tyr Asp Phe Gln Phe
740 745 750
Gln Asp Thr Gly Lys Tyr Gln Asn Ile Lys Glu Phe Thr Asp Asp Val
755 760 765
Gln Lys Tyr Gly Tyr Lys Ile Ser Phe Arg Asp Ile Asp Asp Glu Tyr
770 775 780
Ile Asn Gln Ala Leu Asn Glu Gly Lys Met Tyr Leu Phe Glu Val Val
785 790 795 800
Asn Lys Asp Ile Tyr Asn Thr Lys Asn Gly Ser Lys Asn Leu His Thr
805 810 815
Leu Tyr Phe Glu His Ile Leu Ser Ala Glu Asn Leu Asn Asp Pro Val
820 825 830
Phe Lys Leu Ser Gly Met Ala Glu Ile Phe Gln Arg Gln Pro Ser Val
835 840 845
Asn Glu Arg Glu Lys Ile Thr Thr Gln Lys Asn Gln Cys Ile Leu Asp
850 855 860
Lys Gly Asp Arg Ala Tyr Lys Tyr Arg Arg Tyr Thr Glu Lys Lys Ile
865 870 875 880
Met Phe His Met Ser Leu Val Leu Asn Thr Gly Lys Gly Glu Ile Lys
885 890 895
Gln Val Gln Phe Asn Lys Ile Ile Asn Gln Arg Ile Ser Ser Ser Asp
900 905 910
Asn Glu Met Arg Val Asn Val Ile Gly Ile Asp Arg Gly Glu Lys Asn
915 920 925
Leu Leu Tyr Tyr Ser Val Val Lys Gln Asn Gly Glu Ile Ile Glu Gln
930 935 940
Ala Ser Leu Asn Glu Ile Asn Gly Val Asn Tyr Arg Asp Lys Leu Ile
945 950 955 960
Glu Arg Glu Lys Glu Arg Leu Lys Asn Arg Gln Ser Trp Lys Pro Val
965 970 975
Val Lys Ile Lys Asp Leu Lys Lys Gly Tyr Ile Ser His Val Ile His
980 985 990
Lys Ile Cys Gln Leu Ile Glu Lys Tyr Ser Ala Ile Val Val Leu Glu
995 1000 1005
Asp Leu Asn Met Arg Phe Lys Gln Ile Arg Gly Gly Ile Glu Arg
1010 1015 1020
Ser Val Tyr Gln Gln Phe Glu Lys Ala Leu Ile Asp Lys Leu Gly
1025 1030 1035
Tyr Leu Val Phe Lys Asp Asn Arg Asp Leu Arg Ala Pro Gly Gly
1040 1045 1050
Val Leu Asn Gly Tyr Gln Leu Ser Ala Pro Phe Val Ser Phe Glu
1055 1060 1065
Lys Met Arg Lys Gln Thr Gly Ile Leu Phe Tyr Thr Gln Ala Glu
1070 1075 1080
Tyr Thr Ser Lys Thr Asp Pro Ile Thr Gly Phe Arg Lys Asn Val
1085 1090 1095
Tyr Ile Ser Asn Ser Ala Ser Leu Asp Lys Ile Lys Glu Ala Val
1100 1105 1110
Lys Lys Phe Asp Ala Ile Gly Trp Asp Gly Lys Glu Gln Ser Tyr
1115 1120 1125
Phe Phe Lys Tyr Asn Pro Tyr Asn Leu Ala Asp Glu Lys Tyr Lys
1130 1135 1140
Asn Ser Thr Val Ser Lys Glu Trp Ala Ile Phe Ala Ser Ala Pro
1145 1150 1155
Arg Ile Arg Arg Gln Lys Gly Glu Asp Gly Tyr Trp Lys Tyr Asp
1160 1165 1170
Arg Val Lys Val Asn Glu Glu Phe Glu Lys Leu Leu Lys Val Trp
1175 1180 1185
Asn Phe Val Asn Pro Lys Ala Thr Asp Ile Lys Gln Glu Ile Ile
1190 1195 1200
Lys Lys Ile Lys Ala Gly Asp Leu Gln Gly Glu Lys Glu Leu Asp
1205 1210 1215
Gly Arg Leu Arg Asn Phe Trp His Ser Phe Ile Tyr Leu Phe Asn
1220 1225 1230
Leu Val Leu Glu Leu Arg Asn Ser Phe Ser Leu Gln Ile Lys Ile
1235 1240 1245
Lys Ala Gly Glu Val Ile Ala Val Asp Glu Gly Val Asp Phe Ile
1250 1255 1260
Ala Ser Pro Val Lys Pro Phe Phe Thr Thr Pro Asn Pro Tyr Ile
1265 1270 1275
Pro Ser Asn Leu Cys Trp Leu Ala Val Glu Asn Ala Asp Ala Asn
1280 1285 1290
Gly Ala Tyr Asn Ile Ala Arg Lys Gly Val Met Ile Leu Lys Lys
1295 1300 1305
Ile Arg Glu His Ala Lys Lys Asp Pro Glu Phe Lys Lys Leu Pro
1310 1315 1320
Asn Leu Phe Ile Ser Asn Ala Glu Trp Asp Glu Ala Ala Arg Asp
1325 1330 1335
Trp Gly Lys Tyr Ala Gly Thr Thr Ala Leu Asn Leu Asp His
1340 1345 1350
<210> 62
<211> 1260
<212> PRT
<213> Porphyromonas crevioricanis
<400> 62
Met Asp Ser Leu Lys Asp Phe Thr Asn Leu Tyr Pro Val Ser Lys Thr
1 5 10 15
Leu Arg Phe Glu Leu Lys Pro Val Gly Lys Thr Leu Glu Asn Ile Glu
20 25 30
Lys Ala Gly Ile Leu Lys Glu Asp Glu His Arg Ala Glu Ser Tyr Arg
35 40 45
Arg Val Lys Lys Ile Ile Asp Thr Tyr His Lys Val Phe Ile Asp Ser
50 55 60
Ser Leu Glu Asn Met Ala Lys Met Gly Ile Glu Asn Glu Ile Lys Ala
65 70 75 80
Met Leu Gln Ser Phe Cys Glu Leu Tyr Lys Lys Asp His Arg Thr Glu
85 90 95
Gly Glu Asp Lys Ala Leu Asp Lys Ile Arg Ala Val Leu Arg Gly Leu
100 105 110
Ile Val Gly Ala Phe Thr Gly Val Cys Gly Arg Arg Glu Asn Thr Val
115 120 125
Gln Asn Glu Lys Tyr Glu Ser Leu Phe Lys Glu Lys Leu Ile Lys Glu
130 135 140
Ile Leu Pro Asp Phe Val Leu Ser Thr Glu Ala Glu Ser Leu Pro Phe
145 150 155 160
Ser Val Glu Glu Ala Thr Arg Ser Leu Lys Glu Phe Asp Ser Phe Thr
165 170 175
Ser Tyr Phe Ala Gly Phe Tyr Glu Asn Arg Lys Asn Ile Tyr Ser Thr
180 185 190
Lys Pro Gln Ser Thr Ala Ile Ala Tyr Arg Leu Ile His Glu Asn Leu
195 200 205
Pro Lys Phe Ile Asp Asn Ile Leu Val Phe Gln Lys Ile Lys Glu Pro
210 215 220
Ile Ala Lys Glu Leu Glu His Ile Arg Ala Asp Phe Ser Ala Gly Gly
225 230 235 240
Tyr Ile Lys Lys Asp Glu Arg Leu Glu Asp Ile Phe Ser Leu Asn Tyr
245 250 255
Tyr Ile His Val Leu Ser Gln Ala Gly Ile Glu Lys Tyr Asn Ala Leu
260 265 270
Ile Gly Lys Ile Val Thr Glu Gly Asp Gly Glu Met Lys Gly Leu Asn
275 280 285
Glu His Ile Asn Leu Tyr Asn Gln Gln Arg Gly Arg Glu Asp Arg Leu
290 295 300
Pro Leu Phe Arg Pro Leu Tyr Lys Gln Ile Leu Ser Asp Arg Glu Gln
305 310 315 320
Leu Ser Tyr Leu Pro Glu Ser Phe Glu Lys Asp Glu Glu Leu Leu Arg
325 330 335
Ala Leu Lys Glu Phe Tyr Asp His Ile Ala Glu Asp Ile Leu Gly Arg
340 345 350
Thr Gln Gln Leu Met Thr Ser Ile Ser Glu Tyr Asp Leu Ser Arg Ile
355 360 365
Tyr Val Arg Asn Asp Ser Gln Leu Thr Asp Ile Ser Lys Lys Met Leu
370 375 380
Gly Asp Trp Asn Ala Ile Tyr Met Ala Arg Glu Arg Ala Tyr Asp His
385 390 395 400
Glu Gln Ala Pro Lys Arg Ile Thr Ala Lys Tyr Glu Arg Asp Arg Ile
405 410 415
Lys Ala Leu Lys Gly Glu Glu Ser Ile Ser Leu Ala Asn Leu Asn Ser
420 425 430
Cys Ile Ala Phe Leu Asp Asn Val Arg Asp Cys Arg Val Asp Thr Tyr
435 440 445
Leu Ser Thr Leu Gly Gln Lys Glu Gly Pro His Gly Leu Ser Asn Leu
450 455 460
Val Glu Asn Val Phe Ala Ser Tyr His Glu Ala Glu Gln Leu Leu Ser
465 470 475 480
Phe Pro Tyr Pro Glu Glu Asn Asn Leu Ile Gln Asp Lys Asp Asn Val
485 490 495
Val Leu Ile Lys Asn Leu Leu Asp Asn Ile Ser Asp Leu Gln Arg Phe
500 505 510
Leu Lys Pro Leu Trp Gly Met Gly Asp Glu Pro Asp Lys Asp Glu Arg
515 520 525
Phe Tyr Gly Glu Tyr Asn Tyr Ile Arg Gly Ala Leu Asp Gln Val Ile
530 535 540
Pro Leu Tyr Asn Lys Val Arg Asn Tyr Leu Thr Arg Lys Pro Tyr Ser
545 550 555 560
Thr Arg Lys Val Lys Leu Asn Phe Gly Asn Ser Gln Leu Leu Ser Gly
565 570 575
Trp Asp Arg Asn Lys Glu Lys Asp Asn Ser Cys Val Ile Leu Arg Lys
580 585 590
Gly Gln Asn Phe Tyr Leu Ala Ile Met Asn Asn Arg His Lys Arg Ser
595 600 605
Phe Glu Asn Lys Met Leu Pro Glu Tyr Lys Glu Gly Glu Pro Tyr Phe
610 615 620
Glu Lys Met Asp Tyr Lys Phe Leu Pro Asp Pro Asn Lys Met Leu Pro
625 630 635 640
Lys Val Phe Leu Ser Lys Lys Gly Ile Glu Ile Tyr Lys Pro Ser Pro
645 650 655
Lys Leu Leu Glu Gln Tyr Gly His Gly Thr His Lys Lys Gly Asp Thr
660 665 670
Phe Ser Met Asp Asp Leu His Glu Leu Ile Asp Phe Phe Lys His Ser
675 680 685
Ile Glu Ala His Glu Asp Trp Lys Gln Phe Gly Phe Lys Phe Ser Asp
690 695 700
Thr Ala Thr Tyr Glu Asn Val Ser Ser Phe Tyr Arg Glu Val Glu Asp
705 710 715 720
Gln Gly Tyr Lys Leu Ser Phe Arg Lys Val Ser Glu Ser Tyr Val Tyr
725 730 735
Ser Leu Ile Asp Gln Gly Lys Leu Tyr Leu Phe Gln Ile Tyr Asn Lys
740 745 750
Asp Phe Ser Pro Cys Ser Lys Gly Thr Pro Asn Leu His Thr Leu Tyr
755 760 765
Trp Arg Met Leu Phe Asp Glu Arg Asn Leu Ala Asp Val Ile Tyr Lys
770 775 780
Leu Asp Gly Lys Ala Glu Ile Phe Phe Arg Glu Lys Ser Leu Lys Asn
785 790 795 800
Asp His Pro Thr His Pro Ala Gly Lys Pro Ile Lys Lys Lys Ser Arg
805 810 815
Gln Lys Lys Gly Glu Glu Ser Leu Phe Glu Tyr Asp Leu Val Lys Asp
820 825 830
Arg Arg Tyr Thr Met Asp Lys Phe Gln Phe His Val Pro Ile Thr Met
835 840 845
Asn Phe Lys Cys Ser Ala Gly Ser Lys Val Asn Asp Met Val Asn Ala
850 855 860
His Ile Arg Glu Ala Lys Asp Met His Val Ile Gly Ile Asp Arg Gly
865 870 875 880
Glu Arg Asn Leu Leu Tyr Ile Cys Val Ile Asp Ser Arg Gly Thr Ile
885 890 895
Leu Asp Gln Ile Ser Leu Asn Thr Ile Asn Asp Ile Asp Tyr His Asp
900 905 910
Leu Leu Glu Ser Arg Asp Lys Asp Arg Gln Gln Glu His Arg Asn Trp
915 920 925
Gln Thr Ile Glu Gly Ile Lys Glu Leu Lys Gln Gly Tyr Leu Ser Gln
930 935 940
Ala Val His Arg Ile Ala Glu Leu Met Val Ala Tyr Lys Ala Val Val
945 950 955 960
Ala Leu Glu Asp Leu Asn Met Gly Phe Lys Arg Gly Arg Gln Lys Val
965 970 975
Glu Ser Ser Val Tyr Gln Gln Phe Glu Lys Gln Leu Ile Asp Lys Leu
980 985 990
Asn Tyr Leu Val Asp Lys Lys Lys Arg Pro Glu Asp Ile Gly Gly Leu
995 1000 1005
Leu Arg Ala Tyr Gln Phe Thr Ala Pro Phe Lys Ser Phe Lys Glu
1010 1015 1020
Met Gly Lys Gln Asn Gly Phe Leu Phe Tyr Ile Pro Ala Trp Asn
1025 1030 1035
Thr Ser Asn Ile Asp Pro Thr Thr Gly Phe Val Asn Leu Phe His
1040 1045 1050
Val Gln Tyr Glu Asn Val Asp Lys Ala Lys Ser Phe Phe Gln Lys
1055 1060 1065
Phe Asp Ser Ile Ser Tyr Asn Pro Lys Lys Asp Trp Phe Glu Phe
1070 1075 1080
Ala Phe Asp Tyr Lys Asn Phe Thr Lys Lys Ala Glu Gly Ser Arg
1085 1090 1095
Ser Met Trp Ile Leu Cys Thr His Gly Ser Arg Ile Lys Asn Phe
1100 1105 1110
Arg Asn Ser Gln Lys Asn Gly Gln Trp Asp Ser Glu Glu Phe Ala
1115 1120 1125
Leu Thr Glu Ala Phe Lys Ser Leu Phe Val Arg Tyr Glu Ile Asp
1130 1135 1140
Tyr Thr Ala Asp Leu Lys Thr Ala Ile Val Asp Glu Lys Gln Lys
1145 1150 1155
Asp Phe Phe Val Asp Leu Leu Lys Leu Phe Lys Leu Thr Val Gln
1160 1165 1170
Met Arg Asn Ser Trp Lys Glu Lys Asp Leu Asp Tyr Leu Ile Ser
1175 1180 1185
Pro Val Ala Gly Ala Asp Gly Arg Phe Phe Asp Thr Arg Glu Gly
1190 1195 1200
Asn Lys Ser Leu Pro Lys Asp Ala Asp Ala Asn Gly Ala Tyr Asn
1205 1210 1215
Ile Ala Leu Lys Gly Leu Trp Ala Leu Arg Gln Ile Arg Gln Thr
1220 1225 1230
Ser Glu Gly Gly Lys Leu Lys Leu Ala Ile Ser Asn Lys Glu Trp
1235 1240 1245
Leu Gln Phe Val Gln Glu Arg Ser Tyr Glu Lys Asp
1250 1255 1260
<210> 63
<211> 1324
<212> PRT
<213> Prevotella desceno
<400> 63
Met Glu Asn Tyr Gln Glu Phe Thr Asn Leu Phe Gln Leu Asn Lys Thr
1 5 10 15
Leu Arg Phe Glu Leu Lys Pro Ile Gly Lys Thr Cys Glu Leu Leu Glu
20 25 30
Glu Gly Lys Ile Phe Ala Ser Gly Ser Phe Leu Glu Lys Asp Lys Val
35 40 45
Arg Ala Asp Asn Val Ser Tyr Val Lys Lys Glu Ile Asp Lys Lys His
50 55 60
Lys Ile Phe Ile Glu Glu Thr Leu Ser Ser Phe Ser Ile Ser Asn Asp
65 70 75 80
Leu Leu Lys Gln Tyr Phe Asp Cys Tyr Asn Glu Leu Lys Ala Phe Lys
85 90 95
Lys Asp Cys Lys Ser Asp Glu Glu Glu Val Lys Lys Thr Ala Leu Arg
100 105 110
Asn Lys Cys Thr Ser Ile Gln Arg Ala Met Arg Glu Ala Ile Ser Gln
115 120 125
Ala Phe Leu Lys Ser Pro Gln Lys Lys Leu Leu Ala Ile Lys Asn Leu
130 135 140
Ile Glu Asn Val Phe Lys Ala Asp Glu Asn Val Gln His Phe Ser Glu
145 150 155 160
Phe Thr Ser Tyr Phe Ser Gly Phe Glu Thr Asn Arg Glu Asn Phe Tyr
165 170 175
Ser Asp Glu Glu Lys Ser Thr Ser Ile Ala Tyr Arg Leu Val His Asp
180 185 190
Asn Leu Pro Ile Phe Ile Lys Asn Ile Tyr Ile Phe Glu Lys Leu Lys
195 200 205
Glu Gln Phe Asp Ala Lys Thr Leu Ser Glu Ile Phe Glu Asn Tyr Lys
210 215 220
Leu Tyr Val Ala Gly Ser Ser Leu Asp Glu Val Phe Ser Leu Glu Tyr
225 230 235 240
Phe Asn Asn Thr Leu Thr Gln Lys Gly Ile Asp Asn Tyr Asn Ala Val
245 250 255
Ile Gly Lys Ile Val Lys Glu Asp Lys Gln Glu Ile Gln Gly Leu Asn
260 265 270
Glu His Ile Asn Leu Tyr Asn Gln Lys His Lys Asp Arg Arg Leu Pro
275 280 285
Phe Phe Ile Ser Leu Lys Lys Gln Ile Leu Ser Asp Arg Glu Ala Leu
290 295 300
Ser Trp Leu Pro Asp Met Phe Lys Asn Asp Ser Glu Val Ile Asp Ala
305 310 315 320
Leu Lys Gly Phe Tyr Ile Glu Asp Gly Phe Glu Asn Asn Val Leu Thr
325 330 335
Pro Leu Ala Thr Leu Leu Ser Ser Leu Asp Lys Tyr Asn Leu Asn Gly
340 345 350
Ile Phe Ile Arg Asn Asn Glu Ala Leu Ser Ser Leu Ser Gln Asn Val
355 360 365
Tyr Arg Asn Phe Ser Ile Asp Glu Ala Ile Asp Ala Gln Asn Ala Glu
370 375 380
Leu Gln Thr Phe Asn Asn Tyr Glu Leu Ile Ala Asn Ala Leu Arg Ala
385 390 395 400
Lys Ile Lys Lys Glu Thr Lys Gln Gly Arg Lys Ser Phe Glu Lys Tyr
405 410 415
Glu Glu Tyr Ile Asp Lys Lys Val Lys Ala Ile Asp Ser Leu Ser Ile
420 425 430
Gln Glu Ile Asn Glu Leu Val Glu Asn Tyr Val Ser Glu Phe Asn Ser
435 440 445
Asn Ser Gly Asn Met Pro Arg Lys Val Glu Asp Tyr Phe Ser Leu Met
450 455 460
Arg Lys Gly Asp Phe Gly Ser Asn Asp Leu Ile Glu Asn Ile Lys Thr
465 470 475 480
Lys Leu Ser Ala Ala Glu Lys Leu Leu Gly Thr Lys Tyr Gln Glu Thr
485 490 495
Ala Lys Asp Ile Phe Lys Lys Asp Glu Asn Ser Lys Leu Ile Lys Glu
500 505 510
Leu Leu Asp Ala Thr Lys Gln Phe Gln His Phe Ile Lys Pro Leu Leu
515 520 525
Gly Thr Gly Glu Glu Ala Asp Arg Asp Leu Val Phe Tyr Gly Asp Phe
530 535 540
Leu Pro Leu Tyr Glu Lys Phe Glu Glu Leu Thr Leu Leu Tyr Asn Lys
545 550 555 560
Val Arg Asn Arg Leu Thr Gln Lys Pro Tyr Ser Lys Asp Lys Ile Arg
565 570 575
Leu Cys Phe Asn Lys Pro Lys Leu Met Thr Gly Trp Val Asp Ser Lys
580 585 590
Thr Glu Lys Ser Asp Asn Gly Thr Gln Tyr Gly Gly Tyr Leu Phe Arg
595 600 605
Lys Lys Asn Glu Ile Gly Glu Tyr Asp Tyr Phe Leu Gly Ile Ser Ser
610 615 620
Lys Ala Gln Leu Phe Arg Lys Asn Glu Ala Val Ile Gly Asp Tyr Glu
625 630 635 640
Arg Leu Asp Tyr Tyr Gln Pro Lys Ala Asn Thr Ile Tyr Gly Ser Ala
645 650 655
Tyr Glu Gly Glu Asn Ser Tyr Lys Glu Asp Lys Lys Arg Leu Asn Lys
660 665 670
Val Ile Ile Ala Tyr Ile Glu Gln Ile Lys Gln Thr Asn Ile Lys Lys
675 680 685
Ser Ile Ile Glu Ser Ile Ser Lys Tyr Pro Asn Ile Ser Asp Asp Asp
690 695 700
Lys Val Thr Pro Ser Ser Leu Leu Glu Lys Ile Lys Lys Val Ser Ile
705 710 715 720
Asp Ser Tyr Asn Gly Ile Leu Ser Phe Lys Ser Phe Gln Ser Val Asn
725 730 735
Lys Glu Val Ile Asp Asn Leu Leu Lys Thr Ile Ser Pro Leu Lys Asn
740 745 750
Lys Ala Glu Phe Leu Asp Leu Ile Asn Lys Asp Tyr Gln Ile Phe Thr
755 760 765
Glu Val Gln Ala Val Ile Asp Glu Ile Cys Lys Gln Lys Thr Phe Ile
770 775 780
Tyr Phe Pro Ile Ser Asn Val Glu Leu Glu Lys Glu Met Gly Asp Lys
785 790 795 800
Asp Lys Pro Leu Cys Leu Phe Gln Ile Ser Asn Lys Asp Leu Ser Phe
805 810 815
Ala Lys Thr Phe Ser Ala Asn Leu Arg Lys Lys Arg Gly Ala Glu Asn
820 825 830
Leu His Thr Met Leu Phe Lys Ala Leu Met Glu Gly Asn Gln Asp Asn
835 840 845
Leu Asp Leu Gly Ser Gly Ala Ile Phe Tyr Arg Ala Lys Ser Leu Asp
850 855 860
Gly Asn Lys Pro Thr His Pro Ala Asn Glu Ala Ile Lys Cys Arg Asn
865 870 875 880
Val Ala Asn Lys Asp Lys Val Ser Leu Phe Thr Tyr Asp Ile Tyr Lys
885 890 895
Asn Arg Arg Tyr Met Glu Asn Lys Phe Leu Phe His Leu Ser Ile Val
900 905 910
Gln Asn Tyr Lys Ala Ala Asn Asp Ser Ala Gln Leu Asn Ser Ser Ala
915 920 925
Thr Glu Tyr Ile Arg Lys Ala Asp Asp Leu His Ile Ile Gly Ile Asp
930 935 940
Arg Gly Glu Arg Asn Leu Leu Tyr Tyr Ser Val Ile Asp Met Lys Gly
945 950 955 960
Asn Ile Val Glu Gln Asp Ser Leu Asn Ile Ile Arg Asn Asn Asp Leu
965 970 975
Glu Thr Asp Tyr His Asp Leu Leu Asp Lys Arg Glu Lys Glu Arg Lys
980 985 990
Ala Asn Arg Gln Asn Trp Glu Ala Val Glu Gly Ile Lys Asp Leu Lys
995 1000 1005
Lys Gly Tyr Leu Ser Gln Ala Val His Gln Ile Ala Gln Leu Met
1010 1015 1020
Leu Lys Tyr Asn Ala Ile Ile Ala Leu Glu Asp Leu Gly Gln Met
1025 1030 1035
Phe Val Thr Arg Gly Gln Lys Ile Glu Lys Ala Val Tyr Gln Gln
1040 1045 1050
Phe Glu Lys Ser Leu Val Asp Lys Leu Ser Tyr Leu Val Asp Lys
1055 1060 1065
Lys Arg Pro Tyr Asn Glu Leu Gly Gly Ile Leu Lys Ala Tyr Gln
1070 1075 1080
Leu Ala Ser Ser Ile Thr Lys Asn Asn Ser Asp Lys Gln Asn Gly
1085 1090 1095
Phe Leu Phe Tyr Val Pro Ala Trp Asn Thr Ser Lys Ile Asp Pro
1100 1105 1110
Val Thr Gly Phe Thr Asp Leu Leu Arg Pro Lys Ala Met Thr Ile
1115 1120 1125
Lys Glu Ala Gln Asp Phe Phe Gly Ala Phe Asp Asn Ile Ser Tyr
1130 1135 1140
Asn Asp Lys Gly Tyr Phe Glu Phe Glu Thr Asn Tyr Asp Lys Phe
1145 1150 1155
Lys Ile Arg Met Lys Ser Ala Gln Thr Arg Trp Thr Ile Cys Thr
1160 1165 1170
Phe Gly Asn Arg Ile Lys Arg Lys Lys Asp Lys Asn Tyr Trp Asn
1175 1180 1185
Tyr Glu Glu Val Glu Leu Thr Glu Glu Phe Lys Lys Leu Phe Lys
1190 1195 1200
Asp Ser Asn Ile Asp Tyr Glu Asn Cys Asn Leu Lys Glu Glu Ile
1205 1210 1215
Gln Asn Lys Asp Asn Arg Lys Phe Phe Asp Asp Leu Ile Lys Leu
1220 1225 1230
Leu Gln Leu Thr Leu Gln Met Arg Asn Ser Asp Asp Lys Gly Asn
1235 1240 1245
Asp Tyr Ile Ile Ser Pro Val Ala Asn Ala Glu Gly Gln Phe Phe
1250 1255 1260
Asp Ser Arg Asn Gly Asp Lys Lys Leu Pro Leu Asp Ala Asp Ala
1265 1270 1275
Asn Gly Ala Tyr Asn Ile Ala Arg Lys Gly Leu Trp Asn Ile Arg
1280 1285 1290
Gln Ile Lys Gln Thr Lys Asn Lys Asp Asp Leu Asn Leu Ser Ile
1295 1300 1305
Ser Ser Thr Glu Trp Leu Asp Phe Val Arg Glu Lys Pro Tyr Leu
1310 1315 1320
Lys
<210> 64
<211> 1484
<212> PRT
<213> unknown
<220>
<223> Peregrinibacteria bacterium
<220>
<221> misc_feature
<222> (1073)..(1073)
<223> Xaa can be any naturally occurring amino acid
<400> 64
Met Ser Asn Phe Phe Lys Asn Phe Thr Asn Leu Tyr Glu Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Glu Leu Lys Pro Val Gly Asp Thr Leu Thr Asn Met
20 25 30
Lys Asp His Leu Glu Tyr Asp Glu Lys Leu Gln Thr Phe Leu Lys Asp
35 40 45
Gln Asn Ile Asp Asp Ala Tyr Gln Ala Leu Lys Pro Gln Phe Asp Glu
50 55 60
Ile His Glu Glu Phe Ile Thr Asp Ser Leu Glu Ser Lys Lys Ala Lys
65 70 75 80
Glu Ile Asp Phe Ser Glu Tyr Leu Asp Leu Phe Gln Glu Lys Lys Glu
85 90 95
Leu Asn Asp Ser Glu Lys Lys Leu Arg Asn Lys Ile Gly Glu Thr Phe
100 105 110
Asn Lys Ala Gly Glu Lys Trp Lys Lys Glu Lys Tyr Pro Gln Tyr Glu
115 120 125
Trp Lys Lys Gly Ser Lys Ile Ala Asn Gly Ala Asp Ile Leu Ser Cys
130 135 140
Gln Asp Met Leu Gln Phe Ile Lys Tyr Lys Asn Pro Glu Asp Glu Lys
145 150 155 160
Ile Lys Asn Tyr Ile Asp Asp Thr Leu Lys Gly Phe Phe Thr Tyr Phe
165 170 175
Gly Gly Phe Asn Gln Asn Arg Ala Asn Tyr Tyr Glu Thr Lys Lys Glu
180 185 190
Ala Ser Thr Ala Val Ala Thr Arg Ile Val His Glu Asn Leu Pro Lys
195 200 205
Phe Cys Asp Asn Val Ile Gln Phe Lys His Ile Ile Lys Arg Lys Lys
210 215 220
Asp Gly Thr Val Glu Lys Thr Glu Arg Lys Thr Glu Tyr Leu Asn Ala
225 230 235 240
Tyr Gln Tyr Leu Lys Asn Asn Asn Lys Ile Thr Gln Ile Lys Asp Ala
245 250 255
Glu Thr Glu Lys Met Ile Glu Ser Thr Pro Ile Ala Glu Lys Ile Phe
260 265 270
Asp Val Tyr Tyr Phe Ser Ser Cys Leu Ser Gln Lys Gln Ile Glu Glu
275 280 285
Tyr Asn Arg Ile Ile Gly His Tyr Asn Leu Leu Ile Asn Leu Tyr Asn
290 295 300
Gln Ala Lys Arg Ser Glu Gly Lys His Leu Ser Ala Asn Glu Lys Lys
305 310 315 320
Tyr Lys Asp Leu Pro Lys Phe Lys Thr Leu Tyr Lys Gln Ile Gly Cys
325 330 335
Gly Lys Lys Lys Asp Leu Phe Tyr Thr Ile Lys Cys Asp Thr Glu Glu
340 345 350
Glu Ala Asn Lys Ser Arg Asn Glu Gly Lys Glu Ser His Ser Val Glu
355 360 365
Glu Ile Ile Asn Lys Ala Gln Glu Ala Ile Asn Lys Tyr Phe Lys Ser
370 375 380
Asn Asn Asp Cys Glu Asn Ile Asn Thr Val Pro Asp Phe Ile Asn Tyr
385 390 395 400
Ile Leu Thr Lys Glu Asn Tyr Glu Gly Val Tyr Trp Ser Lys Ala Ala
405 410 415
Met Asn Thr Ile Ser Asp Lys Tyr Phe Ala Asn Tyr His Asp Leu Gln
420 425 430
Asp Arg Leu Lys Glu Ala Lys Val Phe Gln Lys Ala Asp Lys Lys Ser
435 440 445
Glu Asp Asp Ile Lys Ile Pro Glu Ala Ile Glu Leu Ser Gly Leu Phe
450 455 460
Gly Val Leu Asp Ser Leu Ala Asp Trp Gln Thr Thr Leu Phe Lys Ser
465 470 475 480
Ser Ile Leu Ser Asn Glu Lys Leu Lys Ile Ile Thr Asp Ser Gln Thr
485 490 495
Pro Ser Glu Ala Leu Leu Lys Met Ile Phe Asn Asp Ile Glu Lys Asn
500 505 510
Met Glu Ser Phe Leu Lys Glu Thr Asn Asp Ile Ile Thr Leu Lys Lys
515 520 525
Tyr Lys Gly Asn Lys Glu Gly Thr Glu Lys Ile Lys Gln Trp Phe Asp
530 535 540
Tyr Thr Leu Ala Ile Asn Arg Met Leu Lys Tyr Phe Leu Val Lys Glu
545 550 555 560
Asn Lys Ile Lys Gly Asn Ser Leu Asp Thr Asn Ile Ser Glu Ala Leu
565 570 575
Lys Thr Leu Ile Tyr Ser Asp Asp Ala Glu Trp Phe Lys Trp Tyr Asp
580 585 590
Ala Leu Arg Asn Tyr Leu Thr Gln Lys Pro Gln Asp Glu Ala Lys Glu
595 600 605
Asn Lys Leu Lys Leu Asn Phe Asp Asn Pro Ser Leu Ala Gly Gly Trp
610 615 620
Asp Val Asn Lys Glu Cys Ser Asn Phe Cys Val Ile Leu Lys Asp Lys
625 630 635 640
Asn Glu Lys Lys Tyr Leu Ala Met Ile Lys Lys Gly Glu Asn Thr Leu
645 650 655
Phe Gln Lys Glu Trp Thr Glu Gly Arg Gly Lys Asn Leu Thr Lys Lys
660 665 670
Ser Asn Pro Leu Phe Glu Ile Asn Asn Cys Glu Ile Leu Ser Lys Met
675 680 685
Glu Tyr Asp Phe Trp Ala Asp Val Ser Lys Met Ile Pro Lys Cys Ser
690 695 700
Thr Gln Leu Lys Ala Val Val Asn His Phe Lys Gln Ser Asp Asn Glu
705 710 715 720
Phe Ile Phe Pro Ile Gly Tyr Lys Val Thr Ser Gly Glu Lys Phe Arg
725 730 735
Glu Glu Cys Lys Ile Ser Lys Gln Asp Phe Glu Leu Asn Asn Lys Val
740 745 750
Phe Asn Lys Asn Glu Leu Ser Val Thr Ala Met Arg Tyr Asp Leu Ser
755 760 765
Ser Thr Gln Glu Lys Gln Tyr Ile Lys Ala Phe Gln Lys Glu Tyr Trp
770 775 780
Glu Leu Leu Phe Lys Gln Glu Lys Arg Asp Thr Lys Leu Thr Asn Asn
785 790 795 800
Glu Ile Phe Asn Glu Trp Ile Asn Phe Cys Asn Lys Lys Tyr Ser Glu
805 810 815
Leu Leu Ser Trp Glu Arg Lys Tyr Lys Asp Ala Leu Thr Asn Trp Ile
820 825 830
Asn Phe Cys Lys Tyr Phe Leu Ser Lys Tyr Pro Lys Thr Thr Leu Phe
835 840 845
Asn Tyr Ser Phe Lys Glu Ser Glu Asn Tyr Asn Ser Leu Asp Glu Phe
850 855 860
Tyr Arg Asp Val Asp Ile Cys Ser Tyr Lys Leu Asn Ile Asn Thr Thr
865 870 875 880
Ile Asn Lys Ser Ile Leu Asp Arg Leu Val Glu Glu Gly Lys Leu Tyr
885 890 895
Leu Phe Glu Ile Lys Asn Gln Asp Ser Asn Asp Gly Lys Ser Ile Gly
900 905 910
His Lys Asn Asn Leu His Thr Ile Tyr Trp Asn Ala Ile Phe Glu Asn
915 920 925
Phe Asp Asn Arg Pro Lys Leu Asn Gly Glu Ala Glu Ile Phe Tyr Arg
930 935 940
Lys Ala Ile Ser Lys Asp Lys Leu Gly Ile Val Lys Gly Lys Lys Thr
945 950 955 960
Lys Asn Gly Thr Trp Ile Ile Lys Asn Tyr Arg Phe Ser Lys Glu Lys
965 970 975
Phe Ile Leu His Val Pro Ile Thr Leu Asn Phe Cys Ser Asn Asn Glu
980 985 990
Tyr Val Asn Asp Ile Val Asn Thr Lys Phe Tyr Asn Phe Ser Asn Leu
995 1000 1005
His Phe Leu Gly Ile Asp Arg Gly Glu Lys His Leu Ala Tyr Tyr
1010 1015 1020
Ser Leu Val Asn Lys Asn Gly Glu Ile Val Asp Gln Gly Thr Leu
1025 1030 1035
Asn Leu Pro Phe Thr Asp Lys Asp Gly Asn Gln Arg Ser Ile Lys
1040 1045 1050
Lys Glu Lys Tyr Phe Tyr Asn Lys Gln Glu Asp Lys Trp Glu Ala
1055 1060 1065
Lys Glu Val Asp Xaa Trp Asn Tyr Asn Asp Leu Leu Asp Ala Met
1070 1075 1080
Ala Ser Asn Arg Asp Met Ala Arg Lys Asn Trp Gln Arg Ile Gly
1085 1090 1095
Thr Ile Lys Glu Ala Lys Asn Gly Tyr Val Ser Leu Val Ile Arg
1100 1105 1110
Lys Ile Ala Asp Leu Ala Val Asn Asn Glu Arg Pro Ala Phe Ile
1115 1120 1125
Val Leu Glu Asp Leu Asn Thr Gly Phe Lys Arg Ser Arg Gln Lys
1130 1135 1140
Ile Asp Lys Ser Val Tyr Gln Lys Phe Glu Leu Ala Leu Ala Lys
1145 1150 1155
Lys Leu Asn Phe Leu Val Asp Lys Asn Ala Lys Arg Asp Glu Ile
1160 1165 1170
Gly Ser Pro Thr Lys Ala Leu Gln Leu Thr Pro Pro Val Asn Asn
1175 1180 1185
Tyr Gly Asp Ile Glu Asn Lys Lys Gln Ala Gly Ile Met Leu Tyr
1190 1195 1200
Thr Arg Ala Asn Tyr Thr Ser Gln Thr Asp Pro Ala Thr Gly Trp
1205 1210 1215
Arg Lys Thr Ile Tyr Leu Lys Ala Gly Pro Glu Glu Thr Thr Tyr
1220 1225 1230
Lys Lys Asp Gly Lys Ile Lys Asn Lys Ser Val Lys Asp Gln Ile
1235 1240 1245
Ile Glu Thr Phe Thr Asp Ile Gly Phe Asp Gly Lys Asp Tyr Tyr
1250 1255 1260
Phe Glu Tyr Asp Lys Gly Glu Phe Val Asp Glu Lys Thr Gly Glu
1265 1270 1275
Ile Lys Pro Lys Lys Trp Arg Leu Tyr Ser Gly Glu Asn Gly Lys
1280 1285 1290
Ser Leu Asp Arg Phe Arg Gly Glu Arg Glu Lys Asp Lys Tyr Glu
1295 1300 1305
Trp Lys Ile Asp Lys Ile Asp Ile Val Lys Ile Leu Asp Asp Leu
1310 1315 1320
Phe Val Asn Phe Asp Lys Asn Ile Ser Leu Leu Lys Gln Leu Lys
1325 1330 1335
Glu Gly Val Glu Leu Thr Arg Asn Asn Glu His Gly Thr Gly Glu
1340 1345 1350
Ser Leu Arg Phe Ala Ile Asn Leu Ile Gln Gln Ile Arg Asn Thr
1355 1360 1365
Gly Asn Asn Glu Arg Asp Asn Asp Phe Ile Leu Ser Pro Val Arg
1370 1375 1380
Asp Glu Asn Gly Lys His Phe Asp Ser Arg Glu Tyr Trp Asp Lys
1385 1390 1395
Glu Thr Lys Gly Glu Lys Ile Ser Met Pro Ser Ser Gly Asp Ala
1400 1405 1410
Asn Gly Ala Phe Asn Ile Ala Arg Lys Gly Ile Ile Met Asn Ala
1415 1420 1425
His Ile Leu Ala Asn Ser Asp Ser Lys Asp Leu Ser Leu Phe Val
1430 1435 1440
Ser Asp Glu Glu Trp Asp Leu His Leu Asn Asn Lys Thr Glu Trp
1445 1450 1455
Lys Lys Gln Leu Asn Ile Phe Ser Ser Arg Lys Ala Met Ala Lys
1460 1465 1470
Arg Lys Lys Lys Arg Pro Ala Ala Thr Lys Lys
1475 1480
<210> 65
<211> 1245
<212> PRT
<213> Porphyromonas macacae
<400> 65
Met Lys Thr Gln His Phe Phe Glu Asp Phe Thr Ser Leu Tyr Ser Leu
1 5 10 15
Ser Lys Thr Ile Arg Phe Glu Leu Lys Pro Ile Gly Lys Thr Leu Glu
20 25 30
Asn Ile Lys Lys Asn Gly Leu Ile Arg Arg Asp Glu Gln Arg Leu Asp
35 40 45
Asp Tyr Glu Lys Leu Lys Lys Val Ile Asp Glu Tyr His Glu Asp Phe
50 55 60
Ile Ala Asn Ile Leu Ser Ser Phe Ser Phe Ser Glu Glu Ile Leu Gln
65 70 75 80
Ser Tyr Ile Gln Asn Leu Ser Ile Ser Glu Ala Arg Ala Lys Ile Glu
85 90 95
Lys Thr Met Arg Asp Thr Leu Ala Lys Ala Phe Ser Glu Asp Glu Arg
100 105 110
Tyr Lys Ser Ile Phe Lys Lys Glu Leu Val Lys Lys Asp Ile Pro Val
115 120 125
Trp Cys Pro Ala Tyr Lys Ser Leu Cys Lys Lys Phe Asp Asn Phe Thr
130 135 140
Thr Ser Leu Val Pro Phe His Glu Asn Arg Lys Asn Leu Tyr Thr Ser
145 150 155 160
Asn Glu Ile Thr Ala Ser Ile Pro Tyr Arg Ile Val His Val Asn Leu
165 170 175
Pro Lys Phe Ile Gln Asn Ile Glu Ala Leu Cys Glu Leu Gln Lys Lys
180 185 190
Met Gly Ala Asp Leu Tyr Leu Glu Met Met Glu Asn Leu Arg Asn Val
195 200 205
Trp Pro Ser Phe Val Lys Thr Pro Asp Asp Leu Cys Asn Leu Lys Thr
210 215 220
Tyr Asn His Leu Met Val Gln Ser Ser Ile Ser Glu Tyr Asn Arg Phe
225 230 235 240
Val Gly Gly Tyr Ser Thr Glu Asp Gly Thr Lys His Gln Gly Ile Asn
245 250 255
Glu Trp Ile Asn Ile Tyr Arg Gln Arg Asn Lys Glu Met Arg Leu Pro
260 265 270
Gly Leu Val Phe Leu His Lys Gln Ile Leu Ala Lys Val Asp Ser Ser
275 280 285
Ser Phe Ile Ser Asp Thr Leu Glu Asn Asp Asp Gln Val Phe Cys Val
290 295 300
Leu Arg Gln Phe Arg Lys Leu Phe Trp Asn Thr Val Ser Ser Lys Glu
305 310 315 320
Asp Asp Ala Ala Ser Leu Lys Asp Leu Phe Cys Gly Leu Ser Gly Tyr
325 330 335
Asp Pro Glu Ala Ile Tyr Val Ser Asp Ala His Leu Ala Thr Ile Ser
340 345 350
Lys Asn Ile Phe Asp Arg Trp Asn Tyr Ile Ser Asp Ala Ile Arg Arg
355 360 365
Lys Thr Glu Val Leu Met Pro Arg Lys Lys Glu Ser Val Glu Arg Tyr
370 375 380
Ala Glu Lys Ile Ser Lys Gln Ile Lys Lys Arg Gln Ser Tyr Ser Leu
385 390 395 400
Ala Glu Leu Asp Asp Leu Leu Ala His Tyr Ser Glu Glu Ser Leu Pro
405 410 415
Ala Gly Phe Ser Leu Leu Ser Tyr Phe Thr Ser Leu Gly Gly Gln Lys
420 425 430
Tyr Leu Val Ser Asp Gly Glu Val Ile Leu Tyr Glu Glu Gly Ser Asn
435 440 445
Ile Trp Asp Glu Val Leu Ile Ala Phe Arg Asp Leu Gln Val Ile Leu
450 455 460
Asp Lys Asp Phe Thr Glu Lys Lys Leu Gly Lys Asp Glu Glu Ala Val
465 470 475 480
Ser Val Ile Lys Lys Ala Leu Asp Ser Ala Leu Arg Leu Arg Lys Phe
485 490 495
Phe Asp Leu Leu Ser Gly Thr Gly Ala Glu Ile Arg Arg Asp Ser Ser
500 505 510
Phe Tyr Ala Leu Tyr Thr Asp Arg Met Asp Lys Leu Lys Gly Leu Leu
515 520 525
Lys Met Tyr Asp Lys Val Arg Asn Tyr Leu Thr Lys Lys Pro Tyr Ser
530 535 540
Ile Glu Lys Phe Lys Leu His Phe Asp Asn Pro Ser Leu Leu Ser Gly
545 550 555 560
Trp Asp Lys Asn Lys Glu Leu Asn Asn Leu Ser Val Ile Phe Arg Gln
565 570 575
Asn Gly Tyr Tyr Tyr Leu Gly Ile Met Thr Pro Lys Gly Lys Asn Leu
580 585 590
Phe Lys Thr Leu Pro Lys Leu Gly Ala Glu Glu Met Phe Tyr Glu Lys
595 600 605
Met Glu Tyr Lys Gln Ile Ala Glu Pro Met Leu Met Leu Pro Lys Val
610 615 620
Phe Phe Pro Lys Lys Thr Lys Pro Ala Phe Ala Pro Asp Gln Ser Val
625 630 635 640
Val Asp Ile Tyr Asn Lys Lys Thr Phe Lys Thr Gly Gln Lys Gly Phe
645 650 655
Asn Lys Lys Asp Leu Tyr Arg Leu Ile Asp Phe Tyr Lys Glu Ala Leu
660 665 670
Thr Val His Glu Trp Lys Leu Phe Asn Phe Ser Phe Ser Pro Thr Glu
675 680 685
Gln Tyr Arg Asn Ile Gly Glu Phe Phe Asp Glu Val Arg Glu Gln Ala
690 695 700
Tyr Lys Val Ser Met Val Asn Val Pro Ala Ser Tyr Ile Asp Glu Ala
705 710 715 720
Val Glu Asn Gly Lys Leu Tyr Leu Phe Gln Ile Tyr Asn Lys Asp Phe
725 730 735
Ser Pro Tyr Ser Lys Gly Ile Pro Asn Leu His Thr Leu Tyr Trp Lys
740 745 750
Ala Leu Phe Ser Glu Gln Asn Gln Ser Arg Val Tyr Lys Leu Cys Gly
755 760 765
Gly Gly Glu Leu Phe Tyr Arg Lys Ala Ser Leu His Met Gln Asp Thr
770 775 780
Thr Val His Pro Lys Gly Ile Ser Ile His Lys Lys Asn Leu Asn Lys
785 790 795 800
Lys Gly Glu Thr Ser Leu Phe Asn Tyr Asp Leu Val Lys Asp Lys Arg
805 810 815
Phe Thr Glu Asp Lys Phe Phe Phe His Val Pro Ile Ser Ile Asn Tyr
820 825 830
Lys Asn Lys Lys Ile Thr Asn Val Asn Gln Met Val Arg Asp Tyr Ile
835 840 845
Ala Gln Asn Asp Asp Leu Gln His Gly Ile Asp Arg Gly Glu Arg Asn
850 855 860
Leu Leu Tyr Ile Ser Arg Ile Asp Thr Arg Gly Asn Leu Leu Glu Gln
865 870 875 880
Phe Ser Leu Asn Val Ile Glu Ser Asp Lys Gly Asp Leu Arg Thr Asp
885 890 895
Tyr Gln Lys Ile Leu Gly Asp Arg Glu Gln Glu Arg Leu Arg Arg Arg
900 905 910
Gln Glu Trp Lys Ser Ile Glu Ser Ile Lys Asp Leu Lys Asp Gly Tyr
915 920 925
Met Ser Gln Val Val His Lys Ile Cys Asn Met Val Val Glu His Lys
930 935 940
Ala Ile Val Val Leu Glu Asn Leu Asn Leu Ser Phe Met Lys Gly Arg
945 950 955 960
Lys Lys Val Glu Lys Ser Val Tyr Glu Lys Phe Glu Arg Met Leu Val
965 970 975
Asp Lys Leu Asn Tyr Leu Val Val Asp Lys Lys Asn Leu Ser Asn Glu
980 985 990
Pro Gly Gly Leu Tyr Ala Ala Tyr Gln Leu Thr Asn Pro Leu Phe Ser
995 1000 1005
Phe Glu Glu Leu His Arg Tyr Pro Gln Ser Gly Ile Leu Phe Phe
1010 1015 1020
Val Asp Pro Trp Asn Thr Ser Leu Thr Asp Pro Ser Thr Gly Phe
1025 1030 1035
Val Asn Leu Leu Gly Arg Ile Asn Tyr Thr Asn Val Gly Asp Ala
1040 1045 1050
Arg Lys Phe Phe Asp Arg Phe Asn Ala Ile Arg Tyr Asp Gly Lys
1055 1060 1065
Gly Asn Ile Leu Phe Asp Leu Asp Leu Ser Arg Phe Asp Val Arg
1070 1075 1080
Val Glu Thr Gln Arg Lys Leu Trp Thr Leu Thr Thr Phe Gly Ser
1085 1090 1095
Arg Ile Ala Lys Ser Lys Lys Ser Gly Lys Trp Met Val Glu Arg
1100 1105 1110
Ile Glu Asn Leu Ser Leu Cys Phe Leu Glu Leu Phe Glu Gln Phe
1115 1120 1125
Asn Ile Gly Tyr Arg Val Glu Lys Asp Leu Lys Lys Ala Ile Leu
1130 1135 1140
Ser Gln Asp Arg Lys Glu Phe Tyr Val Arg Leu Ile Tyr Leu Phe
1145 1150 1155
Asn Leu Met Met Gln Ile Arg Asn Ser Asp Gly Glu Glu Asp Tyr
1160 1165 1170
Ile Leu Ser Pro Ala Leu Asn Glu Lys Asn Leu Gln Phe Asp Ser
1175 1180 1185
Arg Leu Ile Glu Ala Lys Asp Leu Pro Val Asp Ala Asp Ala Asn
1190 1195 1200
Gly Ala Tyr Asn Val Ala Arg Lys Gly Leu Met Val Val Gln Arg
1205 1210 1215
Ile Lys Arg Gly Asp His Glu Ser Ile His Arg Ile Gly Arg Ala
1220 1225 1230
Gln Trp Leu Arg Tyr Val Gln Glu Gly Ile Val Glu
1235 1240 1245
<210> 66
<211> 1250
<212> PRT
<213> Smithella sp.
<400> 66
Met Gln Thr Leu Phe Glu Asn Phe Thr Asn Gln Tyr Pro Val Ser Lys
1 5 10 15
Thr Leu Arg Phe Glu Leu Ile Pro Gln Gly Lys Thr Lys Asp Phe Ile
20 25 30
Glu Gln Lys Gly Leu Leu Lys Lys Asp Glu Asp Arg Ala Glu Lys Tyr
35 40 45
Lys Lys Val Lys Asn Ile Ile Asp Glu Tyr His Lys Asp Phe Ile Glu
50 55 60
Lys Ser Leu Asn Gly Leu Lys Leu Asp Gly Leu Glu Lys Tyr Lys Thr
65 70 75 80
Leu Tyr Leu Lys Gln Glu Lys Asp Asp Lys Asp Lys Lys Ala Phe Asp
85 90 95
Lys Glu Lys Glu Asn Leu Arg Lys Gln Ile Ala Asn Ala Phe Arg Asn
100 105 110
Asn Glu Lys Phe Lys Thr Leu Phe Ala Lys Glu Leu Ile Lys Asn Asp
115 120 125
Leu Met Ser Phe Ala Cys Glu Glu Asp Lys Lys Asn Val Lys Glu Phe
130 135 140
Glu Ala Phe Thr Thr Tyr Phe Thr Gly Phe His Gln Asn Arg Ala Asn
145 150 155 160
Met Tyr Val Ala Asp Glu Lys Arg Thr Ala Ile Ala Ser Arg Leu Ile
165 170 175
His Glu Asn Leu Pro Lys Phe Ile Asp Asn Ile Lys Ile Phe Glu Lys
180 185 190
Met Lys Lys Glu Ala Pro Glu Leu Leu Ser Pro Phe Asn Gln Thr Leu
195 200 205
Lys Asp Met Lys Asp Val Ile Lys Gly Thr Thr Leu Glu Glu Ile Phe
210 215 220
Ser Leu Asp Tyr Phe Asn Lys Thr Leu Thr Gln Ser Gly Ile Asp Ile
225 230 235 240
Tyr Asn Ser Val Ile Gly Gly Arg Thr Pro Glu Glu Gly Lys Thr Lys
245 250 255
Ile Lys Gly Leu Asn Glu Tyr Ile Asn Thr Asp Phe Asn Gln Lys Gln
260 265 270
Thr Asp Lys Lys Lys Arg Gln Pro Lys Phe Lys Gln Leu Tyr Lys Gln
275 280 285
Ile Leu Ser Asp Arg Gln Ser Leu Ser Phe Ile Ala Glu Ala Phe Lys
290 295 300
Asn Asp Thr Glu Ile Leu Glu Ala Ile Glu Lys Phe Tyr Val Asn Glu
305 310 315 320
Leu Leu His Phe Ser Asn Glu Gly Lys Ser Thr Asn Val Leu Asp Ala
325 330 335
Ile Lys Asn Ala Val Ser Asn Leu Glu Ser Phe Asn Leu Thr Lys Met
340 345 350
Tyr Phe Arg Ser Gly Ala Ser Leu Thr Asp Val Ser Arg Lys Val Phe
355 360 365
Gly Glu Trp Ser Ile Ile Asn Arg Ala Leu Asp Asn Tyr Tyr Ala Thr
370 375 380
Thr Tyr Pro Ile Lys Pro Arg Glu Lys Ser Glu Lys Tyr Glu Glu Arg
385 390 395 400
Lys Glu Lys Trp Leu Lys Gln Asp Phe Asn Val Ser Leu Ile Gln Thr
405 410 415
Ala Ile Asp Glu Tyr Asp Asn Glu Thr Val Lys Gly Lys Asn Ser Gly
420 425 430
Lys Val Ile Ala Asp Tyr Phe Ala Lys Phe Cys Asp Asp Lys Glu Thr
435 440 445
Asp Leu Ile Gln Lys Val Asn Glu Gly Tyr Ile Ala Val Lys Asp Leu
450 455 460
Leu Asn Thr Pro Cys Pro Glu Asn Glu Lys Leu Gly Ser Asn Lys Asp
465 470 475 480
Gln Val Lys Gln Ile Lys Ala Phe Met Asp Ser Ile Met Asp Ile Met
485 490 495
His Phe Val Arg Pro Leu Ser Leu Lys Asp Thr Asp Lys Glu Lys Asp
500 505 510
Glu Thr Phe Tyr Ser Leu Phe Thr Pro Leu Tyr Asp His Leu Thr Gln
515 520 525
Thr Ile Ala Leu Tyr Asn Lys Val Arg Asn Tyr Leu Thr Gln Lys Pro
530 535 540
Tyr Ser Thr Glu Lys Ile Lys Leu Asn Phe Glu Asn Ser Thr Leu Leu
545 550 555 560
Gly Gly Trp Asp Leu Asn Lys Glu Thr Asp Asn Thr Ala Ile Ile Leu
565 570 575
Arg Lys Asp Asn Leu Tyr Tyr Leu Gly Ile Met Asp Lys Arg His Asn
580 585 590
Arg Ile Phe Arg Asn Val Pro Lys Ala Asp Lys Lys Asp Phe Cys Tyr
595 600 605
Glu Lys Met Val Tyr Lys Leu Leu Pro Gly Ala Asn Lys Met Leu Pro
610 615 620
Lys Val Phe Phe Ser Gln Ser Arg Ile Gln Glu Phe Thr Pro Ser Ala
625 630 635 640
Lys Leu Leu Glu Asn Tyr Ala Asn Glu Thr His Lys Lys Gly Asp Asn
645 650 655
Phe Asn Leu Asn His Cys His Lys Leu Ile Asp Phe Phe Lys Asp Ser
660 665 670
Ile Asn Lys His Glu Asp Trp Lys Asn Phe Asp Phe Arg Phe Ser Ala
675 680 685
Thr Ser Thr Tyr Ala Asp Leu Ser Gly Phe Tyr His Glu Val Glu His
690 695 700
Gln Gly Tyr Lys Ile Ser Phe Gln Ser Val Ala Asp Ser Phe Ile Asp
705 710 715 720
Asp Leu Val Asn Glu Gly Lys Leu Tyr Leu Phe Gln Ile Tyr Asn Lys
725 730 735
Asp Phe Ser Pro Phe Ser Lys Gly Lys Pro Asn Leu His Thr Leu Tyr
740 745 750
Trp Lys Met Leu Phe Asp Glu Asn Asn Leu Lys Asp Val Val Tyr Lys
755 760 765
Leu Asn Gly Glu Ala Glu Val Phe Tyr Arg Lys Lys Ser Ile Ala Glu
770 775 780
Lys Asn Thr Thr Ile His Lys Ala Asn Glu Ser Ile Ile Asn Lys Asn
785 790 795 800
Pro Asp Asn Pro Lys Ala Thr Ser Thr Phe Asn Tyr Asp Ile Val Lys
805 810 815
Asp Lys Arg Tyr Thr Ile Asp Lys Phe Gln Phe His Ile Pro Ile Thr
820 825 830
Met Asn Phe Lys Ala Glu Gly Ile Phe Asn Met Asn Gln Arg Val Asn
835 840 845
Gln Phe Leu Lys Ala Asn Pro Asp Ile Asn Ile Ile Gly Ile Asp Arg
850 855 860
Gly Glu Arg His Leu Leu Tyr Tyr Ala Leu Ile Asn Gln Lys Gly Lys
865 870 875 880
Ile Leu Lys Gln Asp Thr Leu Asn Val Ile Ala Asn Glu Lys Gln Lys
885 890 895
Val Asp Tyr His Asn Leu Leu Asp Lys Lys Glu Gly Asp Arg Ala Thr
900 905 910
Ala Arg Gln Glu Trp Gly Val Ile Glu Thr Ile Lys Glu Leu Lys Glu
915 920 925
Gly Tyr Leu Ser Gln Val Ile His Lys Leu Thr Asp Leu Met Ile Glu
930 935 940
Asn Asn Ala Ile Ile Val Met Glu Asp Leu Asn Phe Gly Phe Lys Arg
945 950 955 960
Gly Arg Gln Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met
965 970 975
Leu Ile Asp Lys Leu Asn Tyr Leu Val Asp Lys Asn Lys Lys Ala Asn
980 985 990
Glu Leu Gly Gly Leu Leu Asn Ala Phe Gln Leu Ala Asn Lys Phe Glu
995 1000 1005
Ser Phe Gln Lys Met Gly Lys Gln Asn Gly Phe Ile Phe Tyr Val
1010 1015 1020
Pro Ala Trp Asn Thr Ser Lys Thr Asp Pro Ala Thr Gly Phe Ile
1025 1030 1035
Asp Phe Leu Lys Pro Arg Tyr Glu Asn Leu Asn Gln Ala Lys Asp
1040 1045 1050
Phe Phe Glu Lys Phe Asp Ser Ile Arg Leu Asn Ser Lys Ala Asp
1055 1060 1065
Tyr Phe Glu Phe Ala Phe Asp Phe Lys Asn Phe Thr Glu Lys Ala
1070 1075 1080
Asp Gly Gly Arg Thr Lys Trp Thr Val Cys Thr Thr Asn Glu Asp
1085 1090 1095
Arg Tyr Gln Trp Asn Arg Ala Leu Asn Asn Asn Arg Gly Ser Gln
1100 1105 1110
Glu Lys Tyr Asp Ile Thr Ala Glu Leu Lys Ser Leu Phe Asp Gly
1115 1120 1125
Lys Val Asp Tyr Lys Ser Gly Lys Asp Leu Lys Gln Gln Ile Ala
1130 1135 1140
Ser Gln Glu Ser Ala Asp Phe Phe Lys Ala Leu Met Lys Asn Leu
1145 1150 1155
Ser Ile Thr Leu Ser Leu Arg His Asn Asn Gly Glu Lys Gly Asp
1160 1165 1170
Asn Glu Gln Asp Tyr Ile Leu Ser Pro Val Ala Asp Ser Lys Gly
1175 1180 1185
Arg Phe Phe Asp Ser Arg Lys Ala Asp Asp Asp Met Pro Lys Asn
1190 1195 1200
Ala Asp Ala Asn Gly Ala Tyr His Ile Ala Leu Lys Gly Leu Trp
1205 1210 1215
Cys Leu Glu Gln Ile Ser Lys Thr Asp Asp Leu Lys Lys Val Lys
1220 1225 1230
Leu Ala Ile Ser Asn Lys Glu Trp Leu Glu Phe Val Gln Thr Leu
1235 1240 1245
Lys Gly
1250
<210> 67
<211> 3987
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 67
atggccggga gcaagaagcg ccggataaag caggacacgc agttcgaggg cttcaccaac 60
ctgtaccaag tctccaagac gctccggttc gagcttatcc cgcaagggaa gaccctgaaa 120
cacatccagg aacaaggttt catcgaggag gacaaggccc gcaacgacca ctacaaggag 180
ctcaagccca taatcgatcg gatctacaag acgtacgccg accagtgcct ccaactggtg 240
cagctcgact gggagaacct gagcgccgcc attgacagct accgcaagga aaagacggag 300
gagacgcgca acgcccttat tgaggagcaa gccacctacc gcaacgccat ccacgactac 360
ttcatcgggc gcaccgacaa cctgacggac gcgatcaaca agcgccacgc ggaaatctac 420
aagggccttt tcaaggccga gctcttcaac gggaaggtcc taaaacagct cgggactgtc 480
acgacaaccg agcatgagaa cgccctcctt cgcagcttcg acaagttcac cacatacttc 540
tcgggcttct accggaaccg caagaacgtt ttcagcgccg aggacatctc caccgccatc 600
ccgcacagga tcgtccagga caacttcccc aagttcaagg agaactgcca catcttcacg 660
cgcctgatta cagccgtacc ttcacttcgt gagcacttcg agaacgtcaa aaaggccatc 720
gggatcttcg tctccacgtc catcgaggag gtattctctt tcccgttcta taaccagctc 780
ctgacccaga cgcagatcga cctctacaac cagctactgg gcggcatcag ccgggaggcc 840
gggaccgaga aaataaaggg cctcaacgaa gttctcaacc tggccatcca gaagaacgac 900
gagaccgcgc atatcatcgc atccctgccg catcgcttca ttcctttgtt caagcagata 960
ttgagcgacc ggaacaccct ctcgttcatc ctcgaagaat tcaagagcga cgaggaggtc 1020
attcagtctt tctgcaagta caagacgctc ctacggaatg agaatgtgct ggagaccgcg 1080
gaggcactct tcaatgagct gaactccatt gacctgaccc acatcttcat tagccacaag 1140
aaactggaga cgatctccag cgccctgtgc gaccactggg acactctccg caacgccctc 1200
tacgaacgcc ggatctccga acttaccggc aagataacta agtcggctaa ggagaaggtg 1260
caacggagcc tcaagcacga ggacatcaac cttcaggaaa tcatctcagc cgcgggcaag 1320
gagctgagcg aggcgtttaa gcagaaaaca tcggagatac tgagccacgc gcacgcggcc 1380
ctggatcaac cgctgccgac gactctcaag aagcaagagg agaaggaaat ccttaagtcc 1440
cagctcgact cgctgctcgg cctctatcac ttgctcgact ggttcgcggt tgatgagtcc 1500
aacgaggtgg acccggagtt ctccgcgcgc ctcacgggta ttaagctgga gatggagcca 1560
agcttaagct tctacaacaa ggcccgcaac tacgcgacca aaaaaccgta ctcagtcgag 1620
aaattcaagc tgaatttcca gatgcctaca ttggcgaggg ggtgggacgt gaaccgcgag 1680
aagaacaatg gagccatcct gttcgtcaaa aatgggttgt actacctggg catcatgccc 1740
aagcagaagg gccgttacaa ggccctgtca ttcgagccta ccgagaagac ctcggagggc 1800
ttcgacaaga tgtactacga ctatttcccg gacgccgcca agatgatccc gaagtgctcc 1860
acgcagctca aagccgtcac ggcccacttc cagacgcata ccacgccgat acttctgagc 1920
aacaacttca ttgagccgct agagatcacg aaggagatat acgacctaaa caaccccgaa 1980
aaggagccca agaagttcca gacagcctac gctaagaaga caggtgatca gaagggatat 2040
agggaggcac tctgcaagtg gatcgacttc acgcgcgact tcctgtcgaa atatacaaag 2100
acgaccagca ttgacctaag ttctctccgc ccatcctccc agtacaagga tctgggcgag 2160
tattatgcgg agctgaaccc attgctgtac cacatcagct tccagaggat cgccgagaag 2220
gagattatgg acgcggtgga gacggggaaa ctatacctgt tccaaatata taacaaggac 2280
ttcgctaaag ggcaccacgg gaagcccaac ctgcacacac tctactggac gggcttgttt 2340
tcgccagaaa atttggccaa gacttcgatc aagctcaacg gccaggcgga gttgttttac 2400
cgtcccaagt ctcgcatgaa gcgcatggcg catcgcctcg gagagaaaat gcttaacaag 2460
aagctcaagg atcagaagac gcccatacct gatacgttgt accaggaatt gtacgactac 2520
gtgaaccacc gcctatcgca cgacctctca gacgaggccc gcgccctcct cccaaacgtg 2580
attactaagg aggtttccca tgaaataatc aaggaccgac ggttcaccag cgacaaattt 2640
tttttccacg tgcctatcac gctcaattac caggcggcca actccccatc gaagttcaac 2700
cagcgcgtga acgcctacct taaggagcac ccggagaccc caatcatcgg gatcgaccgt 2760
ggcgagcgga acctgatcta tattacggtg atcgatagca ccgggaagat cctggagcag 2820
cgctccctga acacaatcca gcagtttgac taccagaaga aactcgacaa ccgggagaag 2880
gagcgcgtcg cagcccggca agcatggagt gtggtcggca ccataaagga cctgaaacag 2940
ggttacctaa gtcaagttat ccacgagatc gttgacctga tgatacacta tcaagccgta 3000
gtcgtgctgg agaacctcaa cttcgggttt aagtccaagc gcaccggcat cgcggagaag 3060
gcggtgtacc agcagttcga gaagatgctg atcgacaagc tgaactgcct ggtgctcaag 3120
gactaccctg cggagaaggt cggcggggtc ttgaacccgt accagctaac cgaccagttc 3180
acgagcttcg ccaaaatggg cacgcagtcc ggattcttgt tttatgtccc ggctccatat 3240
acaagtaaga tcgacccgct gacagggttt gttgacccat tcgtgtggaa gaccatcaag 3300
aaccacgaga gcaggaaaca cttcttagag ggcttcgact tcctgcatta cgacgttaag 3360
acaggcgact tcatcctgca cttcaagatg aaccgcaacc tgtcgttcca gaggggcctg 3420
cccggcttca tgcccgcctg ggatatcgtc tttgagaaga atgagacgca gttcgacgcg 3480
aaggggacgc cgttcatcgc tggaaagcgg atcgtgccgg tcatcgagaa ccaccgcttc 3540
acgggtcgct accgagattt ataccccgcc aacgaactaa ttgcgctgct ggaggagaag 3600
gggatcgtgt tccgagatgg cagcaacatt ctcccgaagc tgctggagaa cgacgactcg 3660
cacgctattg acacgatggt cgccctcata cggagcgtgc ttcagatgcg gaacagtaac 3720
gctgccacgg gcgaggacta cattaactcc cccgtccgcg acctcaacgg ggtctgcttc 3780
gatagccgct tccagaaccc ggagtggcct atggatgcgg acgcgaacgg ggcctaccac 3840
atcgccctca agggccaact cctgctcaac cacttgaagg aaagcaaaga cctcaaattg 3900
cagaatggca tcagtaacca ggactggctc gcgtacatcc aggaactgag aaacgggtcc 3960
aagaagcggc gtatcaagca agattga 3987
<210> 68
<211> 3987
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 68
atggcgggaa gcaaaaagcg ccggattaag caagacacgc agttcgaggg cttcacgaac 60
ctctaccaag tcagcaagac cctccggttc gagctgatac cacagggaaa gacgctcaag 120
cacatccagg aacagggctt catcgaggag gacaaggcgc gcaacgacca ctacaaggag 180
ttgaaaccga tcatcgaccg catctacaag acgtacgccg accagtgcct ccagctcgtg 240
cagctcgact gggagaacct ctccgccgcc attgactcgt accggaagga gaagactgag 300
gagacccgca acgccctgat cgaggagcaa gcaacctacc ggaacgccat ccacgactac 360
ttcatcggcc gcaccgacaa cctcaccgac gcgatcaaca agcggcacgc ggagatatac 420
aaagggctgt tcaaggcgga gctgttcaac ggcaaggtgc tcaagcagct agggacggtg 480
accacgaccg agcacgagaa cgcgctcctc cgcagcttcg acaagttcac cacctacttc 540
agcggcttct accggaaccg caagaatgtg ttcagcgcgg aggacatcag cacggccatc 600
ccgcaccgca tcgtccagga caacttcccg aagttcaagg agaactgcca catcttcacc 660
cgcctgataa ccgccgtccc ctccctgcgg gagcacttcg agaacgtcaa aaaggcaatt 720
gggatcttcg tctcgaccag cattgaggag gtgttcagct tccccttcta caaccagctc 780
ctcacccaga cgcagatcga cctgtacaat cagttgctcg gcgggataag ccgcgaggcg 840
ggaaccgaaa aaatcaaggg gctgaacgaa gtgttgaacc tcgccatcca gaagaacgac 900
gagaccgcgc acatcatcgc ctccctgccc caccggttca tcccgctgtt caagcagatc 960
ctctctgacc ggaacaccct gtccttcatt cttgaggagt tcaagtcgga cgaggaggtc 1020
atccagagct tctgcaagta caagacgctg ctacggaacg agaacgtgct ggagacggcg 1080
gaggcactgt tcaacgagct aaacagcatc gacctcacgc acatcttcat cagtcacaag 1140
aaactggaga ccatctcctc cgcgctgtgc gaccactggg acacgctcag gaacgcgctc 1200
tacgagcgcc gaatcagtga gctgacgggc aagatcacga agtccgcgaa ggagaaggtg 1260
cagcggtccc tcaagcacga ggacatcaac ctccaggaga tcatctcagc ggctgggaaa 1320
gagctgtccg aggcgttcaa gcagaaaacg agcgaaatcc tgtcccacgc gcacgcggcc 1380
ctggatcagc ctctgccgac gaccctcaag aaacaagaag aaaaggaaat cctcaagtcg 1440
cagctcgact cgctgctggg cctgtaccat ctcctcgact ggttcgccgt ggacgagagc 1500
aacgaggtgg accccgagtt ctccgcgcgg cttacgggga tcaagctgga gatggagccc 1560
agcctgtcct tctacaacaa ggcgcgcaac tacgccacca agaagcccta cagcgtggag 1620
aagttcaagc tcaacttcca gatgcccact ctcgcacgtg ggtgggacgt caaccgcgaa 1680
aaaaataatg gggcgatcct gttcgtcaag aacggcctgt actacttggg catcatgccg 1740
aaacagaagg gccgctacaa ggccctgagc ttcgaaccga ccgagaaaac gagcgagggg 1800
ttcgacaaga tgtactacga ctacttcccc gacgccgcga agatgattcc aaagtgctcc 1860
acgcagctta aggccgtgac ggcccacttc cagacgcaca cgaccccgat cctcctcagc 1920
aacaacttca tcgagcccct ggagatcacg aaggagatat acgacctgaa caacccggag 1980
aaggagccca agaaattcca gaccgcctac gccaagaaga caggcgacca aaagggttac 2040
agggaggccc tctgcaagtg gatcgacttc actagggact tcctgtccaa gtacaccaag 2100
actacctcta tcgacctgtc cagcctccgc ccgtcgtccc agtacaaaga tttgggcgag 2160
tattacgcgg agctgaaccc actgctctac cacatcagct tccagcgcat cgcggagaag 2220
gagatcatgg acgcagtgga gacgggcaag ctatacctat ttcagatata caacaaagac 2280
ttcgctaagg gacaccacgg caagcctaac ctgcacaccc tctactggac ggggctcttc 2340
agcccggaga acctcgccaa gacctcgatc aagctcaacg gccaggccga gctgttctac 2400
cggcccaagt cccgcatgaa gcggatggcc caccggctcg gggagaaaat gctcaacaag 2460
aaattgaagg accaaaaaac gccgataccc gacaccctat accaggagct gtacgactat 2520
gtgaaccacc gcctgagcca cgacctcagc gacgaggcgc gggccctcct gccgaacgtc 2580
atcacaaagg aggtcagcca cgagatcatc aaggaccggc gcttcacctc cgacaagttt 2640
ttctttcacg tgcccatcac gctcaactac caggccgcca actcgccgtc caagttcaac 2700
cagcgcgtga acgcctacct caaggagcac cccgagaccc cgatcatcgg gattgaccga 2760
ggggagcgga acctcatcta catcaccgtc atcgacagca ccgggaagat ccttgaacag 2820
cggtcgctca acaccatcca gcagttcgac taccagaaga aactcgacaa ccgggagaag 2880
gagagagtgg cggcccgcca ggcttggtcc gtcgtcggga cgattaagga cttgaaacaa 2940
ggttacctgt cgcaagtgat ccacgagatc gttgacctga tgatccacta ccaagccgtc 3000
gtggtcctgg agaacctcaa cttcggcttc aagagcaaac gaaccggcat cgcggagaag 3060
gccgtgtacc agcagttcga aaaaatgctg atcgacaagc tgaactgcct cgtgctcaag 3120
gactaccccg ctgagaaggt cggcggggtg ctgaacccgt accagctcac tgaccagttc 3180
accagcttcg caaagatggg cacccagtcc ggcttcctgt tctacgtgcc tgcgccatac 3240
acctcgaaga tcgacccgct caccgggttc gtggacccct tcgtctggaa gaccatcaag 3300
aaccacgaga gccgcaagca cttcctggag ggcttcgact tcctccacta cgacgtcaag 3360
accggggact tcatcctgca cttcaagatg aaccgcaacc tcagtttcca gcgcggcctg 3420
ccggggttca tgcccgcttg ggatatagtc ttcgagaaga atgagacgca gttcgacgcg 3480
aagggcaccc cgttcatcgc cgggaagcgc atcgtgccgg tcatcgagaa ccaccggttc 3540
accgggcgct accgcgacct atacccggcg aacgagttga tcgccctcct ggaggagaag 3600
ggcatcgtgt tccgcgacgg ctccaacatc ctcccgaagc tgctcgaaaa cgacgactcc 3660
cacgccatcg acacgatggt cgcgctgatc cggtcggtgc tccagatgcg gaactccaac 3720
gccgcgacgg gcgaggacta catcaacagt ccggtccgcg atctgaacgg cgtctgcttc 3780
gactcccggt tccagaaccc cgagtggccg atggacgcgg acgcgaacgg cgcataccac 3840
atcgccctaa aagggcaatt gctgctcaac cacctcaagg aatccaaaga cctaaagctc 3900
cagaacggca tctccaacca ggactggctg gcgtacatcc aggaactgcg gaacgggagc 3960
aaaaaacgtc ggatcaagca agattga 3987
<210> 69
<211> 3987
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 69
atggcgggct ccaagaaacg ccggattaag caagataccc agttcgaggg gttcacgaac 60
ctctaccaag tgagcaagac cctccgattc gaactgattc ctcaggggaa gaccctcaag 120
cacatccagg agcaagggtt catcgaggag gacaaggcgc ggaacgacca ctacaaggaa 180
ctcaaaccca tcatcgaccg catctacaag acctacgccg atcagtgcct ccagctcgtg 240
cagttggact gggagaacct cagcgcggcc attgactcct accggaagga gaaaacggag 300
gagacgcgca acgcgctcat cgaggaacag gcaacctatc gcaacgccat ccacgactac 360
ttcatcggga ggactgacaa cctcactgac gcgattaaca agcgccacgc ggagatatac 420
aagggactct tcaaagcgga gctgtttaac ggcaaggttc tcaagcaact cggcactgtg 480
accacgaccg agcatgagaa cgccctgctc cgctccttcg acaagttcac cacctacttc 540
tccgggttct accgcaaccg caagaatgtc ttcagcgcgg aggacatcag cacggccatt 600
ccacatcgaa tcgtccaaga taacttcccg aagttcaagg agaactgcca catcttcacc 660
cgactcatta ctgctgtacc gtcgttacgc gaacacttcg agaacgtcaa gaaggcaatt 720
ggaatcttcg tctctacgtc aatagaggag gtgttcagct tccctttcta caaccagctc 780
cttacgcaga cccagataga cctgtacaat cagctcctcg gtgggatcag ccgggaggcg 840
gggactgaga agattaaagg gctcaacgag gtcttgaacc tggccatcca aaaaaacgat 900
gagacggcgc acatcatcgc ctcgctgccc caccggttca tcccgctgtt caagcagatc 960
ctcagtgaca ggaacacctt gagctttatc ctagaggagt tcaagagcga cgaggaggtg 1020
atccagagct tctgcaagta caaaaccctg ctgaggaacg agaacgtcct ggagacggcg 1080
gaggcgctgt tcaacgagct gaactctatc gacttaactc acatattcat ctcgcacaag 1140
aagctggaga ctattagctc tgcactctgc gaccactggg acaccctccg caacgcgctc 1200
tacgagcgcc gcatctcgga gctgaccggg aagatcacca aatccgcgaa ggaaaaggtc 1260
cagcgttccc tcaaacacga ggatattaac ttacaggaga ttatctcagc ggctgggaag 1320
gagttgtcag aggcgttcaa gcagaaaact tccgagatcc tgagccacgc gcacgcagcg 1380
ctcgaccagc ctctgcccac caccctcaaa aagcaggaag aaaaagagat cctcaagagc 1440
cagttggact ccctgctggg gctctatcac cttctcgact ggttcgccgt cgatgagtcg 1500
aacgaggtgg accccgagtt ctccgcccgg ctgaccggca tcaagctaga gatggagccg 1560
tccctcagct tctacaataa ggcccgcaac tacgcgacca aaaaacccta cagcgtggag 1620
aagttcaagc tgaacttcca gatgccgacc ttagcacgcg gttgggacgt aaacagggag 1680
aagaacaatg gagccatcct gttcgtcaag aacgggcttt actacctcgg gataatgccc 1740
aagcagaagg gccgctacaa ggccctttcc ttcgagccga cggagaaaac ctccgagggg 1800
ttcgacaaga tgtactacga ctacttcccc gacgccgcca agatgatccc gaagtgctca 1860
acgcagctaa aagccgtgac cgcccacttc cagacccaca cgacgccgat cctgctgagc 1920
aacaacttca tcgagcccct tgagatcact aaggagatat acgacctgaa caaccccgag 1980
aaggagccca agaagtttca aaccgcctac gccaaaaaaa ctggcgacca aaagggctac 2040
agggaggcgc tgtgtaagtg gatcgacttc acacgcgact tcctttcgaa gtatacgaag 2100
acaacctcta ttgacctgag cagcctgcgt cctagctccc agtacaaaga tttgggcgag 2160
tactacgcgg agcttaatcc actactctac cacatctcat tccagcgcat cgctgagaag 2220
gaaatcatgg acgcggtgga gacaggcaaa ctgtacctct tccagatata caacaaagac 2280
ttcgctaagg ggcaccacgg gaagcccaac cttcatacgc tctactggac gggcctattc 2340
agccccgaaa atctggccaa gacctccatc aagctgaacg gccaagcgga gctgttctac 2400
agacccaaga gccggatgaa gcggatggcc cacaggctcg gcgagaaaat gcttaacaaa 2460
aagttgaagg accagaaaac ccctatcccc gacaccctct accaggaact gtacgactac 2520
gtgaaccaca ggctctcgca cgacctttcc gacgaggccc gtgccctact cccgaacgtc 2580
attaccaaag aggtttcgca cgagatcatc aaggaccggc ggttcacgag cgacaagttt 2640
ttctttcacg tccccatcac ccttaactac caggcggcca actccccatc caagttcaac 2700
cagcgtgtga atgcctacct caaggagcac ccagagaccc cgatcattgg gatcgaccgg 2760
ggcgagcgga acctgatcta catcaccgtc atcgactcga cgggcaagat tcttgagcag 2820
agatcgttga ataccataca gcagttcgac taccagaaga aactcgacaa ccgcgagaag 2880
gagcgcgtgg cggcccgcca ggcgtggtcc gtcgttggga cgattaagga cttgaaacaa 2940
ggttatctgt cccaagtcat ccacgagatc gttgatctga tgatccacta tcaggcagtg 3000
gtggtgctgg agaatctcaa cttcggcttc aagagtaagc ggacgggaat cgccgagaag 3060
gccgtgtacc agcagttcga gaagatgctg atcgacaagc tcaactgcct tgtgctgaaa 3120
gactacccgg ccgagaaggt cggcggcgtc ctcaacccgt accaacttac cgaccagttc 3180
acctccttcg ccaagatggg cactcagtcc gggttcttgt tctacgtccc cgcaccttac 3240
acctctaaga tcgaccctct gactggcttc gtagatccat tcgtgtggaa gaccattaag 3300
aaccacgaga gccgcaagca cttcctggag ggcttcgact tcctgcacta cgacgtgaag 3360
accggggact tcatccttca cttcaagatg aaccggaacc tcagcttcca gcggggcctg 3420
ccggggttca tgcccgcctg ggacatcgtg ttcgagaaga acgagaccca gttcgacgcg 3480
aagggcacgc ccttcatcgc cgggaagcgt atcgtgccgg tgatcgagaa ccatcgtttc 3540
acgggtcgct accgtgacct ctacccggcg aacgagctta tcgcactcct ggaggagaag 3600
ggcatcgtct tccgggacgg ctccaacatc ctcccgaaac tgctggaaaa cgacgactct 3660
cacgccatcg acacgatggt ggccctcatc cggtccgtgc tccaaatgcg gaacagcaac 3720
gccgccaccg gtgaggacta catcaacagc ccggtccggg atctgaacgg ggtgtgcttc 3780
gattcgcggt tccagaatcc tgagtggccg atggacgcgg atgcaaacgg ggcgtaccac 3840
atcgcgctca agggccagtt acttctgaac caccttaagg agtctaaaga tttgaaactc 3900
cagaacggga tctcgaacca ggactggctg gcctacatcc aagagttgcg gaacggcagc 3960
aagaagcggc ggattaagca agattag 3987
<210> 70
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 70
gacaagaagt acagcatcgg gctggcgatc gggaccaact ccgtcggctg ggctgtgatt 60
accgacgagt acaaggtgcc atccaagaag ttcaaggtcc tcggcaacac tgaccggcac 120
agcattaaga agaacctgat tggggcgctg ctgttcgatt cgggggagac tgcggaggcg 180
accaggctga agcggactgc gcgccggagg tacaccagga ggaagaatcg gatctgctac 240
ctccaggaga ttttctcgaa tgagatggcc aaggtggacg attccttctt ccatcgcctg 300
gaggagtcgt tcctcgttga ggaggacaag aagcatgaga ggcatcccat tttcgggaat 360
atcgttgacg aggtggctta ccatgagaag tacccgacca tctaccatct gcggaagaag 420
ctcgtcgatt cgaccgataa ggccgacctg cggctgatct acctggccct cgcgcacatg 480
attaagttcc ggggccattt cctcatcgag ggcgacctca acccggacaa ctcggacgtg 540
gataagctct tcattcagct cgtgcagaca tacaaccagc tcttcgagga gaatcccatt 600
aacgcctcgg gggtcgacgc taaggctatt ctctcggctc ggctgtcgaa gtcgcgccgg 660
ctggagaatc tcattgccca gctcccaggc gagaagaaga acggcctctt cggcaacctg 720
attgccctgt cgctggggct cacaccgaat ttcaagtcga acttcgacct cgccgaggac 780
gctaagctcc agctcagcaa ggatacttac gatgatgacc tcgataacct gctcgcccag 840
attggggatc agtacgcgga tctgttcctc gcggccaaga atctcagcga tgctattctc 900
ctgtcggaca ttctccgcgt caacacagag attactaagg ccccactgtc ggcgagcatg 960
attaagaggt acgatgagca tcatcaggac ctgacactgc tcaaggcgct ggtccggcag 1020
cagctccccg agaagtacaa ggagattttc ttcgatcagt caaagaatgg gtacgcgggc 1080
tacattgatg gcggcgcgtc ccaggaggag ttctacaagt tcattaagcc catcctggag 1140
aagatggacg ggaccgagga gctgctggtg aagctcaatc gggaggacct gctccggaag 1200
cagcgcacat tcgacaatgg ctcgattcct caccagattc acctgggcga gctgcacgcc 1260
attctccgca ggcaggagga cttctacccg ttcctcaagg acaaccgcga gaagatcgag 1320
aagatcctga ccttccggat tccatactac gtggggccgc tcgcgcgggg gaactcccgg 1380
ttcgcgtgga tgactcgcaa gtccgaagaa acgattacac cgtggaattt cgaggaggtc 1440
gtcgacaagg gcgctagtgc gcagtcattc attgagagga tgaccaattt cgataagaac 1500
ctgcctaacg agaaggtgct gccgaagcat tcgctgctct acgagtactt caccgtttac 1560
aatgagctga ccaaggtgaa gtatgtgact gagggcatga ggaagccagc gttcctgagc 1620
ggcgagcaga agaaggctat cgtggacctg ctcttcaaga ctaaccggaa ggtgactgtg 1680
aagcagctca aggaggacta cttcaagaag attgagtgct tcgattccgt tgagattagc 1740
ggggtggagg atcggttcaa tgcttcgctc gggacatacc acgatctcct gaagatcatt 1800
aaggataagg acttcctcga caacgaggag aacgaggaca ttctcgaaga tattgtcctg 1860
accctcaccc tcttcgagga tcgggagatg atcgaggaga ggctcaagac atacgctcat 1920
ctgttcgatg ataaggtcat gaagcagctg aagcgcaggc ggtacacagg gtgggggcgg 1980
ctgagccgga agctgatcaa cgggattcgg gataagcagt ccgggaagac aattctcgac 2040
ttcctcaagt ccgacgggtt cgctaaccgg aacttcatgc agctcattca tgatgactcg 2100
ctgacattca aggaggatat tcagaaggcg caggtttcgg ggcagggcga ctcgctccac 2160
gagcatattg cgaatctggc gggctccccc gcgattaaga agggcattct gcaaaccgtc 2220
aaggtggttg atgagctggt caaggtcatg gggcggcata agccagagaa tattgtcatc 2280
gagatggcgc gggagaatca gaccacacag aaggggcaga agaactcacg ggagcggatg 2340
aagcgcatcg aggagggcat caaggagctg gggtcgcaga tcctgaagga gcatcccgtg 2400
gagaacactc agctgcaaaa tgagaagctg tacctctact acctccagaa cgggagggac 2460
atgtatgtgg atcaggagct ggatattaat aggctgagcg attacgatgt cgaccacatt 2520
gtcccacagt cgttcctgaa ggacgacagc attgacaaca aggtgctgac ccgctcggat 2580
aagaacaggg gcaagagcga taatgttcca agcgaggagg ttgtgaagaa gatgaagaac 2640
tactggcggc agctcctgaa cgcgaagctc atcacacagc ggaagttcga caacctcacc 2700
aaggctgagc gcgggggcct gagcgagctg gacaaggcgg ggttcattaa gaggcagctg 2760
gtcgagacac ggcagattac aaagcatgtt gcgcagattc tcgattcccg gatgaacacc 2820
aagtacgatg agaacgataa gctgattcgg gaggtcaagg taattaccct gaagtccaag 2880
ctggtgtccg acttcaggaa ggacttccag ttctacaagg ttcgggagat caacaactac 2940
caccacgcgc atgatgccta cctcaacgcg gtcgtgggga ccgctctcat caagaagtac 3000
ccaaagctgg agtcagagtt cgtctacggg gattacaagg tttacgacgt gcggaagatg 3060
atcgctaaga gcgagcagga gattggcaag gctaccgcta agtacttctt ctactccaac 3120
atcatgaact tcttcaagac agagattacc ctcgcgaatg gcgagatccg gaagaggccc 3180
ctcatcgaga caaatgggga gacaggggag attgtctggg ataaggggcg ggatttcgcg 3240
accgtccgga aggtcctgtc gatgccccag gttaatattg tcaagaagac tgaggtccag 3300
actggcggct tctcaaagga gtcgattctc ccaaagagga actccgataa gctcattgct 3360
cggaagaagg attgggaccc caagaagtac gggggattcg actcccccac tgttgcttac 3420
tctgttctgg ttgttgctaa ggtggagaag gggaagtcga agaagctgaa gagcgtgaag 3480
gagctgctcg ggattacaat tatggagagg tcatccttcg agaagaatcc catcgacttc 3540
ctggaggcca agggctacaa ggaggtgaag aaggacctga ttattaagct gcccaagtac 3600
tcgctcttcg agctggagaa tgggcggaag cggatgctgg cgtccgcggg ggagctgcaa 3660
aaggggaacg agctggcgct cccctccaag tatgtgaact tcctctacct ggcgtcgcac 3720
tacgagaagc tgaaggggtc cccagaggat aatgagcaga agcagctctt cgtcgagcag 3780
cataagcact acctggacga gattatcgag cagattagcg agttctcgaa gcgggtcatc 3840
ctcgcggatg cgaacctgga taaggtgctc agcgcctaca ataagcaccg ggacaagccg 3900
attcgggagc aggcggagaa tattattcac ctcttcacac tcaccaacct cggggcacca 3960
gctgcgttca agtacttcga cactactatc gaccggaagc ggtacacctc gacgaaggag 4020
gtgctcgacg ccaccctcat tcaccagtcg atcacaggcc tgtacgagac acggattgac 4080
ctgtcccagc tcgggggcga c 4101
<210> 71
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 71
gacaagaagt actccattgg cctggcgatt gggacaaact cggtggggtg ggccgtgatt 60
acggatgagt acaaggttcc aagcaagaag ttcaaggtcc tcgggaacac agatcggcat 120
tcgattaaga agaatctcat tggggcgctc ctcttcgact cgggggagac agcggaggct 180
accaggctca agcggacagc caggcggcgg tacacaaggc ggaagaatcg catctgctac 240
ctccaggaga ttttctcgaa tgagatggcg aaggtggacg acagcttctt ccatcggctg 300
gaggagtcct tcctggtgga ggaggataag aagcacgaga ggcatccaat tttcgggaac 360
atcgtggacg aggttgcgta ccatgagaag taccctacaa tctaccatct gcggaagaag 420
ctggttgact ccacagacaa ggcggacctg aggctgatct acctcgctct ggcccacatg 480
attaagttcc gcgggcattt cctgatcgag ggggacctga atcccgacaa ttcggatgtg 540
gacaagctct tcatccagct ggtgcagacc tacaaccagc tgttcgagga gaatcccatc 600
aatgcgtcgg gcgttgacgc taaggccatt ctgtccgcta ggctgtcgaa gagcaggagg 660
ctggagaacc tgatcgccca gctgccaggc gagaagaaga atgggctctt cgggaatctg 720
attgcgctct ccctggggct gacaccgaac ttcaagagca atttcgatct ggctgaggac 780
gcgaagctcc agctctcgaa ggacacttac gacgatgacc tcgataacct cctcgcgcag 840
atcggggacc agtacgctga tctcttcctc gccgctaaga acctctcgga tgctatcctg 900
ctctccgaca ttctccgggt taataccgag attacaaagg ccccactgtc ggcgtccatg 960
atcaagcggt acgatgagca tcatcaggat ctcaccctgc tcaaggccct cgtgcggcag 1020
cagctgcccg agaagtacaa ggagattttc ttcgaccaga gcaagaatgg gtacgctggc 1080
tacattgacg gcggggcctc acaggaggag ttctacaagt tcatcaagcc aatcctggag 1140
aagatggatg ggacagagga gctgctggtg aagctcaacc gggaggatct gctcaggaag 1200
cagcggacgt tcgacaacgg gtcgattccc catcagatcc acctggggga gctgcacgcg 1260
atcctgcgcc ggcaggagga tttctaccct ttcctgaagg ataatcggga gaagatcgag 1320
aagattctca ccttccggat tccctactac gtcgggccac tcgcgcgggg caatagcagg 1380
ttcgcctgga tgacacggaa gagcgaggag acaatcaccc cctggaactt cgaggaggtt 1440
gtcgacaagg gggcgtccgc ccagtcattc attgagcgga tgaccaattt cgacaagaat 1500
ctgccaaatg agaaggttct cccaaagcat agcctcctct acgagtactt cactgtttac 1560
aacgagctga ccaaggtgaa gtatgtgacc gagggcatgc ggaagcccgc gttcctgtcc 1620
ggcgagcaga agaaggccat tgtggacctc ctgttcaaga ccaatcgcaa ggtcacagtc 1680
aagcagctca aggaggatta cttcaagaag atcgagtgct tcgactcggt tgagattagc 1740
ggggtggagg atcggttcaa cgcgagcctc ggcacttacc acgacctcct gaagatcatc 1800
aaggataagg acttcctcga caacgaggag aacgaggata ttctggagga catcgtgctc 1860
accctgacgc tgttcgagga tcgggagatg atcgaggagc gcctgaagac ctacgctcat 1920
ctcttcgatg ataaggtcat gaagcagctg aagaggaggc ggtacaccgg gtggggccgc 1980
ctgagcagga agctcattaa cgggatcagg gacaagcaga gcggcaagac catcctggac 2040
ttcctcaaga gcgatggctt cgccaaccgg aatttcatgc agctcatcca cgacgactcc 2100
ctcaccttca aggaggacat tcagaaggct caggtcagcg gccagggcga ctcgctgcat 2160
gagcacatcg ctaacctggc gggcagccca gccatcaaga agggcatcct ccagacagtg 2220
aaggtcgtgg atgagctggt gaaggtcatg ggccggcata agcccgagaa tattgtgatt 2280
gagatggcgc gggagaatca gaccactcag aagggccaga agaactcgcg ggagcgcatg 2340
aagaggatcg aggaggggat taaggagctg ggcagccaga ttctcaagga gcaccccgtg 2400
gagaataccc agctccagaa cgagaagctg tacctctact acctccagaa tgggcgggac 2460
atgtatgttg atcaggagct ggacatcaat cgcctctcgg attacgacgt ggaccacatc 2520
gtgccccaga gcttcctgaa ggatgatagc atcgacaata aggtcctgac ccgctccgac 2580
aagaatcgcg gcaagagcga caacgtgccg agcgaggagg tcgtgaagaa gatgaagaac 2640
tactggcggc agctgctgaa cgcgaagctc attacacagc ggaagttcga taacctgacg 2700
aaggcggaga ggggcggcct ctccgagctg gacaaggcgg gcttcattaa gaggcagctc 2760
gtggagactc gccagatcac caagcacgtg gctcagatcc tcgatagccg gatgaatacg 2820
aagtacgatg agaatgacaa gctcatccgg gaggtgaagg taatcaccct gaagtcaaag 2880
ctcgttagcg atttccggaa ggacttccag ttctacaagg tgcgggagat taacaactac 2940
catcatgcgc acgatgcgta cctcaatgcg gtggtgggca cagccctgat taagaagtac 3000
cccaagctgg agagcgagtt cgtctacggg gactacaagg tgtacgatgt tcggaagatg 3060
atcgccaaga gcgagcagga gattgggaag gccaccgcta agtacttctt ctactcgaat 3120
attatgaatt tcttcaagac cgagatcaca ctcgctaatg gggagattcg gaagcggccc 3180
ctcatcgaga ctaacgggga gactggcgag attgtgtggg acaaggggcg cgacttcgct 3240
accgtgcgca aggtcctctc gatgccccag gttaatattg ttaagaagac agaggtgcag 3300
acgggcgggt tctccaagga gtctatcctg ccgaagcgga actcggacaa gctgatcgcc 3360
cgcaagaagg attgggaccc caagaagtac gggggattcg atagcccaac cgtggcttac 3420
agcgtcctgg tggtcgccaa ggttgagaag gggaagtcga agaagctcaa gagcgttaag 3480
gagctgctgg gcatcaccat catggagcgg tccagcttcg agaagaatcc tatcgacttc 3540
ctggaggcta aggggtacaa ggaggtcaag aaggacctga tcattaagct gcccaagtac 3600
tctctgttcg agctggagaa cgggaggaag cggatgctgg cgtctgctgg cgagctacag 3660
aagggcaatg agctggcgct cccctcgaag tatgtcaact tcctctacct ggcttcccat 3720
tacgagaagc tgaagggctc gcccgaggat aatgagcaga agcagctctt cgtggagcag 3780
cacaagcact acctcgacga gatcattgag cagatttcgg agttctcgaa gcgggtcatt 3840
ctcgcggacg cgaacctcga caaggtcctc tcggcgtaca acaagcaccg ggacaagccc 3900
atccgggagc aggccgagaa cattatccac ctcttcacac tgaccaacct cggcgctccc 3960
gccgcgttca agtacttcga caccaccatt gaccgcaaga gatacacatc caccaaggag 4020
gtgctggacg cgaccctcat ccaccagagc atcacaggcc tctacgagac acggatcgac 4080
ctctcgcagc tcgggggcga t 4101
<210> 72
<211> 4092
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 72
gacaagaagt actcgatcgg cctggcgatt ggcacaaaca gcgtggggtg ggctgtgatc 60
actgatgagt acaaggtgcc atcgaagaag ttcaaggtgc tggggaatac agaccggcat 120
tcgatcaaga agaatctcat tggcgctctc ctcttcgatt ccggcgagac tgctgaggcg 180
acccgcctga agcgcaccgc ccggcggcgc tacactcggc ggaagaatag gatttgctac 240
ctccaggaga ttttctcgaa tgagatggcc aaggtggatg acagcttctt ccaccgcctg 300
gaggagtcgt tcctggtcga ggaggacaag aagcatgagc ggcaccctat cttcgggaat 360
atcgttgatg aggtcgccta ccacgagaag taccccacta tctaccatct ccgcaagaag 420
ctcgtggaca gcacagataa ggccgacctc cgcctgatct acctcgccct cgcgcacatg 480
attaagttcc gggggcactt cctcattgag ggggatctga atcccgataa ctccgacgtg 540
gacaagctgt tcatccagct ggtgcagaca tacaaccagc tgttcgagga gaatcccatc 600
aacgcgagcg gcgtggacgc taaggccatt ctgtcggcta ggctctcgaa gtcgaggcgg 660
ctggagaacc tgattgcgca gctccccggc gagaagaaga acgggctgtt cgggaatctc 720
atcgccctct ccctcggcct cacaccaaac ttcaagagca atttcgacct ggctgaggac 780
gctaagctgc aactctcaaa ggatacatac gatgacgacc tggacaatct cctggctcag 840
atcggcgacc agtacgctga cctgttcctc gcggccaaga atctgtcgga cgcgattctc 900
ctcagcgaca tcctgcgcgt caataccgag attacgaagg ctccactgtc tgcgtcaatg 960
attaagcggt acgatgagca tcaccaggat ctgaccctcc tgaaggcgct cgtgcggcag 1020
cagctgcccg agaagtacaa ggagattttc ttcgatcaga gcaagaatgg ctacgccggc 1080
tacatcgacg ggggcgcgag ccaggaggag ttctacaagt tcatcaagcc catcctggag 1140
aagatggacg gcaccgagga gctactcgtg aagctcaatc gggaggatct cctccggaag 1200
cagcggacat tcgataacgg gtctatccca caccagatcc acctcggcga gctgcatgcg 1260
attctgcggc ggcaggagga tttctaccct ttcctgaagg acaaccggga gaagatcgag 1320
aagatcctca cattccggat tccatactac gtcggccccc tggcgagggg caatagccgg 1380
ttcgcgtgga tgacaaggaa gtccgaggag actattaccc cgtggaattt cgaggaggtg 1440
gttgacaagg gcgcttccgc gcagagcttc attgagcgga tgacaaactt cgacaagaat 1500
ctccccaacg agaaggtcct gccgaagcat agcctcctgt acgagtactt caccgtctac 1560
aatgagctaa ctaaggtcaa gtatgtgaca gagggcatga ggaagccagc cttcctctca 1620
ggcgagcaga agaaggccat tgtggacctc ctgttcaaga caaaccgcaa ggtgacagtg 1680
aagcagctga aggaggatta cttcaagaag attgagtgct tcgactcagt ggagatttca 1740
ggcgtggagg atcggttcaa cgcgagcctg gggacttacc acgacctgct gaagattatt 1800
aaggacaagg acttcctgga taacgaggag aatgaggaca tcctggagga tattgtgctc 1860
accctcaccc tgttcgagga cagggagatg attgaggaga ggctcaagac ctacgcgcac 1920
ctgttcgatg acaaggtcat gaagcagctg aagaggcggc gctacactgg gtggggccgc 1980
ctgtcgcgga agctgatcaa cggcattcgg gataagcagt ccgggaagac cattctggat 2040
ttcctgaagt cggacggctt cgccaacagg aatttcatgc agctgatcca cgacgactcc 2100
ctcaccttca aggaggacat tcagaaggcc caggttagcg gccaggggga ctcactccac 2160
gagcatattg ccaatctggc cggctctcca gctatcaaga agggcatcct gcaaacagtt 2220
aaggttgttg acgagctggt taaggtcatg gggcggcata agcccgagaa cattgtcatc 2280
gagatggctc gggagaacca gacaactcag aagggccaga agaactccag ggagcgcatg 2340
aagcggattg aggagggcat taaggagctg gggtcccaga tcctcaagga gcaccctgtc 2400
gagaacactc agctgcaaaa cgagaagctc tacctgtact acctccagaa cgggcgggat 2460
atgtatgtgg atcaggagct ggacatcaac aggctctccg actacgacgt ggatcacatt 2520
gtcccacagt ctttcctcaa ggatgattcc atcgacaaca aggtgctgac gcgcagcgac 2580
aagaataggg ggaagtcgga caacgttccg agcgaggagg tcgtgaagaa gatgaagaat 2640
tactggaggc agctcctgaa tgcgaagctg atcactcaga ggaagttcga caatctgaca 2700
aaggcggaga ggggcgggct ctcggagctg gataaggcgg gcttcatcaa gcggcagctc 2760
gttgaaaccc ggcagatcac caagcatgtc gcccagatcc tcgatagccg catgaacacc 2820
aagtacgatg agaacgacaa gctcattcgg gaggttaagg tcattacgct gaagtccaag 2880
ctcgtcagcg acttcaggaa ggatttccag ttctacaagg ttcgggagat taacaactac 2940
caccacgcgc atgatgcgta cctgaacgct gttgtcggca ctgctctcat caagaagtac 3000
ccaaagctgg agtccgagtt cgtctacggg gactacaagg tctacgatgt ccggaagatg 3060
atcgccaagt cggagcagga gatcgggaag gctactgcga agtacttctt ctacagcaac 3120
attatgaatt tcttcaagac ggagattacg ctggcgaacg gggagattag gaagaggccc 3180
ctcattgaga ctaatgggga gacaggcgag attgtttggg acaagggccg cgacttcgcg 3240
actgtgcgga aggtcctgtc catgccacag gtgaatattg ttaagaagac agaggtgcag 3300
actgggggct tctcgaagga gagcattctc ccaaagcgga acagcgataa gctcatcgcg 3360
cgcaagaagg attgggaccc taagaagtac ggcggcttcg attctcccac tgtggcctac 3420
tccgttctcg tggttgccaa ggttgagaag gggaagtcga agaagctgaa gtcggtcaag 3480
gagctgctcg ggattacaat catggagcgg agcagcttcg agaagaaccc tattgatttc 3540
ctggaggcca agggctacaa ggaggttaag aaggatctca ttatcaagct ccctaagtac 3600
tctctgttcg agctggagaa tggccggaag aggatgctgg cctcggctgg cgagctacag 3660
aaggggaatg agctggccct cccgtcgaag tatgtgaatt tcctgtacct cgcgtcgcac 3720
tacgagaagc tcaagggcag cccggaggat aatgagcaga agcagctctt cgtggagcag 3780
cataagcact acctggacga gatcattgag cagatcagcg agttctcgaa gcgggttatt 3840
ctggctgatg ctaacctgga caaggttctg agcgcctaca ataagcatcg cgacaagccg 3900
attcgcgagc aggcggagaa tattatccac ctgttcaccc tcactaacct cggggctccc 3960
gcggccttca agtacttcga taccacaata gataggaagc ggtacacctc gacgaaggag 4020
gtcctcgacg ccacactcat ccatcagtcg attacaggcc tgtacgagac acggattgac 4080
ctctcgcagc tg 4092
<210> 73
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 73
gacaagaagt attccatagg cctggctatc ggcaccaaca gcgtgggctg ggccgtcatc 60
accgacgagt acaaagtgcc gagtaaaaag ttcaaagtgc tcggcaacac cgaccgccac 120
tccataaaga aaaacctgat cggggcgctc ctgttcgaca gcggcgagac ggcggaggcc 180
acccgcttga aacgcacggc ccgacggcgc tacacgcggc gcaagaaccg gatctgttac 240
ctacaggaga ttttctctaa cgagatggcg aaggtggacg actcgttctt tcaccgcctc 300
gaagagtcct tcctcgtgga ggaggacaag aaacacgagc gccacccgat cttcggcaac 360
atcgtggacg aggtggccta ccacgagaag tacccgacca tctaccacct ccggaagaaa 420
ctcgtggaca gcacggacaa ggccgacctg aggctcatct acctcgccct ggcgcacatg 480
attaagttcc ggggccactt cctgatcgag ggcgacctga acccggacaa cagcgacgtg 540
gacaagctgt tcatccagct agtccagacc tacaaccagc ttttcgagga aaaccccatc 600
aacgccagcg gggtggacgc gaaggcgatc ctgtccgccc ggctgagcaa gtcccggcgg 660
ctggagaacc tcatcgcgca gttgcccggc gagaagaaga acgggctgtt cgggaacctg 720
atcgccctct ccctggggct caccccgaac ttcaagtcca acttcgacct cgccgaggac 780
gccaaactac agctgagcaa ggacacctac gacgacgacc tcgacaacct gctggcccag 840
atcggggacc agtacgcaga cctgttcctc gccgccaaga acctctccga cgccatcctg 900
ctgtcggaca tcctgcgggt gaacacggag atcacgaagg ccccgctctc ggcctcgatg 960
attaaacgct acgacgagca ccaccaggac ttgaccctcc tcaaggcgct ggtccgccag 1020
cagcttcccg agaagtacaa ggaaatcttt ttcgatcaga gcaagaacgg gtacgccggg 1080
tacatcgacg gcggggcgtc ccaggaggag ttctacaagt tcatcaagcc catcctggag 1140
aaaatggacg ggaccgagga gctgctcgtg aagctcaacc gcgaagattt gctccgcaag 1200
cagcgcacgt tcgacaacgg gtcgatcccg caccagatcc acctgggcga gctgcacgcg 1260
atcctcaggc gtcaggaaga cttctacccc ttcctcaagg acaaccgcga gaagatagag 1320
aagattctga ccttcagaat tccttattac gtgggcccgc tggctcgggg caactcgcgc 1380
ttcgcctgga tgacgcgcaa gtccgaggag accatcaccc cgtggaactt cgaggaggtg 1440
gtggataagg gtgcctcggc ccagtccttc atcgagcgga tgaccaactt cgacaagaac 1500
ctgccgaacg agaaggtgct ccccaagcac agcctgctct acgaatattt cacggtgtac 1560
aacgagctga cgaaggtcaa gtacgtgacc gagggaatga ggaaacctgc attcctctcc 1620
ggggagcaga agaaagccat agtcgacctc ctgttcaaga ccaaccggaa ggtcaccgtc 1680
aagcagctca aggaggacta cttcaagaag atcgagtgct tcgattcagt ggagatcagc 1740
ggcgtcgagg accggttcaa cgccagcctg ggcacctacc acgacctgct caagatcatc 1800
aaggacaagg acttcctcga caacgaggag aacgaggaca tcctggagga catcgtgctg 1860
accctgacgc tcttcgagga ccgcgagatg atcgaggagc gcctcaagac ctacgcccac 1920
ctgttcgacg acaaggtgat gaagcagctc aagcggcgga gatatactgg gtggggccgc 1980
ctctcccgga agctcattaa cggtatcagg gataagcagt ccgggaagac gatcctcgac 2040
ttcctcaagt cggacgggtt cgccaaccgc aacttcatgc agctcatcca cgacgactcc 2100
ctgacgttca aggaggacat ccagaaggcc caagtgtctg gtcaaggtga ctcgctccac 2160
gagcacatcg ccaacctcgc gggcagcccg gccatcaaga agggaatact ccagaccgtc 2220
aaggtggtgg acgagctggt gaaggtcatg ggccgccaca agccggagaa catcgtcatc 2280
gagatggcgc gggagaacca gaccacgcag aaggggcaga aaaatagccg tgagcgcatg 2340
aagcgcatcg aggaggggat taaggagttg ggcagccaga tcctcaagga gcaccctgtg 2400
gagaacacgc agttgcaaaa cgagaagctc tacctgtact acctccagaa cgggagggat 2460
atgtacgtgg accaagaact ggacatcaac cgcctgtccg actacgacgt ggaccacatc 2520
gtgccgcaga gcttcctcaa ggacgacagc atcgacaaca aggtgctcac ccggtccgac 2580
aagaatcggg gcaagtccga caacgtgccc agcgaggagg tcgtcaaaaa gatgaaaaac 2640
tactggcgac aactactgaa cgccaagctc atcacccagc gcaagttcga caacctcaca 2700
aaagccgagc gcggcgggtt gagcgagctg gacaaggccg ggttcatcaa gcgccagctc 2760
gtcgagacgc gccagatcac gaagcacgtc gcgcagatac tcgacagccg gatgaacacc 2820
aagtacgacg agaacgacaa gctcatccgg gaggtgaagg tcatcaccct caagtcgaag 2880
ctcgtgagcg acttccgcaa ggacttccag ttctacaagg tccgggagat caacaactac 2940
caccacgccc acgatgctta tcttaacgcc gtggtgggga cggccctcat taagaaatac 3000
ccgaagctgg agtcggagtt cgtgtacggc gactacaagg tgtacgacgt caggaagatg 3060
atcgccaagt ccgaacagga gatcgggaag gccacggcga aatacttctt ctacagcaac 3120
atcatgaact tcttcaagac cgagatcacc ctcgccaacg gcgagatccg caagcgcccg 3180
ctcatcgaga cgaacgggga gaccggcgag atcgtctggg acaaggggcg cgacttcgcc 3240
actgtgcgga aggtgctgtc gatgccccag gtcaacatcg tcaagaagac ggaggtccag 3300
acgggcgggt tcagcaagga gagcatcctg ccgaagcgca acagcgacaa gctgatcgcc 3360
cgcaaaaagg actgggatcc aaaaaagtac ggcggcttcg acagccccac cgtcgcctac 3420
agcgtcctcg tcgtcgctaa agtcgagaag ggcaagtcca aaaagctcaa gagcgtcaag 3480
gagctgctcg ggatcaccat catggagcgg tccagcttcg agaagaaccc aattgatttc 3540
ctggaggcga agggctacaa ggaggtcaag aaagacctca tcataaagct gccgaagtac 3600
tcactcttcg agctggagaa cgggcgcaag cggatgctgg cgtcggccgg agagctccaa 3660
aagggcaacg agctggcgct gccgagcaag tacgtgaact tcctctacct ggcgtcccac 3720
tacgagaagc tcaagggcag tccagaggat aacgagcaga agcagctatt cgtggagcag 3780
cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gcgcgtcatc 3840
ctggcggacg ccaacctgga caaggtgctg tccgcgtaca acaagcaccg cgacaagccg 3900
atccgcgagc aagccgagaa catcatccac ctgttcaccc tcacgaacct cggggcaccc 3960
gccgccttca aatatttcga cacgaccatc gaccgcaagc gctacaccag cacgaaggag 4020
gtgctcgacg ccaccctgat ccaccagagc atcaccgggc tgtacgagac ccgcatcgac 4080
ctctcgcagc tcggcgggga c 4101
<210> 74
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 74
gacaagaagt acagtattgg attggccatc gggacgaaca gcgtgggctg ggccgtcatc 60
accgacgagt acaaggtgcc atccaagaag tttaaggttc tggggaatac cgaccgccac 120
tcgatcaaga aaaatctcat cggggcgctg cttttcgaca gcggcgagac ggcggaagcg 180
acgcggctca agcggacggc tcgtcgccgt tacacccggc gtaagaaccg catctgttac 240
ctccaggaga tattcagcaa cgagatggcg aaggtggacg actccttttt ccaccgtctt 300
gaggagtcct tcctggtcga ggaggacaag aagcacgagc gccacccgat cttcgggaac 360
atcgtggacg aggtggccta ccacgagaag taccccacga tctaccacct ccgcaaaaaa 420
ctcgtggact caactgacaa ggccgatttg aggcttatct acctcgccct cgcccacatg 480
attaagttcc gtgggcactt cctaatcgag ggtgacctca accccgacaa ctctgacgtg 540
gacaagctgt tcatccagct tgtgcagacc tacaatcagc tctttgagga gaatccgatc 600
aacgcatctg gtgtggacgc aaaggccatc ctcagcgcgc ggctgagcaa gtctaggcgg 660
ttggagaacc tgatcgccca actgcccggc gagaagaaaa atggcctctt cggcaacctg 720
atcgccctgt cgctggggct cacgccgaac ttcaagagta actttgacct ggcggaggac 780
gctaagctcc agctatctaa ggacacatac gacgacgacc tggacaacct gctggcccag 840
atcggcgacc agtacgccga cctcttccta gccgccaaga acctgtccga cgccatcctc 900
ctcagcgaca tcctgcgcgt gaacacggag atcacgaagg ctccgctcag cgcctccatg 960
attaagcggt acgacgagca ccaccaagac ctaactttac tcaaagccct cgtgcggcag 1020
cagcttcccg agaagtacaa agagatattt tttgatcagt ccaagaacgg ttatgcgggc 1080
tacatcgacg gcggcgcgag ccaggaggag ttctacaagt tcatcaagcc catcctggag 1140
aagatggacg gcacggagga gctgctcgtg aagctcaacc gtgaagacct cctgcgaaag 1200
cagcgaacct tcgacaacgg ttcgatcccg caccagatcc acctcgggga gctgcacgcc 1260
atcctgaggc gacaggagga cttctaccct ttcctaaagg acaaccgcga gaagattgaa 1320
aaaatcctga cgtttcgcat accctactac gtcggcccgc tggcgcgcgg caactcccgg 1380
ttcgcctgga tgacccgtaa gagcgaggag acgatcaccc cgtggaactt cgaggaggtc 1440
gtggacaagg gcgcgagcgc gcagagcttc atcgagcgca tgaccaactt cgacaagaac 1500
ctcccgaacg agaaggtgct cccaaagcac tccctcctgt acgagtattt caccgtgtac 1560
aacgagttga caaaggtgaa gtacgtgacg gagggaatgc ggaagcctgc gttcctctcg 1620
ggcgagcaga agaaggcaat cgtggacctg ctcttcaaga ccaaccggaa ggtgacggtg 1680
aagcagctca aggaggacta cttcaaaaaa atcgagtgct tcgactccgt ggagataagc 1740
ggcgtggagg accgattcaa cgcctccctc ggcacctacc acgacctcct taagatcatc 1800
aaggacaagg acttcctgga caacgaggag aacgaggaca tcctggagga catcgtgctc 1860
accctgaccc tcttcgagga ccgggagatg atcgaggagc gcctcaagac gtacgcccac 1920
ttgttcgacg acaaggtgat gaagcagctc aagcggcggc gatacaccgg gtggggccgc 1980
ctatcccgca aacttatcaa cggcatccgc gacaagcagt ccggcaagac gatcctggat 2040
ttcctcaagt cggacgggtt cgccaaccgg aacttcatgc agctcatcca cgacgacagc 2100
ctcacgttca aggaggacat ccagaaggcc caagtgagcg gtcaagggga cagcctccac 2160
gagcacattg cgaaccttgc tgggagccct gcgatcaaga aggggatatt gcaaaccgtg 2220
aaggtcgtgg acgagttggt gaaggtcatg gggcgacaca agcccgagaa catcgtgatc 2280
gagatggcca gggaaaatca gaccacgcag aagggccaaa aaaacagccg cgagcggatg 2340
aagcggatcg aggagggcat caaggagctg gggtcgcaga tcctcaagga gcacccggtg 2400
gagaacacgc agctccagaa cgagaagctg tacctctatt acctacagaa cgggcgggat 2460
atgtacgtgg accaggagct agacatcaac cgcctgtccg actacgacgt ggaccatatc 2520
gtcccgcagt cgttcttgaa ggacgacagc atcgacaaca aggtgctcac aagatcggat 2580
aagaatcgag gcaagtccga caacgtgccc tcggaggagg tggtcaagaa aatgaaaaac 2640
tactggcggc agttgctgaa cgccaagctc attacgcagc ggaagttcga caacctgacg 2700
aaggctgaac gtggtgggct cagcgagcta gacaaggcgg ggttcatcaa gcggcagctc 2760
gtcgagaccc ggcagatcac caagcacgtg gcgcagatcc tggactcgcg catgaacacc 2820
aagtacgacg agaacgacaa gctcatccgt gaggtgaagg tcatcaccct taagtctaag 2880
ctggtcagtg acttccgcaa ggacttccag ttctacaagg tccgggagat caacaactac 2940
caccacgcgc acgacgccta cctcaacgcg gtggtgggga cggcgcttat taagaaatat 3000
cccaagctgg aaagcgagtt cgtttacggc gactacaagg tgtacgacgt ccgcaagatg 3060
atcgcaaagt cggaacagga aatcggaaag gcgacggcca aatatttctt ttactccaac 3120
atcatgaatt tttttaagac ggagatcacc ctggcgaacg gggagatccg caagcggccc 3180
ctcatcgaga ccaacgggga gacgggcgag atcgtctggg acaagggccg ggacttcgcc 3240
accgtgcgga aggtgctttc tatgcctcaa gtcaatatcg tcaaaaagac agaggtgcag 3300
accggcgggt tcagcaagga gtctatcctg ccgaagcgca actcggacaa gctcatcgcg 3360
cgcaagaaag actgggaccc caaaaaatat ggcgggttcg actcgccgac cgtcgcctac 3420
agcgtcctcg tggtggctaa ggtcgagaag ggcaagagca aaaagctaaa gtcggtgaag 3480
gagctgctgg gcatcaccat catggagcgc tcgtctttcg agaagaatcc aatcgacttc 3540
ctagaggcga aggggtacaa ggaggtcaaa aaggatctta tcatcaaact gccgaagtac 3600
agtctgttcg agctggagaa cgggcggaag cggatgctgg ctagtgcggg cgagttgcag 3660
aagggcaacg agttggcact gccctccaag tacgtgaact tcctgtacct ggcctcccac 3720
tacgagaagc tcaaggggag ccccgaggac aacgagcaga agcagctatt cgtcgagcag 3780
cacaagcact acctggacga gatcatcgag cagatcagtg agttctccaa gcgggtcatc 3840
ctcgcggacg ccaacctgga caaggtgctg agcgcgtaca acaagcacag ggacaagcca 3900
atcagggaac aggccgagaa catcatccac ctgttcaccc tgaccaacct gggtgcaccg 3960
gctgccttca agtactttga cacgaccatc gaccggaagc gctacacctc cacgaaggag 4020
gtgctggacg ccacgctgat ccaccagagc atcaccgggc tctacgagac acggatcgac 4080
ctgagccagc ttggcgggga c 4101
<210> 75
<211> 4092
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 75
gacaaaaagt attccattgg actcgctatc ggcacgaaca gcgtcgggtg ggcggtcatc 60
actgacgagt acaaggtgcc gagcaagaag tttaaggtgc tgggaaacac cgacaggcac 120
tcgatcaaga aaaatcttat cggggcccta ctcttcgact ccggagaaac cgccgaggcc 180
acccggttga agcgcacggc ccgccgtcgc tacaccaggc gcaagaaccg gatctgctac 240
ctccaggaga tattcagcaa tgagatggcg aaggtggacg actcgttttt tcacaggcta 300
gaggagtctt tcctcgtgga ggaggacaag aaacacgagc gccaccccat cttcggcaac 360
atcgtggatg aggtggcata tcacgagaag tacccaacca tctaccacct ccgcaaaaag 420
ctcgtggact ctaccgacaa ggccgacctc cgtctgatct acctcgcgct ggcccacatg 480
attaagttcc gaggacactt tctgatcgag ggcgacctga acccagacaa cagcgacgtg 540
gacaagctgt tcatccaact tgtccagacc tacaatcagc tcttcgagga gaaccctatc 600
aacgcctcgg gcgtggacgc gaaggccatc ctgtccgccc gcctgagcaa gtcgcggcgg 660
ctggagaacc tgatcgccca gctccccggc gaaaaaaaga acggcctctt cggcaacctc 720
atcgcgttgt cgctggggct caccccgaac ttcaagtcca acttcgacct ggccgaggac 780
gctaaactcc agctctcgaa ggatacctac gacgacgacc tcgacaacct gctggcccag 840
atcggcgacc agtacgcgga ccttttcctg gcggccaaga acctgagcga cgcgatcctc 900
cttagcgaca tactccgtgt gaacaccgag atcacgaagg ccccgctctc cgcgtccatg 960
attaagcgct acgacgagca ccaccaagac cttaccctgc ttaaggcgct ggtcaggcag 1020
cagttaccgg agaagtacaa ggagatcttt tttgatcaat ctaagaacgg ttacgccggg 1080
tacatcgacg gcggcgcgtc ccaggaggag ttctacaagt tcatcaagcc gatcttggag 1140
aaaatggacg ggaccgagga gctgctcgtg aagctcaacc gcgaagacct cctccgcaag 1200
cagcgcacct tcgacaacgg gagcatcccg caccagatcc acctgggaga gctgcacgcg 1260
atcctgcgga gacaagagga cttctacccc ttcctcaagg acaaccggga gaagattgaa 1320
aaaatactta cttttcgtat cccgtactac gtcgggcccc ttgcgagggg caactccaga 1380
ttcgcgtgga tgacccgcaa gtccgaggag accatcaccc cgtggaactt cgaggaggtg 1440
gtggacaagg gcgcgtcggc ccagtcgttc atcgagcgca tgaccaactt cgacaagaac 1500
cttccgaacg agaaggtgct cccgaagcac agcctgctct acgaatattt tactgtgtac 1560
aacgagctga cgaaggtcaa gtacgttacg gaggggatga ggaagcccgc cttcctctcc 1620
ggcgagcaga agaaagccat tgtggatctc ctgttcaaga ccaaccgcaa ggtgacggtg 1680
aaacagctca aagaggacta cttcaagaag atcgagtgct tcgactccgt agagatcagc 1740
ggggtcgagg accgcttcaa cgcctcgctg ggcacgtacc acgacctgct aaagattatc 1800
aaggacaaag acttcctaga caatgaggag aacgaggaca ttctggagga catcgtgctg 1860
actctgacgc tgttcgaaga ccgcgagatg atcgaggagc ggcttaagac gtacgcccac 1920
ctgttcgacg acaaggtgat gaagcagttg aaacggcggc gctacaccgg gtggggccgc 1980
ctctcccgca agctcatcaa cggcatccgc gacaagcagt cggggaagac gatcctggac 2040
ttcctcaaga gcgacggctt cgccaaccga aacttcatgc agctaatcca cgacgacagc 2100
ctgacgttca aggaggacat ccagaaggcc caagtgagcg gccagggaga ctcgctacac 2160
gagcatatcg ccaacctggc tggcagcccg gcgattaaga aaggaatcct ccaaaccgtc 2220
aaagtggtgg acgagctggt gaaggtgatg ggccgccaca agcccgagaa cattgtgatc 2280
gagatggcgc gggagaacca gacgacgcag aagggccaaa aaaatagcag ggaaaggatg 2340
aagcgaatag aggaggggat caaggagctg gggagccaga ttctcaaaga gcacccggtc 2400
gagaacacac agctccagaa cgagaagctg tacctctact acctccaaaa cggccgcgat 2460
atgtacgtgg accaggaact agacatcaac cggctgagcg actatgacgt ggaccacatc 2520
gtgccgcagt ccttcctcaa ggacgactcg attgacaaca aagtgctcac tagatccgac 2580
aagaacagag gcaagagcga taacgtcccg tcggaggagg tcgtcaagaa aatgaaaaac 2640
tactggcggc agctcctaaa cgccaagctc atcacgcagc gtaagttcga caacctgacg 2700
aaggcggagc ggggcgggct gagcgagctg gacaaagcgg ggttcatcaa gcggcagctc 2760
gttgagacgc ggcagatcac aaagcacgtc gcgcaaatcc tcgactcccg catgaacacc 2820
aagtacgacg agaacgacaa gctcatccgg gaggtgaagg tcattaccct taaatcgaag 2880
ctcgtcagcg actttcgtaa ggacttccag ttctacaagg tcagagagat caacaactac 2940
caccacgccc acgacgccta tctgaacgcc gtggtgggca ccgcgcttat taagaagtac 3000
cccaagctgg agtccgagtt cgtgtacggc gactacaagg tttatgacgt caggaagatg 3060
atcgccaagt cggaacagga gatcggaaaa gctaccgcca aatatttctt ctatagcaac 3120
atcatgaact tcttcaaaac cgagatcacc ctcgccaacg gcgagatccg gaagcgcccg 3180
ctcatcgaga ccaacgggga gaccggggag atcgtctggg acaaggggcg ggacttcgct 3240
actgtccgaa aggtgctctc catgccacaa gtgaatatcg tcaagaaaac agaggtgcag 3300
accggagggt tcagtaagga gtccatcctg cccaagcgga actccgacaa gctaattgct 3360
cgcaaaaagg attgggatcc taaaaaatat ggcggcttcg actcgcccac ggtcgcctac 3420
tctgtgctgg tcgtggcgaa ggtggagaag ggcaagtcca agaagctcaa gagcgtcaag 3480
gagctgctgg ggatcacgat catggagcgt agttcgtttg agaagaatcc catcgacttc 3540
ctggaggcta agggctacaa ggaggtcaaa aaggacctca tcattaagct gccgaagtac 3600
agcctcttcg agctggagaa cgggcggaag cgtatgctcg cctccgctgg ggagttacaa 3660
aaggggaacg agctggcgct gccgtctaag tacgtcaact tcctgtacct ggcctcccac 3720
tacgagaagc tcaaggggtc gccggaggac aacgagcaga agcagctctt cgtagagcag 3780
cacaagcact acctggacga gatcatcgag cagatttcag agttctcaaa gcgggtcatc 3840
ctcgccgacg ccaacctgga caaggtgctc tcggcctaca acaagcaccg ggacaagccg 3900
atccgcgaac aggccgaaaa catcatccac ctgttcacgc tcaccaacct cggtgccccg 3960
gcggccttca agtactttga cacgaccatc gaccggaagc gctatacctc gacgaaggag 4020
gtgctggacg ccaccctgat ccaccagtcc atcaccgggc tttacgagac ccggatcgac 4080
ctctcgcagc ta 4092
<210> 76
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 76
gacaagaagt atagtattgg actcgccatc ggaaccaact ctgtggggtg ggctgttatt 60
acagatgaat ataaggtgcc atccaaaaag tttaaagttc tgggcaatac tgatagacac 120
tcaatcaaga agaatctgat aggtgcactt ctgtttgata gtggagagac tgccgaggca 180
accagactta aaaggactgc aagaagaaga tataccagaa gaaagaatag gatttgctat 240
ttgcaggaaa tcttcagcaa cgaaatggcc aaggttgatg actcattttt ccataggttg 300
gaggagagtt ttcttgtgga ggaagataag aagcacgaaa gacacccaat tttcgggaat 360
atagtggacg aggtggctta tcatgagaag tatcccacta tctaccacct gagaaagaaa 420
cttgtggact caaccgataa ggctgatctt aggcttatat acttggccct tgcacatatg 480
atcaaattca ggggccattt tcttatcgaa ggcgatctta atcccgataa ctcagatgtg 540
gacaagctgt ttatacaact tgtgcaaacc tacaatcaac tcttcgagga gaatcccatt 600
aacgcctccg gcgtggatgc aaaagccata ctgtcagcca gactgagcaa aagtaggaga 660
ctggagaatc ttatagccca actgcccggt gaaaagaaga atgggctctt cggaaatctg 720
atcgctcttt cattggggtt gacacccaac tttaagagta actttgactt ggcagaagat 780
gcaaagttgc agctcagtaa agacacatat gacgatgacc ttgacaatct cttggcacaa 840
ataggggatc aatacgctga ccttttcctc gctgccaaga acctcagcga cgctatactg 900
ttgtccgaca ttcttagggt taataccgaa attacaaagg cccctcttag tgcaagtatg 960
atcaaaaggt atgatgagca tcaccaagac cttacactgc tgaaggctct ggttagacag 1020
caactccctg aaaagtataa ggaaatattc ttcgaccaaa gtaagaacgg gtacgccggt 1080
tatattgatg ggggcgcaag tcaagaagaa ttttacaaat tcatcaagcc aattcttgaa 1140
aagatggacg ggactgagga attgctggtg aaactgaata gagaggacct tcttagaaaa 1200
cagaggacat ttgacaatgg gtccatccca caccagattc atctggggga actccacgca 1260
atattgagga gacaagaaga cttttaccca ttccttaagg ataatagaga gaaaatcgaa 1320
aaaatcctga ctttcaggat tccttactat gttgggccac tggccagggg gaactcaaga 1380
ttcgcttgga tgacaaggaa gtcagaagaa accataaccc cttggaattt tgaagaggtg 1440
gttgataagg gggcatcagc ccagtctttc atagagagga tgaccaactt tgataaaaat 1500
cttccaaatg agaaggtttt gccaaaacat agtcttttgt acgagtactt tactgtttat 1560
aacgaattga ccaaggtgaa gtatgtgacc gagggaatga ggaagccagc atttttgtcc 1620
ggggagcaaa agaaagcaat cgttgatctt ctcttcaaga ccaacagaaa agtgaccgtg 1680
aaacaactga aggaagacta cttcaaaaag atagaatgtt tcgattcagt ggaaattagc 1740
ggtgttgaag acaggttcaa tgcttcattg ggtacttacc acgacctgtt gaagataatc 1800
aaagacaagg actttctcga taatgaggag aacgaagaca tcttggaaga cattgtgctt 1860
acactcactt tgtttgagga cagggaaatg attgaggaaa gactcaaaac ttacgctcat 1920
ttgtttgatg ataaggttat gaaacaacta aaaagaagaa ggtacaccgg ctggggaaga 1980
ttgagtagga aactgatcaa cggtattaga gataaacaat ccggaaagac tatcctcgat 2040
ttccttaaga gtgatggctt tgcaaatagg aattttatgc agctgattca tgacgactca 2100
cttaccttca aagaagacat ccaaaaagct caggtgtctg ggcaaggcga cagtctgcat 2160
gaacatatag ctaacttggc tgggagtccc gccatcaaga aggggatact tcaaacagtt 2220
aaagttgtgg acgaattggt gaaggtaatg ggaaggcaca agcctgaaaa tatagtgata 2280
gaaatggcaa gggaaaatca aacaacccag aagggacaga agaacagtag ggaaaggatg 2340
aaaaggatag aagaggggat caaagagctt ggtagccaga tcctcaagga acatccagtg 2400
gagaataccc aacttcaaaa cgagaaactc tatttgtact acttgcagaa cggaagagat 2460
atgtatgtgg accaagagct tgatattaac aggctgagcg attatgacgt tgaccacata 2520
gtgccccaat cattcctcaa ggatgactct attgataata aggtgctgac aaggagtgac 2580
aagaatagag ggaaatccga caacgttcca tccgaggaag ttgtgaagaa gatgaagaac 2640
tactggaggc agttgctgaa cgctaagctc attacccaga ggaaattcga taacctgacc 2700
aaagcagaga gaggcgggct gagcgaactc gataaagcag gtttcatcaa gagacaactc 2760
gtggagacta ggcaaattac taagcacgtg gctcaaatac tcgacagcag gatgaacaca 2820
aagtacgacg agaacgacaa gctcattaga gaggttaagg ttattactct gaaaagtaaa 2880
ttggttagcg atttcagaaa ggatttccaa ttctataagg ttagagagat caacaattat 2940
catcatgcac atgatgccta tctgaatgct gtggttggta cagcccttat caagaagtac 3000
cctaagctag agagcgagtt tgtgtacgga gattataagg tgtatgatgt gaggaaaatg 3060
atcgctaaaa gtgagcaaga gattggaaag gctaccgcca aatacttctt ttattccaat 3120
attatgaatt tcttcaagac agaaatcacc ctggctaacg gcgagataag gaagaggccg 3180
cttatcgaaa ctaatgggga gacaggcgaa atagtgtggg acaaagggag ggatttcgca 3240
actgtgagga aggttttgag catgcctcag gtgaatatcg ttaagaaaac cgaagttcaa 3300
actggagggt tctctaagga aagcattctc cccaagagga actccgacaa gctgattgct 3360
agaaagaaag actgggaccc caagaagtat ggcggattcg actcacccac tgtggcatat 3420
agcgttctcg tggtggcaaa ggttgaaaag ggtaaatcca aaaaactcaa atccgtgaag 3480
gaactccttg gcataactat tatggaaagg agtagctttg aaaagaatcc catcgacttt 3540
ctcgaagcta agggctataa ggaagttaag aaggacctta taatcaaact tccaaaatac 3600
tccctttttg agttggaaaa cggcagaaag agaatgttgg ccagtgccgg ggagcttcaa 3660
aagggcaacg aactggctct gcctagcaaa tatgtgaact ttttgtatct ggcatcacac 3720
tacgagaaac ttaaaggctc tcctgaggac aacgagcaaa aacagctctt tgttgaacag 3780
cataagcact acctcgacga gattattgag cagatcagcg agttctcaaa gagagttatt 3840
ctggctgacg ctaatcttga caaggttttg tccgcttaca acaaacacag ggataagcca 3900
atcagggagc aggcagaaaa cataatccat ctctttaccc tgacaaacct cggtgccccc 3960
gctgctttca agtattttga tactaccatt gacaggaaga gatatacttc cactaaggaa 4020
gtgctcgacg caaccctcat acaccaaagt atcacaggcc tctatgaaac taggatagat 4080
ttgtctcaac ttgggggcga t 4101
<210> 77
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 77
gacaaaaagt attccatcgg gcttgctatc ggaaccaact ctgtggggtg ggcagttatt 60
accgacgaat acaaggtgcc cagcaagaag tttaaggttc tggggaacac agatagacat 120
agcataaaga aaaacctgat aggcgcactg ttgttcgact ccggggaaac agccgaagct 180
accaggctga agagaactgc aagaagaagg tacaccagaa gaaaaaacag aatatgttat 240
ctccaagaga ttttctctaa cgagatggcc aaggtggacg actcattctt tcacagactg 300
gaagaatctt tccttgtgga agaagataag aaacacgaga ggcaccctat ttttggcaat 360
atcgtggatg aggtggctta ccacgaaaaa taccctacaa tataccacct caggaaaaaa 420
ttggttgata gtacagacaa ggccgacctc aggctcatct atttggccct ggcccatatg 480
attaaattca gggggcactt tctcatcgag ggagatttga accccgacaa cagtgatgtt 540
gataagctct ttattcagct cgtgcagact tacaatcagt tgtttgagga aaaccccatt 600
aatgcttccg gggtggacgc caaggcaatc ctttctgcaa gactctcaaa gtcaaggaga 660
ctcgaaaatc tgatagcaca gcttccagga gagaagaaga acgggctctt tggaaacctg 720
atcgctctgt cactcggact cacacccaat ttcaaaagca attttgattt ggcagaggac 780
gctaagctgc aactcagtaa ggatacctac gacgatgact tggataatct gctcgcacaa 840
attggggacc agtatgcaga cctgtttctc gcagctaaga acttgagtga cgccatattg 900
ctcagtgaca tcctcagggt taataccgag attacaaaag ctccactctc tgcaagcatg 960
atcaagaggt atgacgagca ccatcaagac ctgacactcc ttaaggcgtt ggttaggcag 1020
caacttcctg aaaagtataa ggaaatcttc ttcgatcaaa gcaaaaacgg ctacgccggc 1080
tatatagacg ggggagcatc ccaagaagaa ttttataagt tcataaaacc tatattggag 1140
aagatggacg ggacagagga attgctcgtg aaactgaaca gggaggatct cctcaggaag 1200
caaaggacct tcgacaatgg ctccatccca catcagattc acctcggcga actgcacgca 1260
atactgagaa gacaagagga cttttatcct ttcctgaagg acaacaggga gaaaatcgag 1320
aaaatcttga cattcagaat cccatactac gttgggcctc tggccagagg taacagtagg 1380
ttcgcctgga tgactaggaa atcagaggag actattacac cctggaactt tgaagaagtt 1440
gttgataagg gagcttcagc acaatcattc atcgaaagaa tgacaaactt tgacaaaaat 1500
ctgcctaatg agaaagtgct cccaaaacat tccctgctgt atgagtattt taccgtttat 1560
aacgagctta ccaaggtgaa atacgttact gaaggtatga gaaagccagc ttttctttca 1620
ggggagcaaa agaaggctat cgtggatctt ctctttaaga ccaacagaaa ggttaccgtg 1680
aagcagctta aggaagacta ctttaaaaag atcgagtgtt ttgactcagt ggaaataagc 1740
ggtgttgaag atagattcaa cgcatccttg ggaacttatc atgatcttct taagataatc 1800
aaggataaag actttctcga caacgaggaa aacgaagata tactggagga catagttctg 1860
acacttactt tgttcgagga tagggagatg atcgaggaaa gactgaaaac atatgctcac 1920
cttttcgacg acaaagttat gaaacaactc aagagaagga gatatacagg gtgggggaga 1980
ttgagcagga aactgattaa tggtatcaga gacaaacagt caggaaaaac aatactcgac 2040
tttttgaaat cagacgggtt cgcaaatagg aatttcatgc agcttataca cgacgattca 2100
cttactttta aagaggacat tcaaaaggct caagttagtg gacaaggtga ctccctccac 2160
gaacacatcg caaatctcgc tggcagccct gcaattaaga agggtatact ccagacagtt 2220
aaggttgttg acgagctggt taaagtgatg ggaagacaca aacccgagaa catagtgata 2280
gagatggcca gggaaaacca aaccactcaa aaagggcaga aaaattccag agagaggatg 2340
aaaaggattg aagaaggtat caaggagctg ggtagccaaa ttctgaaaga acatcctgtg 2400
gaaaacactc aactccagaa tgagaaactc tatctgtact atctgcaaaa tgggagagat 2460
atgtatgtgg accaggaact ggacataaac aggctctcag attacgatgt ggatcatatc 2520
gtgccacagt cctttcttaa ggatgatagc atcgacaata aggtgcttac caggtccgac 2580
aagaacaggg gaaagtcaga taacgtgcct tctgaagaag ttgttaaaaa gatgaagaac 2640
tactggagac agctgcttaa cgctaagctc ataacacaga ggaagtttga caacttgacc 2700
aaggccgaga gaggcggact ctcagaattg gataaggcag ggttcataaa aaggcagctg 2760
gtggaaacaa ggcagataac taaacatgtg gctcagatcc tcgatagtag gatgaataca 2820
aaatacgatg agaacgacaa gctcataagg gaggttaaag tgataactct gaaatccaaa 2880
ctggttagcg attttaggaa ggatttccag ttttacaaag ttagggagat caacaattat 2940
catcacgccc acgatgccta cttgaacgca gttgtgggta ctgcacttat caaaaagtac 3000
cctaagctgg aatccgagtt tgtttatgga gactataagg tgtacgacgt tagaaaaatg 3060
attgcaaagt cagagcagga gatagggaaa gccactgcaa aatatttctt ttatagcaat 3120
atcatgaatt tctttaagac agaaatcaca ctggccaatg gggaaataag gaagaggccc 3180
ctgatcgaaa ctaatggcga gacaggggag attgtgtggg ataaaggtag ggactttgca 3240
acagtgagga aagtgctgag catgccccaa gttaatatcg ttaaaaagac cgaggttcaa 3300
acagggggct ttagtaagga aagcattttg cccaagagga atagtgacaa attgattgct 3360
aggaaaaaag attgggaccc caaaaagtat ggcggatttg atagccccac tgttgcttac 3420
tccgtgctcg tggttgcaaa ggtggagaag ggaaagagca agaaactgaa gtcagttaag 3480
gaactccttg gtatcactat catggaaaga agctcctttg agaagaaccc tattgacttc 3540
ctggaggcta aagggtacaa agaggttaag aaagacctta tcattaaatt gcccaaatat 3600
agtcttttcg agcttgaaaa cggaagaaag aggatgcttg catccgctgg cgaattgcaa 3660
aagggcaatg agcttgctct cccttccaag tatgtgaact tcctttatct tgcctcacac 3720
tatgaaaaac tcaaaggttc acccgaagac aacgaacaaa agcaactatt tgtggaacaa 3780
cacaagcact acctggacga aatcattgag caaatttctg agttttcaaa aagggtaatc 3840
ttggctgacg caaatctcga caaagttttg tcagcttaca acaaacatag agataagcca 3900
attagagagc aagctgagaa tatcatccat ctgtttaccc tgactaacct tggagcgcct 3960
gctgctttta aatatttcga caccacaatc gacaggaaga ggtacactag cactaaggaa 4020
gttctcgacg ccaccctcat ccaccagagt attacaggcc tgtacgagac aagaattgat 4080
ctttctcaac ttggtggtga c 4101
<210> 78
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 78
gataagaagt actcaatcgg tctggcaatc ggaaccaact ctgtgggttg ggcagtgatt 60
acagatgagt ataaggtgcc aagcaaaaaa ttcaaggtgc tgggtaatac cgacagacac 120
agcattaaga agaatttgat tggagcactc ctctttgact caggggaaac agcagaggca 180
acaaggctga agaggacagc aaggcggagg tacacaaggc ggaaaaacag gatatgctac 240
ctccaggaaa tctttagcaa cgagatggct aaagtggatg atagcttttt ccatagactc 300
gaagaatcct ttcttgttga agaggacaaa aagcatgaaa ggcatcccat cttcggcaat 360
atagttgatg aggttgcata ccatgagaag taccccacaa tctaccacct cagaaagaaa 420
cttgtggact ccacagataa agcagacctg aggctcatat acctcgcact cgcacacatg 480
atcaagttca gagggcactt tctcatcgaa ggtgacctga atccagataa ttcagatgtg 540
gataaactgt ttatacagct ggtgcaaaca tacaaccaac ttttcgagga aaacccaatc 600
aatgcctccg gtgttgatgc aaaggccatc ctgtcagcaa gactcagcaa aagcaggcgg 660
ctcgaaaacc tcatcgccca gcttcccggt gaaaagaaga acgggctctt tggtaatctc 720
atcgcattga gccttggtct tactccaaac ttcaagagca attttgatct ggcagaggat 780
gctaaactgc aactctcaaa ggacacatat gacgatgacc ttgacaatct gttggcccag 840
atcggggacc aatatgcaga cctcttcctg gccgcaaaga atctgtcaga tgcaatcctc 900
ttgtccgaca tactgagagt taacactgag atcacaaagg cacctctgtc cgcctccatg 960
attaagagat acgatgagca tcaccaggat ctgactttgc tcaaagccct cgttagacag 1020
cagttgccag aaaagtacaa agaaatattc tttgatcaat caaaaaacgg atatgcaggg 1080
tacatcgacg gtggggcaag ccaggaagag ttctacaaat tcatcaaacc tatcctggaa 1140
aagatggatg ggacagaaga gctgctggtt aagctgaata gggaagacct cctcagaaag 1200
cagaggacat ttgataacgg gagcatccct catcaaatcc acctcggtga actccatgct 1260
atcctgagaa ggcaggaaga cttttatcca tttttgaagg acaataggga gaaaatcgaa 1320
aaaatcctga cattcagaat cccatactac gttggtcctc tggcaagagg taacagtagg 1380
ttcgcatgga tgacaaggaa aagcgaggag acaatcacac cctggaattt tgaggaagtt 1440
gttgacaagg gtgccagcgc acaatccttt atcgaaagaa tgacaaattt cgacaagaat 1500
ctgcctaacg aaaaggttct cccaaagcat tcactcctgt acgaatattt tacagtttat 1560
aacgaactga ctaaagttaa atacgttacc gagggtatga ggaagccagc attcctttcc 1620
ggggaacaga agaaagctat tgtggacctc ctgttcaaga caaatagaaa agtgacagtt 1680
aagcaactca aagaggatta cttcaaaaag atcgaatgtt ttgactctgt ggagatcagc 1740
ggggtggagg atagattcaa cgccagcctg ggtacatatc atgatctcct gaaaatcatt 1800
aaagacaagg acttccttga caacgaggag aacgaggaca ttctggaaga cattgttctg 1860
accctcacac tctttgagga tagggagatg attgaggaaa gactgaagac ctacgcccac 1920
ctctttgacg ataaagtgat gaaacagctc aagagaagaa ggtatacagg ttgggggaga 1980
ctgagcagga agttgatcaa tgggattagg gacaaacagt ccgggaaaac aatcctcgat 2040
tttctgaagt cagacggttt cgcaaacaga aattttatgc agctcattca cgatgacagc 2100
ttgacattca aggaagacat ccaaaaggct caagtgagcg gccaagggga tagcctccac 2160
gagcatattg caaatctggc aggttcacca gccatcaaaa agggcatact tcagacagtt 2220
aaggttgtgg acgaattggt taaagttatg ggcaggcata agccagagaa tatcgttatc 2280
gaaatggcaa gggagaacca aacaactcaa aaagggcaga aaaatagcag agagaggatg 2340
aaaagaatcg aggaagggat caaggaactt gggtcccaaa tcctcaagga gcacccagtt 2400
gaaaatactc aactgcaaaa cgagaagctc tatctctact atctccaaaa cgggagggat 2460
atgtatgttg accaggagct ggatattaac agactgtcag attatgatgt tgatcatatc 2520
gtgccccagt cattcctgaa ggacgattcc atcgacaaca aagttctcac aaggtccgat 2580
aaaaacaggg gcaagtccga taacgttcca agcgaagaag tggtgaaaaa gatgaaaaac 2640
tattggagac aacttctgaa tgcaaagttg attactcaga gaaagtttga caacctcaca 2700
aaagcagaaa gaggcgggct tagcgaactc gataaggcag ggtttatcaa aagacagctg 2760
gttgagacaa ggcagatcac aaaacatgtg gcacagatcc ttgactcaag gatgaatacc 2820
aagtatgatg agaatgataa gttgatcagg gaggttaaag ttatcacact caaatccaaa 2880
ctggtgtcag acttcaggaa agactttcaa ttttataagg tgagggagat caataactac 2940
caccatgcac atgacgccta cctgaacgca gtggtgggta cagcattgat taaaaaatac 3000
cctaagctgg agtctgagtt tgtgtacggg gactacaagg tgtacgacgt gaggaaaatg 3060
atagccaagt ccgagcagga gatcgggaaa gcaacagcta agtatttctt ttacagtaat 3120
atcatgaatt tctttaaaac tgagattact ctggcaaacg gggagatcag gaaaagaccc 3180
ctcatcgaga ctaatggtga aacaggtgag atcgtttggg acaaggggag ggattttgct 3240
actgttagaa aagttctgag tatgccacaa gtgaatattg tgaaaaagac agaagttcag 3300
acaggtgggt tctccaaaga atccatcctg cccaagagaa attcagacaa gctcatcgca 3360
agaaagaagg actgggaccc taagaagtac ggaggatttg acagccccac cgtggcctat 3420
tccgtgcttg ttgtggcaaa ggtggagaaa gggaagagca aaaaactgaa atccgtgaaa 3480
gaactgctgg gaattaccat catggaaaga agctcctttg agaagaaccc aatcgacttc 3540
ctggaagcaa aaggatataa ggaagtgaaa aaggacctca ttatcaagct cccaaaatac 3600
tcacttttcg agttggagaa cggtagaaag aggatgctgg caagcgcagg ggaacttcag 3660
aaaggcaatg agctggcatt gccatcaaag tatgtgaact tcctctactt ggccagccat 3720
tacgagaaac ttaaaggtag cccagaagat aacgagcaaa aacagctctt tgtggaacag 3780
cataagcatt atctggatga gatcatagaa caaatctcag agttttccaa gagagttatc 3840
ctcgcagatg caaacctgga taaggttctc tcagcctata ataagcatag agacaagcca 3900
attagagagc aagcagagaa cattatccac ttgttcactc ttacaaacct gggggcacca 3960
gccgccttca aatatttcga tacaacaata gacagaaaga ggtataccag caccaaagaa 4020
gttctcgacg ccacactgat ccatcaatca atcacaggcc tttacgaaac taggatcgac 4080
ttgtcacaac tgggtgggga t 4101
<210> 79
<211> 3307
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 79
gagcaaggac acctacgacg acgacttgga caacctattg gcccagatag gtgaccagta 60
tgcagacctc ttccttgcgg ccaagaactt gagtgacgct atactgctca gtgacatcct 120
gagggtgaac actgagatca ctaaggcccc tctctctgcc tcaatgatta agcgttacga 180
cgagcatcac caggatctca ccctgcttaa ggcccttgtt cggcagcagc tccctgagaa 240
gtacaaggag atattttttg accagtctaa gaacggctac gccggttaca ttgacggtgg 300
ggcaagccag gaggagttct acaagttcat caagccgatc cttgagaaga tggacggcac 360
cgaggagcta cttgtcaagt tgaaccggga agacctgctc cggaaacagc gtacattcga 420
caacggcagc atccctcacc agatccacct gggcgaacta cacgccatcc tccgacgtca 480
ggaggacttc tatccattct tgaaagataa cagggaaaaa atcgaaaaaa tacttacgtt 540
tcgaatacct tactacgtgg ggccccttgc tcggggaaac tccagattcg catggatgac 600
caggaagtca gaggagacca tcacaccctg gaactttgag gaggtggttg acaaaggtgc 660
ttctgcccag tccttcattg agcggatgac taacttcgac aagaacctgc ccaacgagaa 720
ggtgctgcca aagcacagcc tgctctacga atactttact gtgtacaatg agctgacgaa 780
ggtgaagtac gtgacagagg ggatgcggaa gcccgctttc ctgagcggcg agcaaaaaaa 840
agcaatcgtg gacctactgt tcaagaccaa ccgaaaggtg acagtgaagc agctcaagga 900
ggactacttc aaaaaaatcg agtgcttcga ctctgttgag ataagcggcg tggaggaccg 960
attcaacgcc tcattgggaa cctatcacga cctgctcaag atcattaagg acaaggactt 1020
cctggataat gaggagaatg aggacatcct ggaggatatt gtgctgaccc ttactctatt 1080
cgaggacagg gagatgatcg aggagcgact caagacctac gctcacctgt tcgacgacaa 1140
ggttatgaag caattgaagc gtaggcgata cacggggtgg ggaagactct cccgaaaact 1200
gataaacggc atcagggaca agcagtcagg gaagacgatc ttggacttcc tgaaatccga 1260
cgggttcgcc aaccgcaact tcatgcagct cattcacgac gactcactaa cgttcaaaga 1320
ggacattcag aaggctcaag tcagtggaca aggcgactcc ctgcacgagc acattgcaaa 1380
ccttgcgggc tccccggcga ttaaaaaggg cattctccaa acggttaagg tggtggacga 1440
gctggtgaag gtgatgggcc gacacaagcc tgagaacatc gtgatcgaga tggccaggga 1500
gaaccagact acccagaagg gtcagaagaa ctctcgggaa cgtatgaagc gtattgagga 1560
ggggattaag gagttgggct ctcaaatcct caaggagcac cctgtggaga acactcagct 1620
ccaaaacgag aagctgtacc tgtactacct gcaaaacggg cgcgatatgt acgtggatca 1680
ggagttggac atcaacaggc ttagcgatta cgacgtggac cacatcgtgc cacagtcatt 1740
cttaaaggac gacagcatcg acaacaaggt tctgacgagg agcgacaaga atcgagggaa 1800
aagtgacaat gttccatccg aggaggtggt caagaaaatg aagaactatt ggcgtcagct 1860
tctgaacgcc aagctcatca cccagcggaa attcgacaac ctgactaagg ctgagcgagg 1920
cggactctcc gagcttgaca aggctggctt catcaagcgg cagttggtcg aaacccgaca 1980
gataacgaag cacgttgccc agatacttga ctcccgtatg aacaccaagt acgacgagaa 2040
cgacaagctc atcagggagg tgaaggtcat tacccttaag tccaaactcg tcagcgactt 2100
tcgtaaggac ttccagttct acaaggtgcg cgagatcaat aactaccacc acgcacacga 2160
cgcctacctg aacgcagtgg ttggaaccgc gttgattaaa aagtacccca agttggagtc 2220
ggagttcgtt tacggggact acaaggtgta cgacgttcgg aagatgatcg ccaagtctga 2280
acaggagatc gggaaagcaa ccgccaagta tttcttctat agcaacatca tgaacttctt 2340
taaaaccgag atcacacttg ccaatggcga gatccgtaag aggccgctga tcgagacaaa 2400
tggggagact ggcgagatcg tgtgggacaa gggccgcgac ttcgcaaccg ttcggaaagt 2460
cttgtccatg cctcaagtca acatcgtcaa gaagactgag gtgcaaacag gcgggttctc 2520
gaaggagtcc atactgccca agaggaactc agacaagctc atagcacgca aaaaagactg 2580
ggatccaaag aaatacggcg ggttcgactc gccgacagtc gcatactccg tgttagtggt 2640
ggctaaagtg gaaaagggga agtccaagaa gctcaagtcc gtcaaggagt tgctcgggat 2700
caccattatg gaacggtcct cattcgagaa gaatcccatt gacttcctag aggcgaaggg 2760
ctacaaagag gtcaaaaagg acctaattat taagctcccc aagtattcac tcttcgaact 2820
tgaaaatggt cgtaagcgga tgttggcaag cgctggagag cttcagaagg ggaacgagct 2880
tgcactgcct tccaagtacg tgaacttcct gtacctcgcc tctcattacg agaagttgaa 2940
gggctcaccg gaggacaacg agcagaagca gttgttcgtg gagcagcaca agcactacct 3000
cgacgagatc attgagcaga taagtgagtt cagcaaacgg gtgatccttg ccgacgctaa 3060
cctggacaag gtgctgagcg cctacaacaa gcacagagac aagccgatcc gagagcaagc 3120
ggagaacatc atacacctgt tcaccctcac gaacctcggg gctcccgcag ccttcaaata 3180
ttttgacacg accatcgacc gtaaacgcta cactagcacg aaggaggtgc tggacgctac 3240
ccttatccac cagtccatca ccggcctgta cgagacgaga atcgacttgt cgcagctcgg 3300
tggtgac 3307
<210> 80
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 80
gacaaaaaat actcaattgg tctggcaatt gggaccaaca gtgtcggatg ggccgtgatt 60
accgacgagt acaaggtgcc gtccaaaaaa ttcaaggtgc ttgggaacac cgaccgccac 120
tcgatcaaga aaaacctaat cggtgcgttg cttttcgaca gtggggagac cgccgaggca 180
acacgcttaa aacgcacagc taggaggaga tatacacggc gcaagaaccg aatatgctac 240
ttacaggaga tattctccaa tgagatggcg aaggtggacg actctttctt ccatcggctt 300
gaggaatcct tcctggtcga ggaggacaag aagcacgagc gacacccgat attcgggaac 360
atcgttgatg aggtggcgta ccacgagaag tacccaacga tataccactt acgcaagaag 420
ctcgtggact ctacggacaa ggccgacttg cgccttatct acttggcact ggcccacatg 480
attaagttcc gaggccactt ccttatcgag ggtgacctga accccgataa ctccgacgtg 540
gacaagctct tcatccaact cgtccagaca tacaaccagc tattcgagga gaatcctatc 600
aacgcctctg gggtggacgc taaagctatc ctctcagccc gcctgtcaaa gtcgaggagg 660
ttggagaacc taatcgccca gcttccaggc gagaagaaaa atgggctgtt cggaaacctt 720
atcgcactct cactgggcct aaccccgaac ttcaagtcca acttcgacct ggcagaggac 780
gcgaaattgc agttgtcgaa agacacctat gacgatgacc tggacaacct gttggcccag 840
ataggggacc agtacgccga cctgttccta gcggccaaga acctgtccga cgccatcttg 900
ctgtcggata tactgcgggt gaacaccgag atcactaaag cacctctctc cgccagcatg 960
attaagcgtt acgacgagca ccaccaagat ttgaccctgc taaaggcact tgtacggcag 1020
cagcttcccg agaagtacaa ggagatcttt ttcgaccaaa gcaagaacgg ctacgccggg 1080
tacatcgacg gaggtgccag ccaggaggag ttctacaagt tcattaagcc catcctggag 1140
aagatggacg ggactgagga actacttgtg aagctgaacc gggaagactt actacggaag 1200
cagcgtacct tcgacaacgg ttctatccca catcagatcc atcttgggga gttgcacgcg 1260
atcctgcgac gccaggagga cttttacccc ttcctgaaag acaaccgcga gaaaatcgag 1320
aagatactga ccttcagaat accttactac gtcggacccc ttgcgcgagg caactcaaga 1380
ttcgcgtgga tgaccaggaa atcagaggag accatcacac cctggaattt cgaggaggtg 1440
gttgacaagg gtgcctccgc ccagtccttt atcgaacgaa tgaccaactt cgacaagaac 1500
ttgcccaacg agaaggtgct ccccaaacac agcctcctct acgaatattt cacagtgtac 1560
aacgagctta ctaaagttaa gtatgttact gagggcatga ggaaacccgc cttcctgtca 1620
ggcgagcaga agaaagctat tgtggacctc cttttcaaga ccaaccggaa ggtgacagtg 1680
aagcagctca aggaggacta cttcaagaag atagagtgct tcgacagcgt ggagatcagc 1740
ggggtggagg acagattcaa tgcctctctc ggaacatacc acgacttgct taagatcatc 1800
aaggacaagg acttcctcga caacgaggaa aacgaggata ttctggagga tattgttctg 1860
actcttaccc tgttcgagga ccgggagatg atcgaggagc gtctcaagac ctacgcccac 1920
ctgttcgacg acaaagttat gaagcagctc aagcgtcgga gatataccgg atggggccgt 1980
ctgtctcgga agctcatcaa cgggatcagg gacaagcagt cagggaagac gatcttagac 2040
ttccttaagt ctgacggctt cgccaacagg aacttcatgc agttgatcca cgacgacagc 2100
cttaccttca aggaggacat ccagaaggcc caagtgagtg gccagggtga cagcctccac 2160
gagcatattg ctaatcttgc gggttcccca gcgattaaaa agggcatact tcaaaccgtt 2220
aaggtggtgg acgagcttgt caaggtgatg gggcgacaca agcccgagaa catcgtgatc 2280
gagatggcca gggagaacca gaccacccag aaggggcaga agaatagccg agaacgcatg 2340
aagcgcatcg aggaggggat taaggagcta gggagccaga tcctcaagga acatcccgtc 2400
gagaacaccc agctccagaa cgagaagcta tacctctact acttgcaaaa cgggagggat 2460
atgtacgtgg atcaggagtt ggacattaac cgcctaagcg actacgacgt agatcacatc 2520
gtgcctcagt cattcctcaa agacgacagc attgacaaca aagtcttgac ccgatccgac 2580
aagaaccgag gaaaatccga caatgtgccc tcagaggagg tcgtcaagaa aatgaagaac 2640
tattggaggc agctacttaa cgccaaactc ataacccagc ggaagttcga caacctgaca 2700
aaggctgagc ggggtgggct cagcgagctt gacaaggctg gcttcatcaa gcggcagttg 2760
gtggagacaa gacagataac gaagcacgtg gctcagatcc tggactctcg catgaacacg 2820
aagtacgacg agaacgacaa attgatccgc gaggtcaagg ttattacgct caagagcaaa 2880
cttgtcagcg atttccgcaa ggacttccag ttctacaagg tgagggagat taacaactac 2940
caccatgcac atgatgccta cttgaacgca gtggtgggga ccgcgcttat taaaaagtac 3000
cctaagttgg agtcagagtt cgtttatggg gactacaagg tgtacgacgt ccggaagatg 3060
attgcaaagt ctgaacagga aatcgggaag gccaccgcca aatatttctt ctacagtaac 3120
attatgaatt tttttaagac tgaaattact ctcgcaaacg gcgagatcag gaagcgtccc 3180
ctcatcgaga caaacgggga gaccggggag atagtctggg acaaggggcg ggacttcgct 3240
acggtgagga aggtgctctc gatgccacaa gtgaacatcg tcaaaaagac agaggtgcag 3300
accggtggct tctcaaagga gtcaatcctg ccaaaacgta acagcgacaa gctcatcgcc 3360
cgcaagaaag actgggaccc taagaagtat ggtgggttcg actcaccgac ggtcgcatac 3420
tccgttctgg tcgtggcaaa ggtggaaaag ggcaagtcca aaaaactgaa atccgtgaag 3480
gagttgcttg gcattaccat catggaacgc agcagcttcg agaagaaccc cattgacttc 3540
ctggaggcta aagggtacaa ggaggtcaag aaagatttaa ttattaagct acctaagtac 3600
agcttgttcg agctggagaa cggccgaaaa cgaatgctcg catccgccgg ggaacttcaa 3660
aagggcaacg agcttgcgct gccctccaag tacgtgaact tcctgtactt ggcatcccac 3720
tacgagaaac tcaagggtag cccagaggac aacgagcaga agcagctatt cgtggagcag 3780
cacaagcact acctcgacga gataatcgag cagatcagtg agttcagtaa gcgggtgata 3840
ctcgcggacg ccaacttgga caaggtgctt agtgcctaca acaagcaccg tgacaagccc 3900
atccgagaac aggctgagaa catcatccac cttttcactc tgacaaacct cggtgctccc 3960
gccgccttca aatacttcga cactaccatc gacaggaagc gctacacatc tacgaaggaa 4020
gttcttgacg ctacgcttat tcatcagtct atcacagggc tgtacgagac aaggatcgac 4080
cttagccaac tcggcgggga t 4101
<210> 81
<211> 1367
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 81
Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val Gly
1 5 10 15
Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe Lys
20 25 30
Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile Gly
35 40 45
Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu Lys
50 55 60
Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys Tyr
65 70 75 80
Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser Phe
85 90 95
Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys His
100 105 110
Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr His
115 120 125
Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp Ser
130 135 140
Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His Met
145 150 155 160
Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro Asp
165 170 175
Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr Asn
180 185 190
Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala Lys
195 200 205
Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn Leu
210 215 220
Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn Leu
225 230 235 240
Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe Asp
245 250 255
Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp Asp
260 265 270
Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp Leu
275 280 285
Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp Ile
290 295 300
Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser Met
305 310 315 320
Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys Ala
325 330 335
Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe Asp
340 345 350
Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser Gln
355 360 365
Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp Gly
370 375 380
Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg Lys
385 390 395 400
Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu Gly
405 410 415
Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe Leu
420 425 430
Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile Pro
435 440 445
Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp Met
450 455 460
Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu Val
465 470 475 480
Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr Asn
485 490 495
Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser Leu
500 505 510
Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys Tyr
515 520 525
Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln Lys
530 535 540
Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr Val
545 550 555 560
Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp Ser
565 570 575
Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly Thr
580 585 590
Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp Asn
595 600 605
Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr Leu
610 615 620
Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala His
625 630 635 640
Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr Thr
645 650 655
Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp Lys
660 665 670
Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe Ala
675 680 685
Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe Lys
690 695 700
Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu His
705 710 715 720
Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly Ile
725 730 735
Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly Arg
740 745 750
His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln Thr
755 760 765
Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu
770 775 780
Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val
785 790 795 800
Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln
805 810 815
Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu
820 825 830
Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp
835 840 845
Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly
850 855 860
Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn
865 870 875 880
Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe
885 890 895
Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys
900 905 910
Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr Lys
915 920 925
His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp Glu
930 935 940
Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys
945 950 955 960
Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg Glu
965 970 975
Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val Val
980 985 990
Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe Val
995 1000 1005
Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala Lys
1010 1015 1020
Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe Tyr
1025 1030 1035
Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala Asn
1040 1045 1050
Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu Thr
1055 1060 1065
Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val Arg
1070 1075 1080
Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr Glu
1085 1090 1095
Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys Arg
1100 1105 1110
Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro Lys
1115 1120 1125
Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val Leu
1130 1135 1140
Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys Ser
1145 1150 1155
Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser Phe
1160 1165 1170
Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys Glu
1175 1180 1185
Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu Phe
1190 1195 1200
Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly Glu
1205 1210 1215
Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val Asn
1220 1225 1230
Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser Pro
1235 1240 1245
Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys His
1250 1255 1260
Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg
1265 1270 1275
Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr
1280 1285 1290
Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile
1295 1300 1305
Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe
1310 1315 1320
Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr
1325 1330 1335
Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr Gly
1340 1345 1350
Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp
1355 1360 1365
<210> 82
<211> 1367
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 82
Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val Gly
1 5 10 15
Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe Lys
20 25 30
Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile Gly
35 40 45
Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu Lys
50 55 60
Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys Tyr
65 70 75 80
Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser Phe
85 90 95
Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys His
100 105 110
Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr His
115 120 125
Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp Ser
130 135 140
Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His Met
145 150 155 160
Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro Asp
165 170 175
Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr Asn
180 185 190
Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala Lys
195 200 205
Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn Leu
210 215 220
Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn Leu
225 230 235 240
Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe Asp
245 250 255
Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp Asp
260 265 270
Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp Leu
275 280 285
Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp Ile
290 295 300
Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser Met
305 310 315 320
Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys Ala
325 330 335
Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe Asp
340 345 350
Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser Gln
355 360 365
Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp Gly
370 375 380
Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg Lys
385 390 395 400
Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu Gly
405 410 415
Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe Leu
420 425 430
Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile Pro
435 440 445
Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp Met
450 455 460
Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu Val
465 470 475 480
Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr Asn
485 490 495
Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser Leu
500 505 510
Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys Tyr
515 520 525
Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln Lys
530 535 540
Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr Val
545 550 555 560
Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp Ser
565 570 575
Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly Thr
580 585 590
Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp Asn
595 600 605
Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr Leu
610 615 620
Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala His
625 630 635 640
Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr Thr
645 650 655
Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp Lys
660 665 670
Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe Ala
675 680 685
Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe Lys
690 695 700
Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu His
705 710 715 720
Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly Ile
725 730 735
Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly Arg
740 745 750
His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln Thr
755 760 765
Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu
770 775 780
Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val
785 790 795 800
Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln
805 810 815
Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu
820 825 830
Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Ala Asp
835 840 845
Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly
850 855 860
Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn
865 870 875 880
Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe
885 890 895
Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys
900 905 910
Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr Lys
915 920 925
His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp Glu
930 935 940
Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys
945 950 955 960
Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg Glu
965 970 975
Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val Val
980 985 990
Gly Thr Ala Leu Ile Lys Lys Tyr Pro Ala Leu Glu Ser Glu Phe Val
995 1000 1005
Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala Lys
1010 1015 1020
Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe Tyr
1025 1030 1035
Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala Asn
1040 1045 1050
Gly Glu Ile Arg Lys Ala Pro Leu Ile Glu Thr Asn Gly Glu Thr
1055 1060 1065
Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val Arg
1070 1075 1080
Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr Glu
1085 1090 1095
Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys Arg
1100 1105 1110
Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro Lys
1115 1120 1125
Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val Leu
1130 1135 1140
Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys Ser
1145 1150 1155
Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser Phe
1160 1165 1170
Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys Glu
1175 1180 1185
Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu Phe
1190 1195 1200
Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly Glu
1205 1210 1215
Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val Asn
1220 1225 1230
Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser Pro
1235 1240 1245
Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys His
1250 1255 1260
Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg
1265 1270 1275
Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr
1280 1285 1290
Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile
1295 1300 1305
Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe
1310 1315 1320
Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr
1325 1330 1335
Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr Gly
1340 1345 1350
Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp
1355 1360 1365
<210> 83
<211> 228
<212> PRT
<213> brown mice
<400> 83
Ser Ser Glu Thr Gly Pro Val Ala Val Asp Pro Thr Leu Arg Arg Arg
1 5 10 15
Ile Glu Pro His Glu Phe Glu Val Phe Phe Asp Pro Arg Glu Leu Arg
20 25 30
Lys Glu Thr Cys Leu Leu Tyr Glu Ile Asn Trp Gly Gly Arg His Ser
35 40 45
Ile Trp Arg His Thr Ser Gln Asn Thr Asn Lys His Val Glu Val Asn
50 55 60
Phe Ile Glu Lys Phe Thr Thr Glu Arg Tyr Phe Cys Pro Asn Thr Arg
65 70 75 80
Cys Ser Ile Thr Trp Phe Leu Ser Trp Ser Pro Cys Gly Glu Cys Ser
85 90 95
Arg Ala Ile Thr Glu Phe Leu Ser Arg Tyr Pro His Val Thr Leu Phe
100 105 110
Ile Tyr Ile Ala Arg Leu Tyr His His Ala Asp Pro Arg Asn Arg Gln
115 120 125
Gly Leu Arg Asp Leu Ile Ser Ser Gly Val Thr Ile Gln Ile Met Thr
130 135 140
Glu Gln Glu Ser Gly Tyr Cys Trp Arg Asn Phe Val Asn Tyr Ser Pro
145 150 155 160
Ser Asn Glu Ala His Trp Pro Arg Tyr Pro His Leu Trp Val Arg Leu
165 170 175
Tyr Val Leu Glu Leu Tyr Cys Ile Ile Leu Gly Leu Pro Pro Cys Leu
180 185 190
Asn Ile Leu Arg Arg Lys Gln Pro Gln Leu Thr Phe Phe Thr Ile Ala
195 200 205
Leu Gln Ser Cys His Tyr Gln Arg Leu Pro Pro His Ile Leu Trp Ala
210 215 220
Thr Gly Leu Lys
225
<210> 84
<211> 199
<212> PRT
<213> Chile person
<400> 84
Met Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met Asp Pro His
1 5 10 15
Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His Lys Thr Tyr
20 25 30
Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser Val Lys Met
35 40 45
Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn Leu Leu Cys
50 55 60
Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp Leu Val Pro
65 70 75 80
Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr Trp Phe Ile
85 90 95
Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu Val Arg Ala
100 105 110
Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe Ala Ala Arg
115 120 125
Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln Met Leu Arg
130 135 140
Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu Phe Lys His
145 150 155 160
Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe Gln Pro Trp
165 170 175
Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg Leu Arg Ala
180 185 190
Ile Leu Gln Asn Gln Gly Asn
195
<210> 85
<211> 621
<212> DNA
<213> sea seven-piece eel
<400> 85
acagatgcag agtatgtgag aattcacgaa aagctggaca tctatacctt caagaagcag 60
ttctttaaca ataagaagtc tgtgagccat aggtgctacg tgctgttcga gctgaagaga 120
aggggtgaaa gaagggcatg tttttggggg tatgctgtga acaagcccca gtctggaact 180
gagagaggca ttcacgccga aattttcagc atcagaaagg tggaggaata cctgagggat 240
aaccctggac agtttacaat taattggtat tctagctggt ctccatgcgc tgactgtgcc 300
gagaagatcc tggaatggta caaccaggag ctgagaggaa atggccatac cctgaagatt 360
tgggcctgca agctgtacta tgaaaagaac gcaagaaatc agatcggact gtggaacctg 420
agggataatg gtgtggggct gaacgtgatg gtgtccgagc actatcagtg ctgtagaaag 480
attttcattc agtcctcaca taatcagctg aacgagaata gatggctgga aaagactctg 540
aagagggctg agaagagaag gtccgaactg tcaattatga tccaggtgaa gatcctgcac 600
accactaagt cacctgccgt g 621
<210> 86
<211> 160
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 86
Phe Glu Arg Asn Tyr Asp Pro Arg Glu Leu Arg Lys Glu Thr Tyr Leu
1 5 10 15
Leu Tyr Glu Ile Lys Trp Gly Lys Ser Gly Lys Leu Trp Arg His Trp
20 25 30
Cys Gln Asn Asn Arg Thr Gln His Ala Glu Val Tyr Phe Leu Glu Asn
35 40 45
Ile Phe Asn Ala Arg Arg Phe Asn Pro Ser Thr His Cys Ser Ile Thr
50 55 60
Trp Tyr Leu Ser Trp Ser Pro Cys Ala Glu Cys Ser Gln Lys Ile Val
65 70 75 80
Asp Phe Leu Lys Glu His Pro Asn Val Leu Glu Ile Tyr Val Ala Arg
85 90 95
Leu Tyr Tyr His Glu Asp Glu Arg Asn Arg Gln Gly Leu Arg Asp Leu
100 105 110
Val Asn Ser Gly Val Thr Ile Arg Ile Met Asp Leu Pro Asp Tyr Asn
115 120 125
Tyr Cys Trp Lys Thr Phe Val Ser Asp Gln Gly Gly Asp Glu Asp Tyr
130 135 140
Trp Pro Gly His Phe Ala Pro Trp Ile Lys Gln Tyr Ser Leu Lys Leu
145 150 155 160
<210> 87
<211> 229
<212> PRT
<213> brown mice
<400> 87
Met Ser Ser Glu Thr Gly Pro Val Ala Val Asp Pro Thr Leu Arg Arg
1 5 10 15
Arg Ile Glu Pro His Glu Phe Glu Val Phe Phe Asp Pro Arg Glu Leu
20 25 30
Arg Lys Glu Thr Cys Leu Leu Tyr Glu Ile Asn Trp Gly Gly Arg His
35 40 45
Ser Ile Trp Arg His Thr Ser Gln Asn Thr Asn Lys His Val Glu Val
50 55 60
Asn Phe Ile Glu Lys Phe Thr Thr Glu Arg Tyr Phe Cys Pro Asn Thr
65 70 75 80
Arg Cys Ser Ile Thr Trp Phe Leu Ser Trp Ser Pro Cys Gly Glu Cys
85 90 95
Ser Arg Ala Ile Thr Glu Phe Leu Ser Arg Tyr Pro His Val Thr Leu
100 105 110
Phe Ile Tyr Ile Ala Arg Leu Tyr His His Ala Asp Pro Arg Asn Arg
115 120 125
Gln Gly Leu Arg Asp Leu Ile Ser Ser Gly Val Thr Ile Gln Ile Met
130 135 140
Thr Glu Gln Glu Ser Gly Tyr Cys Trp Arg Asn Phe Val Asn Tyr Ser
145 150 155 160
Pro Ser Asn Glu Ala His Trp Pro Arg Tyr Pro His Leu Trp Val Arg
165 170 175
Leu Tyr Val Leu Glu Leu Tyr Cys Ile Ile Leu Gly Leu Pro Pro Cys
180 185 190
Leu Asn Ile Leu Arg Arg Lys Gln Pro Gln Leu Thr Phe Phe Thr Ile
195 200 205
Ala Leu Gln Ser Cys His Tyr Gln Arg Leu Pro Pro His Ile Leu Trp
210 215 220
Ala Thr Gly Leu Lys
225
<210> 88
<211> 198
<212> PRT
<213> Chile person
<400> 88
Met Asp Ser Leu Leu Met Asn Arg Arg Lys Phe Leu Tyr Gln Phe Lys
1 5 10 15
Asn Val Arg Trp Ala Lys Gly Arg Arg Glu Thr Tyr Leu Cys Tyr Val
20 25 30
Val Lys Arg Arg Asp Ser Ala Thr Ser Phe Ser Leu Asp Phe Gly Tyr
35 40 45
Leu Arg Asn Lys Asn Gly Cys His Val Glu Leu Leu Phe Leu Arg Tyr
50 55 60
Ile Ser Asp Trp Asp Leu Asp Pro Gly Arg Cys Tyr Arg Val Thr Trp
65 70 75 80
Phe Thr Ser Trp Ser Pro Cys Tyr Asp Cys Ala Arg His Val Ala Asp
85 90 95
Phe Leu Arg Gly Asn Pro Asn Leu Ser Leu Arg Ile Phe Thr Ala Arg
100 105 110
Leu Tyr Phe Cys Glu Asp Arg Lys Ala Glu Pro Glu Gly Leu Arg Arg
115 120 125
Leu His Arg Ala Gly Val Gln Ile Ala Ile Met Thr Phe Lys Asp Tyr
130 135 140
Phe Tyr Cys Trp Asn Thr Phe Val Glu Asn His Glu Arg Thr Phe Lys
145 150 155 160
Ala Trp Glu Gly Leu His Glu Asn Ser Val Arg Leu Ser Arg Gln Leu
165 170 175
Arg Arg Ile Leu Leu Pro Leu Tyr Glu Val Asp Asp Leu Arg Asp Ala
180 185 190
Phe Arg Thr Leu Gly Leu
195
<210> 89
<211> 197
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 89
Met Asp Ser Leu Leu Met Asn Arg Arg Glu Phe Leu Tyr Gln Phe Lys
1 5 10 15
Asn Val Arg Trp Ala Lys Gly Arg Arg Glu Thr Tyr Leu Cys Tyr Val
20 25 30
Val Lys Arg Arg Asp Ser Ala Thr Ser Phe Ser Leu Asp Phe Gly Tyr
35 40 45
Leu Arg Asn Lys Asn Gly Cys His Val Glu Leu Leu Phe Leu Arg Tyr
50 55 60
Ile Ser Asp Trp Asp Leu Asp Pro Gly Arg Cys Tyr Arg Val Thr Trp
65 70 75 80
Phe Ile Ser Trp Ser Pro Cys Tyr Asp Cys Ala Arg His Val Ala Asp
85 90 95
Phe Leu Arg Gly Asn Pro Asn Leu Ser Leu Arg Ile Phe Thr Ala Arg
100 105 110
Leu Tyr Phe Cys Glu Asp Arg Lys Ala Glu Pro Glu Gly Leu Arg Arg
115 120 125
Leu His Arg Ala Gly Val Gln Ile Ala Ile Met Thr Phe Lys Asp Tyr
130 135 140
Phe Tyr Cys Trp Asn Thr Phe Val Glu Asn His Gly Arg Thr Phe Lys
145 150 155 160
Ala Trp Glu Gly Leu His Glu Asn Ser Val Arg Leu Ser Arg Gln Leu
165 170 175
Arg Arg Ile Leu Leu Pro Leu Tyr Glu Val Asp Asp Leu Arg Asp Ala
180 185 190
Phe Arg Thr Cys Thr
195
<210> 90
<211> 207
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 90
Thr Asp Ala Glu Tyr Val Arg Ile His Glu Lys Leu Asp Ile Tyr Thr
1 5 10 15
Phe Lys Lys Gln Phe Ser Asn Asn Lys Lys Ser Val Ser His Arg Cys
20 25 30
Tyr Val Leu Phe Glu Leu Lys Arg Arg Gly Glu Arg Arg Ala Cys Phe
35 40 45
Trp Gly Tyr Ala Val Asn Lys Pro Gln Ser Gly Thr Glu Arg Gly Ile
50 55 60
His Ala Glu Ile Phe Ser Ile Arg Lys Val Glu Glu Tyr Leu Arg Asp
65 70 75 80
Asn Pro Gly Gln Phe Thr Ile Asn Trp Tyr Ser Ser Trp Ser Pro Cys
85 90 95
Ala Asp Cys Ala Glu Lys Ile Leu Glu Trp Tyr Asn Gln Glu Leu Arg
100 105 110
Gly Asn Gly His Thr Leu Lys Ile Trp Val Cys Lys Leu Tyr Tyr Glu
115 120 125
Lys Asn Ala Arg Asn Gln Ile Gly Leu Trp Asn Leu Arg Asp Asn Gly
130 135 140
Val Gly Leu Asn Val Met Val Ser Glu His Tyr Gln Cys Cys Arg Lys
145 150 155 160
Ile Phe Ile Gln Ser Ser His Asn Gln Leu Asn Glu Asn Arg Trp Leu
165 170 175
Glu Lys Thr Leu Lys Arg Ala Glu Lys Arg Arg Ser Glu Leu Ser Ile
180 185 190
Met Phe Gln Val Lys Ile Leu His Thr Thr Lys Ser Pro Ala Val
195 200 205
<210> 91
<211> 228
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 91
Ser Ser Lys Thr Gly Pro Val Ala Val Asp Pro Thr Leu Arg Arg Arg
1 5 10 15
Ile Glu Pro His Glu Phe Glu Val Phe Phe Asp Pro Arg Glu Leu Arg
20 25 30
Lys Glu Thr Cys Leu Leu Tyr Glu Ile Asn Trp Gly Gly Arg His Ser
35 40 45
Ile Trp Arg His Thr Ser Gln Asn Thr Asn Lys His Val Glu Val Asn
50 55 60
Phe Ile Glu Lys Phe Thr Thr Glu Arg Tyr Phe Cys Pro Asn Thr Arg
65 70 75 80
Cys Ser Ile Thr Trp Phe Leu Ser Trp Ser Pro Cys Gly Glu Cys Ser
85 90 95
Arg Ala Ile Thr Glu Phe Leu Ser Arg Tyr Pro Asn Val Thr Leu Phe
100 105 110
Ile Tyr Ile Ala Arg Leu Tyr His Leu Ala Asn Pro Arg Asn Arg Gln
115 120 125
Gly Leu Arg Asp Leu Ile Ser Ser Gly Val Thr Ile Gln Ile Met Thr
130 135 140
Glu Gln Glu Ser Gly Tyr Cys Trp His Asn Phe Val Asn Tyr Ser Pro
145 150 155 160
Ser Asn Glu Ser His Trp Pro Arg Tyr Pro His Leu Trp Val Arg Leu
165 170 175
Tyr Val Leu Glu Leu Tyr Cys Ile Ile Leu Gly Leu Pro Pro Cys Leu
180 185 190
Asn Ile Leu Arg Arg Lys Gln Ser Gln Leu Thr Ser Phe Thr Ile Ala
195 200 205
Leu Gln Ser Cys His Tyr Gln Arg Leu Pro Pro His Ile Leu Trp Ala
210 215 220
Thr Gly Leu Lys
225
<210> 92
<211> 162
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 92
Ser Phe Glu Arg Asn Tyr Asp Pro Arg Glu Leu Arg Lys Glu Thr Tyr
1 5 10 15
Leu Leu Tyr Glu Ile Lys Trp Gly Lys Ser Gly Lys Leu Trp Arg His
20 25 30
Trp Cys Gln Asn Asn Arg Thr Gln His Ala Glu Val Tyr Phe Leu Glu
35 40 45
Asn Ile Phe Asn Ala Arg Arg Phe Asn Pro Ser Thr His Cys Ser Ile
50 55 60
Thr Trp Tyr Leu Ser Trp Ser Pro Cys Ala Glu Cys Ser Gln Lys Ile
65 70 75 80
Val Asp Phe Leu Lys Glu His Pro Asn Val Asn Leu Glu Ile Tyr Val
85 90 95
Ala Arg Leu Tyr Tyr Pro Glu Asn Glu Arg Asn Arg Gln Gly Leu Arg
100 105 110
Asp Leu Val Asn Ser Gly Val Thr Ile Arg Ile Met Asp Leu Pro Asp
115 120 125
Tyr Asn Tyr Cys Trp Lys Thr Phe Val Ser Asp Gln Gly Gly Asp Glu
130 135 140
Asp Tyr Trp Pro Gly His Phe Ala Pro Trp Ile Lys Gln Tyr Ser Leu
145 150 155 160
Lys Leu
<210> 93
<211> 166
<212> PRT
<213> Escherichia coli
<400> 93
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Trp Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val His Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Pro Ile
35 40 45
Gly Arg His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Leu Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Ala Arg Asp Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His His Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Ser Asp Phe Phe Arg Met Arg Arg Gln Glu Ile Lys Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp
165
<210> 94
<211> 166
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 94
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala Ile
35 40 45
Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His Tyr Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Cys Tyr Phe Phe Arg Met Pro Arg Gln Val Phe Asn Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp
165
<210> 95
<211> 166
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 95
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Trp Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ser Ile
35 40 45
Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His Tyr Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Cys Tyr Phe Phe Arg Met Arg Arg Gln Val Phe Asn Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp
165
<210> 96
<211> 166
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 96
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Leu Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala Ile
35 40 45
Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His Tyr Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Asn Ala Leu Leu
130 135 140
Cys Tyr Phe Phe Arg Met Arg Arg Gln Val Phe Asn Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp
165
<210> 97
<211> 166
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 97
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Leu Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala Ile
35 40 45
Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His Tyr Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Asn Ala Leu Leu
130 135 140
Cys Tyr Phe Phe Arg Met Pro Arg Gln Val Phe Asn Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp
165
<210> 98
<211> 1763
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 98
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Trp Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val His Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Pro Ile
35 40 45
Gly Arg His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Leu Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Ala Arg Asp Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His His Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Ser Asp Phe Phe Arg Met Arg Arg Gln Glu Ile Lys Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly
165 170 175
Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Ser Gly
180 185 190
Gly Ser Ser Gly Gly Ser Ser Glu Val Glu Phe Ser His Glu Tyr Trp
195 200 205
Met Arg His Ala Leu Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu
210 215 220
Val Pro Val Gly Ala Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu
225 230 235 240
Gly Trp Asn Arg Ala Ile Gly Leu His Asp Pro Thr Ala His Ala Glu
245 250 255
Ile Met Ala Leu Arg Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu
260 265 270
Ile Asp Ala Thr Leu Tyr Val Thr Phe Glu Pro Cys Val Met Cys Ala
275 280 285
Gly Ala Met Ile His Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg
290 295 300
Asn Ala Lys Thr Gly Ala Ala Gly Ser Leu Met Asp Val Leu His Tyr
305 310 315 320
Pro Gly Met Asn His Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp
325 330 335
Glu Cys Ala Ala Leu Leu Cys Tyr Phe Phe Arg Met Pro Arg Gln Val
340 345 350
Phe Asn Ala Gln Lys Lys Ala Gln Ser Ser Thr Asp Ser Gly Gly Ser
355 360 365
Ser Gly Gly Ser Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala
370 375 380
Thr Pro Glu Ser Ser Gly Gly Ser Ser Gly Gly Ser Asp Lys Lys Tyr
385 390 395 400
Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile
405 410 415
Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn
420 425 430
Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe
435 440 445
Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg
450 455 460
Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile
465 470 475 480
Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu
485 490 495
Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro
500 505 510
Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro
515 520 525
Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala
530 535 540
Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg
545 550 555 560
Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val
565 570 575
Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu
580 585 590
Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser
595 600 605
Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu
610 615 620
Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser
625 630 635 640
Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp
645 650 655
Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn
660 665 670
Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala
675 680 685
Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn
690 695 700
Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr
705 710 715 720
Asp Glu His His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln
725 730 735
Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn
740 745 750
Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr
755 760 765
Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Leu
770 775 780
Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe
785 790 795 800
Asp Asn Gly Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala
805 810 815
Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg
820 825 830
Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly
835 840 845
Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser
850 855 860
Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly
865 870 875 880
Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn
885 890 895
Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr
900 905 910
Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly
915 920 925
Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val
930 935 940
Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys
945 950 955 960
Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser
965 970 975
Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu
980 985 990
Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu
995 1000 1005
Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp
1010 1015 1020
Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe
1025 1030 1035
Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly
1040 1045 1050
Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp Lys
1055 1060 1065
Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe
1070 1075 1080
Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr
1085 1090 1095
Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp
1100 1105 1110
Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile
1115 1120 1125
Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val
1130 1135 1140
Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met
1145 1150 1155
Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg
1160 1165 1170
Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser
1175 1180 1185
Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn
1190 1195 1200
Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr
1205 1210 1215
Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val
1220 1225 1230
Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp
1235 1240 1245
Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
1250 1255 1260
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp
1265 1270 1275
Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp
1280 1285 1290
Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys
1295 1300 1305
Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr
1310 1315 1320
Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr
1325 1330 1335
Asp Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu
1340 1345 1350
Lys Ser Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr
1355 1360 1365
Lys Val Arg Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr
1370 1375 1380
Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys
1385 1390 1395
Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val
1400 1405 1410
Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr
1415 1420 1425
Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr
1430 1435 1440
Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile
1445 1450 1455
Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg
1460 1465 1470
Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn
1475 1480 1485
Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu
1490 1495 1500
Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys
1505 1510 1515
Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr
1520 1525 1530
Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys
1535 1540 1545
Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile
1550 1555 1560
Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu
1565 1570 1575
Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu
1580 1585 1590
Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met
1595 1600 1605
Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu
1610 1615 1620
Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu
1625 1630 1635
Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe
1640 1645 1650
Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile
1655 1660 1665
Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp
1670 1675 1680
Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys Pro Ile Arg
1685 1690 1695
Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu Thr Asn Leu
1700 1705 1710
Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg
1715 1720 1725
Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala Thr Leu Ile
1730 1735 1740
His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser
1745 1750 1755
Gln Leu Gly Gly Asp
1760
<210> 99
<211> 1565
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 99
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala Ile
35 40 45
Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ser Lys Arg Gly Ala
100 105 110
Ala Gly Ser Leu Met Asn Val Leu Asn Tyr Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Cys Asp Phe Tyr Arg Met Pro Arg Gln Val Phe Asn Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Ile Asn Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly
165 170 175
Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Ser Gly
180 185 190
Gly Ser Ser Gly Gly Ser Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile
195 200 205
Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val
210 215 220
Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile
225 230 235 240
Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala
245 250 255
Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg
260 265 270
Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala
275 280 285
Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val
290 295 300
Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly Asn Ile Val
305 310 315 320
Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg
325 330 335
Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr
340 345 350
Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu
355 360 365
Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln
370 375 380
Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala
385 390 395 400
Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser
405 410 415
Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn
420 425 430
Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn
435 440 445
Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser
450 455 460
Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly
465 470 475 480
Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala
485 490 495
Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala
500 505 510
Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His Gln Asp
515 520 525
Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr
530 535 540
Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile
545 550 555 560
Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile
565 570 575
Leu Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg
580 585 590
Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro
595 600 605
His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu
610 615 620
Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile
625 630 635 640
Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn
645 650 655
Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro
660 665 670
Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe
675 680 685
Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val
690 695 700
Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu
705 710 715 720
Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe
725 730 735
Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr
740 745 750
Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys
755 760 765
Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe
770 775 780
Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp
785 790 795 800
Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile
805 810 815
Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg
820 825 830
Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met Lys Gln Leu
835 840 845
Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile
850 855 860
Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu
865 870 875 880
Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp
885 890 895
Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly
900 905 910
Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro
915 920 925
Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu
930 935 940
Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met
945 950 955 960
Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu
965 970 975
Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile
980 985 990
Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu
995 1000 1005
Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln
1010 1015 1020
Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile
1025 1030 1035
Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val
1040 1045 1050
Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro
1055 1060 1065
Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu
1070 1075 1080
Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
1085 1090 1095
Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe
1100 1105 1110
Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr Lys His Val
1115 1120 1125
Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn
1130 1135 1140
Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys
1145 1150 1155
Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg
1160 1165 1170
Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala
1175 1180 1185
Val Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser
1190 1195 1200
Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met
1205 1210 1215
Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr
1220 1225 1230
Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr
1235 1240 1245
Leu Ala Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn
1250 1255 1260
Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala
1265 1270 1275
Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys
1280 1285 1290
Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu
1295 1300 1305
Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp
1310 1315 1320
Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr
1325 1330 1335
Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys
1340 1345 1350
Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg
1355 1360 1365
Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly
1370 1375 1380
Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr
1385 1390 1395
Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser
1400 1405 1410
Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys
1415 1420 1425
Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys
1430 1435 1440
Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln
1445 1450 1455
His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe
1460 1465 1470
Ser Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu
1475 1480 1485
Ser Ala Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala
1490 1495 1500
Glu Asn Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro
1505 1510 1515
Ala Ala Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr
1520 1525 1530
Thr Ser Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser
1535 1540 1545
Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly
1550 1555 1560
Gly Asp
1565
<210> 100
<211> 1565
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 100
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala Ile
35 40 45
Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Tyr Asp Ala Thr Leu Tyr
65 70 75 80
Ser Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His His Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Cys Arg Phe Phe Arg Met Pro Arg Arg Val Phe Asn Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly
165 170 175
Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Ser Gly
180 185 190
Gly Ser Ser Gly Gly Ser Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile
195 200 205
Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val
210 215 220
Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile
225 230 235 240
Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala
245 250 255
Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg
260 265 270
Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala
275 280 285
Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val
290 295 300
Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly Asn Ile Val
305 310 315 320
Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg
325 330 335
Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr
340 345 350
Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu
355 360 365
Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln
370 375 380
Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala
385 390 395 400
Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser
405 410 415
Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn
420 425 430
Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn
435 440 445
Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser
450 455 460
Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly
465 470 475 480
Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala
485 490 495
Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala
500 505 510
Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His Gln Asp
515 520 525
Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr
530 535 540
Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile
545 550 555 560
Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile
565 570 575
Leu Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg
580 585 590
Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro
595 600 605
His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu
610 615 620
Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile
625 630 635 640
Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn
645 650 655
Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro
660 665 670
Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe
675 680 685
Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val
690 695 700
Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu
705 710 715 720
Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe
725 730 735
Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr
740 745 750
Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys
755 760 765
Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe
770 775 780
Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp
785 790 795 800
Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile
805 810 815
Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg
820 825 830
Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met Lys Gln Leu
835 840 845
Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile
850 855 860
Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu
865 870 875 880
Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp
885 890 895
Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly
900 905 910
Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro
915 920 925
Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu
930 935 940
Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met
945 950 955 960
Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu
965 970 975
Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile
980 985 990
Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu
995 1000 1005
Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln
1010 1015 1020
Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile
1025 1030 1035
Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val
1040 1045 1050
Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro
1055 1060 1065
Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu
1070 1075 1080
Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
1085 1090 1095
Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe
1100 1105 1110
Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr Lys His Val
1115 1120 1125
Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn
1130 1135 1140
Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys
1145 1150 1155
Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg
1160 1165 1170
Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala
1175 1180 1185
Val Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser
1190 1195 1200
Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met
1205 1210 1215
Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr
1220 1225 1230
Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr
1235 1240 1245
Leu Ala Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn
1250 1255 1260
Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala
1265 1270 1275
Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys
1280 1285 1290
Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu
1295 1300 1305
Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp
1310 1315 1320
Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr
1325 1330 1335
Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys
1340 1345 1350
Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg
1355 1360 1365
Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly
1370 1375 1380
Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr
1385 1390 1395
Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser
1400 1405 1410
Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys
1415 1420 1425
Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys
1430 1435 1440
Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln
1445 1450 1455
His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe
1460 1465 1470
Ser Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu
1475 1480 1485
Ser Ala Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala
1490 1495 1500
Glu Asn Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro
1505 1510 1515
Ala Ala Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr
1520 1525 1530
Thr Ser Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser
1535 1540 1545
Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly
1550 1555 1560
Gly Asp
1565
<210> 101
<211> 364
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 101
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Trp Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val His Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Pro Ile
35 40 45
Gly Arg His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Leu Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Ala Arg Asp Ala Lys Thr Gly Ala
100 105 110
Ala Gly Ser Leu Met Asp Val Leu His His Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Ser Asp Phe Phe Arg Met Arg Arg Gln Glu Ile Lys Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Thr Asp Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly
165 170 175
Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Ser Gly
180 185 190
Gly Ser Ser Gly Gly Ser Ser Glu Val Glu Phe Ser His Glu Tyr Trp
195 200 205
Met Arg His Ala Leu Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu
210 215 220
Val Pro Val Gly Ala Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu
225 230 235 240
Gly Trp Asn Arg Ala Ile Gly Leu His Asp Pro Thr Ala His Ala Glu
245 250 255
Ile Met Ala Leu Arg Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu
260 265 270
Ile Asp Ala Thr Leu Tyr Val Thr Phe Glu Pro Cys Val Met Cys Ala
275 280 285
Gly Ala Met Ile His Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg
290 295 300
Asn Ala Lys Thr Gly Ala Ala Gly Ser Leu Met Asp Val Leu His Tyr
305 310 315 320
Pro Gly Met Asn His Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp
325 330 335
Glu Cys Ala Ala Leu Leu Cys Tyr Phe Phe Arg Met Pro Arg Gln Val
340 345 350
Phe Asn Ala Gln Lys Lys Ala Gln Ser Ser Thr Asp
355 360
<210> 102
<211> 167
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 102
Met Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu
1 5 10 15
Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val Gly Ala
20 25 30
Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala
35 40 45
Ile Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg
50 55 60
Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Tyr Asp Ala Thr Leu
65 70 75 80
Tyr Ser Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His
85 90 95
Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ala Lys Thr Gly
100 105 110
Ala Ala Gly Ser Leu Met Asp Val Leu His His Pro Gly Met Asn His
115 120 125
Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu
130 135 140
Leu Cys Arg Phe Phe Arg Met Pro Arg Arg Val Phe Asn Ala Gln Lys
145 150 155 160
Lys Ala Gln Ser Ser Thr Asp
165
<210> 103
<211> 167
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 103
Met Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu
1 5 10 15
Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val Gly Ala
20 25 30
Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala
35 40 45
Ile Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg
50 55 60
Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu
65 70 75 80
Tyr Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His
85 90 95
Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ser Lys Arg Gly
100 105 110
Ala Ala Gly Ser Leu Met Asn Val Leu Asn Tyr Pro Gly Met Asn His
115 120 125
Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu
130 135 140
Leu Cys Asp Phe Tyr Arg Met Pro Arg Gln Val Phe Asn Ala Gln Lys
145 150 155 160
Lys Ala Gln Ser Ser Ile Asn
165
<210> 104
<211> 83
<212> PRT
<213> Bacillus phage AR9
<400> 104
Thr Asn Leu Ser Asp Ile Ile Glu Lys Glu Thr Gly Lys Gln Leu Val
1 5 10 15
Ile Gln Glu Ser Ile Leu Met Leu Pro Glu Glu Val Glu Glu Val Ile
20 25 30
Gly Asn Lys Pro Glu Ser Asp Ile Leu Val His Thr Ala Tyr Asp Glu
35 40 45
Ser Thr Asp Glu Asn Val Met Leu Leu Thr Ser Asp Ala Pro Glu Tyr
50 55 60
Lys Pro Trp Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn Lys Ile
65 70 75 80
Lys Met Leu
<210> 105
<211> 19
<212> RNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<220>
<221> misc_feature
<222> (1)..(19)
<223> n is a, c, g, or u
<400> 105
nnnnnnnnnn nnnnnnnnn 19
<210> 106
<211> 22
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<220>
<221> misc_feature
<222> (4)..(22)
<223> n is a, c, g, or t
<400> 106
aaannnnnnn nnnnnnnnnn nn 22
<210> 107
<211> 22
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<220>
<221> misc_feature
<222> (4)..(22)
<223> n is a, c, g, or t
<400> 107
tttnnnnnnn nnnnnnnnnn nn 22
<210> 108
<211> 66
<212> DNA
<213> Saccharomyces cerevisiae
<400> 108
ttcttgtcgt acttatagat cgctacgtta tttcaatttt gaaaatctga gtcctgggag 60
tgcgga 66
<210> 109
<211> 605
<212> PRT
<213> Chile person
<400> 109
Met Ser Gly Trp Glu Ser Tyr Tyr Lys Thr Glu Gly Asp Glu Glu Ala
1 5 10 15
Glu Glu Glu Gln Glu Glu Asn Leu Glu Ala Ser Gly Asp Tyr Lys Tyr
20 25 30
Ser Gly Arg Asp Ser Leu Ile Phe Leu Val Asp Ala Ser Lys Ala Met
35 40 45
Phe Glu Ser Gln Ser Glu Asp Glu Leu Thr Pro Phe Asp Met Ser Ile
50 55 60
Gln Cys Ile Gln Ser Val Tyr Ile Ser Lys Ile Ile Ser Ser Asp Arg
65 70 75 80
Asp Leu Leu Ala Trp Phe Tyr Gly Thr Glu Lys Asp Lys Asn Ser Val
85 90 95
Asn Phe Lys Ile Tyr Val Leu Gln Glu Leu Asp Asn Pro Gly Ala Lys
100 105 110
Arg Ile Leu Glu Leu Asp Gln Phe Lys Gly Gln Gln Gly Gln Lys Arg
115 120 125
Phe Gln Asp Met Met Gly His Gly Ser Asp Tyr Ser Leu Ser Glu Val
130 135 140
Leu Trp Val Cys Ala Asn Leu Phe Ser Asp Val Gln Phe Lys Met Ser
145 150 155 160
His Lys Arg Ile Met Leu Phe Thr Asn Glu Asp Asn Pro His Gly Asn
165 170 175
Asp Ser Ala Lys Ala Ser Arg Ala Arg Thr Lys Ala Gly Asp Leu Arg
180 185 190
Asp Thr Gly Ile Phe Leu Asp Leu His Leu Lys Lys Pro Gly Gly Phe
195 200 205
Asp Ile Ser Leu Phe Tyr Arg Asp Ile Ile Ser Ile Ala Glu Asp Glu
210 215 220
Asp Leu Arg Val His Phe Glu Glu Ser Ser Lys Leu Glu Asp Leu Leu
225 230 235 240
Arg Lys Val Arg Ala Lys Glu Thr Arg Lys Arg Ala Leu Ser Arg Leu
245 250 255
Lys Leu Lys Leu Asn Lys Asp Ile Val Ile Ser Val Gly Ile Tyr Asn
260 265 270
Leu Val Gln Lys Ala Leu Lys Pro Pro Pro Ile Lys Leu Tyr Arg Glu
275 280 285
Thr Asn Glu Pro Val Lys Thr Lys Thr Arg Thr Phe Asn Thr Ser Thr
290 295 300
Gly Gly Leu Leu Leu Pro Ser Asp Thr Lys Arg Ser Gln Ile Tyr Gly
305 310 315 320
Ser Arg Gln Ile Ile Leu Glu Lys Glu Glu Thr Glu Glu Leu Lys Arg
325 330 335
Phe Asp Asp Pro Gly Leu Met Leu Met Gly Phe Lys Pro Leu Val Leu
340 345 350
Leu Lys Lys His His Tyr Leu Arg Pro Ser Leu Phe Val Tyr Pro Glu
355 360 365
Glu Ser Leu Val Ile Gly Ser Ser Thr Leu Phe Ser Ala Leu Leu Ile
370 375 380
Lys Cys Leu Glu Lys Glu Val Ala Ala Leu Cys Arg Tyr Thr Pro Arg
385 390 395 400
Arg Asn Ile Pro Pro Tyr Phe Val Ala Leu Val Pro Gln Glu Glu Glu
405 410 415
Leu Asp Asp Gln Lys Ile Gln Val Thr Pro Pro Gly Phe Gln Leu Val
420 425 430
Phe Leu Pro Phe Ala Asp Asp Lys Arg Lys Met Pro Phe Thr Glu Lys
435 440 445
Ile Met Ala Thr Pro Glu Gln Val Gly Lys Met Lys Ala Ile Val Glu
450 455 460
Lys Leu Arg Phe Thr Tyr Arg Ser Asp Ser Phe Glu Asn Pro Val Leu
465 470 475 480
Gln Gln His Phe Arg Asn Leu Glu Ala Leu Ala Leu Asp Leu Met Glu
485 490 495
Pro Glu Gln Ala Val Asp Leu Thr Leu Pro Lys Val Glu Ala Met Asn
500 505 510
Lys Arg Leu Gly Ser Leu Val Asp Glu Phe Lys Glu Leu Val Tyr Pro
515 520 525
Pro Asp Tyr Asn Pro Glu Gly Lys Val Thr Lys Arg Lys His Asp Asn
530 535 540
Glu Gly Ser Gly Ser Lys Arg Pro Lys Val Glu Tyr Ser Glu Glu Glu
545 550 555 560
Leu Lys Thr His Ile Ser Lys Gly Thr Leu Gly Lys Phe Thr Val Pro
565 570 575
Leu Lys Glu Ala Cys Arg Ala Tyr Gly Leu Lys Ser Gly Leu Lys Lys
580 585 590
Gln Glu Leu Leu Glu Ala Leu Thr Lys His Phe Gln Asp
595 600 605
<210> 110
<211> 482
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 110
Met Val Arg Ser Gly Asn Lys Ala Ala Trp Leu Cys Met Asp Val Gly
1 5 10 15
Phe Thr Met Ser Asn Ser Ile Pro Gly Ile Glu Ser Pro Phe Glu Gln
20 25 30
Ala Lys Lys Val Ile Thr Met Phe Val Gln Arg Gln Val Phe Ala Glu
35 40 45
Asn Lys Asp Glu Ile Ala Leu Val Leu Phe Gly Thr Asp Gly Thr Asp
50 55 60
Asn Pro Leu Ser Gly Gly Asp Gln Tyr Gln Asn Ile Thr Val His Arg
65 70 75 80
His Leu Met Leu Pro Asp Phe Asp Leu Leu Glu Asp Ile Glu Ser Lys
85 90 95
Ile Gln Pro Gly Ser Gln Gln Ala Asp Phe Leu Asp Ala Leu Ile Val
100 105 110
Ser Met Asp Val Ile Gln His Glu Thr Ile Gly Lys Lys Phe Glu Lys
115 120 125
Arg His Ile Glu Ile Phe Thr Asp Leu Ser Ser Arg Phe Ser Lys Ser
130 135 140
Gln Leu Asp Ile Ile Ile His Ser Leu Lys Lys Cys Asp Ile Ser Glu
145 150 155 160
Arg His Ser Ile His Trp Pro Cys Arg Leu Thr Ile Gly Ser Asn Leu
165 170 175
Ser Ile Arg Ile Ala Ala Tyr Lys Ser Ile Leu Gln Glu Arg Val Lys
180 185 190
Lys Thr Thr Trp Asp Ala Lys Thr Leu Lys Lys Glu Asp Ile Gln Lys
195 200 205
Glu Thr Val Tyr Cys Leu Asn Asp Asp Asp Glu Thr Glu Val Leu Lys
210 215 220
Glu Asp Ile Ile Gln Gly Phe Arg Tyr Gly Ser Asp Ile Val Pro Phe
225 230 235 240
Ser Lys Val Asp Glu Glu Gln Met Lys Tyr Lys Ser Glu Gly Lys Cys
245 250 255
Phe Ser Val Leu Gly Phe Cys Lys Ser Ser Gln Val Gln Arg Arg Phe
260 265 270
Phe Met Gly Asn Gln Val Leu Lys Val Phe Ala Ala Arg Asp Asp Glu
275 280 285
Ala Ala Ala Val Ala Leu Ser Ser Leu Ile His Ala Leu Asp Asp Leu
290 295 300
Asp Ile Trp Ala Ile Val Arg Tyr Ala Tyr Asp Lys Arg Ala Asn Pro
305 310 315 320
Gln Val Gly Val Ala Phe Pro His Ile Lys His Asn Tyr Glu Cys Leu
325 330 335
Val Tyr Val Gln Leu Pro Phe Met Glu Asp Leu Arg Gln Tyr Met Phe
340 345 350
Ser Ser Leu Lys Asn Ser Lys Lys Tyr Ala Pro Thr Glu Ala Gln Leu
355 360 365
Asn Ala Val Asp Ala Leu Ile Asp Ser Met Ser Leu Ala Lys Lys Asp
370 375 380
Glu Lys Thr Asp Thr Leu Glu Asp Leu Phe Pro Thr Thr Lys Ile Pro
385 390 395 400
Asn Pro Arg Phe Gln Arg Leu Phe Gln Cys Leu Leu His Arg Ala Leu
405 410 415
His Pro Arg Glu Pro Leu Pro Pro Ile Gln Gln His Ile Trp Asn Met
420 425 430
Leu Asn Pro Pro Ala Glu Val Thr Thr Lys Ser Gln Ile Pro Leu Ser
435 440 445
Lys Ile Lys Thr Leu Phe Pro Leu Ile Glu Ala Lys Lys Lys Asp Gln
450 455 460
Val Thr Ala Gln Glu Ile Phe Gln Asp Asn His Glu Asp Gly Pro Thr
465 470 475 480
Ala Lys
<210> 111
<211> 10
<212> DNA
<213> thermophilic Methanobacterium alkaline (Methanobacterium thermoautotrophicum)
<400> 111
aatttttgga 10
<210> 112
<211> 83
<212> PRT
<213> thermophilic Methanobacterium alkaline (Methanobacterium thermoautotrophicum)
<400> 112
Gly Ser Val Ile Asp Val Ser Ser Gln Arg Val Asn Val Gln Arg Pro
1 5 10 15
Leu Asp Ala Leu Gly Asn Ser Leu Asn Ser Pro Val Ile Ile Lys Leu
20 25 30
Lys Gly Asp Arg Glu Phe Arg Gly Val Leu Lys Ser Phe Asp Leu His
35 40 45
Met Asn Leu Val Leu Asn Asp Ala Glu Glu Leu Glu Asp Gly Glu Val
50 55 60
Thr Arg Arg Leu Gly Thr Val Leu Ile Arg Gly Asp Asn Ile Val Tyr
65 70 75 80
Ile Ser Pro
<210> 113
<211> 25
<212> DNA
<213> Escherichia virus MS2
<400> 113
gcgcacatga ggatcaccca tgtgc 25
<210> 114
<211> 116
<212> PRT
<213> Escherichia virus MS2
<400> 114
Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn Gly Gly Thr
1 5 10 15
Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Ile Ala Glu
20 25 30
Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr Cys Ser Val
35 40 45
Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile Lys Val Glu Val
50 55 60
Pro Lys Gly Ala Trp Arg Ser Tyr Leu Asn Met Glu Leu Thr Ile Pro
65 70 75 80
Ile Phe Ala Thr Asn Ser Asp Cys Glu Leu Ile Val Lys Ala Met Gln
85 90 95
Gly Leu Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile Ala Ala Asn
100 105 110
Ser Gly Ile Tyr
115
<210> 115
<211> 26
<212> DNA
<213> phage PP7
<400> 115
ataaggagtt tatatggaaa ccctta 26
<210> 116
<211> 127
<212> PRT
<213> phage PP7
<400> 116
Met Ser Lys Thr Ile Val Leu Ser Val Gly Glu Ala Thr Arg Thr Leu
1 5 10 15
Thr Glu Ile Gln Ser Thr Ala Asp Arg Gln Ile Phe Glu Glu Lys Val
20 25 30
Gly Pro Leu Val Gly Arg Leu Arg Leu Thr Ala Ser Leu Arg Gln Asn
35 40 45
Gly Ala Lys Thr Ala Tyr Arg Val Asn Leu Lys Leu Asp Gln Ala Asp
50 55 60
Trp Asp Cys Ser Thr Ser Val Cys Gly Glu Leu Pro Lys Val Arg Tyr
65 70 75 80
Thr Gln Val Trp Ser His Asp Val Thr Ile Val Ala Asn Ser Thr Glu
85 90 95
Ala Ser Arg Lys Ser Leu Tyr Asp Leu Thr Lys Ser Leu Val Ala Thr
100 105 110
Ser Gln Val Glu Asp Leu Val Val Asn Leu Val Pro Leu Gly Arg
115 120 125
<210> 117
<211> 19
<212> DNA
<213> Shigella flexneri
<400> 117
ctgaatgcct gcgagcatc 19
<210> 118
<211> 62
<212> PRT
<213> Shigella flexneri
<400> 118
Met Lys Ser Ile Arg Cys Lys Asn Cys Asn Lys Leu Leu Phe Lys Ala
1 5 10 15
Asp Ser Phe Asp His Ile Glu Ile Arg Cys Pro Arg Cys Lys Arg His
20 25 30
Ile Ile Met Leu Asn Ala Cys Glu His Pro Thr Glu Lys His Cys Gly
35 40 45
Lys Arg Glu Lys Ile Thr His Ser Asp Glu Thr Val Arg Tyr
50 55 60
<210> 119
<211> 24
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 119
Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg
1 5 10 15
Leu Lys Lys Gly Ser Gly Ser Gly
20
<210> 120
<211> 241
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 120
Glu Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
1 5 10 15
Arg Leu Lys Lys Gly Ser Gly Ser Gly Glu Glu Leu Leu Ser Lys Asn
20 25 30
Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly Ser Gly Ser
35 40 45
Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
50 55 60
Arg Leu Lys Lys Gly Ser Gly Ser Gly Glu Glu Leu Leu Ser Lys Asn
65 70 75 80
Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly Ser Gly Ser
85 90 95
Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
100 105 110
Arg Leu Lys Lys Gly Ser Gly Ser Gly Glu Glu Leu Leu Ser Lys Asn
115 120 125
Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly Ser Gly Ser
130 135 140
Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
145 150 155 160
Arg Leu Lys Lys Gly Ser Gly Ser Gly Glu Glu Leu Leu Ser Lys Asn
165 170 175
Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly Ser Gly Ser
180 185 190
Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
195 200 205
Arg Leu Lys Lys Gly Ser Gly Ser Gly Glu Glu Leu Leu Ser Lys Asn
210 215 220
Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly Ser Gly Ser
225 230 235 240
Gly
<210> 121
<211> 277
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 121
Met Gly Pro Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
1 5 10 15
Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala
20 25 30
Val Thr Thr Ser Asn Tyr Ala Ser Trp Val Gln Glu Lys Pro Gly Lys
35 40 45
Leu Phe Lys Gly Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Gly Val
50 55 60
Pro Ser Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Ala Leu
85 90 95
Trp Tyr Ser Asn His Trp Val Phe Gly Gln Gly Thr Lys Val Glu Leu
100 105 110
Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Ser Gly Gly Gly Ser Glu Val Lys Leu Leu Glu Ser Gly Gly Gly
130 135 140
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Val Ser Gly
145 150 155 160
Phe Ser Leu Thr Asp Tyr Gly Val Asn Trp Val Arg Gln Ala Pro Gly
165 170 175
Arg Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Asp Gly Ile Thr Asp
180 185 190
Tyr Asn Ser Ala Leu Lys Asp Arg Phe Ile Ile Ser Lys Asp Asn Gly
195 200 205
Lys Asn Thr Val Tyr Leu Gln Met Ser Lys Val Arg Ser Asp Asp Thr
210 215 220
Ala Leu Tyr Tyr Cys Val Thr Gly Leu Phe Asp Tyr Trp Gly Gln Gly
225 230 235 240
Thr Leu Val Thr Val Ser Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
245 250 255
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
260 265 270
Gly Gly Gly Gly Ser
275
<210> 122
<211> 11
<212> PRT
<213> unknown
<220>
<223> Mao Luoke bacterium
<400> 122
Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys
1 5 10
<210> 123
<211> 27
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 123
tttaggaatc ccttctgcag cacctgg 27
<210> 124
<211> 43
<212> RNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 124
aauuucuacu aaguguagau ggaaucccuu cugcagcacc ugg 43
<210> 125
<211> 1373
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 125
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser
290 295 300
Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser
305 310 315 320
Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu
325 330 335
Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp
340 345 350
Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile
355 360 365
Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu
370 375 380
Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu
385 390 395 400
Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala
405 410 415
Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg
420 425 430
Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val
435 440 445
Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys
450 455 460
Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly
465 470 475 480
Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile
485 490 495
Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp
500 505 510
Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp
515 520 525
Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln
530 535 540
Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys
545 550 555 560
Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser
565 570 575
Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys
580 585 590
Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val
595 600 605
Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu
610 615 620
Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp
625 630 635 640
Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val
645 650 655
Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn
660 665 670
Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg
675 680 685
Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp
690 695 700
Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn
705 710 715 720
Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys
725 730 735
Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn
740 745 750
Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys
755 760 765
Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe
770 775 780
Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe
785 790 795 800
Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
805 810 815
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
820 825 830
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln
835 840 845
Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
850 855 860
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln
865 870 875 880
Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu
885 890 895
Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn
900 905 910
Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val
915 920 925
Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro
930 935 940
Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu
945 950 955 960
Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile
965 970 975
Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys
980 985 990
Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe
995 1000 1005
Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys
1010 1015 1020
Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile
1025 1030 1035
Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val
1040 1045 1050
His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala
1055 1060 1065
Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val
1070 1075 1080
Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys
1085 1090 1095
Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly
1100 1105 1110
Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe
1115 1120 1125
Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala
1130 1135 1140
Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu
1145 1150 1155
Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile
1160 1165 1170
Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe
1175 1180 1185
Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp
1190 1195 1200
Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg
1205 1210 1215
Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu
1220 1225 1230
Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly
1235 1240 1245
Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln
1250 1255 1260
Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu
1265 1270 1275
Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp
1280 1285 1290
Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp
1295 1300 1305
Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn
1310 1315 1320
Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp
1325 1330 1335
Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys
1340 1345 1350
Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln
1355 1360 1365
Thr Ser Val Lys His
1370
<210> 126
<211> 1375
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 126
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys
290 295 300
Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu
305 310 315 320
Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln
325 330 335
Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr
340 345 350
Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp
355 360 365
His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys
370 375 380
Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro
385 390 395 400
Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu
405 410 415
Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala
420 425 430
Glu Arg Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu
435 440 445
Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser
450 455 460
Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser
465 470 475 480
Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys
485 490 495
Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu
500 505 510
Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr
515 520 525
Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu
530 535 540
Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys
545 550 555 560
Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr
565 570 575
Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser
580 585 590
Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp
595 600 605
Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly
610 615 620
Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala
625 630 635 640
Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn
645 650 655
Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe
660 665 670
Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp
675 680 685
Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile
690 695 700
Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp
705 710 715 720
Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro
725 730 735
Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr
740 745 750
Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe
755 760 765
Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp
770 775 780
Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr
785 790 795 800
Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe
805 810 815
Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala
820 825 830
Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
835 840 845
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
850 855 860
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His
865 870 875 880
Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
885 890 895
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile
900 905 910
Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr
915 920 925
Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His
930 935 940
Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn
945 950 955 960
Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile
965 970 975
Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp
980 985 990
Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn
995 1000 1005
Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu
1010 1015 1020
Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr
1025 1030 1035
Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln
1040 1045 1050
Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val
1055 1060 1065
Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val
1070 1075 1080
Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile
1085 1090 1095
Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala
1100 1105 1110
Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu
1115 1120 1125
Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile
1130 1135 1140
Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val
1145 1150 1155
Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys
1160 1165 1170
Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp
1175 1180 1185
Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp
1190 1195 1200
Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg
1205 1210 1215
Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp
1220 1225 1230
Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys
1235 1240 1245
Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys
1250 1255 1260
Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met
1265 1270 1275
Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp
1280 1285 1290
Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe
1295 1300 1305
Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro
1310 1315 1320
Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val
1325 1330 1335
Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu
1340 1345 1350
Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr
1355 1360 1365
Ala Gln Thr Ser Val Lys His
1370 1375
<210> 127
<211> 1377
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 127
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly
290 295 300
Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys
305 310 315 320
Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln
325 330 335
Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp
340 345 350
Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp
355 360 365
Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp
370 375 380
Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn
385 390 395 400
Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln
405 410 415
Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
420 425 430
Lys Ala Glu Arg Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu Glu
435 440 445
Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe
450 455 460
Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr
465 470 475 480
Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile
485 490 495
Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn
500 505 510
Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu
515 520 525
Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe
530 535 540
Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val
545 550 555 560
Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys
565 570 575
Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu
580 585 590
Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu
595 600 605
Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly
610 615 620
Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val
625 630 635 640
Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile
645 650 655
Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu
660 665 670
Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu
675 680 685
Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu
690 695 700
Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys
705 710 715 720
Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro
725 730 735
Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met
740 745 750
Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly
755 760 765
Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu
770 775 780
Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn
785 790 795 800
Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala
805 810 815
Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu
820 825 830
Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu
835 840 845
Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly
850 855 860
Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
865 870 875 880
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
885 890 895
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser
900 905 910
Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
915 920 925
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu
930 935 940
Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys
945 950 955 960
Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr
965 970 975
Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val
980 985 990
Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile
995 1000 1005
Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser
1010 1015 1020
Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn
1025 1030 1035
Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile
1040 1045 1050
Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp
1055 1060 1065
Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser
1070 1075 1080
Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met
1085 1090 1095
Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro
1100 1105 1110
Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys
1115 1120 1125
Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe
1130 1135 1140
Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly
1145 1150 1155
Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser
1160 1165 1170
Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu
1175 1180 1185
Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg
1190 1195 1200
Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly
1205 1210 1215
Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe
1220 1225 1230
Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe
1235 1240 1245
Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu
1250 1255 1260
Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala
1265 1270 1275
Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg
1280 1285 1290
Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly
1295 1300 1305
Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile
1310 1315 1320
Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg
1325 1330 1335
Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu
1340 1345 1350
Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu
1355 1360 1365
Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 128
<211> 1379
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 128
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly
290 295 300
Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys
305 310 315 320
Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln
325 330 335
Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp
340 345 350
Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp
355 360 365
Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp
370 375 380
Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn
385 390 395 400
Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln
405 410 415
Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr
420 425 430
Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Glu Gly Tyr Thr Ser Asp
435 440 445
Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu
450 455 460
Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp
465 470 475 480
Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser
485 490 495
Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys
500 505 510
Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val
515 520 525
Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly
530 535 540
Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser
545 550 555 560
Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile
565 570 575
Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val
580 585 590
Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys
595 600 605
Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe
610 615 620
Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp
625 630 635 640
Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp
645 650 655
Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe
660 665 670
Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp
675 680 685
Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr
690 695 700
Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile
705 710 715 720
Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu
725 730 735
Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys
740 745 750
Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys
755 760 765
Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His
770 775 780
Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp
785 790 795 800
Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp
805 810 815
Ile Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser
820 825 830
Phe Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly
835 840 845
Lys Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser
850 855 860
His Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp
865 870 875 880
Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe
885 890 895
Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
900 905 910
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
915 920 925
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln
930 935 940
Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
945 950 955 960
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn
965 970 975
Pro Tyr Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile
980 985 990
Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
995 1000 1005
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1010 1015 1020
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1025 1030 1035
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1040 1045 1050
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1055 1060 1065
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1070 1075 1080
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1085 1090 1095
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1100 1105 1110
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1115 1120 1125
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1130 1135 1140
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1145 1150 1155
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1160 1165 1170
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1175 1180 1185
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1190 1195 1200
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1205 1210 1215
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1220 1225 1230
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1235 1240 1245
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1250 1255 1260
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1265 1270 1275
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1280 1285 1290
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1295 1300 1305
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1310 1315 1320
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1325 1330 1335
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1340 1345 1350
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1355 1360 1365
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 129
<211> 1373
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 129
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn
290 295 300
Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly
305 310 315 320
Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn
325 330 335
Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val
340 345 350
Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His
355 360 365
Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val
370 375 380
Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser
385 390 395 400
Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn
405 410 415
Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu
420 425 430
Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val
435 440 445
Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys
450 455 460
Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly
465 470 475 480
Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile
485 490 495
Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp
500 505 510
Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp
515 520 525
Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln
530 535 540
Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys
545 550 555 560
Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser
565 570 575
Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys
580 585 590
Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val
595 600 605
Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu
610 615 620
Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp
625 630 635 640
Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val
645 650 655
Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn
660 665 670
Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg
675 680 685
Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp
690 695 700
Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn
705 710 715 720
Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys
725 730 735
Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn
740 745 750
Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys
755 760 765
Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe
770 775 780
Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe
785 790 795 800
Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
805 810 815
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
820 825 830
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln
835 840 845
Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
850 855 860
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln
865 870 875 880
Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu
885 890 895
Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn
900 905 910
Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val
915 920 925
Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro
930 935 940
Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu
945 950 955 960
Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile
965 970 975
Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys
980 985 990
Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe
995 1000 1005
Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys
1010 1015 1020
Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile
1025 1030 1035
Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val
1040 1045 1050
His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala
1055 1060 1065
Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val
1070 1075 1080
Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys
1085 1090 1095
Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly
1100 1105 1110
Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe
1115 1120 1125
Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala
1130 1135 1140
Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu
1145 1150 1155
Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile
1160 1165 1170
Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe
1175 1180 1185
Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp
1190 1195 1200
Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg
1205 1210 1215
Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu
1220 1225 1230
Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly
1235 1240 1245
Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln
1250 1255 1260
Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu
1265 1270 1275
Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp
1280 1285 1290
Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp
1295 1300 1305
Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn
1310 1315 1320
Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp
1325 1330 1335
Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys
1340 1345 1350
Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln
1355 1360 1365
Thr Ser Val Lys His
1370
<210> 130
<211> 1375
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 130
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Glu Asn Gln Thr Thr Gln Lys Gly Gln
290 295 300
Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu
305 310 315 320
Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu
325 330 335
Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met
340 345 350
Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val
355 360 365
Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn
370 375 380
Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val
385 390 395 400
Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu
405 410 415
Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys
420 425 430
Ala Glu Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu Val Leu
435 440 445
Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser
450 455 460
Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser
465 470 475 480
Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys
485 490 495
Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu
500 505 510
Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr
515 520 525
Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu
530 535 540
Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys
545 550 555 560
Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr
565 570 575
Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser
580 585 590
Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp
595 600 605
Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly
610 615 620
Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala
625 630 635 640
Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn
645 650 655
Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe
660 665 670
Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp
675 680 685
Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile
690 695 700
Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp
705 710 715 720
Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro
725 730 735
Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr
740 745 750
Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe
755 760 765
Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp
770 775 780
Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr
785 790 795 800
Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe
805 810 815
Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala
820 825 830
Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
835 840 845
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
850 855 860
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His
865 870 875 880
Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
885 890 895
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile
900 905 910
Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr
915 920 925
Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His
930 935 940
Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn
945 950 955 960
Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile
965 970 975
Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp
980 985 990
Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn
995 1000 1005
Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu
1010 1015 1020
Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr
1025 1030 1035
Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln
1040 1045 1050
Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val
1055 1060 1065
Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val
1070 1075 1080
Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile
1085 1090 1095
Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala
1100 1105 1110
Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu
1115 1120 1125
Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile
1130 1135 1140
Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val
1145 1150 1155
Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys
1160 1165 1170
Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp
1175 1180 1185
Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp
1190 1195 1200
Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg
1205 1210 1215
Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp
1220 1225 1230
Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys
1235 1240 1245
Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys
1250 1255 1260
Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met
1265 1270 1275
Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp
1280 1285 1290
Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe
1295 1300 1305
Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro
1310 1315 1320
Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val
1325 1330 1335
Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu
1340 1345 1350
Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr
1355 1360 1365
Ala Gln Thr Ser Val Lys His
1370 1375
<210> 131
<211> 1377
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 131
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
290 295 300
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
305 310 315 320
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
325 330 335
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
340 345 350
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
355 360 365
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
370 375 380
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
385 390 395 400
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
405 410 415
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
420 425 430
Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu Glu
435 440 445
Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe
450 455 460
Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr
465 470 475 480
Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile
485 490 495
Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn
500 505 510
Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr Glu
515 520 525
Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe
530 535 540
Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val
545 550 555 560
Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys
565 570 575
Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu
580 585 590
Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu
595 600 605
Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly
610 615 620
Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val
625 630 635 640
Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile
645 650 655
Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu
660 665 670
Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu
675 680 685
Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu
690 695 700
Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys
705 710 715 720
Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro
725 730 735
Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met
740 745 750
Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly
755 760 765
Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu
770 775 780
Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn
785 790 795 800
Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala
805 810 815
Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu
820 825 830
Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu
835 840 845
Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly
850 855 860
Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
865 870 875 880
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
885 890 895
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser
900 905 910
Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
915 920 925
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu
930 935 940
Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys
945 950 955 960
Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr
965 970 975
Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val
980 985 990
Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile
995 1000 1005
Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr His Ser
1010 1015 1020
Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn
1025 1030 1035
Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile
1040 1045 1050
Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp
1055 1060 1065
Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser
1070 1075 1080
Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu Lys Met
1085 1090 1095
Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser Asn Pro
1100 1105 1110
Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys
1115 1120 1125
Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe Ile Phe
1130 1135 1140
Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly
1145 1150 1155
Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser
1160 1165 1170
Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu
1175 1180 1185
Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg
1190 1195 1200
Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly
1205 1210 1215
Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe
1220 1225 1230
Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe
1235 1240 1245
Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu
1250 1255 1260
Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala
1265 1270 1275
Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly Arg
1280 1285 1290
Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp Gly
1295 1300 1305
Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile
1310 1315 1320
Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg
1325 1330 1335
Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu
1340 1345 1350
Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu
1355 1360 1365
Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 132
<211> 1379
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 132
Met Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys
1 5 10 15
Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile
20 25 30
Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr
35 40 45
Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn
50 55 60
Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser
65 70 75 80
Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu
85 90 95
Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly
100 105 110
Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile
115 120 125
Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser
130 135 140
Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu
145 150 155 160
Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys
165 170 175
Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu
180 185 190
Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu
195 200 205
Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu
210 215 220
Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala
225 230 235 240
Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu
245 250 255
Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro
260 265 270
Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu
275 280 285
Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
290 295 300
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
305 310 315 320
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
325 330 335
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
340 345 350
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
355 360 365
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
370 375 380
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
385 390 395 400
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
405 410 415
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
420 425 430
Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Gly Tyr Thr Ser Asp
435 440 445
Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu
450 455 460
Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp
465 470 475 480
Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser
485 490 495
Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys
500 505 510
Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val
515 520 525
Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly
530 535 540
Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser
545 550 555 560
Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile
565 570 575
Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val
580 585 590
Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys
595 600 605
Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe
610 615 620
Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp
625 630 635 640
Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp
645 650 655
Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe
660 665 670
Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp
675 680 685
Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr
690 695 700
Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile
705 710 715 720
Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu
725 730 735
Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys
740 745 750
Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys
755 760 765
Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His
770 775 780
Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp
785 790 795 800
Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp
805 810 815
Ile Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser
820 825 830
Phe Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly
835 840 845
Lys Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser
850 855 860
His Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp
865 870 875 880
Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe
885 890 895
Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
900 905 910
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
915 920 925
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln
930 935 940
Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
945 950 955 960
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn
965 970 975
Pro Tyr Val Ile Gly Ile Asp Arg Gly Glu Arg Asn Leu Leu Tyr Ile
980 985 990
Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
995 1000 1005
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1010 1015 1020
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1025 1030 1035
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1040 1045 1050
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1055 1060 1065
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1070 1075 1080
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1085 1090 1095
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1100 1105 1110
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1115 1120 1125
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1130 1135 1140
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1145 1150 1155
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1160 1165 1170
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1175 1180 1185
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1190 1195 1200
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1205 1210 1215
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1220 1225 1230
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1235 1240 1245
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1250 1255 1260
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1265 1270 1275
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1280 1285 1290
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1295 1300 1305
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1310 1315 1320
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1325 1330 1335
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1340 1345 1350
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1355 1360 1365
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His
1370 1375
<210> 133
<211> 46
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 133
gatgctttag gaatcccttc tgcagcacct gggcgcaggt cacgag 46
<210> 134
<211> 99
<212> DNA
<213> Chile person
<400> 134
cctccggatt cctaccccga aaagacagtg gttaggacag ggatcaccgg ggtgacaccc 60
cacctcccct gtctattttc atgggtcttg gtctcggtg 99
<210> 135
<211> 99
<212> DNA
<213> Chile person
<400> 135
ggaggcctaa ggatggggct tttctgtcac caatcctgtc cctagtggcc ccactgtggg 60
gtggagggga cagataaaag tacccagaac cagagccac 99
<210> 136
<211> 20
<212> DNA
<213> Chile person
<400> 136
gcattttcag gaggaagcga 20
<210> 137
<211> 23
<212> DNA
<213> Chile person
<400> 137
caggaggaag cgatggcttc aga 23
<210> 138
<211> 20
<212> DNA
<213> Chile person
<400> 138
gtcccctcca ccccacagtg 20
<210> 139
<211> 23
<212> DNA
<213> Chile person
<400> 139
tctgtcccct ccaccccaca gtg 23
<210> 140
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 140
gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 60
accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 120
agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 180
acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 240
ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 300
gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 360
atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 420
ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 480
atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 540
gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 600
aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 660
ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggaaacctg 720
attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 780
gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 840
atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 900
ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 960
atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1020
cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1080
tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1140
aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1200
cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1260
attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1320
aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1380
ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1440
gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1500
ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1560
aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1620
ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1680
aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1740
ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1800
aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1860
accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 1920
ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 1980
ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2040
ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2100
ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2160
gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2220
aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2280
gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2340
aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2400
gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2460
atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2520
gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2580
aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2640
tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2700
aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2760
gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2820
aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 2880
ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 2940
caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3000
cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3060
atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3120
atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3180
ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3240
accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3300
acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3360
agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3420
tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3480
gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3540
ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3600
tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3660
aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3720
tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3780
cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3840
ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 3900
atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 3960
gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 4020
gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 4080
ctgtctcagc tgggaggtga c 4101
<210> 141
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 141
gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 60
accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 120
agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 180
acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 240
ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 300
gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 360
atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 420
ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 480
atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 540
gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 600
aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 660
ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggaaacctg 720
attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 780
gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 840
atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 900
ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 960
atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1020
cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1080
tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1140
aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1200
cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1260
attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1320
aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1380
ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1440
gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1500
ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1560
aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1620
ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1680
aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1740
ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1800
aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1860
accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 1920
ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 1980
ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2040
ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2100
ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2160
gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2220
aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2280
gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2340
aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2400
gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2460
atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2520
gtgcctcaga gctttctggc cgacgactcc atcgacaaca aggtgctgac cagaagcgac 2580
aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2640
tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2700
aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2760
gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2820
aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 2880
ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 2940
caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3000
cctgccctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3060
atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3120
atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaaggcccct 3180
ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3240
accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3300
acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3360
agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3420
tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3480
gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3540
ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3600
tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3660
aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3720
tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3780
cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3840
ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 3900
atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 3960
gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 4020
gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 4080
ctgtctcagc tgggaggtga c 4101
<210> 142
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 142
gacaagaagt acagcatcgg cctggccatc ggcaccaact ctgtgggctg ggccgtgatc 60
accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 120
agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 180
acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 240
ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 300
gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 360
atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 420
ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 480
atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 540
gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 600
aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 660
ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggaaacctg 720
attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 780
gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 840
atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 900
ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 960
atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1020
cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1080
tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1140
aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1200
cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1260
attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1320
aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1380
ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1440
gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1500
ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1560
aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1620
ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1680
aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1740
ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1800
aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1860
accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 1920
ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 1980
ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2040
ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2100
ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2160
gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2220
aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2280
gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2340
aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2400
gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2460
atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2520
gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2580
aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2640
tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2700
aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2760
gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2820
aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 2880
ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 2940
caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3000
cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3060
atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3120
atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3180
ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3240
accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3300
acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3360
agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3420
tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3480
gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3540
ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3600
tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3660
aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3720
tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3780
cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3840
ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 3900
atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 3960
gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 4020
gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 4080
ctgtctcagc tgggaggtga c 4101
<210> 143
<211> 4101
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of Polynucleotide
<400> 143
gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 60
accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 120
agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 180
acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 240
ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 300
gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 360
atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 420
ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 480
atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 540
gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 600
aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 660
ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggaaacctg 720
attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 780
gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 840
atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 900
ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 960
atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1020
cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1080
tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1140
aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1200
cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1260
attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1320
aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1380
ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1440
gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1500
ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1560
aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1620
ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1680
aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1740
ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1800
aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1860
accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 1920
ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 1980
ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2040
ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2100
ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2160
gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2220
aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2280
gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2340
aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2400
gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2460
atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggacgccatc 2520
gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2580
aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2640
tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2700
aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2760
gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2820
aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 2880
ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 2940
caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3000
cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3060
atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3120
atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3180
ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3240
accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3300
acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3360
agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3420
tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3480
gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3540
ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3600
tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3660
aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3720
tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3780
cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3840
ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 3900
atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 3960
gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 4020
gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 4080
ctgtctcagc tgggaggtga c 4101
<210> 144
<211> 23
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 144
accttggaga cggcgactct ctg 23
<210> 145
<211> 23
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 145
gcggatgttc caatcagtac gca 23
<210> 146
<211> 23
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 146
tgtcaccaat cctgtcccta gtg 23
<210> 147
<211> 23
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 147
tctgtcccct ccaccccaca gtg 23
<210> 148
<211> 23
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 148
tatgagttac aacgaacacc tca 23
<210> 149
<211> 23
<212> DNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 149
cacgtctcat atgccccttg gca 23
<210> 150
<211> 23
<212> RNA
<213> artificial sequence
<220>
<223> Synthesis of oligonucleotide
<400> 150
ugucaccaau ccugucccua gug 23
<210> 151
<211> 1129
<212> PRT
<213> acid soil alicyclic acid Bacillus huashlar (Alicyclobacillus acidoterrestris)
<400> 151
Met Ala Val Lys Ser Ile Lys Val Lys Leu Arg Leu Asp Asp Met Pro
1 5 10 15
Glu Ile Arg Ala Gly Leu Trp Lys Leu His Lys Glu Val Asn Ala Gly
20 25 30
Val Arg Tyr Tyr Thr Glu Trp Leu Ser Leu Leu Arg Gln Glu Asn Leu
35 40 45
Tyr Arg Arg Ser Pro Asn Gly Asp Gly Glu Gln Glu Cys Asp Lys Thr
50 55 60
Ala Glu Glu Cys Lys Ala Glu Leu Leu Glu Arg Leu Arg Ala Arg Gln
65 70 75 80
Val Glu Asn Gly His Arg Gly Pro Ala Gly Ser Asp Asp Glu Leu Leu
85 90 95
Gln Leu Ala Arg Gln Leu Tyr Glu Leu Leu Val Pro Gln Ala Ile Gly
100 105 110
Ala Lys Gly Asp Ala Gln Gln Ile Ala Arg Lys Phe Leu Ser Pro Leu
115 120 125
Ala Asp Lys Asp Ala Val Gly Gly Leu Gly Ile Ala Lys Ala Gly Asn
130 135 140
Lys Pro Arg Trp Val Arg Met Arg Glu Ala Gly Glu Pro Gly Trp Glu
145 150 155 160
Glu Glu Lys Glu Lys Ala Glu Thr Arg Lys Ser Ala Asp Arg Thr Ala
165 170 175
Asp Val Leu Arg Ala Leu Ala Asp Phe Gly Leu Lys Pro Leu Met Arg
180 185 190
Val Tyr Thr Asp Ser Glu Met Ser Ser Val Glu Trp Lys Pro Leu Arg
195 200 205
Lys Gly Gln Ala Val Arg Thr Trp Asp Arg Asp Met Phe Gln Gln Ala
210 215 220
Ile Glu Arg Met Met Ser Trp Glu Ser Trp Asn Gln Arg Val Gly Gln
225 230 235 240
Glu Tyr Ala Lys Leu Val Glu Gln Lys Asn Arg Phe Glu Gln Lys Asn
245 250 255
Phe Val Gly Gln Glu His Leu Val His Leu Val Asn Gln Leu Gln Gln
260 265 270
Asp Met Lys Glu Ala Ser Pro Gly Leu Glu Ser Lys Glu Gln Thr Ala
275 280 285
His Tyr Val Thr Gly Arg Ala Leu Arg Gly Ser Asp Lys Val Phe Glu
290 295 300
Lys Trp Gly Lys Leu Ala Pro Asp Ala Pro Phe Asp Leu Tyr Asp Ala
305 310 315 320
Glu Ile Lys Asn Val Gln Arg Arg Asn Thr Arg Arg Phe Gly Ser His
325 330 335
Asp Leu Phe Ala Lys Leu Ala Glu Pro Glu Tyr Gln Ala Leu Trp Arg
340 345 350
Glu Asp Ala Ser Phe Leu Thr Arg Tyr Ala Val Tyr Asn Ser Ile Leu
355 360 365
Arg Lys Leu Asn His Ala Lys Met Phe Ala Thr Phe Thr Leu Pro Asp
370 375 380
Ala Thr Ala His Pro Ile Trp Thr Arg Phe Asp Lys Leu Gly Gly Asn
385 390 395 400
Leu His Gln Tyr Thr Phe Leu Phe Asn Glu Phe Gly Glu Arg Arg His
405 410 415
Ala Ile Arg Phe His Lys Leu Leu Lys Val Glu Asn Gly Val Ala Arg
420 425 430
Glu Val Asp Asp Val Thr Val Pro Ile Ser Met Ser Glu Gln Leu Asp
435 440 445
Asn Leu Leu Pro Arg Asp Pro Asn Glu Pro Ile Ala Leu Tyr Phe Arg
450 455 460
Asp Tyr Gly Ala Glu Gln His Phe Thr Gly Glu Phe Gly Gly Ala Lys
465 470 475 480
Ile Gln Cys Arg Arg Asp Gln Leu Ala His Met His Arg Arg Arg Gly
485 490 495
Ala Arg Asp Val Tyr Leu Asn Val Ser Val Arg Val Gln Ser Gln Ser
500 505 510
Glu Ala Arg Gly Glu Arg Arg Pro Pro Tyr Ala Ala Val Phe Arg Leu
515 520 525
Val Gly Asp Asn His Arg Ala Phe Val His Phe Asp Lys Leu Ser Asp
530 535 540
Tyr Leu Ala Glu His Pro Asp Asp Gly Lys Leu Gly Ser Glu Gly Leu
545 550 555 560
Leu Ser Gly Leu Arg Val Met Ser Val Asp Leu Gly Leu Arg Thr Ser
565 570 575
Ala Ser Ile Ser Val Phe Arg Val Ala Arg Lys Asp Glu Leu Lys Pro
580 585 590
Asn Ser Lys Gly Arg Val Pro Phe Phe Phe Pro Ile Lys Gly Asn Asp
595 600 605
Asn Leu Val Ala Val His Glu Arg Ser Gln Leu Leu Lys Leu Pro Gly
610 615 620
Glu Thr Glu Ser Lys Asp Leu Arg Ala Ile Arg Glu Glu Arg Gln Arg
625 630 635 640
Thr Leu Arg Gln Leu Arg Thr Gln Leu Ala Tyr Leu Arg Leu Leu Val
645 650 655
Arg Cys Gly Ser Glu Asp Val Gly Arg Arg Glu Arg Ser Trp Ala Lys
660 665 670
Leu Ile Glu Gln Pro Val Asp Ala Ala Asn His Met Thr Pro Asp Trp
675 680 685
Arg Glu Ala Phe Glu Asn Glu Leu Gln Lys Leu Lys Ser Leu His Gly
690 695 700
Ile Cys Ser Asp Lys Glu Trp Met Asp Ala Val Tyr Glu Ser Val Arg
705 710 715 720
Arg Val Trp Arg His Met Gly Lys Gln Val Arg Asp Trp Arg Lys Asp
725 730 735
Val Arg Ser Gly Glu Arg Pro Lys Ile Arg Gly Tyr Ala Lys Asp Val
740 745 750
Val Gly Gly Asn Ser Ile Glu Gln Ile Glu Tyr Leu Glu Arg Gln Tyr
755 760 765
Lys Phe Leu Lys Ser Trp Ser Phe Phe Gly Lys Val Ser Gly Gln Val
770 775 780
Ile Arg Ala Glu Lys Gly Ser Arg Phe Ala Ile Thr Leu Arg Glu His
785 790 795 800
Ile Asp His Ala Lys Glu Asp Arg Leu Lys Lys Leu Ala Asp Arg Ile
805 810 815
Ile Met Glu Ala Leu Gly Tyr Val Tyr Ala Leu Asp Glu Arg Gly Lys
820 825 830
Gly Lys Trp Val Ala Lys Tyr Pro Pro Cys Gln Leu Ile Leu Leu Glu
835 840 845
Glu Leu Ser Glu Tyr Gln Phe Asn Asn Asp Arg Pro Pro Ser Glu Asn
850 855 860
Asn Gln Leu Met Gln Trp Ser His Arg Gly Val Phe Gln Glu Leu Ile
865 870 875 880
Asn Gln Ala Gln Val His Asp Leu Leu Val Gly Thr Met Tyr Ala Ala
885 890 895
Phe Ser Ser Arg Phe Asp Ala Arg Thr Gly Ala Pro Gly Ile Arg Cys
900 905 910
Arg Arg Val Pro Ala Arg Cys Thr Gln Glu His Asn Pro Glu Pro Phe
915 920 925
Pro Trp Trp Leu Asn Lys Phe Val Val Glu His Thr Leu Asp Ala Cys
930 935 940
Pro Leu Arg Ala Asp Asp Leu Ile Pro Thr Gly Glu Gly Glu Ile Phe
945 950 955 960
Val Ser Pro Phe Ser Ala Glu Glu Gly Asp Phe His Gln Ile His Ala
965 970 975
Asp Leu Asn Ala Ala Gln Asn Leu Gln Gln Arg Leu Trp Ser Asp Phe
980 985 990
Asp Ile Ser Gln Ile Arg Leu Arg Cys Asp Trp Gly Glu Val Asp Gly
995 1000 1005
Glu Leu Val Leu Ile Pro Arg Leu Thr Gly Lys Arg Thr Ala Asp
1010 1015 1020
Ser Tyr Ser Asn Lys Val Phe Tyr Thr Asn Thr Gly Val Thr Tyr
1025 1030 1035
Tyr Glu Arg Glu Arg Gly Lys Lys Arg Arg Lys Val Phe Ala Gln
1040 1045 1050
Glu Lys Leu Ser Glu Glu Glu Ala Glu Leu Leu Val Glu Ala Asp
1055 1060 1065
Glu Ala Arg Glu Lys Ser Val Val Leu Met Arg Asp Pro Ser Gly
1070 1075 1080
Ile Ile Asn Arg Gly Asn Trp Thr Arg Gln Lys Glu Phe Trp Ser
1085 1090 1095
Met Val Asn Gln Arg Ile Glu Gly Tyr Leu Val Lys Gln Ile Arg
1100 1105 1110
Ser Arg Val Pro Leu Gln Asp Ser Ala Cys Glu Asn Thr Gly Asp
1115 1120 1125
Ile
<210> 152
<211> 198
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 152
Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met Asp Pro His Ile
1 5 10 15
Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His Lys Thr Tyr Leu
20 25 30
Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser Val Lys Met Asp
35 40 45
Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn Leu Leu Cys Gly
50 55 60
Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp Leu Val Pro Ser
65 70 75 80
Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr Trp Phe Ile Ser
85 90 95
Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu Val Arg Ala Phe
100 105 110
Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe Ala Ala Arg Ile
115 120 125
Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln Met Leu Arg Asp
130 135 140
Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu Phe Lys His Cys
145 150 155 160
Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe Gln Pro Trp Asp
165 170 175
Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg Leu Arg Ala Ile
180 185 190
Leu Gln Asn Gln Gly Asn
195
<210> 153
<211> 17
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 153
Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser
1 5 10 15
Met
<210> 154
<211> 13
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 154
Gly Ser Pro Lys Lys Lys Arg Lys Val Ser Gly Gly Ser
1 5 10
<210> 155
<211> 166
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 155
Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr
1 5 10 15
Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val Gly Ala Val
20 25 30
Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala Ile
35 40 45
Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln
50 55 60
Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr
65 70 75 80
Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser
85 90 95
Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ser Lys Arg Gly Ala
100 105 110
Ala Gly Ser Leu Met Asn Val Leu Asn Tyr Pro Gly Met Asn His Arg
115 120 125
Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu
130 135 140
Cys Asp Phe Tyr Arg Met Pro Arg Gln Val Phe Asn Ala Gln Lys Lys
145 150 155 160
Ala Gln Ser Ser Ile Asn
165
<210> 156
<211> 397
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 156
Gly Ser Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Gly
1 5 10 15
Gly Ser Gly Gly Ser Gly Ser Glu Ala Ser Pro Ala Ser Gly Pro Arg
20 25 30
His Leu Met Asp Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile
35 40 45
Gly Arg His Lys Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn
50 55 60
Gly Thr Ser Val Lys Met Asp Gln His Arg Gly Phe Leu His Asn Gln
65 70 75 80
Ala Lys Asn Leu Leu Cys Gly Phe Tyr Gly Arg His Ala Glu Leu Arg
85 90 95
Phe Leu Asp Leu Val Pro Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr
100 105 110
Arg Val Thr Trp Phe Ile Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys
115 120 125
Ala Gly Glu Val Arg Ala Phe Leu Gln Glu Asn Thr His Val Arg Leu
130 135 140
Arg Ile Phe Ala Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu
145 150 155 160
Ala Leu Gln Met Leu Arg Asp Ala Gly Ala Gln Val Ser Ile Met Thr
165 170 175
Tyr Asp Glu Phe Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly
180 185 190
Cys Pro Phe Gln Pro Trp Asp Gly Leu Asp Glu His Ser Gln Ala Leu
195 200 205
Ser Gly Arg Leu Arg Ala Ile Leu Gln Asn Gln Gly Asn Gly Gly Gly
210 215 220
Gly Ser Thr Asn Leu Ser Asp Ile Ile Glu Lys Glu Thr Gly Lys Gln
225 230 235 240
Leu Val Ile Gln Glu Ser Ile Leu Met Leu Pro Glu Glu Val Glu Glu
245 250 255
Val Ile Gly Asn Lys Pro Glu Ser Asp Ile Leu Val His Thr Ala Tyr
260 265 270
Asp Glu Ser Thr Asp Glu Asn Val Met Leu Leu Thr Ser Asp Ala Pro
275 280 285
Glu Tyr Lys Pro Trp Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn
290 295 300
Lys Ile Lys Met Leu Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Tyr
305 310 315 320
Lys Leu Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu
325 330 335
Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn
340 345 350
Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr
355 360 365
Phe Thr Val Thr Glu Ser Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser
370 375 380
Glu Phe Glu Pro Lys Lys Lys Arg Lys Val Gly Ser Gly
385 390 395
<210> 157
<211> 1787
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 157
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser
20 25 30
Lys Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn
35 40 45
Ile Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp
50 55 60
Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile
65 70 75 80
Asn Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile
85 90 95
Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu
100 105 110
Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys
115 120 125
Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr
130 135 140
Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn
145 150 155 160
Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg
165 170 175
Glu Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg
180 185 190
Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe
195 200 205
Glu Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys
210 215 220
Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly
225 230 235 240
Glu Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn
245 250 255
Ala Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly
260 265 270
Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu
275 280 285
Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser
290 295 300
Leu Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln
305 310 315 320
Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly
325 330 335
Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn
340 345 350
Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly
355 360 365
Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp
370 375 380
Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser
385 390 395 400
Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser
405 410 415
Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp
420 425 430
Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn
435 440 445
Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Tyr Thr Ser Asp Glu
450 455 460
Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile
465 470 475 480
Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu
485 490 495
Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr
500 505 510
Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp
515 520 525
Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr
530 535 540
Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser
545 550 555 560
Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val
565 570 575
Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr
580 585 590
Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu
595 600 605
Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp
610 615 620
Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe
625 630 635 640
Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe
645 650 655
Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala
660 665 670
Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys
675 680 685
Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys
690 695 700
Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr
705 710 715 720
Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp
725 730 735
Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu
740 745 750
Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp
755 760 765
Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn
770 775 780
Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys
785 790 795 800
Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser
805 810 815
Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile
820 825 830
Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe
835 840 845
Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys
850 855 860
Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His
865 870 875 880
Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu
885 890 895
Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met
900 905 910
Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn
915 920 925
Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr
930 935 940
Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr
945 950 955 960
Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe
965 970 975
Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro
980 985 990
Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val
995 1000 1005
Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
1010 1015 1020
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1025 1030 1035
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1040 1045 1050
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1055 1060 1065
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1070 1075 1080
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1085 1090 1095
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1100 1105 1110
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1115 1120 1125
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1130 1135 1140
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1145 1150 1155
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1160 1165 1170
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1175 1180 1185
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1190 1195 1200
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1205 1210 1215
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1220 1225 1230
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1235 1240 1245
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1250 1255 1260
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1265 1270 1275
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1280 1285 1290
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1295 1300 1305
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1310 1315 1320
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1325 1330 1335
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1340 1345 1350
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1355 1360 1365
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1370 1375 1380
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His Gly Gly Gly Gly
1385 1390 1395
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Pro Lys Lys
1400 1405 1410
Lys Arg Lys Val Ala Ala Ala Gly Ser Glu Glu Leu Leu Ser Lys
1415 1420 1425
Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly Ser
1430 1435 1440
Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Ser Gly
1445 1450 1455
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu Leu Leu Ser
1460 1465 1470
Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly
1475 1480 1485
Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Ser
1490 1495 1500
Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu Leu Leu
1505 1510 1515
Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys
1520 1525 1530
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly
1535 1540 1545
Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu Leu
1550 1555 1560
Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys
1565 1570 1575
Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser
1580 1585 1590
Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu
1595 1600 1605
Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu
1610 1615 1620
Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly
1625 1630 1635
Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu
1640 1645 1650
Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg
1655 1660 1665
Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser
1670 1675 1680
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly
1685 1690 1695
Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
1700 1705 1710
Arg Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly
1715 1720 1725
Ser Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser
1730 1735 1740
Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val
1745 1750 1755
Ala Arg Leu Lys Lys Ser Gly Gly Ser Lys Arg Thr Ala Asp Gly
1760 1765 1770
Ser Glu Phe Glu Pro Lys Lys Lys Arg Lys Val Gly Ser Gly
1775 1780 1785
<210> 158
<211> 1787
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 158
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser
20 25 30
Lys Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn
35 40 45
Ile Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp
50 55 60
Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile
65 70 75 80
Asn Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile
85 90 95
Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu
100 105 110
Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys
115 120 125
Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr
130 135 140
Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn
145 150 155 160
Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg
165 170 175
Glu Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg
180 185 190
Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe
195 200 205
Glu Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys
210 215 220
Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly
225 230 235 240
Glu Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn
245 250 255
Ala Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly
260 265 270
Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu
275 280 285
Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser
290 295 300
Leu Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
305 310 315 320
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
325 330 335
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
340 345 350
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
355 360 365
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
370 375 380
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
385 390 395 400
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
405 410 415
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
420 425 430
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
435 440 445
Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Gly Tyr Thr Ser Asp Glu
450 455 460
Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile
465 470 475 480
Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu
485 490 495
Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile Ser Thr
500 505 510
Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp Lys Trp
515 520 525
Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val Val Thr
530 535 540
Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser
545 550 555 560
Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val
565 570 575
Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr
580 585 590
Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe Val Leu
595 600 605
Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met Lys Asp
610 615 620
Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe
625 630 635 640
Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe
645 650 655
Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr Asp Ala
660 665 670
Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys
675 680 685
Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys Asp Lys
690 695 700
Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr
705 710 715 720
Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp
725 730 735
Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu
740 745 750
Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys Lys Trp
755 760 765
Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn
770 775 780
Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys His Lys
785 790 795 800
Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser
805 810 815
Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile
820 825 830
Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe
835 840 845
Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys
850 855 860
Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His
865 870 875 880
Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu
885 890 895
Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met
900 905 910
Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn
915 920 925
Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr
930 935 940
Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr
945 950 955 960
Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe
965 970 975
Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp Asn Pro
980 985 990
Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val
995 1000 1005
Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser Leu Asn
1010 1015 1020
Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr Asp Tyr
1025 1030 1035
His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu Ala Arg
1040 1045 1050
Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys Ala Gly
1055 1060 1065
Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val Glu Lys
1070 1075 1080
Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly Phe Lys
1085 1090 1095
Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys Phe Glu
1100 1105 1110
Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys Lys Ser
1115 1120 1125
Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile Thr
1130 1135 1140
Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe
1145 1150 1155
Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser
1160 1165 1170
Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala
1175 1180 1185
Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val
1190 1195 1200
Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe
1205 1210 1215
Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu Tyr Ser
1220 1225 1230
Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn
1235 1240 1245
Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu
1250 1255 1260
Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg
1265 1270 1275
Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe
1280 1285 1290
Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr
1295 1300 1305
Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser
1310 1315 1320
Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn
1325 1330 1335
Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile
1340 1345 1350
Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu
1355 1360 1365
Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu
1370 1375 1380
Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His Gly Gly Gly Gly
1385 1390 1395
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Pro Lys Lys
1400 1405 1410
Lys Arg Lys Val Ala Ala Ala Gly Ser Glu Glu Leu Leu Ser Lys
1415 1420 1425
Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly Ser
1430 1435 1440
Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Ser Gly
1445 1450 1455
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu Leu Leu Ser
1460 1465 1470
Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Gly
1475 1480 1485
Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Ser
1490 1495 1500
Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu Leu Leu
1505 1510 1515
Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys
1520 1525 1530
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly
1535 1540 1545
Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu Leu
1550 1555 1560
Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys
1565 1570 1575
Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser
1580 1585 1590
Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu
1595 1600 1605
Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu
1610 1615 1620
Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly
1625 1630 1635
Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu
1640 1645 1650
Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg
1655 1660 1665
Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser
1670 1675 1680
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly
1685 1690 1695
Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
1700 1705 1710
Arg Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly
1715 1720 1725
Ser Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser
1730 1735 1740
Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val
1745 1750 1755
Ala Arg Leu Lys Lys Ser Gly Gly Ser Lys Arg Thr Ala Asp Gly
1760 1765 1770
Ser Glu Phe Glu Pro Lys Lys Lys Arg Lys Val Gly Ser Gly
1775 1780 1785
<210> 159
<211> 1789
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 159
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser
20 25 30
Lys Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn
35 40 45
Ile Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp
50 55 60
Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile
65 70 75 80
Asn Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile
85 90 95
Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu
100 105 110
Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys
115 120 125
Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr
130 135 140
Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn
145 150 155 160
Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg
165 170 175
Glu Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg
180 185 190
Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe
195 200 205
Glu Lys Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys
210 215 220
Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly
225 230 235 240
Glu Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn
245 250 255
Ala Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly
260 265 270
Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu
275 280 285
Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser
290 295 300
Leu Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln Thr Thr Gln Lys
305 310 315 320
Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile
325 330 335
Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr
340 345 350
Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg
355 360 365
Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr
370 375 380
Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile
385 390 395 400
Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp
405 410 415
Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg
420 425 430
Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu
435 440 445
Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Glu Gly Tyr Thr Ser
450 455 460
Asp Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys Asn Ser
465 470 475 480
Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys Asn Phe
485 490 495
Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro Ala Ile
500 505 510
Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile Arg Asp
515 520 525
Lys Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys Ala Val
530 535 540
Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys Lys Ile
545 550 555 560
Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala Asp Leu
565 570 575
Ser Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val Asp Glu
580 585 590
Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala Asp Phe
595 600 605
Val Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala Ile Met
610 615 620
Lys Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile Lys Ala
625 630 635 640
Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe Tyr Gly
645 650 655
Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His Ile Tyr
660 665 670
Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys Asp Lys
675 680 685
Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp Asp Lys
690 695 700
Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly Ser Lys
705 710 715 720
Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu Gln Lys
725 730 735
Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn Tyr Lys
740 745 750
Leu Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe Ser Lys
755 760 765
Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys Ile Tyr
770 775 780
Lys Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu Asn Asp Cys
785 790 795 800
His Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser Arg Tyr Pro Lys
805 810 815
Trp Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys
820 825 830
Asp Ile Ala Gly Phe Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val
835 840 845
Ser Phe Glu Ser Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu
850 855 860
Gly Lys Leu Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys
865 870 875 880
Ser His Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe
885 890 895
Asp Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu
900 905 910
Phe Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro
915 920 925
Ala Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr
930 935 940
Thr Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp
945 950 955 960
Gln Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn
965 970 975
Ile Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp
980 985 990
Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu Tyr
995 1000 1005
Ile Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr Ser
1010 1015 1020
Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys Thr
1025 1030 1035
Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe Glu
1040 1045 1050
Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu Lys
1055 1060 1065
Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu Val
1070 1075 1080
Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser Gly
1085 1090 1095
Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln Lys
1100 1105 1110
Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys
1115 1120 1125
Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln
1130 1135 1140
Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn
1145 1150 1155
Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp
1160 1165 1170
Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser
1175 1180 1185
Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met
1190 1195 1200
Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys
1205 1210 1215
Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys Leu
1220 1225 1230
Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys
1235 1240 1245
Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr
1250 1255 1260
Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp
1265 1270 1275
Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser
1280 1285 1290
Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser
1295 1300 1305
Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys
1310 1315 1320
Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln
1325 1330 1335
Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr
1340 1345 1350
Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys
1355 1360 1365
Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn
1370 1375 1380
Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His Gly Gly
1385 1390 1395
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Pro
1400 1405 1410
Lys Lys Lys Arg Lys Val Ala Ala Ala Gly Ser Glu Glu Leu Leu
1415 1420 1425
Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys
1430 1435 1440
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly
1445 1450 1455
Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu Leu
1460 1465 1470
Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys
1475 1480 1485
Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser
1490 1495 1500
Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu Glu
1505 1510 1515
Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu
1520 1525 1530
Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly
1535 1540 1545
Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Glu
1550 1555 1560
Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg
1565 1570 1575
Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser
1580 1585 1590
Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly
1595 1600 1605
Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala
1610 1615 1620
Arg Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly
1625 1630 1635
Ser Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser
1640 1645 1650
Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val
1655 1660 1665
Ala Arg Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly
1670 1675 1680
Gly Ser Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly
1685 1690 1695
Ser Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu
1700 1705 1710
Val Ala Arg Leu Lys Lys Gly Ser Gly Ser Gly Gly Ser Gly Ser
1715 1720 1725
Gly Gly Ser Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser
1730 1735 1740
Gly Ser Gly Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn
1745 1750 1755
Glu Val Ala Arg Leu Lys Lys Ser Gly Gly Ser Lys Arg Thr Ala
1760 1765 1770
Asp Gly Ser Glu Phe Glu Pro Lys Lys Lys Arg Lys Val Gly Ser
1775 1780 1785
Gly
<210> 160
<211> 1739
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 160
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met Asp
20 25 30
Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His Lys
35 40 45
Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser Val
50 55 60
Lys Met Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn Leu
65 70 75 80
Leu Cys Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp Leu
85 90 95
Val Pro Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr Trp
100 105 110
Phe Ile Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu Val
115 120 125
Arg Ala Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe Ala
130 135 140
Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln Met
145 150 155 160
Leu Arg Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu Phe
165 170 175
Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe Gln
180 185 190
Pro Trp Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg Leu
195 200 205
Arg Ala Ile Leu Gln Asn Gln Gly Asn Ser Thr Ser Gln Ser Asp Gly
210 215 220
Ser Ser Val Pro Ala Asp Ile Asp Gln Ser Ser Asp Ser Asp Gln Ser
225 230 235 240
Ser Ser Gln Gly Gln Pro Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys
245 250 255
Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys
260 265 270
Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys
275 280 285
Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr
290 295 300
Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu
305 310 315 320
Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu
325 330 335
Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala
340 345 350
Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp
355 360 365
Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile
370 375 380
Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe
385 390 395 400
Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser
405 410 415
Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn
420 425 430
Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp Lys His Glu Val
435 440 445
Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp
450 455 460
Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile
465 470 475 480
Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu
485 490 495
Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr
500 505 510
Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser
515 520 525
Asp Arg Glu Ser Leu Ser Phe Tyr Gly Glu Gly Ser Ser Gly Glu Asn
530 535 540
Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg
545 550 555 560
Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His
565 570 575
Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr
580 585 590
Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn
595 600 605
Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu
610 615 620
Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn
625 630 635 640
Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met
645 650 655
Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg
660 665 670
Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Tyr
675 680 685
Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys
690 695 700
Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys
705 710 715 720
Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro
725 730 735
Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile
740 745 750
Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys
755 760 765
Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys
770 775 780
Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala
785 790 795 800
Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val
805 810 815
Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala
820 825 830
Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala
835 840 845
Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile
850 855 860
Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe
865 870 875 880
Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His
885 890 895
Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys
900 905 910
Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp
915 920 925
Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly
930 935 940
Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu
945 950 955 960
Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn
965 970 975
Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe
980 985 990
Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys
995 1000 1005
Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu
1010 1015 1020
Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser
1025 1030 1035
Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu
1040 1045 1050
Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu Val Glu
1055 1060 1065
Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys Glu
1070 1075 1080
Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile
1085 1090 1095
Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
1100 1105 1110
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly
1115 1120 1125
Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
1130 1135 1140
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro
1145 1150 1155
Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
1160 1165 1170
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr
1175 1180 1185
Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
1190 1195 1200
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp
1205 1210 1215
Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu
1220 1225 1230
Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr
1235 1240 1245
Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys
1250 1255 1260
Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe
1265 1270 1275
Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu
1280 1285 1290
Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu
1295 1300 1305
Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser
1310 1315 1320
Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln
1325 1330 1335
Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp
1340 1345 1350
Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr
1355 1360 1365
Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln
1370 1375 1380
Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile
1385 1390 1395
Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr
1400 1405 1410
Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile
1415 1420 1425
Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr
1430 1435 1440
Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys
1445 1450 1455
Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys
1460 1465 1470
Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala
1475 1480 1485
Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly
1490 1495 1500
Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr
1505 1510 1515
Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn
1520 1525 1530
Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val
1535 1540 1545
Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala
1550 1555 1560
Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala
1565 1570 1575
Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys
1580 1585 1590
Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser
1595 1600 1605
Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His Ser
1610 1615 1620
Gly Gly Ser Gly Gly Ser Gly Gly Ser Thr Asn Leu Ser Asp Ile
1625 1630 1635
Ile Glu Lys Glu Thr Gly Lys Gln Leu Val Ile Gln Glu Ser Ile
1640 1645 1650
Leu Met Leu Pro Glu Glu Val Glu Glu Val Ile Gly Asn Lys Pro
1655 1660 1665
Glu Ser Asp Ile Leu Val His Thr Ala Tyr Asp Glu Ser Thr Asp
1670 1675 1680
Glu Asn Val Met Leu Leu Thr Ser Asp Ala Pro Glu Tyr Lys Pro
1685 1690 1695
Trp Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn Lys Ile Lys
1700 1705 1710
Met Leu Ser Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe
1715 1720 1725
Glu Pro Lys Lys Lys Arg Lys Val Gly Ser Gly
1730 1735
<210> 161
<211> 1739
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 161
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met Asp
20 25 30
Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His Lys
35 40 45
Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser Val
50 55 60
Lys Met Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn Leu
65 70 75 80
Leu Cys Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp Leu
85 90 95
Val Pro Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr Trp
100 105 110
Phe Ile Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu Val
115 120 125
Arg Ala Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe Ala
130 135 140
Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln Met
145 150 155 160
Leu Arg Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu Phe
165 170 175
Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe Gln
180 185 190
Pro Trp Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg Leu
195 200 205
Arg Ala Ile Leu Gln Asn Gln Gly Asn Ser Thr Ser Gln Ser Asp Gly
210 215 220
Ser Ser Val Pro Ala Asp Ile Asp Gln Ser Ser Asp Ser Asp Gln Ser
225 230 235 240
Ser Ser Gln Gly Gln Pro Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys
245 250 255
Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys
260 265 270
Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys
275 280 285
Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr
290 295 300
Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu
305 310 315 320
Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu
325 330 335
Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala
340 345 350
Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp
355 360 365
Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile
370 375 380
Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe
385 390 395 400
Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser
405 410 415
Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn
420 425 430
Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp Lys His Glu Val
435 440 445
Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp
450 455 460
Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile
465 470 475 480
Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu
485 490 495
Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr
500 505 510
Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser
515 520 525
Asp Arg Glu Ser Leu Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln
530 535 540
Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile
545 550 555 560
Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro
565 570 575
Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu
580 585 590
Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg
595 600 605
Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys
610 615 620
Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg
625 630 635 640
Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys
645 650 655
Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys
660 665 670
Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Gly Tyr
675 680 685
Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu Asn Lys
690 695 700
Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu Phe Lys
705 710 715 720
Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn Gly Pro
725 730 735
Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn Val Ile
740 745 750
Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys Lys Lys
755 760 765
Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser Phe Lys
770 775 780
Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala Asp Ala
785 790 795 800
Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln Lys Val
805 810 815
Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe Asp Ala
820 825 830
Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val Val Ala
835 840 845
Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn Tyr Ile
850 855 860
Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu Ser Phe
865 870 875 880
Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val Asp His
885 890 895
Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr Ser Lys
900 905 910
Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly Gly Trp
915 920 925
Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg Tyr Gly
930 935 940
Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys Cys Leu
945 950 955 960
Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys Ile Asn
965 970 975
Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe Phe
980 985 990
Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile Gln Lys
995 1000 1005
Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn Leu
1010 1015 1020
Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser
1025 1030 1035
Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu
1040 1045 1050
Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu Val Glu
1055 1060 1065
Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys Glu
1070 1075 1080
Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile
1085 1090 1095
Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
1100 1105 1110
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly
1115 1120 1125
Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
1130 1135 1140
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro
1145 1150 1155
Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
1160 1165 1170
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr
1175 1180 1185
Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
1190 1195 1200
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp
1205 1210 1215
Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu
1220 1225 1230
Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr
1235 1240 1245
Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys
1250 1255 1260
Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe
1265 1270 1275
Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu
1280 1285 1290
Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu
1295 1300 1305
Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser
1310 1315 1320
Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln
1325 1330 1335
Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp
1340 1345 1350
Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr
1355 1360 1365
Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln
1370 1375 1380
Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile
1385 1390 1395
Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr
1400 1405 1410
Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile
1415 1420 1425
Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr
1430 1435 1440
Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys
1445 1450 1455
Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys
1460 1465 1470
Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala
1475 1480 1485
Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly
1490 1495 1500
Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr
1505 1510 1515
Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn
1520 1525 1530
Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val
1535 1540 1545
Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala
1550 1555 1560
Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala
1565 1570 1575
Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys
1580 1585 1590
Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser
1595 1600 1605
Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His Ser
1610 1615 1620
Gly Gly Ser Gly Gly Ser Gly Gly Ser Thr Asn Leu Ser Asp Ile
1625 1630 1635
Ile Glu Lys Glu Thr Gly Lys Gln Leu Val Ile Gln Glu Ser Ile
1640 1645 1650
Leu Met Leu Pro Glu Glu Val Glu Glu Val Ile Gly Asn Lys Pro
1655 1660 1665
Glu Ser Asp Ile Leu Val His Thr Ala Tyr Asp Glu Ser Thr Asp
1670 1675 1680
Glu Asn Val Met Leu Leu Thr Ser Asp Ala Pro Glu Tyr Lys Pro
1685 1690 1695
Trp Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn Lys Ile Lys
1700 1705 1710
Met Leu Ser Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe
1715 1720 1725
Glu Pro Lys Lys Lys Arg Lys Val Gly Ser Gly
1730 1735
<210> 162
<211> 1741
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 162
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met Asp
20 25 30
Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His Lys
35 40 45
Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser Val
50 55 60
Lys Met Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn Leu
65 70 75 80
Leu Cys Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp Leu
85 90 95
Val Pro Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr Trp
100 105 110
Phe Ile Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu Val
115 120 125
Arg Ala Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe Ala
130 135 140
Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln Met
145 150 155 160
Leu Arg Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu Phe
165 170 175
Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe Gln
180 185 190
Pro Trp Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg Leu
195 200 205
Arg Ala Ile Leu Gln Asn Gln Gly Asn Ser Thr Ser Gln Ser Asp Gly
210 215 220
Ser Ser Val Pro Ala Asp Ile Asp Gln Ser Ser Asp Ser Asp Gln Ser
225 230 235 240
Ser Ser Gln Gly Gln Pro Gly Ser Lys Leu Glu Lys Phe Thr Asn Cys
245 250 255
Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile Pro Val Gly Lys
260 265 270
Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val Glu Asp Glu Lys
275 280 285
Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr
290 295 300
Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys Leu Lys Asn Leu
305 310 315 320
Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu
325 330 335
Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala
340 345 350
Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp
355 360 365
Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile
370 375 380
Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe
385 390 395 400
Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala Lys Ser Thr Ser
405 410 415
Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn
420 425 430
Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp Lys His Glu Val
435 440 445
Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp
450 455 460
Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr Gln Glu Gly Ile
465 470 475 480
Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr Glu Ser Gly Glu
485 490 495
Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr
500 505 510
Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser
515 520 525
Asp Arg Glu Ser Leu Ser Phe Tyr Gly Gly Ser Ser Gly Glu Asn Gln
530 535 540
Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile
545 550 555 560
Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro
565 570 575
Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu
580 585 590
Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg
595 600 605
Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys
610 615 620
Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg
625 630 635 640
Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys
645 650 655
Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys
660 665 670
Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly Ser Glu
675 680 685
Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu
690 695 700
Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu
705 710 715 720
Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn
725 730 735
Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn
740 745 750
Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys
755 760 765
Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser
770 775 780
Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala
785 790 795 800
Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln
805 810 815
Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe
820 825 830
Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val
835 840 845
Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn
850 855 860
Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu
865 870 875 880
Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val
885 890 895
Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr
900 905 910
Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly
915 920 925
Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg
930 935 940
Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys
945 950 955 960
Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys
965 970 975
Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val
980 985 990
Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile
995 1000 1005
Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met Phe
1010 1015 1020
Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp Ser
1025 1030 1035
Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn Phe
1040 1045 1050
Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu
1055 1060 1065
Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
1070 1075 1080
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe
1085 1090 1095
Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
1100 1105 1110
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn
1115 1120 1125
His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
1130 1135 1140
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn
1145 1150 1155
Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
1160 1165 1170
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp
1175 1180 1185
Gln Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys
1190 1195 1200
Asn Ile Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His
1205 1210 1215
Asp Asp Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn
1220 1225 1230
Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val Glu
1235 1240 1245
Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg
1250 1255 1260
Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys Glu
1265 1270 1275
Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys
1280 1285 1290
Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys
1295 1300 1305
Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu
1310 1315 1320
Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val
1325 1330 1335
Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met
1340 1345 1350
Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys
1355 1360 1365
Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser
1370 1375 1380
Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser
1385 1390 1395
Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr Lys
1400 1405 1410
Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp
1415 1420 1425
Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu
1430 1435 1440
Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys
1445 1450 1455
Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn
1460 1465 1470
Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu Thr
1475 1480 1485
Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln
1490 1495 1500
Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala
1505 1510 1515
Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln Met
1520 1525 1530
Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile Ser
1535 1540 1545
Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr
1550 1555 1560
Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn
1565 1570 1575
Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln
1580 1585 1590
Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala
1595 1600 1605
Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys
1610 1615 1620
His Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Thr Asn Leu Ser
1625 1630 1635
Asp Ile Ile Glu Lys Glu Thr Gly Lys Gln Leu Val Ile Gln Glu
1640 1645 1650
Ser Ile Leu Met Leu Pro Glu Glu Val Glu Glu Val Ile Gly Asn
1655 1660 1665
Lys Pro Glu Ser Asp Ile Leu Val His Thr Ala Tyr Asp Glu Ser
1670 1675 1680
Thr Asp Glu Asn Val Met Leu Leu Thr Ser Asp Ala Pro Glu Tyr
1685 1690 1695
Lys Pro Trp Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn Lys
1700 1705 1710
Ile Lys Met Leu Ser Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser
1715 1720 1725
Glu Phe Glu Pro Lys Lys Lys Arg Lys Val Gly Ser Gly
1730 1735 1740
<210> 163
<211> 1734
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 163
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Met Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met
20 25 30
Asp Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His
35 40 45
Lys Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser
50 55 60
Val Lys Met Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn
65 70 75 80
Leu Leu Cys Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp
85 90 95
Leu Val Pro Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr
100 105 110
Trp Phe Ile Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu
115 120 125
Val Arg Ala Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe
130 135 140
Ala Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln
145 150 155 160
Met Leu Arg Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu
165 170 175
Phe Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe
180 185 190
Gln Pro Trp Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg
195 200 205
Leu Arg Ala Ile Leu Gln Asn Gln Gly Asn Ser Gly Ser Glu Thr Pro
210 215 220
Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Met Ser Lys Leu Glu Lys
225 230 235 240
Phe Thr Asn Cys Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile
245 250 255
Pro Val Gly Lys Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val
260 265 270
Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu
275 280 285
Asp Arg Tyr Tyr Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys
290 295 300
Leu Lys Asn Leu Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg
305 310 315 320
Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg
325 330 335
Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu
340 345 350
Phe Lys Lys Asp Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp
355 360 365
Lys Asp Glu Ile Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala
370 375 380
Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala
385 390 395 400
Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg
405 410 415
Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp
420 425 430
Lys His Glu Val Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr
435 440 445
Asp Val Glu Asp Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr
450 455 460
Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr
465 470 475 480
Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr
485 490 495
Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys
500 505 510
Gln Val Leu Ser Asp Arg Glu Ser Leu Ser Phe Tyr Gly Glu Gly Ser
515 520 525
Ser Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu
530 535 540
Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile
545 550 555 560
Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu
565 570 575
Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu
580 585 590
Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro
595 600 605
Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg
610 615 620
Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val
625 630 635 640
Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu
645 650 655
Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly
660 665 670
Leu Ser Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn
675 680 685
Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu
690 695 700
Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val
705 710 715 720
Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu
725 730 735
Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His
740 745 750
Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg
755 760 765
Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu
770 775 780
Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile
785 790 795 800
Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys
805 810 815
Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp
820 825 830
Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe
835 840 845
Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg
850 855 860
Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu
865 870 875 880
Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys
885 890 895
Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe
900 905 910
Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile
915 920 925
Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr
930 935 940
Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr
945 950 955 960
Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro
965 970 975
Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu
980 985 990
Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met
995 1000 1005
Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp
1010 1015 1020
Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn
1025 1030 1035
Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
1040 1045 1050
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser
1055 1060 1065
Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
1070 1075 1080
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr
1085 1090 1095
Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
1100 1105 1110
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met
1115 1120 1125
Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
1130 1135 1140
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr
1145 1150 1155
Thr Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu
1160 1165 1170
Asp Gln Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro
1175 1180 1185
Lys Asn Ile Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys
1190 1195 1200
His Asp Asp Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg
1205 1210 1215
Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val
1220 1225 1230
Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile
1235 1240 1245
Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys
1250 1255 1260
Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile
1265 1270 1275
Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile
1280 1285 1290
Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp
1295 1300 1305
Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln
1310 1315 1320
Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr
1325 1330 1335
Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu
1340 1345 1350
Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met
1355 1360 1365
Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr
1370 1375 1380
Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr
1385 1390 1395
Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe
1400 1405 1410
Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala
1415 1420 1425
Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys
1430 1435 1440
Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg
1445 1450 1455
Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu
1460 1465 1470
Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr
1475 1480 1485
Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys
1490 1495 1500
Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln
1505 1510 1515
Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile
1520 1525 1530
Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn
1535 1540 1545
Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala
1550 1555 1560
Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly
1565 1570 1575
Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile
1580 1585 1590
Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val
1595 1600 1605
Lys His Gly Ser Pro Lys Lys Lys Arg Lys Val Ser Gly Gly Ser
1610 1615 1620
Thr Asn Leu Ser Asp Ile Ile Glu Lys Glu Thr Gly Lys Gln Leu
1625 1630 1635
Val Ile Gln Glu Ser Ile Leu Met Leu Pro Glu Glu Val Glu Glu
1640 1645 1650
Val Ile Gly Asn Lys Pro Glu Ser Asp Ile Leu Val His Thr Ala
1655 1660 1665
Tyr Asp Glu Ser Thr Asp Glu Asn Val Met Leu Leu Thr Ser Asp
1670 1675 1680
Ala Pro Glu Tyr Lys Pro Trp Ala Leu Val Ile Gln Asp Ser Asn
1685 1690 1695
Gly Glu Asn Lys Ile Lys Met Leu Thr Lys Tyr Asp Ser Gly Gly
1700 1705 1710
Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Pro Lys Lys Lys
1715 1720 1725
Arg Lys Val Gly Ser Gly
1730
<210> 164
<211> 1734
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 164
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Met Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met
20 25 30
Asp Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His
35 40 45
Lys Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser
50 55 60
Val Lys Met Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn
65 70 75 80
Leu Leu Cys Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp
85 90 95
Leu Val Pro Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr
100 105 110
Trp Phe Ile Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu
115 120 125
Val Arg Ala Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe
130 135 140
Ala Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln
145 150 155 160
Met Leu Arg Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu
165 170 175
Phe Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe
180 185 190
Gln Pro Trp Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg
195 200 205
Leu Arg Ala Ile Leu Gln Asn Gln Gly Asn Ser Gly Ser Glu Thr Pro
210 215 220
Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Met Ser Lys Leu Glu Lys
225 230 235 240
Phe Thr Asn Cys Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile
245 250 255
Pro Val Gly Lys Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val
260 265 270
Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu
275 280 285
Asp Arg Tyr Tyr Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys
290 295 300
Leu Lys Asn Leu Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg
305 310 315 320
Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg
325 330 335
Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu
340 345 350
Phe Lys Lys Asp Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp
355 360 365
Lys Asp Glu Ile Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala
370 375 380
Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala
385 390 395 400
Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg
405 410 415
Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp
420 425 430
Lys His Glu Val Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr
435 440 445
Asp Val Glu Asp Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr
450 455 460
Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr
465 470 475 480
Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr
485 490 495
Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys
500 505 510
Gln Val Leu Ser Asp Arg Glu Ser Leu Ser Phe Tyr Gly Gly Ser Ser
515 520 525
Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg
530 535 540
Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu
545 550 555 560
Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr
565 570 575
Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu
580 585 590
Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln
595 600 605
Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser
610 615 620
Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val
625 630 635 640
Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile
645 650 655
Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu
660 665 670
Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn
675 680 685
Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu
690 695 700
Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val
705 710 715 720
Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu
725 730 735
Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His
740 745 750
Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg
755 760 765
Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu
770 775 780
Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile
785 790 795 800
Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys
805 810 815
Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp
820 825 830
Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe
835 840 845
Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg
850 855 860
Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu
865 870 875 880
Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys
885 890 895
Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe
900 905 910
Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile
915 920 925
Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr
930 935 940
Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr
945 950 955 960
Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro
965 970 975
Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu
980 985 990
Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met
995 1000 1005
Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp
1010 1015 1020
Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn
1025 1030 1035
Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg
1040 1045 1050
Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser
1055 1060 1065
Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met
1070 1075 1080
Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr
1085 1090 1095
Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn
1100 1105 1110
Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met
1115 1120 1125
Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala
1130 1135 1140
Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr
1145 1150 1155
Thr Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu
1160 1165 1170
Asp Gln Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro
1175 1180 1185
Lys Asn Ile Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys
1190 1195 1200
His Asp Asp Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg
1205 1210 1215
Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val
1220 1225 1230
Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile
1235 1240 1245
Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys
1250 1255 1260
Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile
1265 1270 1275
Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile
1280 1285 1290
Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp
1295 1300 1305
Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln
1310 1315 1320
Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr
1325 1330 1335
Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu
1340 1345 1350
Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met
1355 1360 1365
Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr
1370 1375 1380
Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr
1385 1390 1395
Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe
1400 1405 1410
Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala
1415 1420 1425
Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys
1430 1435 1440
Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg
1445 1450 1455
Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu
1460 1465 1470
Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr
1475 1480 1485
Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys
1490 1495 1500
Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln
1505 1510 1515
Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile
1520 1525 1530
Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn
1535 1540 1545
Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala
1550 1555 1560
Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly
1565 1570 1575
Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile
1580 1585 1590
Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val
1595 1600 1605
Lys His Gly Ser Pro Lys Lys Lys Arg Lys Val Ser Gly Gly Ser
1610 1615 1620
Thr Asn Leu Ser Asp Ile Ile Glu Lys Glu Thr Gly Lys Gln Leu
1625 1630 1635
Val Ile Gln Glu Ser Ile Leu Met Leu Pro Glu Glu Val Glu Glu
1640 1645 1650
Val Ile Gly Asn Lys Pro Glu Ser Asp Ile Leu Val His Thr Ala
1655 1660 1665
Tyr Asp Glu Ser Thr Asp Glu Asn Val Met Leu Leu Thr Ser Asp
1670 1675 1680
Ala Pro Glu Tyr Lys Pro Trp Ala Leu Val Ile Gln Asp Ser Asn
1685 1690 1695
Gly Glu Asn Lys Ile Lys Met Leu Thr Lys Tyr Asp Ser Gly Gly
1700 1705 1710
Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Pro Lys Lys Lys
1715 1720 1725
Arg Lys Val Gly Ser Gly
1730
<210> 165
<211> 1736
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 165
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Met Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met
20 25 30
Asp Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His
35 40 45
Lys Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser
50 55 60
Val Lys Met Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn
65 70 75 80
Leu Leu Cys Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp
85 90 95
Leu Val Pro Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr
100 105 110
Trp Phe Ile Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu
115 120 125
Val Arg Ala Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe
130 135 140
Ala Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln
145 150 155 160
Met Leu Arg Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu
165 170 175
Phe Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe
180 185 190
Gln Pro Trp Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg
195 200 205
Leu Arg Ala Ile Leu Gln Asn Gln Gly Asn Ser Gly Ser Glu Thr Pro
210 215 220
Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Met Ser Lys Leu Glu Lys
225 230 235 240
Phe Thr Asn Cys Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile
245 250 255
Pro Val Gly Lys Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val
260 265 270
Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu
275 280 285
Asp Arg Tyr Tyr Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys
290 295 300
Leu Lys Asn Leu Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg
305 310 315 320
Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg
325 330 335
Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu
340 345 350
Phe Lys Lys Asp Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp
355 360 365
Lys Asp Glu Ile Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala
370 375 380
Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala
385 390 395 400
Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg
405 410 415
Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp
420 425 430
Lys His Glu Val Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr
435 440 445
Asp Val Glu Asp Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr
450 455 460
Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr
465 470 475 480
Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr
485 490 495
Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys
500 505 510
Gln Val Leu Ser Asp Arg Glu Ser Leu Ser Phe Tyr Gly Gly Ser Ser
515 520 525
Gly Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg
530 535 540
Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu
545 550 555 560
Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr
565 570 575
Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu
580 585 590
Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln
595 600 605
Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser
610 615 620
Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val
625 630 635 640
Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile
645 650 655
Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu
660 665 670
Ser Gly Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe
675 680 685
Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys
690 695 700
Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile
705 710 715 720
Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe
725 730 735
Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp
740 745 750
Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp
755 760 765
Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu
770 775 780
Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu
785 790 795 800
Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser
805 810 815
Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys
820 825 830
Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys
835 840 845
Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr
850 855 860
Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile
865 870 875 880
Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr
885 890 895
Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro
900 905 910
Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala
915 920 925
Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys
930 935 940
Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly
945 950 955 960
Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met
965 970 975
Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro
980 985 990
Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly
995 1000 1005
Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe
1010 1015 1020
Lys Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp
1025 1030 1035
Phe Asn Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe
1040 1045 1050
Tyr Arg Glu Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser
1055 1060 1065
Ala Ser Lys Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu
1070 1075 1080
Tyr Met Phe Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His
1085 1090 1095
Gly Thr Pro Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp
1100 1105 1110
Glu Asn Asn His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu
1115 1120 1125
Phe Met Arg Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His
1130 1135 1140
Pro Ala Asn Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys
1145 1150 1155
Lys Thr Thr Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe
1160 1165 1170
Ser Glu Asp Gln Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys
1175 1180 1185
Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu Val Arg Val Leu
1190 1195 1200
Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly
1205 1210 1215
Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly Asn
1220 1225 1230
Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn
1235 1240 1245
Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys
1250 1255 1260
Glu Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu
1265 1270 1275
Asn Ile Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His
1280 1285 1290
Lys Ile Cys Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu
1295 1300 1305
Glu Asp Leu Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu
1310 1315 1320
Lys Gln Val Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys Leu
1325 1330 1335
Asn Tyr Met Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly
1340 1345 1350
Ala Leu Lys Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys
1355 1360 1365
Ser Met Ser Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp
1370 1375 1380
Leu Thr Ser Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu Leu
1385 1390 1395
Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser
1400 1405 1410
Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe Glu
1415 1420 1425
Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr
1430 1435 1440
Ile Lys Lys Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile
1445 1450 1455
Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu Val
1460 1465 1470
Cys Leu Thr Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile
1475 1480 1485
Asn Tyr Gln Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser
1490 1495 1500
Asp Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu Met
1505 1510 1515
Leu Gln Met Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp Phe
1520 1525 1530
Leu Ile Ser Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser
1535 1540 1545
Arg Asn Tyr Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala
1550 1555 1560
Asp Ala Asn Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala
1565 1570 1575
Ile Gly Gln Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys Val
1580 1585 1590
Lys Ile Ala Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr
1595 1600 1605
Ser Val Lys His Gly Ser Pro Lys Lys Lys Arg Lys Val Ser Gly
1610 1615 1620
Gly Ser Thr Asn Leu Ser Asp Ile Ile Glu Lys Glu Thr Gly Lys
1625 1630 1635
Gln Leu Val Ile Gln Glu Ser Ile Leu Met Leu Pro Glu Glu Val
1640 1645 1650
Glu Glu Val Ile Gly Asn Lys Pro Glu Ser Asp Ile Leu Val His
1655 1660 1665
Thr Ala Tyr Asp Glu Ser Thr Asp Glu Asn Val Met Leu Leu Thr
1670 1675 1680
Ser Asp Ala Pro Glu Tyr Lys Pro Trp Ala Leu Val Ile Gln Asp
1685 1690 1695
Ser Asn Gly Glu Asn Lys Ile Lys Met Leu Thr Lys Tyr Asp Ser
1700 1705 1710
Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Pro Lys
1715 1720 1725
Lys Lys Arg Lys Val Gly Ser Gly
1730 1735
<210> 166
<211> 1616
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 166
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His
20 25 30
Ala Leu Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val
35 40 45
Gly Ala Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn
50 55 60
Arg Ala Ile Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala
65 70 75 80
Leu Arg Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala
85 90 95
Thr Leu Tyr Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met
100 105 110
Ile His Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ser Lys
115 120 125
Arg Gly Ala Ala Gly Ser Leu Met Asn Val Leu Asn Tyr Pro Gly Met
130 135 140
Asn His Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala
145 150 155 160
Ala Leu Leu Cys Asp Phe Tyr Arg Met Pro Arg Gln Val Phe Asn Ala
165 170 175
Gln Lys Lys Ala Gln Ser Ser Ile Asn Ser Gly Gly Ser Ser Gly Gly
180 185 190
Ser Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu
195 200 205
Ser Ser Gly Gly Ser Ser Gly Gly Ser Ser Lys Leu Glu Lys Phe Thr
210 215 220
Asn Cys Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile Pro Val
225 230 235 240
Gly Lys Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val Glu Asp
245 250 255
Glu Lys Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg
260 265 270
Tyr Tyr Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys Leu Lys
275 280 285
Asn Leu Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu
290 295 300
Lys Glu Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu
305 310 315 320
Ile Ala Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys
325 330 335
Lys Asp Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp
340 345 350
Glu Ile Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr
355 360 365
Gly Phe Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala Lys Ser
370 375 380
Thr Ser Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile
385 390 395 400
Ser Asn Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp Lys His
405 410 415
Glu Val Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val
420 425 430
Glu Asp Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr Gln Glu
435 440 445
Gly Ile Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr Glu Ser
450 455 460
Gly Glu Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln
465 470 475 480
Lys Thr Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val
485 490 495
Leu Ser Asp Arg Glu Ser Leu Ser Phe Tyr Gly Glu Gly Ser Ser Gly
500 505 510
Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met
515 520 525
Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys
530 535 540
Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu
545 550 555 560
Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp
565 570 575
Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser
580 585 590
Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp
595 600 605
Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys
610 615 620
Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr
625 630 635 640
Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser
645 650 655
Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu
660 665 670
Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu
675 680 685
Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn
690 695 700
Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn
705 710 715 720
Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys
725 730 735
Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser
740 745 750
Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala
755 760 765
Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln
770 775 780
Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe
785 790 795 800
Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val
805 810 815
Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn
820 825 830
Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu
835 840 845
Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val
850 855 860
Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr
865 870 875 880
Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly
885 890 895
Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg
900 905 910
Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys
915 920 925
Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys
930 935 940
Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val
945 950 955 960
Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile
965 970 975
Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn
980 985 990
Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser
995 1000 1005
Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu
1010 1015 1020
Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu Val Glu
1025 1030 1035
Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys Glu
1040 1045 1050
Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile
1055 1060 1065
Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
1070 1075 1080
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly
1085 1090 1095
Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
1100 1105 1110
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro
1115 1120 1125
Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
1130 1135 1140
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr
1145 1150 1155
Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
1160 1165 1170
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp
1175 1180 1185
Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu
1190 1195 1200
Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr
1205 1210 1215
Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys
1220 1225 1230
Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe
1235 1240 1245
Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu
1250 1255 1260
Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu
1265 1270 1275
Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser
1280 1285 1290
Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln
1295 1300 1305
Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp
1310 1315 1320
Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr
1325 1330 1335
Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln
1340 1345 1350
Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile
1355 1360 1365
Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr
1370 1375 1380
Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile
1385 1390 1395
Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr
1400 1405 1410
Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys
1415 1420 1425
Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys
1430 1435 1440
Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala
1445 1450 1455
Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly
1460 1465 1470
Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr
1475 1480 1485
Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn
1490 1495 1500
Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val
1505 1510 1515
Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala
1520 1525 1530
Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala
1535 1540 1545
Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys
1550 1555 1560
Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser
1565 1570 1575
Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His Ser
1580 1585 1590
Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Pro Lys
1595 1600 1605
Lys Lys Arg Lys Val Gly Ser Gly
1610 1615
<210> 167
<211> 1616
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 167
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His
20 25 30
Ala Leu Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val
35 40 45
Gly Ala Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn
50 55 60
Arg Ala Ile Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala
65 70 75 80
Leu Arg Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala
85 90 95
Thr Leu Tyr Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met
100 105 110
Ile His Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ser Lys
115 120 125
Arg Gly Ala Ala Gly Ser Leu Met Asn Val Leu Asn Tyr Pro Gly Met
130 135 140
Asn His Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala
145 150 155 160
Ala Leu Leu Cys Asp Phe Tyr Arg Met Pro Arg Gln Val Phe Asn Ala
165 170 175
Gln Lys Lys Ala Gln Ser Ser Ile Asn Ser Gly Gly Ser Ser Gly Gly
180 185 190
Ser Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu
195 200 205
Ser Ser Gly Gly Ser Ser Gly Gly Ser Ser Lys Leu Glu Lys Phe Thr
210 215 220
Asn Cys Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile Pro Val
225 230 235 240
Gly Lys Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val Glu Asp
245 250 255
Glu Lys Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg
260 265 270
Tyr Tyr Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys Leu Lys
275 280 285
Asn Leu Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu
290 295 300
Lys Glu Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu
305 310 315 320
Ile Ala Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys
325 330 335
Lys Asp Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp
340 345 350
Glu Ile Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr
355 360 365
Gly Phe Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala Lys Ser
370 375 380
Thr Ser Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile
385 390 395 400
Ser Asn Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp Lys His
405 410 415
Glu Val Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val
420 425 430
Glu Asp Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr Gln Glu
435 440 445
Gly Ile Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr Glu Ser
450 455 460
Gly Glu Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln
465 470 475 480
Lys Thr Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val
485 490 495
Leu Ser Asp Arg Glu Ser Leu Ser Phe Tyr Gly Gly Ser Ser Gly Glu
500 505 510
Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys
515 520 525
Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu
530 535 540
His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr
545 550 555 560
Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile
565 570 575
Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe
580 585 590
Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys
595 600 605
Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys
610 615 620
Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln
625 630 635 640
Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu
645 650 655
Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn Thr Leu
660 665 670
Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu Lys Leu
675 680 685
Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val Lys Asn
690 695 700
Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu Trp Asn
705 710 715 720
Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His Leu Lys
725 730 735
Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg Lys Ser
740 745 750
Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu Tyr Ala
755 760 765
Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile Ile Gln
770 775 780
Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys Leu Phe
785 790 795 800
Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp Ala Val
805 810 815
Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe Glu Asn
820 825 830
Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg Asp Glu
835 840 845
Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu Lys Val
850 855 860
Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys Pro Tyr
865 870 875 880
Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe Met Gly
885 890 895
Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile Leu Arg
900 905 910
Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr Ala Lys
915 920 925
Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr Glu Lys
930 935 940
Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val
945 950 955 960
Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu Asp Ile
965 970 975
Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met Phe Asn
980 985 990
Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp Ser Ile Ser
995 1000 1005
Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn Phe Ser Glu
1010 1015 1020
Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu Val Glu
1025 1030 1035
Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys Glu
1040 1045 1050
Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile
1055 1060 1065
Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu
1070 1075 1080
His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly
1085 1090 1095
Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala
1100 1105 1110
Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro
1115 1120 1125
Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu
1130 1135 1140
Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr
1145 1150 1155
Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys Asn Ile
1160 1165 1170
Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His Asp Asp
1175 1180 1185
Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn Leu Leu
1190 1195 1200
Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val Glu Gln Tyr
1205 1210 1215
Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg Ile Lys
1220 1225 1230
Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys Glu Arg Phe
1235 1240 1245
Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys Glu Leu
1250 1255 1260
Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys Glu Leu
1265 1270 1275
Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn Ser
1280 1285 1290
Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln
1295 1300 1305
Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp
1310 1315 1320
Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr
1325 1330 1335
Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln
1340 1345 1350
Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile
1355 1360 1365
Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr
1370 1375 1380
Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile
1385 1390 1395
Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr
1400 1405 1410
Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys Trp Lys
1415 1420 1425
Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys
1430 1435 1440
Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala
1445 1450 1455
Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly
1460 1465 1470
Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr
1475 1480 1485
Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn
1490 1495 1500
Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val
1505 1510 1515
Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala
1520 1525 1530
Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala
1535 1540 1545
Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys
1550 1555 1560
Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser
1565 1570 1575
Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His Ser
1580 1585 1590
Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Pro Lys
1595 1600 1605
Lys Lys Arg Lys Val Gly Ser Gly
1610 1615
<210> 168
<211> 1618
<212> PRT
<213> artificial sequence
<220>
<223> synthetic polypeptide
<400> 168
Met Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu Ser Pro Lys Lys Lys
1 5 10 15
Arg Lys Val Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His
20 25 30
Ala Leu Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val
35 40 45
Gly Ala Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn
50 55 60
Arg Ala Ile Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala
65 70 75 80
Leu Arg Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala
85 90 95
Thr Leu Tyr Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met
100 105 110
Ile His Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ser Lys
115 120 125
Arg Gly Ala Ala Gly Ser Leu Met Asn Val Leu Asn Tyr Pro Gly Met
130 135 140
Asn His Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala
145 150 155 160
Ala Leu Leu Cys Asp Phe Tyr Arg Met Pro Arg Gln Val Phe Asn Ala
165 170 175
Gln Lys Lys Ala Gln Ser Ser Ile Asn Ser Gly Gly Ser Ser Gly Gly
180 185 190
Ser Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu
195 200 205
Ser Ser Gly Gly Ser Ser Gly Gly Ser Ser Lys Leu Glu Lys Phe Thr
210 215 220
Asn Cys Tyr Ser Leu Ser Lys Thr Leu Arg Phe Lys Ala Ile Pro Val
225 230 235 240
Gly Lys Thr Gln Glu Asn Ile Asp Asn Lys Arg Leu Leu Val Glu Asp
245 250 255
Glu Lys Arg Ala Glu Asp Tyr Lys Gly Val Lys Lys Leu Leu Asp Arg
260 265 270
Tyr Tyr Leu Ser Phe Ile Asn Asp Val Leu His Ser Ile Lys Leu Lys
275 280 285
Asn Leu Asn Asn Tyr Ile Ser Leu Phe Arg Lys Lys Thr Arg Thr Glu
290 295 300
Lys Glu Asn Lys Glu Leu Glu Asn Leu Glu Ile Asn Leu Arg Lys Glu
305 310 315 320
Ile Ala Lys Ala Phe Lys Gly Asn Glu Gly Tyr Lys Ser Leu Phe Lys
325 330 335
Lys Asp Ile Ile Glu Thr Ile Leu Pro Glu Phe Leu Asp Asp Lys Asp
340 345 350
Glu Ile Ala Leu Val Asn Ser Phe Asn Gly Phe Thr Thr Ala Phe Thr
355 360 365
Gly Phe Phe Asp Asn Arg Glu Asn Met Phe Ser Glu Glu Ala Lys Ser
370 375 380
Thr Ser Ile Ala Phe Arg Cys Ile Asn Glu Asn Leu Thr Arg Tyr Ile
385 390 395 400
Ser Asn Met Asp Ile Phe Glu Lys Val Asp Ala Ile Phe Asp Lys His
405 410 415
Glu Val Gln Glu Ile Lys Glu Lys Ile Leu Asn Ser Asp Tyr Asp Val
420 425 430
Glu Asp Phe Phe Glu Gly Glu Phe Phe Asn Phe Val Leu Thr Gln Glu
435 440 445
Gly Ile Asp Val Tyr Asn Ala Ile Ile Gly Gly Phe Val Thr Glu Ser
450 455 460
Gly Glu Lys Ile Lys Gly Leu Asn Glu Tyr Ile Asn Leu Tyr Asn Gln
465 470 475 480
Lys Thr Lys Gln Lys Leu Pro Lys Phe Lys Pro Leu Tyr Lys Gln Val
485 490 495
Leu Ser Asp Arg Glu Ser Leu Ser Phe Tyr Gly Gly Ser Ser Gly Glu
500 505 510
Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys
515 520 525
Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu
530 535 540
His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr
545 550 555 560
Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile
565 570 575
Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe
580 585 590
Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys
595 600 605
Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys
610 615 620
Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln
625 630 635 640
Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Gly
645 650 655
Ser Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe Arg Asn
660 665 670
Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys Leu Glu
675 680 685
Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile Phe Val
690 695 700
Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe Gly Glu
705 710 715 720
Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp Ile His
725 730 735
Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp Arg Arg
740 745 750
Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu Gln Glu
755 760 765
Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu Ile Ile
770 775 780
Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser Glu Lys
785 790 795 800
Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys Asn Asp
805 810 815
Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys Ser Phe
820 825 830
Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr Asn Arg
835 840 845
Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile Leu Leu
850 855 860
Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr Gln Lys
865 870 875 880
Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro Gln Phe
885 890 895
Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala Thr Ile
900 905 910
Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys Lys Tyr
915 920 925
Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly Asn Tyr
930 935 940
Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro
945 950 955 960
Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro Ser Glu
965 970 975
Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly Asp Met
980 985 990
Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys Asp Ser
995 1000 1005
Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn Phe
1010 1015 1020
Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu
1025 1030 1035
Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys
1040 1045 1050
Lys Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe
1055 1060 1065
Gln Ile Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro
1070 1075 1080
Asn Leu His Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn
1085 1090 1095
His Gly Gln Ile Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg
1100 1105 1110
Arg Ala Ser Leu Lys Lys Glu Glu Leu Val Val His Pro Ala Asn
1115 1120 1125
Ser Pro Ile Ala Asn Lys Asn Pro Asp Asn Pro Lys Lys Thr Thr
1130 1135 1140
Thr Leu Ser Tyr Asp Val Tyr Lys Asp Lys Arg Phe Ser Glu Asp
1145 1150 1155
Gln Tyr Glu Leu His Ile Pro Ile Ala Ile Asn Lys Cys Pro Lys
1160 1165 1170
Asn Ile Phe Lys Ile Asn Thr Glu Val Arg Val Leu Leu Lys His
1175 1180 1185
Asp Asp Asn Pro Tyr Val Ile Gly Ile Ala Arg Gly Glu Arg Asn
1190 1195 1200
Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly Asn Ile Val Glu
1205 1210 1215
Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn Gly Ile Arg
1220 1225 1230
Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu Lys Glu
1235 1240 1245
Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile Lys
1250 1255 1260
Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys
1265 1270 1275
Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu
1280 1285 1290
Asn Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val
1295 1300 1305
Tyr Gln Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met
1310 1315 1320
Val Asp Lys Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys
1325 1330 1335
Gly Tyr Gln Ile Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser
1340 1345 1350
Thr Gln Asn Gly Phe Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser
1355 1360 1365
Lys Ile Asp Pro Ser Thr Gly Phe Val Asn Leu Leu Lys Thr Lys
1370 1375 1380
Tyr Thr Ser Ile Ala Asp Ser Lys Lys Phe Ile Ser Ser Phe Asp
1385 1390 1395
Arg Ile Met Tyr Val Pro Glu Glu Asp Leu Phe Glu Phe Ala Leu
1400 1405 1410
Asp Tyr Lys Asn Phe Ser Arg Thr Asp Ala Asp Tyr Ile Lys Lys
1415 1420 1425
Trp Lys Leu Tyr Ser Tyr Gly Asn Arg Ile Arg Ile Phe Arg Asn
1430 1435 1440
Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu Val Cys Leu Thr
1445 1450 1455
Ser Ala Tyr Lys Glu Leu Phe Asn Lys Tyr Gly Ile Asn Tyr Gln
1460 1465 1470
Gln Gly Asp Ile Arg Ala Leu Leu Cys Glu Gln Ser Asp Lys Ala
1475 1480 1485
Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln Met
1490 1495 1500
Arg Asn Ser Ile Thr Gly Arg Thr Asp Val Asp Phe Leu Ile Ser
1505 1510 1515
Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr
1520 1525 1530
Glu Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn
1535 1540 1545
Gly Ala Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln
1550 1555 1560
Phe Lys Lys Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala
1565 1570 1575
Ile Ser Asn Lys Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys
1580 1585 1590
His Ser Gly Gly Ser Lys Arg Thr Ala Asp Gly Ser Glu Phe Glu
1595 1600 1605
Pro Lys Lys Lys Arg Lys Val Gly Ser Gly
1610 1615
<210> 169
<211> 53
<212> PRT
<213> Vibrio cansonii
<400> 169
Cys Arg Val Thr Gly Val Gln Leu Lys Asn His Leu Ile Ala Ser His
1 5 10 15
Ile Lys Pro Trp Ala Val Ser Asn Asn Gln Glu Arg Leu Asp Gly His
20 25 30
Asn Gly Leu Leu Leu Ala Pro His Val Asp His Leu Phe Asp Lys Gly
35 40 45
Phe Ile Ser Phe Glu
50
<210> 170
<211> 137
<212> PRT
<213> Bacillus caldovicius
<400> 170
Met Pro Asn Arg Pro Leu Lys Pro Cys Asn Lys Ile Gly Cys Thr Asn
1 5 10 15
Leu Thr Arg Asp Arg Tyr Cys Glu Gln His Lys His Leu Ala Glu Gln
20 25 30
Arg Gln Arg Thr Arg Arg Asn Asp Lys Glu Tyr Asp Lys His Lys Arg
35 40 45
Asn Gln Gln Ala Arg Ala Phe Tyr His Ser Arg Glu Trp Glu Arg Val
50 55 60
Arg Leu Ala Val Leu Ala Arg Asp Asn Tyr Leu Cys Gln His Cys Leu
65 70 75 80
Lys Glu Lys Lys Ile Thr Arg Ala Val Ile Val Asp His Val Val Pro
85 90 95
Leu Leu Val Asp Trp Ser Lys Arg Leu Asp Met Asp Asn Leu Gln Ser
100 105 110
Leu Cys Gln Ser Cys His Asn Arg Lys Thr Ala Glu Asp Lys Arg Arg
115 120 125
Tyr Gly Gln Gly Arg Ser Gly Lys Phe
130 135
<210> 171
<211> 49
<212> PRT
<213> Bacillus phage SP01
<400> 171
Lys Gly Lys Thr Phe Gln Val His Arg Leu Val Ala Ile His Phe Cys
1 5 10 15
Glu Gly Tyr Glu Glu Gly Leu Val Val Asp His Lys Asp Gly Asn Lys
20 25 30
Asp Asn Asn Leu Ser Thr Asn Leu Arg Trp Val Thr Gln Lys Ile Asn
35 40 45
Val
<210> 172
<211> 156
<212> PRT
<213> Neisseria meningitidis
<400> 172
Ser Phe Lys Asp Arg Lys Glu Ile Glu Lys Arg Gln Glu Glu Asn Arg
1 5 10 15
Lys Asp Arg Glu Lys Ala Ala Ala Lys Phe Arg Glu Tyr Phe Pro Asn
20 25 30
Phe Val Gly Glu Pro Lys Ser Lys Asp Ile Leu Lys Leu Arg Leu Tyr
35 40 45
Glu Gln Gln His Gly Lys Cys Leu Tyr Ser Gly Lys Glu Ile Asn Leu
50 55 60
Gly Arg Leu Asn Glu Lys Gly Tyr Val Glu Ile Asp His Ala Leu Pro
65 70 75 80
Phe Ser Arg Thr Trp Asp Asp Ser Phe Asn Asn Lys Val Leu Val Leu
85 90 95
Gly Ser Glu Asn Gln Asn Lys Gly Asn Gln Thr Pro Tyr Glu Tyr Phe
100 105 110
Asn Gly Lys Asp Asn Ser Arg Glu Trp Gln Glu Phe Lys Ala Arg Val
115 120 125
Glu Thr Ser Arg Phe Pro Arg Ser Lys Lys Gln Arg Ile Leu Leu Gln
130 135 140
Lys Phe Asp Glu Asp Gly Phe Lys Glu Arg Asn Leu
145 150 155
<210> 173
<211> 53
<212> PRT
<213> Vibrio cansonii
<400> 173
Cys Arg Val Thr Gly Val Gln Leu Lys Asn His Leu Ile Ala Ser His
1 5 10 15
Ile Lys Pro Trp Ala Val Ser Asn Asn Gln Glu Arg Leu Asp Gly His
20 25 30
Asn Gly Leu Leu Leu Ala Pro His Val Asp His Leu Phe Asp Lys Gly
35 40 45
Phe Ile Ser Phe Glu
50
<210> 174
<211> 62
<212> PRT
<213> Streptomyces coelicolor
<400> 174
Ser Ala Arg Gly Ala Val Leu Lys Arg Cys Gln Lys Arg Cys Glu Asn
1 5 10 15
Pro Glu Cys Ala Gly His Pro Thr Glu Leu Thr Lys Ala Gly Leu Pro
20 25 30
Ile Leu Gln Val Asp His Val Asn Asp Leu Ala Lys Gly Gly Pro Asp
35 40 45
Val Pro Trp Asn Met Ile Ala Leu Cys Pro Asn Cys His Ala
50 55 60
<210> 175
<211> 4
<212> PRT
<213> artificial sequence
<220>
<223> synthetic peptides
<400> 175
Gly Ser Ser Gly
1

Claims (74)

1. An engineered protein comprising at least two different polypeptides,
wherein one of the at least two different polypeptides is a first CRISPR-Cas effect polypeptide that is a first portion of a first V-type CRISPR-Cas effect protein and the first CRISPR-Cas effect polypeptide is free of nuclease domains; and
Wherein another of the at least two different polypeptides is a heterologous polypeptide that is heterologous to the first V-type CRISPR-Cas effect protein and is not part of the V-type CRISPR-Cas effect protein.
2. The engineered protein of claim 1, wherein the heterologous polypeptide has a length of about 10 to about 200 amino acids and/or the first CRISPR-Cas effect polypeptide has a length of about 100 to about 400 amino acids, optionally wherein the heterologous polypeptide has a length of about 140 to about 160 amino acids and/or the first CRISPR-Cas effect polypeptide has a length of about 250 to about 350 amino acids.
3. The engineered protein of claim 1 or 2, wherein the heterologous polypeptide comprises a first nuclease domain or portion thereof heterologous to the first CRISPR-Cas effect polypeptide.
4. The engineered protein of any one of claims 1-3, wherein the heterologous polypeptide comprises a target strand-nicking enzyme domain or portion thereof, optionally wherein the heterologous polypeptide comprises a target strand-specific nicking enzyme domain, a non-target strand-specific nicking enzyme domain, or a target strand-nicking enzyme domain and a non-target strand-nicking enzyme domain.
5. The engineered protein of any one of claims 1-4, further comprising a second CRISPR-Cas effect polypeptide comprising a second nuclease domain or a portion thereof, optionally wherein the first CRISPR-Cas effect polypeptide and the second CRISPR-Cas effect polypeptide are non-contiguous (i.e., separated from each other (optionally by at least 10, 50, 100, or more amino acids) and not directly linked to each other).
6. The engineered protein of claim 5, wherein the heterologous polypeptide is heterologous to the second CRISPR-Cas effect polypeptide.
7. The engineered protein of claim 5 or 6, wherein the first and second CRISPR-Cas effect polypeptides are each part (e.g., different parts) of the same CRISPR-Cas effect protein.
8. The engineered protein of any one of claims 5-7, wherein the second nuclease domain or portion thereof is a non-target strand and a target strand nickase domain or portion thereof.
9. The engineered protein of any one of claims 5-8, wherein the second nuclease domain is active.
10. The engineered protein of any one of claims 5-8, wherein the second nuclease domain is inactive.
11. The engineered protein of any one of claims 1-10, wherein the heterologous polypeptide comprises a HNH domain, optionally wherein the HNH domain comprises a mutation (e.g., an H840A mutation) that modifies the activity of the HNH domain.
12. The engineered protein of any one of claims 5-11, wherein the first and second CRISPR-Cas effect polypeptides are each part of a first CRISPR-Cas effect protein and the heterologous polypeptide is between and/or linked (e.g., directly or indirectly) to two amino acids that are two consecutive or non-consecutive amino acids of the first CRISPR-Cas effect protein.
13. The engineered protein of claim 12, wherein the heterologous polypeptide is located in the engineered protein at a position corresponding to an inter-domain junction region of the first CRISPR-Cas effect protein.
14. The engineered protein of any one of claims 1-13, wherein the heterologous polypeptide comprises a sequence that hybridizes to SEQ ID NO:1 or 169-174, and optionally wherein the heterologous polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:1 or 169-174.
15. The engineered protein of any one of claims 5-14, wherein the engineered protein comprises a first CRISPR-Cas effect polypeptide, a heterologous polypeptide, and a second CRISPR-Cas effect polypeptide in an amino-terminal to carboxy-terminal direction, optionally wherein the second CRISPR-Cas effect polypeptide has a length of about 800 to about 1,100 amino acids (e.g., about 900 to about 950 or 1,000 amino acids).
16. The engineered protein of any one of claims 1-15, further comprising all or a portion of the wedge domain, rec1 domain, rec2 domain, PAM interaction domain, ruvC domain, bridged helix, and/or Nuc domain of the first V-type CRISPR-Cas effect protein, optionally wherein the engineered protein comprises all or a portion of the wedge domain, rec1 domain, rec2 domain, PAM interaction domain, ruvC domain, bridged helix, and/or Nuc domain of Cas12a or Cas12 b.
17. The engineered protein of claim 16, wherein the engineered protein comprises a Rec1 domain and a Rec2 domain, and the heterologous polypeptide is located between the Rec1 domain and the Rec2 domain.
18. The engineered protein of any one of claims 1-17, wherein the engineered protein lacks at least a portion of a first V-type CRISPR-Cas effector protein, optionally wherein the engineered protein lacks at least a portion of Cas12a or Cas12 b.
19. The engineered protein of any one of claims 5-18, further comprising a first linker between the first CRISPR-Cas effect polypeptide and the heterologous polypeptide and/or a second linker between the heterologous polypeptide and the second CRISPR-Cas effect polypeptide.
20. The engineered protein of claim 19, wherein the first linker and/or second linker comprises 1 to 10 amino acids, optionally wherein the first linker and/or second linker comprises 1, 2, 3, or 4 amino acids.
21. The engineered protein of claim 19 or 20, wherein the first linker and/or the second linker comprises glycine and/or serine.
22. The engineered protein of any one of claims 1-21, wherein the engineered protein comprises an amino acid sequence having about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence of a wild-type CRISPR-Cas effect protein, optionally wherein the engineered protein comprises the amino acid sequence of SEQ ID NO:50-66 or 151 has an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity.
23. The engineered protein of any one of claims 1-22, wherein the engineered protein comprises a sequence that hybridizes to SEQ ID NO:2-17, 125-132, or 157-168, optionally wherein the engineered protein comprises an amino acid sequence having about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2-17, 125-132 or 157-168.
24. The engineered protein of any one of claims 1-23, wherein the engineered protein is a nuclease, optionally wherein the engineered protein is a target strand-cutting enzyme, a non-target strand-cutting enzyme, or a target strand and a non-target strand-cutting enzyme.
25. The engineered protein of any one of claims 1-24, wherein the engineered protein has increased efficiency of nicking a target strand and/or non-target strand of a target nucleic acid compared to a CRISPR-Cas effect protein (e.g., a wild-type CRISPR-Cas effect protein and/or a protein having the sequence of one of SEQ ID NOs 50-66 or 151).
26. An engineered protein comprising:
a first nuclease domain, wherein the first nuclease domain is a target strand nickase domain or portion thereof, wherein the first nuclease domain is not a V-type nuclease domain or portion thereof; and
A first CRISPR-Cas effect polypeptide that is part of a V-type CRISPR-Cas effect protein.
27. The engineered protein of claim 26, wherein the first nuclease domain is a target strand-specific nickase domain or a target strand-nickase domain and a non-target strand-nickase domain.
28. The engineered protein of claim 27 or 28, further comprising a second nuclease domain, optionally wherein the second nuclease domain is a non-target strand and a target strand nickase domain or portion thereof.
29. The engineered protein of claim 28, wherein the second nuclease domain is active.
30. The engineered protein of claim 28, wherein the second nuclease domain is inactive.
31. The engineered protein of any one of claims 26-30, wherein the first nuclease domain comprises a HNH domain, optionally wherein the HNH domain comprises an inactivating mutation (e.g., an H840A mutation).
32. The engineered protein of any one of claims 28-31, wherein the first CRISPR-Cas effect polypeptide and the second nuclease domain are each part of a first CRISPR-Cas effect protein and the first nuclease domain is located between and/or linked (e.g., directly or indirectly) to two contiguous or non-contiguous amino acids of the first CRISPR-Cas effect protein.
33. The engineered protein of claim 33, wherein the first nuclease domain is located in the engineered protein at a position corresponding to an inter-domain junction region of the first CRISPR-Cas effect protein.
34. The engineered protein of any one of claims 26-33, wherein the first nuclease domain comprises a sequence that hybridizes to SEQ ID NO:1 or 169-174, or wherein the first nuclease domain comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:1 or 169-174.
35. The engineered protein of any one of claims 26-34, further comprising a first CRISPR-Cas effect polypeptide, a first nuclease domain, and a second nuclease domain in an amino-terminal to carboxy-terminal direction.
36. The engineered protein of any one of claims 26-35, further comprising all or a portion of the wedge domain, rec1 domain, rec2 domain, PAM interaction domain, ruvC domain, bridged helix, and/or Nuc domain of a V-type CRISPR-Cas effect protein, optionally wherein the engineered protein comprises all or a portion of the wedge domain, rec1 domain, rec2 domain, PAM interaction domain, ruvC domain, bridged helix, and/or Nuc domain of Cas12a or Cas12 b.
37. The engineered protein of claim 36, wherein the engineered protein comprises a Rec1 domain and a Rec2 domain and the first nuclease domain is located between the Rec1 domain and the Rec2 domain.
38. The engineered protein of any one of claims 26-37, wherein the engineered protein lacks at least a portion of a type V CRISPR-Cas effect protein, optionally wherein the engineered protein lacks at least a portion of Cas12a or Cas12 b.
39. The engineered protein of any one of claims 28-38, further comprising a first linker between the first CRISPR-Cas effect polypeptide and the first nuclease domain and/or a second linker between the first nuclease domain and the second nuclease domain.
40. The engineered protein of claim 39, wherein the first linker and/or second linker comprises 1 to 10 amino acids, optionally wherein the first linker and/or second linker comprises 1, 2, 3, or 4 amino acids.
41. The engineered protein of claim 39 or 40, wherein the first linker and/or the second linker comprises glycine and/or serine.
42. The engineered protein of any one of claims 26-41, wherein the engineered protein comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a wild-type CRISPR-Cas effect protein, optionally wherein the engineered protein comprises an amino acid sequence identical to SEQ ID NO:50-66 or 151 has an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity.
43. The engineered protein of any one of claims 26-42, wherein the engineered protein comprises a sequence that hybridizes to SEQ ID NO:2-17, 125-132, or 157-168, optionally wherein the engineered protein comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2-17, 125-132 or 157-168.
44. The engineered protein of any one of claims 26-42, wherein the engineered protein is a nuclease, optionally wherein the engineered protein is a target strand-cutting enzyme, a non-target strand-cutting enzyme, or a target strand and a non-target strand-cutting enzyme.
45. The engineered protein of any one of claims 26-44, wherein the engineered protein has increased efficiency of nicking a target strand and/or a non-target strand of a target nucleic acid compared to a CRISPR-Cas effect protein (e.g., a wild-type CRISPR-Cas effect protein and/or a protein having the sequence of one of SEQ ID NOs 50-66 or 151).
46. An engineered protein comprising a sequence identical to SEQ ID NO:2-17, 125-132, or 157-168, optionally wherein the engineered protein has an amino acid sequence of at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2-17, 125-132 or 157-168.
47. An engineered protein comprising:
a first polypeptide that is a first portion of a first V-type CRISPR-Cas effect protein;
a second polypeptide that is a second portion of the first V-type CRISPR-Cas effect protein; and
a heterologous polypeptide heterologous to the first V-type CRISPR-Cas effect protein,
wherein the heterologous polypeptide is located between the first polypeptide and the second polypeptide and the heterologous polypeptide is located in the engineered protein at a position corresponding to the inter-domain region of the first V-type CRISPR-Cas effect protein.
48. The engineered protein of claim 47, wherein the inter-domain junction region comprises SEQ ID NO:50 or amino acid residues 283-293 of SEQ ID NO:50 (e.g., amino acid residues corresponding to amino acid residues 283-293 when the sequence (e.g., SEQ ID NO: 52) is optimally aligned with SEQ ID NO: 50).
49. The engineered protein of claim 47 or 48, wherein the first polypeptide comprises all or a portion of the wedge domain and/or the Rec1 domain of the first V-type CRISPR-Cas effect protein; and/or
The second polypeptide comprises all or a portion of the wedge domain, rec2 domain, PAM interaction domain, ruvC domain, bridged helix, and/or Nuc domain of the first V-type CRISPR-Cas effect protein.
50. The engineered protein of claim 49, wherein the engineered protein comprises a Rec1 domain and a Rec2 domain, and the heterologous polypeptide is located between the Rec1 domain and the Rec2 domain.
51. The engineered protein of any one of claims 47-50, wherein the engineered protein lacks at least a portion of a first V-type CRISPR-Cas effector protein (e.g., cas12a or Cas12 b).
52. The engineered protein of any one of claims 47-51, wherein the heterologous polypeptide comprises a target strand-nicking enzyme domain or portion thereof, optionally wherein the heterologous polypeptide comprises a target strand-specific nicking enzyme domain, a non-target strand-specific nicking enzyme domain, or a target strand-nicking enzyme domain and a non-target strand-nicking enzyme domain.
53. The engineered protein of any one of claims 47-52, wherein the second polypeptide comprises a nuclease domain or portion thereof, optionally wherein the nuclease domain or portion thereof is a non-target strand and a target strand nickase domain or portion thereof (e.g., ruvC domain or portion thereof).
54. The engineered protein of claim 53, wherein the nuclease domain is active.
55. The engineered protein of claim 53, wherein the nuclease domain is inactive.
56. The engineered protein of any one of claims 47-55, wherein the heterologous polypeptide comprises a HNH domain, optionally wherein the HNH domain comprises a mutation (e.g., an H840A mutation) that modifies HNH domain activity.
57. The engineered protein of any one of claims 47-56, wherein the heterologous polypeptide comprises a sequence that hybridizes to SEQ ID NO:1 or 169-174, optionally wherein the heterologous polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:1 or 169-174.
58. The engineered protein of any one of claims 47-57, further comprising a first linker between the first polypeptide and the heterologous polypeptide and/or a second linker between the heterologous polypeptide and the second polypeptide.
59. The engineered protein of claim 58, wherein the first linker and/or second linker comprises 1 to 10 amino acids, optionally wherein the first linker and/or second linker comprises 1, 2, 3, or 4 amino acids.
60. The engineered protein of claim 58 or 59, wherein the first linker and/or the second linker comprises glycine and/or serine.
61. The engineered protein of any one of claims 47-60, wherein the engineered protein comprises an amino acid sequence having about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence of a wild-type CRISPR-Cas effect protein, optionally wherein the engineered protein comprises the amino acid sequence of SEQ ID NO:50-66 or 151 has an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity.
62. The engineered protein of any one of claims 47-61, wherein the engineered protein comprises a sequence that hybridizes to SEQ ID NO:2-17, 125-132, or 157-168, optionally wherein the engineered protein comprises an amino acid sequence having about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2-17, 125-132 or 157-168.
63. The engineered protein of any one of claims 47-62, wherein the engineered protein is a nuclease, optionally wherein the engineered protein is a target strand-cutting enzyme, a non-target strand-cutting enzyme, or a target strand and a non-target strand-cutting enzyme.
64. The engineered protein of any one of claims 47-63, wherein the engineered protein has increased efficiency of nicking the target strand and/or non-target strand of a target nucleic acid compared to a CRISPR-Cas effect protein (e.g., a wild-type CRISPR-Cas effect protein and/or a protein having the sequence of one of SEQ ID NOs 50-66 or 151).
65. A composition (e.g., base editing composition) or system comprising:
the engineered protein of any one of claims 1-64;
guide nucleic acid (e.g., guide RNA), and
optionally, a deaminase,
optionally, wherein the engineered protein, the guide nucleic acid and optionally the deaminase form or are comprised in a complex.
66. A complex, comprising:
the engineered protein of any one of claims 1-64;
guide nucleic acids (e.g., guide RNAs); and
optionally deaminase.
67. A nucleic acid molecule comprising a nucleotide sequence encoding the engineered protein of any one of claims 1-64.
68. An expression cassette or vector comprising the nucleic acid molecule of claim 67 or a nucleotide sequence encoding an engineered protein of any one of claims 1-64.
69. A method of modifying a target nucleic acid, the method comprising:
Contacting the target nucleic acid with:
the engineered protein of any one of claims 1-64, and
guide nucleic acids (e.g., guide RNA),
optionally, wherein the engineered protein and the guide nucleic acid form or are contained in a complex, thereby modifying the target nucleic acid.
70. The method of claim 69, wherein the method has increased efficiency of modifying the target nucleic acid and/or nicking the target strand and/or non-target strand of the target nucleic acid compared to the efficiency of a control method (e.g., a method comprising contacting the target nucleic acid with a wild-type CRISPR-Cas effect protein).
71. A method of increasing the efficiency of modifying a target nucleic acid, the method comprising:
contacting the target nucleic acid with:
the engineered protein of any one of claims 1-64, and
guide nucleic acids (e.g., guide RNA),
optionally, wherein the engineered protein and the guide nucleic acid form or are contained in a complex, thereby modifying the target nucleic acid, thereby increasing the efficiency of modifying the target nucleic acid compared to a control method (e.g., a method comprising contacting the target nucleic acid with a wild-type CRISPR-Cas effect protein and excluding the engineered protein).
72. The method of claims 69-71, wherein the target nucleic acid is present in a eukaryotic cell, optionally wherein the target nucleic acid is present in a plant cell.
73. The method of any one of claims 69-72, wherein the engineered protein provides a different editing profile for the target nucleic acid compared to the editing profile for the target nucleic acid of a wild-type CRISPR-Cas effect protein.
74. The method of any one of claims 69-73, wherein the engineered protein provides a different cleavage pattern for the target nucleic acid compared to the cleavage pattern for a target nucleic acid of a wild-type CRISPR-Cas effect protein.
CN202180072987.6A 2020-08-28 2021-08-27 Engineered CRISPR-CAS proteins and methods of use thereof Pending CN116745415A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071734P 2020-08-28 2020-08-28
US63/071,734 2020-08-28
PCT/US2021/047913 WO2022047135A1 (en) 2020-08-28 2021-08-27 Engineered crispr-cas proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
CN116745415A true CN116745415A (en) 2023-09-12

Family

ID=77951805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180072987.6A Pending CN116745415A (en) 2020-08-28 2021-08-27 Engineered CRISPR-CAS proteins and methods of use thereof

Country Status (11)

Country Link
US (1) US20220112473A1 (en)
EP (1) EP4204436A1 (en)
JP (1) JP2023539668A (en)
KR (1) KR20230058090A (en)
CN (1) CN116745415A (en)
AU (1) AU2021331344A1 (en)
CA (1) CA3192195A1 (en)
CL (1) CL2023000554A1 (en)
IL (1) IL300823A (en)
MX (1) MX2023002160A (en)
WO (1) WO2022047135A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230383271A1 (en) * 2022-02-28 2023-11-30 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof
WO2024015920A1 (en) * 2022-07-13 2024-01-18 The Broad Institute, Inc. Hybrid crispr-cas systems and methods of use thereof
US20240200102A1 (en) 2022-12-16 2024-06-20 Pairwise Plants Services, Inc. Fusion proteins comprising an intein polypeptide and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221259A (en) 1986-07-31 1990-05-28 Calgene Inc Seed specific transcriptional regulation
US6040504A (en) 1987-11-18 2000-03-21 Novartis Finance Corporation Cotton promoter
DE68918494T2 (en) 1988-05-17 1995-03-23 Lubrizol Genetics Inc Herbal ubiquitin promoter system.
US5641876A (en) 1990-01-05 1997-06-24 Cornell Research Foundation, Inc. Rice actin gene and promoter
EP0452269B1 (en) 1990-04-12 2002-10-09 Syngenta Participations AG Tissue-preferential promoters
US5459252A (en) 1991-01-31 1995-10-17 North Carolina State University Root specific gene promoter
HU219057B (en) 1991-08-27 2001-02-28 Novartis Ag. Proteins with insecticidal properties against homopteran insects and their use in plant protection
UA48104C2 (en) 1991-10-04 2002-08-15 Новартіс Аг Dna fragment including sequence that codes an insecticide protein with optimization for corn, dna fragment providing directed preferable for the stem core expression of the structural gene of the plant related to it, dna fragment providing specific for the pollen expression of related to it structural gene in the plant, recombinant dna molecule, method for obtaining a coding sequence of the insecticide protein optimized for corn, method of corn plants protection at least against one pest insect
CN1301300A (en) 1998-02-20 2001-06-27 曾尼卡有限公司 Pollen specific promoter
US7166770B2 (en) 2000-03-27 2007-01-23 Syngenta Participations Ag Cestrum yellow leaf curling virus promoters
AR044724A1 (en) 2000-03-27 2005-10-05 Syngenta Participations Ag PROMOTERS OF THE VIRUS OF THE RIZADURA AMARILLA DEL CESTRUM
WO2005037993A2 (en) 2003-10-06 2005-04-28 Syngenta Participations Ag Promoters functional in plant plastids
KR100537955B1 (en) 2003-10-29 2005-12-20 학교법인고려중앙학원 A solely pollen-specific promoter
US9540654B2 (en) 2012-02-01 2017-01-10 Dow Agrosciences Llc Synthetic brassica-derived chloroplast transit peptides
WO2016011070A2 (en) 2014-07-14 2016-01-21 The Regents Of The University Of California A protein tagging system for in vivo single molecule imaging and control of gene transcription
ES2847311T3 (en) 2014-08-05 2021-08-02 MabQuest SA Immunological reagents that bind to PD-1
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN108513575A (en) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 Nucleobase editing machine and application thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2018209969B2 (en) 2017-01-20 2024-02-29 The Regents Of The University Of California Targeted gene activation in plants
US20210071163A1 (en) * 2017-12-22 2021-03-11 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted rna base editing
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing

Also Published As

Publication number Publication date
EP4204436A1 (en) 2023-07-05
IL300823A (en) 2023-04-01
CL2023000554A1 (en) 2023-08-25
AU2021331344A1 (en) 2023-03-16
KR20230058090A (en) 2023-05-02
MX2023002160A (en) 2023-04-25
JP2023539668A (en) 2023-09-15
WO2022047135A1 (en) 2022-03-03
US20220112473A1 (en) 2022-04-14
CA3192195A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
US20210147862A1 (en) Compositions and methods for rna-templated editing in plants
KR20220110739A (en) Type V CRISPR-CAS base editors and methods of use thereof
WO2021092130A1 (en) Compositions and methods for rna-encoded dna-replacement of alleles
JP2022552409A (en) Mutants of CAS12A Nuclease and Methods of Making and Using The Same
CN116745415A (en) Engineered CRISPR-CAS proteins and methods of use thereof
CN115380111A (en) Compositions, systems, and methods for base diversification
WO2022098993A2 (en) Compositions and methods for rna-encoded dna-replacement of alleles
KR20220125304A (en) Recruitment of DNA polymerases for templated editing
US20210403898A1 (en) Compositions, systems, and methods for base diversification
US20210171947A1 (en) Recruitment methods and compounds, compositions and systems for recruitment
US20230383271A1 (en) Engineered proteins and methods of use thereof
US20240200102A1 (en) Fusion proteins comprising an intein polypeptide and methods of use thereof
US20230266293A1 (en) Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same
US20230295646A1 (en) Model editing systems and methods relating to the same
US20220403475A1 (en) Reporter constructs, compositions comprising the same, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination